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Acquired resistance to endocrine therapy is a significant clinical problem in breast
cancer. 'Cross-talk' between the ligand dependent and independent pathways, in
particular the erbB receptor family, has been implicated in the development of
resistance in ERa-positive breast cancer, with erbB2 overexpression occurring in
approximately a quarter of cases. Overexpression of downstream signalling molecules
Akt and ERK has also been implicated in carcinogenesis. The aim of this study was
to evaluate the importance of 'cross-talk' in oestrogen insensitive and endocrine
therapy resistant breast cancer.
A panel of breast cancer cells lines (Mill, LCC1, LCC2, LCC9, LY2) derived from
the MCF-7 breast cancer cell line was used as a model to determine the signalling
pathways which may contribute to the development of oestrogen independence and
anti-oestrogen resistance. For ease of comparison to the parental oestrogen-dependent
and anti-oestrogen-responsive MCF-7 cell line, the Mill, LCC1, LCC2, LCC9 and
LY2 cell lines were termed 'resistant'. TheMill, LCC1 and LCC2 cell lines retained
some degree ofE2 sensitivity.
Growth assays were performed and confirmed the phenotypes of the cell lines, where
the resistant cell lines proliferated in the absence of stimuli. InM 17p-oestradiol (E2)
significantly stimulated growth in MCF-7 and Mill cell lines on days 3, 5 and 7. For
example, by day 7 InM E2 increased growth by ~63-fold and -2-fold compared to day
7 control in the MCF-7 andMill cell lines respectively (PO.OOl). The growth of the
LCC1 and LCC2 cell lines was only significantly enhanced after 5 days of treatment
with InM E2 (-1.4 and -1.5-fold increases compared to day 5 control respectively,
PO.OOl). LCC9 cells were not growth stimulated by InM E2 (days 3, 5 and 7,
P>0.05). LY2 cells were not E2 responsive at this concentration after 7 days.
Resistant cell lines were insensitive to growth factors (TGFa and HRG|3), while
MCF-7 cells remained responsive (-11- and -9-fold increases by day 7 compared to
control respectively, PO.OOl). Mill and LCC1 cells retained some tamoxifen
sensitivity, while the remaining cell lines were unaffected. ERa expression was
determined and 'cross-talk' was investigated by monitoring ERa activation via
phosphorylation of serine residues 118 and 167 (P-S118/167) using western blotting.
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Mill, LCC1 and LCC2 cell lines expressed more ERa than MCF-7 cells, which may
account for elevated basal growth in these lines. The remaining cell lines expressed
similar ERG levels to the MCF-7 cell line, hence another mechanism must account
for elevated basal growth in these cells. ERa was subject to E2 'turnover' in all cells,
indicating all cells contain functional ERa. ERa activation was then elucidated by
observing P-Sl 18 and P-S167. Of interest, E2 significantly enhanced P-Sl 18 in LCC1
cells to a greater extent than MCF-7 cells (-22-fold increase in the LCC1 cell line
compared to -5-fold increase, although both were considered to be significant
compared to their relative controls and other treatments analysed simultaneously,
PO.OOl). Little or no P-Sl 18 was observed in LCC9 cells irrespective of treatment.
LCC1 and LCC9 cell lines were further investigated in comparison to MCF-7 cells as
they displayed a progressive loss of E2 and anti-E2 sensitivity. No differences in
P-Sl67 expression were observed between cell lines subject to control or E2
treatment; HRG(3 enhanced P-S167 to an equal extent in all cells.
To investigate which upstream molecules may account for the changes in P-Sl 18, the
expression and activation of Akt, MEK and ERK were determined. Total levels of
each of the three proteins were equivalent across the panel of cell lines. Akt was
significantly constitutively phosphorylated in the LCC1 and LCC9 cell lines
compared to the MCF-7 cell line (-2.2-fold increases for both cell lines compared to
the MCF-7 cell line after 15 min control treatment, P<0.001), suggesting this pathway
is important in the development of resistance. TGFa enhanced P-Akt to a similar
final expression level in all three cell lines, with the constitutive activated Akt in the
resistant cell lines producing a lower fold increase than that required in the MCF-7
cell line (~6-fold (P<0.001), ~1.5-fold (P>0.05) and ~1.8-fold (PO.OOl) increases in
the MCF-7, LCC1 and LCC9 cell lines respectively compared to control). HRGf also
significantly enhanced P-Akt to a similar final level, although this was greater than
that observed with TGFa, with increases of over -30-fold (PO.OOl) in the MCF-7
cell line, ~3.3-fold in LCC1 cells (PO.OOl) and ~3.5-fold in the LCC9 cell line
(PO.Ol).
TGFa and HRG(3 increased P-MEK extremely significantly in MCF-7 cells (mean
OD values of 1 and 5+/-0.2 arbitary units compared to a control value of zero,
xii
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PO.OOl). TGFa significantly elevated the P-MEK in LCC1 cells by -300-fold
(PO.OOl, when analysed separately from HRG(3 data), and by -43-fold in the LCC9
cell line (PO.OOl, when analysed separately separately from HRG|3 data). P-MEK
expression was elevated by -3000-fold and -1500-fold with HRG(1 treatment in the
LCC1 (PO.OOl) and LCC9 (PO.Ol) cell lines respectively when compared across
several treatments. However, the relative HRGfl-enhanced P-MEK expression was
significantly reduced by -1.8-fold between the MCF-7 and LCC1 cell lines (PO.05),
and reduced further still between the LCC1 and LCC9 cell lines (~1.7-fold reduction,
PO.Ol). The diminished signal was extremely statistically significant between the
MCF-7 and LCC9 cell line (-3-fold reduction, PO.OOl).
However, expression ofP-ERK, which is downstream ofMEK, was equivalent across
all three cell lines, indicating that P-ERK was not responsible for endocrine resistance
in this model. Akt, ERKI/II and PLCy were inhibited by PI3-Kinase inhibitor LY
294002, MEK inhibitor U0126 and U-71322 respectively in order to assess their role
in the signalling and proliferation of these cells. LY 294002 and U0126 reduced cell
proliferation via diminished P-Akt and P-ERKI/Il respectively in a concentration-
dependent manner in all cells. LY 294002 decreased cell proliferation to a greater
extent than U0126 in all cells. HRG(3 had a 'protective' effect against either
inhibitor, demonstrating some form of Akt dependence in all the cell lines. U-71322
was found to have oestrogenic-like action but this was disregarded as the metabolite
of U-71322 is structurally similar to E2. Gene expression changes of a series of E2-
responsive genes (ERa, PR, pS2, CTD) were investigated using qRT-PCR to monitor
differences downstream of ERa. Generally, the resistant cell lines retained E2-
sensitivity, but lost TGFa-sensitivity at the mRNA level, contrasting with MCF-7
cells.
Basal ERa mRNA levels were elevated in all three resistant cell lines compared to
MCF-7 cells, with increases of -4.3-fold (P<0.001), -2.2-fold (PO.05) and -2.5-fold
(PO.Ol) in LCC1, LCC9 and LY2 cell lines. Basal levels of pS2 mRNA were
significantly elevated in all the resistant cell lines compared to MCF-7 cells (~19-fold
(P0.0002), -21-fold (P0.0001) and -3.7-fold (P0.0001) higher in LCC1, LCC9
and LY2 cells respectively). Neither lOpM LY 294002 nor U0126 were able to
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significantly affect basal or E2 treated ERa mRNA expression in any of the four cell
lines tested in this model. In contrast, U0126 significantly reversed pS2 expression
when elevated by E2 treatment in three of the four cell lines tested by -2-fold
(P<0.05) in MCF-7 cells, ~2.6-fold (PO.OOl) in LCC1 cells, and -1.7-fold (PO.Ol)
in the LCC9 cell lines. U0126 did not significantly affect pS2 expression in the LY2
cell line (P>0.05 comparison across all treatments).
The novel recombinant humanised anti-erbB2 monoclonal antibody 2C4 (2C4) was
used to evaluate the importance of erbB2 and related signalling pathways in this
model. 2C4 inhibited growth factor enhanced proliferation in MCF-7 cells via
diminished P-Akt and P-ERKI/II activation as expected. 2C4 significantly reduced
HRGD-enhanced P-Akt (-38- and -33- fold reductions in LCC1 and LCC9 cells
respectively, PO.OOl compared across treatments with and without 2C4 and control)
whilst P-ERKEII was abolished in the LCC1 cell line, and reduced by -143-fold in
the LCC9 cell line (PO.OOl across all 4 treatments conditions). This indicates these
pathways may be partially responsible for some growth of these cell lines. However,
2C4 was unable to reduce resistant cell proliferation.
Initial results show tamoxifen appears to increase HRG|3-enhanced P-Akt in MCF-7
and LCC1 cells by -1.5-fold (PO.05), but this increase was not observed in the
LCC9 cell line. Tamoxifen significantly enhanced the proliferation of MCF-7 cells
already increased by HRGp alone (PO.Ol compared to all other treatments). A -0.9-
fold (-92%, PO.OOl) increase with the two agents was noted compared to a -0.6-fold
(-62%, PO.OOl) increase when cells were treated with HRGp alone. This increase
was significantly reduced when cells were pre-treated with 2C4 (PO.OOl) to a level
just above that produced by HRG(1 + 2C4. It should be noted that tamoxifen appears
to be preventing the same extent of reversal as seen with 2C4 and growth factor alone
(tamoxifen elevated the proliferation of this combination by -16.5% compared to
HRGp + 2C4 alone). This suggests tamoxifen interferes with the mechanism of
action of 2C4. Apoptotic levels and cell cycle distribution were measured using
FACS analysis. The resistant cells had a significantly increased proportion of cells in
S-phase compared to MCF-7 cells (-30% and -14% of LCC1 and LCC9 cells
respectively are in the S-phase compared to only -3% of MCF-7 cells (PO.OOl for
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comparisons between all cell lines)). This may account for their elevated basal
growth.
These data suggest that a combination of several factors including ERa and P-Akt
overexpression, changes in P-MEK activation and P-S118 expression and an
increased number of cells in S-phase contribute to the development and progression of




DCSS = Double charcoal stripped serum.
e2 oestrogen/ 17p-oestradiol.
era = Oestrogen receptor a
HRGp = Heregulin p.
LCC1 = MCF-7/LCC1 breast cancer cell line.
LCC2 = MCF-7/LCC2 breast cancer cell line.
LCC9 = MCF-7/LCC9 breast cancer cell line.
LY2 = MCF-7/LY2 breast cancer cell line.
TGFa = Transforming growth factor-a.
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Figure 2. 5. Schematic diagram depicting the flipping of phospholipids during
apoptosis and the subsequent binding of annexin V molecules to the
surface of the cell
Figure 2. 6. Representative example of an apoptosis experiment produced using the
annexin-v assay and FACS analysis with MCF-7 cells.
Figure 2. 7. Confirmation ofmRNA products.
Figure 3.1. The effect of various E2 concentrations on growth of resistant breast
cancer cell lines versus the sensitive parental MCF-7 breast cell line.
Figure 3. 2. The effect of endocrine therapy on the growth of resistant breast cancer
cell lines versus the sensitive parental MCF-7 breast cell line.
Figure 3. 3. The effects of growth factors on the growth of resistant breast cancer
cell lines versus the sensitive parental MCF-7 breast cell line.
Figure 3. 4. The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell
line (A, MCF-7; B, LCC1; C, LCC2; D, LCC9; E, LY2).
Figure 3. 5 The effect of various E2 concentrations on the growth of resistant
ovarian cancer cell lines versus the sensitive parental MCF-7 breast
cell line
Figure 3. 6 The effect of various TGFa concentrations on the growth of resistant
ovarian cancer cell lines versus the sensitive parental MCF-7 breast
cell line.
Figure 3. 7 The effect of E2 and TGFa stimulation on ERa expression in resistant
breast cancer cell lines versus MCF-7 cell line.
Figure 3. 8 The effect of E2 and TGFa stimulation on pS2 expression in resistant
breast cancer cell lines versus sensitive parental MCF-7 breast cell.
Figure 3. 9 The effect of ligand stimulation on PR expression in resistant breast
cancer cell lines versus sensitive parental MCF-7 breast cell
Figure 3.10 The effect of ligand stimulation on cathepsin D (CTD) expression in
resistant breast cancer cell lines versus sensitive parental MCF-7 breast
cell.
Figure 3.11 The effect of ligand stimulation on the cell cycle of resistant breast




Figure 1.1. The anatomy of a normal mammaiy gland.
Figure 1. 2. The structure of the female reproductive organs including the ovary and
the stages of the ovulatory cycle
Figure 1. 3. Normal breast with (A) lobular carcinoma in situ (LCIS) and (B) non¬
invasive ductal carcinoma in situ (DCIS) in an enlarged cross-section of
the lobule.
Figure 1. 4. The chemical structure of tamoxifen.
Figure 1. 5. Structure of raloxifene.
Figure 1. 6. The structures of three aromatase inhibitors, letrozole, anastrozole and
exemestane.
Figure 1. 7. The mechanism of action of aromatase inhibitors compared with
tamoxifen in post menopausal women.
Figure 1. 8. A model for the proposed mechanism of 2C4 activity.
Figure 1. 9. The points of origin of ovarian cancer.
Figure 1.10. The ERa and ERp protein domains (A & B respectively).
Figure 1.11. ER activation mechanisms.
Figure 1.12. Schematic diagram ofERa domains.
Figure 1.13. Schematic diagram of the 'cross-talk' between the ligand dependent
and independent pathways ofERa.
Figure 1. 14. The erbB family of receptors and their associated ligands.
Figure 1.15. Schematic representation of the derivation of MCF-7 variant breast
cancer cell lines and their relationship to the MCF-7 parental line.
Figure 2.1. Determination of the optimum seeding density ofMCF-7 and LCC1
cells for the SRB assay in cytotoxicity and growth studies.
Figure 2. 2. Determination of the optimum seeding density of LCC2 and LCC9
cells for the SRB assay in cytotoxicity and growth studies.
Figure 2. 3. Determination of the optimum seeding density ofLY2 cells for the
SRB assay in cytotoxicity and growth studies.




Figure 3.12 The effect of endocrine therapy on the cell cycle of resistant breast
cancer cell lines versus sensitive parental MCF-7 breast cell.
Figure 3.13 The effect of endocrine agents on apoptosis of resistant breast cancer
cell line LCC1 versus sensitive parental MCF-7 breast cell.
Figure 3.14 The effect of HRGp and tamoxifen treatment on apoptosis of resistant
breast cancer cell lines versus sensitive parental MCF-7 breast cell.
Figure 4.1. ERa and ERp protein expression levels.
Figure 4. 2. ERa protein expression levels decreased in the presence ofE2 over
time in parental and resistant cancer cell lines.
Figure 4. 3. Effect of various treatment on the level ofERa P-Sl 18 in resistant
versus parental breast cancer cell lines.
Figure 4. 4. Effect of E2 and tamoxifen on the level of ERa P-S118 in MCF-7
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Kate Moore Chapter 1: Introduction
1. Introduction
Breast and ovarian cancer are the first and fourth most commonly diagnosed female
cancers annually in the United Kingdom (U.K.) (http://wvvw.cancerhelp.org.uk/help/
default.asp?page=l 43). Oestrogen receptor (ER)-positive breast and ovarian cancer
are hormone dependent. However, endocrine therapy resistance in ER-positive breast
cancer remains a significant clinical problem for many patients, while ovarian cancers
are often ER-positive and tend to be inherently resistant to endocrine therapy. One
major theory as to why resistance to oestrogen and anti-oestrogens develops in these
cancers is "cross-talk" between the oestrogen and epidermal growth factor (erbB)
receptor signalling pathways. "Cross-talk" at the ER can be observed through
specific serine residue phosphorylation. ER activation is associated with this
phosphorylation. The purpose of this investigation was firstly to identify evidence of
cross-talk in vitro using both breast and ovarian cancer model systems.
1. 1. Normal breast
The key role of a normal breast or mammary gland is the production of milk for the
provision of nutrition to the young. The development of mammary glands begins
during embryogenesis and is similar in both males and females until puberty. At
puberty in females, mammary gland development is increased due to high levels of
oestrogen produced by the ovaries, as well as elevated progesterone levels. The
menstrual cycle, pregnancy and lactation all regulate the mammary gland through
cycles of growth and involution (Mol et al, 2000). Further branching and end buds
develop during pregnancy, which almost entirely regress post-partum through
apoptotic cell death (Russo and Russo, 1987; Russo and Russo, 1994). The anatomy
of a normal mammary gland is shown in figure 1.1.
The shape of the breast is due to the fibrous septa system which attaches it to the skin
which covers it, and the fatty deposits which are also enclosed (Marieb, 2006). A
normal mammary gland contains between 15 and 20 lobes, and each lobe consists of
a network of branched ducts which drain into the nipple (Marieb, 2006). The
branched network of ducts lies on a fat pad which is attached to the chest wall by
loose connective tissue and muscle. Lobules are distributed throughout the breast.
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Figure 1. 1 The anatomy of a normal mammary gland. Each breast comprises of 15-20
lobes which are in turn made up of a network of branched ducts. The ducts drain into the
nipple. The ducts and lobules rest in fibrotic stroma which lies on the chest wall above the
ribs attached by loose connective tissue and muscle (reproduced from AN and Coombes,
2002).
A continuous layer of epithelial cells line the surface of each duct, which are
surrounded by an outer layer of myoepithelial cells. These cells possess contractile
properties, but are not found in the lactiferous ducts close to the nipple. The
glandular ducts are surrounded by fibroblast stroma. Stroma is the loose connective
tissue which is separated from the epithelial compartment by the basement
membrane. Together the epithelial cells, myoepithelial cells, and fibroblasts form the
ducts, with the former being the site of oestrogenic action. The fibroblasts may also
be involved in the oestrogen-induced breast development. During carcinogenesis, the
fibroblast stromal tissue is drastically altered. Degradation and/or a reduction of
synthesis of the basement membrane occurs. Direct contact between tumour cells and
the surrounding stroma occurs simultaneously with inflammatory cell influx,
neovascularisation and extensive remodelling of the extracellular matrix (Ronnov-
Jessen et al, 1996).
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1. 2. Normal Ovary
The ovaries form part of and play a significant role in the female reproductive system.
They naturally produce oestrogen and progesterone and are responsible for breast
development, body shape and egg production. The ovaries are dull white oval masses
(3 x 2 x lcm) of ~5-8g which lie in small depressions of the posterior wall of the
broad ligament on either side of the peritoneal cavity just above the brim of the
pelvis. They are connected to the fallopian tubes at the fimbriated ends and are
enclosed in the tunica albuginea, a tough fibrous capsule. Each ovary consists of an
outer cortex and an inner medulla. The outer cortex contains the follicles (including
the remains of ruptured follicles) which are embedded in vascular fibrous tissue. The
blood vessels, nerves and lymphatics enter the ovaries via the inner medulla (Marieb,
2006). Figure 1.2 depicts the structure of the female reproductive organs including
the ovaries and an internal view of an ovary and the ovulatory cycle.
The ovaries control puberty and the menstrual cycle and stimulate the production of
luteinising hormone (LH) and suppress the production of follicle stimulating hormone
(FSH) in the pituitary gland. The ovaries require both LH and FSH to produce sex
steroids. The thecal cells surrounding the follicle are stimulated into producing
progesterone and androgens by LH. The androgens diffuse through to the granulosa
cell layer via the basement membrane where they are converted under the action of
FSH to oestrogens, mainly oestradiol. This enables the dominant developing follicle
to fully mature (Marieb, 2006; Nussey and Whitehead, 2001).
Prior to puberty the ovaries are smooth, solid glands containing many primordial
follicles. The surface of the glands becomes more corrugated between puberty and
menopause as a result of the activity of the ovary during each ovarian cycle. The
ovaries are shrunken and are scarred after the menopause due to these monthly
follicular ruptures. Many cycles of ovulation are associated with repetitive disruption
and repair of the ovarian surface epithelium. The stimulation of epithelial cells may
increase the probability of spontaneous mutations in proto-oncogenes or tumour
suppressor genes which may contribute to oncogenesis. It is also possible that
inclusion cysts are formed when epithelial cells are trapped within the stroma, which
subjects the epithelial cells to an alternative environment. Therefore, epidemiological
studies have suggested that the number of ovulatory cycles is an important
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contributory factor in the development of ovarian cancer (Nussey and Whitehead,
2001). The risk factors associated with ovarian cancer will be discussed further in












































Figure 1. 2 The structure of the female reproductive organs including the ovary and the
stages of the ovulatory cycle. A, the structure of the female reproductive organs
(reproduced from www.cdc.gov/cancer/ nbccedp/bccqif/cc basic.gif) B, the ovary and the
ovulatory cycle. The cycle is shown from the development of primary follicles to ovulation
and the degeneration of the corpus luteum (image reproduced from
www.lakemichiqancolleqe.edu/. ../anat/reprod.html).
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1. 3. Breast Cancer
1. 3. 1. Incidence and Survival Rates
Breast cancer accounts for 1 in 4 of all female cancers in the Western World, is the
most frequent cancer in women and is the second leading cause of cancer death in
women after lung cancer in the United States (U.S) (Stewart et al, 2004). It is the
leading cause of death for women between the ages of 40-55 years in the U.S. A little
under 42, 000 women and 300 men are diagnosed with breast cancer annually in the
U.K. It is the most prevalent cancer in the U.K. as a whole, excluding non melanoma
skin cancer. The majority of women who develop breast cancer are postmenopausal,
however almost 8, 000 women under 50 years of age are diagnosed each year (U.K
statistics reviewed at http://www.cancerhelp.org.uk/help).
There is a lifetime risk of developing breast cancer of 1 in 9 for women in the U.S.A
and U.K (www.BreastCancerInfo.org/breast-cancer-riskfactors.html) and the
incidence increases with every passing decade after 40 years of age (Lindley, 2002).
The overall survival rates 5 years post-treatment are dependent on the tumour stage.
The stage at which a tumour is diagnosed predicts the outcome and survival of the
patient, with stage I having an overall 5 year survival of 84-93%, which falls
dramatically to 18% in woman diagnosed with stage IV breast cancer (Taucher &
Jakesz, 2004). Breast cancers diagnosed at stages I and II are considered curable,
whilst those diagnosed at stage III show a decline in disease free survival, which falls
to almost a zero value for those patients diagnosed with stage IV breast cancer
(Lindley, 2002).
1. 3. 2. Epidemiology
There are several forms of breast cancer which can be categorised into stages and will
be discussed in this section. Lobular carcinoma in situ, (LCIS, figure 1. 3A) is
confined to the lobules and is generally considered to be a pre-cancerous condition
which arises in the skin or other tissues that cover the internal organs. Breast cancer
arises through hyperproliferation of epithelial cells, progressing through ductal
carcinoma in situ (DCIS, a preneoplastic phase, figure 1. 3B) to invasive breast
cancer, where the basement membrane is breached (Fentiman and D'Arrigo, 2004).
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The several forms of breast cancer include DCIS, invasive ductal carcinoma, invasive
lobular carcinoma, inflammatory breast cancer, Paget's disease and male breast
cancer.
DCIS may cover a small or large area of the breast, but does not spread outside the
ducts and is occasionally termed "pre-cancer" or "tumour in situ" (Tis) because of
this. Approximately 20% of all breast cancer cases are classified as DCIS each year
in the U.S (Adamovich and Simmons, 2003).
Figure 1. 3 Normal breast with (A) lobular carcinoma in situ (LCIS) and (B) non¬
invasive ductal carcinoma in situ (DCIS) in an enlarged cross-section of the lobule;
Breast profile: A Ducts, B Lobules, C Dilated section of duct to hold milk, D Nipple, E Fat, F
Pectoralis major muscle, G Chest wall/rib cage Enlargements: A; A Normal lobular cells, B
Lobular cancer cells, C Basement membrane; B; A normal duct cells, B ductal cancer cells,
C basement membrane, D lumen (centre of duct) (reproduced from www.breastcancer.orqj.
Approximately 70-80% of breast cancers are diagnosed as invasive ductal
carcinoma (IDC), and can be further subcategorised into tubular, cribriform, mucoid
(or mucinous) or papillary, although the majority of cases that present are diagnosed
as of'no specific type' (NST). Approximately 10% of breast cancers are classified as
invasive lobular carcinoma (ILC), and develop in women of any age, with the most
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diagnoses in women between 45 and 55 years of age. ILC is difficult to diagnose by
mammography as it does not always form a firm lump and may present instead as a
thickened area of breast tissue. Therefore this may lead to ILC be of a larger size at
diagnosis. Paget's disease constitutes ~l-2% of cases annually and is often mistaken
for eczema as the symptoms are a scaly red rash of the skin of the areola and nipple.
This can sometimes be itchy and if disturbed can bleed, ulcerate and scab over.
Approximately 50% of patients diagnosed with Paget's disease, via a biopsy and
mammogram, will have a cancerous lump or mass in the tissues behind the nipple, of
which ~90% of cases are invasive. Four in ten patients diagnosed with Paget's
disease have invasive breast cancer, but the majority of cases are DCIS.
1. 3. 3. Stages of breast cancer
Edlich et al (2005) report that a clinical examination and mammography are essential
in detecting breast cancer. There is a universal staging system which is in operation
for the classification of the extent of cancer once detected. The staging system
enables physicians to understand and treat a variety of cancers worldwide, including
that of the breast, and also allows the patient to have an understanding of their
prognosis. The staging system when applied to breast cancer is discussed in depth at
the www.breastcancer.org website.
Stage 0 applies to non-invasive breast cancer, thus DCIS is classified as Stage 0
breast cancer as it confined to the ducts and does not spread to the lymph nodes or
other organs. Stage I cancer describes the disease when it has become invasive and
the tumour measures up to 2cm but has not spread to the lymph nodes. Stage II
breast cancer describes a tumour which is between 2 and 5cm in size, or the tumour
has spread to the lymph node under the arm nearest the breast tumour which can be of
any size.
The Stage III classification is further divided into Stages 111A and B. Stage 111A is
applicable to cancers where the tumour is invasive and is larger than 5cm or the
tumour has spread to the lymph nodes and the surrounding tissues and nodes are
sticking to one another and clumping together. Stage 11 IB breast cancer is invasive
and has spread to the breast skin, internal mammary lymph nodes or chest wall. This
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sub classification includes the uncommon but very aggressive inflammatory breast
cancer, which manifests as redness of part or all of the breast and symptoms may
include ridges and welts.
Stage IV, or advanced breast cancer is where the cancer is invasive and has spread
beyond the breast, underarm, and internal mammary lymph nodes. The tumour may
have metastasised to the supraclavicular lymph nodes (nodes located at the base of
the neck), lung, brain, bone or liver.
1. 3. 4. Causes and risk factors ofbreast cancer
The majority of cases of breast cancer arise sporadically, however, there are a number
of genetic and environmental factors which have been shown to affect the risk of
occurrence. The epidemiological risk factors for breast cancer are reviewed by
Okobia and Bunker (2005) and Dumitrescu and Cotarla (2005). This section details
some of the risk factors associated with the development of breast cancer and table
1. 1. summarises the majority of these factors in order ofmagnitude of risk.
1. 3. 4. 1. Endogenous oestrogens
Oestrogens and other hormones play a crucial role in female sexual organ
development and secondary sex characteristics, reproduction and regulation of the
menstrual cycle (Greenstein, 1994). Oestrogen is a steroid hormone produced by the
ovaries and the most abundant circulating form is 17(3-oestradiol, or E2. It was first
reported by Beatson (1896) that remission occurred in a proportion of women with
metastatic breast cancer who had their ovaries removed. Subsequently, Jensen and
Jacobson (1960; 1962) demonstrated using tritium labelled 17P-oestradiol that
oestradiol was specifically retained by oestrogen target tissues, leading to the theory
that an oestrogen-specific receptor must be present (the oestrogen receptor will be
discussed in a later section). Oestrogen and other steroid hormones in the blood are
bound largely with a high affinity to the sex hormone binding globulin, while the
remainder are non-specifically bound to albumin with a low affinity. A small
percentage of the hormone is in free circulation, which has been shown to diffuse
readily into cells.
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Abnormal oestrogenic signalling has been well documented over a long period of
time as having a known association with breast cancer (reviewed by Russo and
Russo, 1998). There is a strong hormonal aspect to breast cancer aetiology (Pike et
al, 1993), where oestrogen exposure over a lifetime may be a critical factor in breast
carcinogenesis (Pike et al, 1993 and reviewed by Okobia and Bunker, 2005). The
risk of breast cancer rises less dramatically with age following the loss of ovarian
function at menopause or due to a bilateral oophorectomy (Eerola et al, 2002), and
this indicates that hormone production by the ovaries is a key breast cancer risk factor
(Travis and Key, 2003). This is also supported by the fact that the disease does not
occur before the onset of puberty.
The exact mechanism by which oestrogen influences the risk of developing breast
cancer has not been fully established. Several mechanisms have been speculated. It
has been hypothesised that oestrogens promote breast cancer via non-ER-mediated
action of some of its metabolites. Cavalieri et al (1997) found evidence to indicate
that catechol-oestrogens, hydroxylated products of oestrogens, can be undergo a
conversion to quinones which cause DNA adduct formation, although this was only
demonstrated in rodents. It is not entirely clear why the action of these and other
carcinogens is restricted on the whole to the breast and uterus in humans.
It may be that these tissues have an increased level of oestrogen-metabolising
enzymes (Clemons and Goss, 2001). Indeed, a four-fold increase in the risk of
developing breast cancer was found to be associated with the genotype for
polymorphism of catechol O-methyltransferase, an enzyme responsible for catchol
oestrogen metabolism (Huang et al, 1999).
The increased risks of breast cancer due to oestrogen exposure may also simply be as
a result of oestrogen's proliferative effects on the breast, as it is certain in a large
number of individuals that oestrogen stimulates the progression of breast cancer by
inducing malignant cell proliferation (Girdler and Brotherick, 2000). The fact that
ER-positivity in breast tumours correlates with response to endocrine therapy sustains
this argument.
10
Kate Moore Chapter 1: Introduction
Table 1.1. Summary of Breast Cancer Risk Factors
Risk Factor Risk Reference
Early onset of menarche -10-20% increase Berkey et al, 1999
Late onset of
menopause
Increased risk Berkey et al, 1999
Menstrual irregularity Increased risk Okobia and Bunker, 2005
Female sex itself 99 in 100 cases are in women Okobia and Bunker, 2005
Nullparous or 1st full-
term pregnancy after 30
Increased risk cf. pregnancy before
20 years
Berkey et al, 1999
Hormone Replacement
Therapy (HRT)
5 extra cases per 1000 E2 alone




Oral contraceptives Slightly elevated risk (although
slight discrepancies as discussed












30% increased risk in obese
postmenopausal women
Increased risk
-20% increase in risk
7.1% increase relative risk per extra
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In addition, ER has been suggested to be involved in the early processes of breast
cancer as benign breast epithelium has a higher ER expression in breast cancer
patients than those who do not have the disease (Khan et al, 1998). Therefore,
although not fully understood, it may be possible that this is linked with the
deregulated expression of ER in preneoplastic breast cancer cells.
Approximately one third of breast cancer cells are ERa-positive, and these proliferate
in response to oestrogen (Cordera and Jordan, 2006). Stimulation of ERa-positive
breast cancer with steroid hormones such as oestrogen results in an increase in cell
proliferation and invasion (Osborne, 1998), with breast cancer cells themselves able
to synthesise oestrogens (Bulun et al, 1993; Zhao et al, 1996). Therefore there is a
link between the expression of ER and the development of breast cancer. The exact
mechanism by which oestrogen signals via ERa will be reviewed in a later section
(1.4).
There are several well-recognised risk factors which are linked with this hormonal
risk including the female sex itself and reproductive characteristics including age at
menarche and menopause, menstrual irregularity, and age at first and last
childbirth (reviewed by Okobia and Bunker, 2005). Breastfeeding and parity have
also been linked to the development of breast cancer. The early onset of menarche
and a late menopause are linked with an elevated lifetime exposure to oestrogens.
Specifically, an extended time period from Tanner stage 2 of breast development
(breast budding with widening of the areola) to onset of ovulatory cycles, a long time
frame of luteal inadequacy and anovulatroy cycles which are characteristic of the
years of perimeopause, harbour extended oestrogen time frames favoured for
carcinogenesis. It has been hypothesised that oestrogens and progesterones may act
in conjunction to stimulate the proliferation of cells (Raafat et al, 2001).
Berkey et al (1999) reported an increased risk of breast cancer of ~10-20% with the
early onset of menarche, with the likely cause being a prolonged exposure of the
breast epithelial cells to oestrogens and progesterone as a result of earlier ovulatory
menstrual cycles (Bernstein, 2002). Adolescent women who had early menarche
(less than 12 years of age) also had elevated levels of oestradiol during this time
compared to those who had started their menstrual cycles at approximately 14 years
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of age. Elevated levels of oestrogen may also be due to higher follicular, but not
luteal, phase oestradiol levels and reduced sex-hormone-binding globulin (SHBG) in
those individuals post adolescence. This results in oestradiol becoming more
bioavaliable allowing diffusion into the breast tissue. An increased number of
menstrual cycles also results in an increased exposure to oestrogen, hence late
menopause is associated with an increased risk of breast cancer.
The protective effect which has been observed with early age first full term
pregnancy, parity and lactation may be due to the intense differentiation of the
terminal duct lobule and the release of various hormones, paracrine and autocrine
growth factors which occur during lactation. Xenoestrogens have thus been
suggested to have a protective role. Miscarriage or induced abortion do not represent
substantive risk factors for the future development of breast cancer (Brewster et al,
2005).
1. 3. 4. 2. Exogenous oestrogens
Exogenous oestrogens play a crucial role in the management ofmany conditions with
the main sources of exposure arising from hormone replacement therapy (HRT) and
the oral contraceptive pill. HRT is used in the management of menopausal
symptoms. HRT is currently taken by ~33% of British women between 50 and 64
years of age either as oestrogen alone or in combination with progestins (Million
Women Study Collaborations, 2002), while over 200 million women worldwide
using the oral contraceptive pill (Beral et al, 1996).
1. 3. 4. 2. 1. Hormone replacement therapy (HRT)
Oestrogen exerts multisystemic effects, which include beneficial effects on blood
lipids leading to a possible reduction in atherosclerosis with direct effects on the
arterial wall endothelial tissue (Hodis et al, 2001). Hormone replacement therapy
(HRT), usually in the form of synthetic 17|3-oestradiol derivatives (ethinyl estradiol
or the 3-methyl ether form, mestranol), has long been prescribed in the management
ofmenopausal women with deleterious affects of the loss of circulating oestrogens.
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However, the use of combined oestrogen and progesterone HRT over a long duration
of time (10 years) has shown to significantly increase the risk of developing breast
cancer (www.cancerresearchuk.org). A study by the Million Women Study
Collaborators (2003) reported that current users of all variations of HRT such as
oestrogen only, oestrogen and progesterone combined, and tibolone, a synthetic
hormone treatment, had an elevated risk of breast cancer than women who had never
received HRT. The combined treatment was found to elevate the risk to a greater
extent than oestrogen alone, with 19 cases for every 1000 post menopausal women
taking the combined therapy as opposed to an extra 5 cases with oestrogen only HRT.
The risk increased with longer term use of HRT, but declined within a few years of
cessation of the treatment, and returned to normal after 5 years.
1. 3. 4. 2. 2. Oral contraceptives
Oral contraceptives haves also been associated with an elevated risk of breast cancer.
A report combining 54 studies of the use of the combined contraceptive pill
(oestrogen and progesterone) in relation to breast cancer risk found a slightly elevated
risk in women who were currently taking the pill, or those who had used them in the
past decade (Collaborative Group on Hormonal Factors in Breast Cancer, 1996). The
linked cancers tended to be localised to the breast. The risk was deemed insignificant
where the individual had ceased to take the pill 10 or more years prior to breast
cancer diagnosis. Several later studies are generally in agreement with these
conclusions, however some discrepancies still exist and alterations to the formulation
of the combined contraceptive pill highlight the need for further research (Travis and
Key, 2003).
1. 3. 4. 2. 3. Phyto-oestrogens
Phyto-oestrogens are naturally occurring plant compounds, or metabolites of these
compounds, which exert weak oestrogenic action, or modulate the actions of a more
potent endogenous oestrogen, more than likely via by binding to oestrogen receptors
(UK Food Standards Agency Committee on Toxicity, 2002). The active element to
the compound is believed to be isoflavone (www.cancerhelp.org.uk). It has been
hypothesised that food rich in phyto-oestrogens, in particular soybeans, have a
protective effect as breast cancer rates are lower in most Asian countries where this
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diet is prevalent compared to Western Europe and the U.S (UK Food Standards
Agency Committee on Toxicity, 2002). Thus this section also relates to diet and
geographical location (country of origin) (see relevant sections for further details).
It has also been suggested that phyto-oestrogens might decrease the risk by reducing
the number of genotoxic metabolites via re-directing oestrogen metabolism or
through non-oestrogenic pathways (Xu et al, 2000). Studies into the protective effect
of phyto-oestrogens in humans remain inconclusive (Keinan-Boker et al, 2004) hence
further investigation is necessary to make an accurate assessment of their role.
1. 3. 4. 3. Other hormones
Elevated circulating levels of the hormone prolactin have been found in nulliparous
rather than parous women and this may be associated with higher breast cancer risk.
In support of this, Perks et al (2004) reported that prolactin protected human breast
cancer cell lines from apoptosis, which may have significant implications for cancer
treatment. Testerosterone may play a role in the aetiology of breast cancer (Lillie et
al, 2003), where a pooled study of postmenopausal women estimated that the risk of
breast cancer was more than double in women who were exposed to higher levels of
testosterone (top quintile versus lowest quintile) (Endogenous Hormones and Breast
Cancer Collaborative Group, 2002)
1. 3. 4. 4. Age
The incidence of breast cancer dramatically increases with age, doubling every 10
years until menopause, whereupon the rate slows. Approximately 25% of breast
cancer develops in women under the age of 50 years, around 50% between 50 and 69
years and the remainder affect women over the age of 70 years
(http://www.netdoctor.co.uk/diseases/facts/breastcancer.htm). The highest incidence
rates and relative breast cancer risk among women carrying the BRCA1 occur before
age 50. However, the risk of breast cancer as a whole actually diminishes
dramatically with age following the loss of ovarian function at menopause or due to a
bilateral oophorectomy (Eerola et al, 2002), but this is more than likely due to the
loss of exposure to oestrogen as the ovaries are crucial to the production of the
hormone as discussed in the previous section.
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1. 3. 4. 5. Lifestyle
There are many factors which have been linked with the prevention or development
of breast cancer. For example, most studies have reported a 20-40% reduction in the
risk of breast cancer in those who are the most physically active (International
Agency for Research on Cancer, 2002). This data is supported by Berstein et al
(2005) who found an inverse association between physical activity and breast cancer
among black and white women. Excess alcohol intake also increases the relative
risk of developing breast cancer by 7.1% for each extra unit (alcoholic drink)
consumed on a daily basis (10 g/day) (Silva, 2002). Li et al (2005) observed that the
recency, length, and intensity of smoking were all associated with a modest increase
in the risk of breast cancer, while the following of a high-fat diet can elevate the risk
of developing breast cancer as excess fat can cause oestrogen-retention and the
conversion of other hormones into a form of oestrogen.
Obesity has been indicated as a risk factor in breast cancer (International Agency for
Research on Cancer, 2002; Tehard and Clavel-Chapelon, 2006), with the risk for an
. O .
obese postmenopausal woman (body mass index (BMI) ofmore than 30kg/nT) being
30% higher than that of a normal woman with a BMI of less than 25kg/mf The
elevated risk in post menopausal women is potentially due to the association between
BMI and endogenous oestrogen concentrations as the latter is dependent on the
extraglandular production of oestrogen in the adipose tissue (Travis and Key, 2003).
Contrastingly, premenopausal women do not share the same elevated risk with
obesity and the development of breast cancer, in fact there is a link with a slight
reduction in risk (International Agency for Research on Cancer, 2002). The majority
of oestrogen production takes place in the ovaries and levels are homeostatically
regulated by a negative feedback loop regulating by gonadotropins such as follicle-
stimulating and lutenising hormones and are hence independent of adipose tissue.
The reduction in breast cancer risk may be mediated by a decrease in exposure to
ovarian progesterone via an increase in the number of anovulatory cycles. This
decreased risk at an early age may also reduce the increased breast cancer risk
observed in obese postmenopausal women (Hankinson and Hunter, 2002).
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1. 3. 4. 6. Geographical location
Geographical location has a significant affect on the risk of breast cancer, with the
most marked differences occurring in post menopausal women (risk factors reviewed
by Dumitrescu and Cortarla, 2005). This is important as postmenopausal women in
the westernised world tend to be more overweight than those in less industrialised
countries (Pathak et al, 2000; Brinton et al, 1988). This factor was theorised to
account for the majority of the difference in breast cancer rates occurring in Asian-
American women after migration to America from China or Japan (Ziegler et al,
1996). Breast cancer studies have shown that migrants adopt the breast cancer risks
of their destination country. For example, migrants who move from a country of low
incidence, such as an Asian country, to a country of higher incidence such as the U.S
have an increased risk of breast cancer as little as a decade after emigrating. These
data highlight the importance of environmental and sociocultural elements in breast
cancer risk (International Agency for Research, 2002; Li et al, 2005,; Silva et al,
2002).
1. 3. 4. 7. Genetic factors
Patients diagnosed with breast cancer are 20-30% more likely to have at least one
relative with the disease (familiar breast cancer). Only 5-10% of the cases are a direct
result of germline mutations in highly penetrable genes, such as BRCA1 and BRCA2
as well as genes p53 and PTEN. Genetic testing for these mutations has been
clinically available since 1996 (breast cancer genetics are reviewed by Edlich et al,
2005).
1. 3. 4. 7. 1. p53
The inactivated form of the tumour suppressor protein p53 plays a crucial role in
tumorigenesis. It was the first tumour suppressor gene to be linked to hereditary
breast cancer and is localised on chromosome 17p13 (Dumitrescu and Cortarla,
2005). Levine et al (1997) reported over 50% of human cancers to contain a mutated
p53 and more specifically, mutations of the p53 gene (also known as TP53) are found
in 20-40% of invasive breast cancers (Cremoux et al, 1999). A recent study showed
that women with early-stage breast cancer with a p53 tumour suppressor mutation
had a poorer prognosis than those who did not have the mutated version of the gene
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(Linjawi et al, 2004). Stage I breast cancer patients with mutated p53 had a five-year
survival rate of 74% compared to 83% for those without the mutation. The mean free
survival was 70% compared to 98% in those with and without a mutation
respectively. This study concluded that an individual with expression of a mutated
p53 gene should receive chemotherapy. Testing for mutations is available for those
considered high risk at specialised centres but results have been deemed inconclusive
by the American Cancer Society (www.cancer.org) in determining the course of
treatment to be followed.
p53 is regulated negatively by murine double minute-2 (Mdm2). Mdm2 is a proto-
oncoprotein and functions as an ubiquitin E3 ligase for p53 to promote degradation
(Haupt et al, 1997; Honda et al, 1997; Kubbutat et al, 1997; Fang et al, 2000). It
physically interacts with and inhibits p53 and is up regulated in tumours in
comparison to normal mammary glands (Murray et al, 2005).
Zheng et al (2004) observed that elevated levels of c-erbB2 reduced wild-type (WT)
p53 protein and stimulated Mdm2 nuclear translocation via the activation of the
PI3-K/Akt pathway in the MCF-7 cell line. Subsequent inhibition of this pathway led
to an increase in WT p53 protein, a reduction in cell proliferation and heightened
sensitivity to chemotherapy agent adriamycin and radiotherapy. However, inhibition
of this pathway did not affect these characteristics in the MDA-MB-453 cell line
which expresses the mutated form ofp53.
1. 3. 4. 7. 2. BRCA1 and BRCA2
Germline mutations of breast cancer-associated gene l (BRCA1) predispose women
to breast and ovarian cancer and is reviewed by Narod and Foulkes (2004). BRCA1
was first identified and cloned as a major breast cancer susceptibility gene over 10
years ago (Hall et al, 1990; Miki et al, 1994). However, families with a high
incidence of male breast cancer did not express this mutation, hence further
investigation lead to the discovery and cloning of the BRCA2 gene (Wooster et al,
1994; Wooster et al, 1995). BRCA1 mutations have been found to show a trend
towards a worse survival for the ductal tumour type (Brekelmans et al, 2005).
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There is an increased risk of 9- to 36-fold, and a 6- to 61-fold of developing breast
and ovarian cancer respectively in women with detrimental mutations in the BRCA1
or BRCA2 genes compared to the general population (Antoniou et al, 2003).
Approximately 50% of people expressing a BRCA1 or 2 gene mutation will develop
breast cancer by the age of 50 years. The BRCA1 gene is highly penetrant, which
results in approximately 85% of people expressing the faulty gene developing breast
cancer in their lifetime. A patient diagnosed at an early age with breast cancer and
the number of first- and second-degree relatives with breast and ovarian cancer are
significantly associated with an increased likelihood of carrying a BRCA1 or BRCA2
mutation (Narod and Foulkes, 2004).
A study by Nanda et al (2005) compared the BRCA1 and 2 mutations in white,
Ashkenazi Jewish, African American, Hispanic and Asian families. African
Americans were found to have a lower rate of deleterious BRCA1 and BRCA2
mutations but a higher rate of sequence variations compared to non-Hispanic and
non-Jewish white families. The highest percentage of deleterious mutations in
BRCA1 and BRCA2 were observed in Ashkenazi Jewish families (69%).
1. 3. 4. 7. 3. Other risk factors
To date, the data provided for the genetic determinants of endogenous hormones in
relation to breast cancer risk has been inconclusive. For example, polymorphisms
have been noted in genes involved in oestrogen synthesis such as CYP17 and CYPJ9,
and HSD17B1 which codes for an enzyme responsible for the conversion of oestrone
(Feigelson et al, 2001; Dunning et al, 1999). In addition, the oestrogen balance may
be altered by polymorphisms in genes such as COMT, which is responsible for the
methylation of oestrogen to harmless metabolites (Comings et al, 2003; Wedren et al,
2003). These have been classified as low-penetrance breast cancer susceptibility
genes and may have a greater contribution to breast tumorigenesis when associated
with exogenous factors, such as diet and smoking, and endogenous factors, such as
hormones (reviewed by Dumitrescu and Cotarla, 2005).
Other mutations include germline mutations of PTEN, which occur in 80% of
Cowden syndrome patients, which is a rare hereditary breast and thyroid
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predisposition disorder which is linked with a 25-50% lifetime breast cancer risk (de
Jong et al, 2002). PTEN (phosphatase and tensin homologue deleted on chromosome
10, also known as MMAC and TEP1) is tumour-suppressor gene which is found on
chromosome 10q23.3. Mutations of other genes also increase the likelihood of
developing the disease, including that of the ATM gene, which causes ataxia
telangiectasia, and has been shown to elevate the risk of breast cancer by ~11% at 50
years, and 30% by the age of 70 (reviewed by Edlich et al, 2005).
Bcl-2 inhibits apoptosis and expression is a strong predictor of ER status of breast
tumours. The gene predicts hormone receptivity and may indicate a favourable
response to tamoxifen (Elledge et al, 1997). Regulation of the cell cycle and
checkpoint machinery is crucial to the maintenance of normal cellular proliferation.
Alterations to these components are central to the process of carcinogenesis and
abnormal cell growth. Upregulated expression of cyclin Dl, murine double minute-
2 (Mdm2), and Akt is found in tumours in comparison to normal mammary glands
(Murray et al, 2005). In particular, cyclin Dl overexpression has been widely
reported in the pathogenesis of breast carcinoma (Buckley et al, 1993; Bartkova et al,
1994) and a high percentage of primary breast cancers have elevated expression
(Bartkova et al, 1994), including early stage cancers (Weinstat-Saslow et al, 1995).
Over expression of other kinases has also been implicated in breast carcinogenesis.
A recent study by Lin et al (2005) showed that PDK-1 is frequently elevated in breast
cancer with subsequent increases in phosphorylation of downstream kinases,
including Akt, mammalian target of rapamycin (mTOR), Stat3, p70S6K and S6. Lin
et al (2005) suggested that PDK-1 may therefore promote oncogenesis to some
degree via Akt and p70S6K activation. The group hypothesised that these molecules
may be potential therapeutic targets for breast cancer treatment.
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1. 3. 5. Current treatment of breast cancer
Treatment of breast cancer is dependent on the stage of the disease at diagnosis
(Lindley, 2002), and usually involves some form of post-operative endocrine therapy,
chemotherapy and/or radiotherapy in an attempt to eradicate the disease to the utmost
extent. The current and future therapies will be discussed in the following sections.
1. 3. 5. 1. Surgery
Primary local therapy of breast cancer involves breast-conserving surgical removal of
tumours. This has been the standard of care for the past decade (Lindley, 2002). The
core aim of beast cancer surgery is to eradicate local disease in the breast and lymph
nodes by complete resection with tumour-free margins. The extent to which surgery
is performed depends on the stage of the tumour. DCIS tumours are usually removed
via a lumpectomy, unless the tumour covers large area of the breast where a
mastectomy may be more appropriate. Treatment involving surgical removal of the
tumour is rarely effective where malignant cells have migrated from the primary
tumour site, and only allows for local control of the disease (Taucher & Jakesz,
2004).
1. 3. 5. 2. Endocrine therapy
Endocrine therapy involves the targeting of hormone-responsive cellular proliferation
through control of the endocrine system whether it is via inhibition of hormone
receptors such as the oestrogen receptor (ER) or blockade of the production of
oestrogen itself. Therefore, endocrine therapy is usually only used in the treatment of
ER-positive patients.
1. 3. 5. 2. 1. Tamoxifen and other SERMs
Tamoxifen (Nolvadex®) was first documented as having anti-oestrogenic activity in
late breast cancer by Cole et al (l971). It is the first choice of triphenylethylene
compounds (figure 1. 4) over agents such as toremifene due to its lower toxicity and
identical activity (Hayes et al, 1995; Holli et al, 2000). Tamoxifen is a selective ERa
modulator (SERM) as it is an antagonist of the actions of oestrogen in relatively high
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doses (lOpM), but like oestrogen, tamoxifen can have an agonistic effect on ERa and
cell proliferation at lower doses (~10nM) (Howell et al, 2001). Tamoxifen has a
complex mechanism of action and binds directly to the activation function-2 of ERa
competing directly with the agonist action of oestrogen (Jordan, 1994). This
mechanism is believed to be partly mediated through not only the repression of co-
activator recruitment but also corepressor recruitment (Ali and Coombes, 2002) (see
later section on the ER).
Figure 1. 4 The chemical structure of tamoxifen (reproduced from Cosman and Lindsay
(1999)).
This is the main mechanism of action, which subsequently blocks the proliferative
actions of oestrogen on mammary epithelium. A second proposed mechanism for this
antiproliferative affect is the induction of the synthesis of the cytokine, transforming
growth factor-beta (TGF-|3) by tamoxifen. This acts as a negative autocrine
regulatory molecule (Knabbe et al, 1987). Also, studies have shown that tamoxifen
promotes the synthesis of TGF-p in breast cancer stromal (mesenchymal) cells, which
implicates a paracrine, as well as autocrine, mechanism of action, independent of an
interaction with the ERa (Butta et al, 1992). There have been observations of a
clinical effect of tamoxifen in ER-negative breast carcinoma which would support
these mechanistic theories (Nolvadex Adjuvant Trial Organization, 1988). There are
several other reports which corroborate of these findings, including the studies where
tamoxifen lowered the levels of circulating insulin-like growth factor 1 (IGF-1) in
breast cancer patients (Colletti et al, 1989; Pollack et al, 1990). IGF-1 stimulates
breast cancer proliferation acting via several possible routes such as paracrine,
endocrine and autocrine mechanisms and will be discussed in further detail in section
1.6.
22
Kate Moore Chapter 1: Introduction
Tamoxifen was shown to be of the greatest benefit in ER-positive breast tumours
(Osborne, 1998), with 5-year treatment reducing recurrence rates annually by 50%,
and the death rate annually by 28% (Early Breast Cancer Trialists' Collaborative
Group, 1998). Tamoxifen is beneficial in both pre- and post menopausal women of
all ages, with a sequential strategy involving chemotherapy followed by tamoxifen
desirable in post menopausal women with high risk breast cancer (Dellapasqua and
Castiglione-Gertsch, 2005). It is now commonplace for pre- and post-menopausal
women whose tumours are ER-positive to receive the first-line anti-oestrogen
tamoxifen and is recommended for the prevention of tumour recurrence in dosages of
20mg/day for a period of 5 years (Lindley, 2002).
Metastatic breast cancer is also treated with tamoxifen, with an overall response rate
of 30% for an average of 1 year, and disease progression is halted for 6 months in a
further 20% of women. The ER-status is an important prognostic indicator, as is
menopausal status, as post menopausal women have higher response rates than those
of pre menopausal women (Osborne, 1998; Ravdin et al, 1992; Bucahanan et al,
1986; Ingle et al, 1986; Muss et al, 1987). Complete or partial remissions were also
reported in 48-63% of advanced breast cancers treated with toremifene (Valavaara et
al, 1988; Gunderson, 1990; Modig et al, 1990).
The effectiveness of tamoxifen as an anti-cancer treatment led to speculation as to
whether the drug could reduce the risk of breast cancer occurrence in high-risk
women. Three studies were carried out, the largest being the National Cancer
Institute (NCI) Breast Cancer Prevention Trial or National Surgical Adjuvant Breast
and Bowel (NSABP) P-l Study (Fisher et al, 1998). This study found there was an
overall breast cancer incidence reduction of approximately 50%. Risk reduction for
invasive breast cancer was 44% in women under 49 years of age and 55% for those
over the age of 60 years. Non-invasive breast cancer risk reduction was -49% in the
tamoxifen-treated group. These reductions were only found in women with ER-
positive tumours.
Preliminary results of the phase III randomized study of tamoxifen and raloxifene
(STAR) for the prevention of breast cancer were released early in 2006
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(www, cancer.gov/pressreleases/STARresu ItsApr172006/). The study was led by the
National Surgical Adjuvant Breast and Bowel Project. Initial results suggested that
the osteoporosis drug raloxifene was as effective as tamoxifen in preventing invasive
breast cancer. Both tamoxifen and raloxifene were found to reduce the risk of
developing invasive breast cancer by approximately 50%. Fewer cases of uterine
cancer and blood clots (36% and 29% reductions respectively) were reported with
raloxifene treatment compared to tamoxifen. Equivalent numbers of heart attacks,
strokes and bone fractures occurred with each treatment. Raloxifene was found to be
ineffective at reducing the incidence of non-invasive breast cancers in agreement with
Continued Outcomes Relevant to Evista (CORE) Trial (2004) data. The final results
of the STAR trial are yet to be published in a peer-reviewed journal. It is only at this
point will a decision regarding whether tamoxifen or raloxifene is more efficacious at
reducing the risk of developing breast cancer be possible.
1. 3. 5. 2. 2. 1. Adverse effects of tamoxifen
There is an increase in the risk of benign uterine disease, including fibroid
tumours, endometrial hyperplasia, and adenomyosis as well as uterine cancer
with tamoxifen treatment (Fisher et al, 1998; Shushan et al, 1996; Cohen et al, 1993;
Fisher et al, 1994; Lahti et al, 1993). There is also an increased risk of endometrial
cancer with five years of tamoxifen therapy (Nordenskjold et al, 2005).
Nordenskjold et al (2005) found that there were few deaths caused by endometrial
cancer. The group reported 41 cases of endometrial cancer and 7 deaths after 5 years
of tamoxifen therapy, compared to 24 cases of endometrial cancer and 6 endometrial
cancer deaths after 2 years of tamoxifen. Toremifene was shown to produce similar
stimulatory effects on the uterus to tamoxifen (Tomas et al, 1995).
Many reports have documented the increased risk of venous thromboembolic
disease in women with breast cancer treated with tamoxifen (Saphner et al, 1991;
Fisher et al, 1994). Healthy women treated with tamoxifen in the Breast Cancer
Prevention Trial also had an elevated risk of pulmonary emboli and deep vein
thrombosis compared to the placebo group (Fisher et al, 1998). Lesser adverse
effects of tamoxifen include increased "hot flushes" in both pre- and post
menopausal women alike (Sawka et al, 1986; Love et al, 1991). The Breast Cancer
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Prevention Trial (Fisher et al, 1998) found that "bothersome" hot flushes occurred in
46% of patients treated with tamoxifen compared to 29% of the control group.
Tamoxifen has also been associated with an increase in vaginal discharge that was
classed as moderately bothersome, and in some instances, worse (Fisher et al, 1998).
Tamoxifen has also been reported to have slightly adverse effects on bone
metabolism (Wright et al, 1994). The STAR trial data will provide further data on
the fracture inducing potential of tamoxifen therapy.
1. 3. 5. 2. 2. 2. Advantageous effects of tamoxifen
Tamoxifen has been reported to decrease the risk of coronary heart disease, with
the Scottish breast cancer trial observing fatal myocardial infarctions (MI) were 63%
less common in those patients treated with tamoxifen than placebo (McDonald and
Stewart, 1991). The follow-up study of this trial also documented a reduction in risk
of MI and favoured of a reduction in other ischaemic heart diseases in those patients
receiving tamoxifen (McDonald et al, 1995). These data are supported by the
Stockholm Breast Cancer Study (Rutqvist and Mattsson, 1993). Updates to these
studies are in agreement with a more recent study by Nordenskjold et al (2005),
which found that five years of tamoxifen reduced the risk of death from coronary
heart disease by more than 30% compared to 2 years treatment. Five years treatment
with tamoxifen also reduced the risk of death from breast cancer or from all causes
combined as well as the reducing the risk of developing contralateral breast cancer.
The effect was delayed however, only emerging after 7 or 8 years.
1. 3. 5. 2. 2. Second- and third-generation SERMs
Raloxifene, arzoxifene (LY35381) and EM-652, like tamoxifen, are also SERMs with
anti-oestrogenic action (Gu et al, 2002). Raloxifene (figure l. 5) has significant
clinical activity, with improved toxicological profiles to that of tamoxifen (Clarke et
al, 2001). Raloxifene was licensed for the prevention of non-traumatic vertebral
fractures in postmenopausal women at increased risk of osteoporosis, in the UK in
August 1998 (Layton et al, 2005). The benzothiophene is generally well tolerated
with only minor gastrointestinal adverse symptoms and vaginal haemorrhage. A few
25
Kate Moore Chapter 1: Introduction
cases of visual disorders and venous thromboembolism were documented, but these
require further investigation.
Figure 1. 5 Structure of raloxifene (reproduced from www.cancerguest.org).
Raloxifene was not originally developed as an anti-oestrogen for breast cancer,
although it does possess this property, and has shown promising early results as a
chemopreventative agent in the treatment of breast cancer in the MORE trial
(Cummings et al, 1999). Raloxifene does not appear to affect the uterine or vaginal
tissue (Delmas et al, 1995), and may even reduce the risk of uterine cancer
(Cummings et al, 1998).
Arzoxifene is a benzothiophene which is more potent than raloxifene or tamoxifen in
inhibiting breast cancer cells in vitro and in vivo (Fuchs-Young et al, 1997). A phase
II study performed by Buzdar et al (1998) in women with tamoxifen-sensitive or
resistant advanced or metastatic breast cancer was subsequently continued into a
phase II trial. This trial was terminated early however as there was no significant
difference between tamoxifen or arzoxifene.
EM-652 is non-steroidal SERM and a so-called pure anti-E2. The agent appeared to
be a much more potent antagonist on a per-dose effect compared to raloxifene or
tamoxifen. Subsequently, the pro-drug of EM-652, EM-800, was administered to
postmenopausal women who had developed tamoxifen-resistance. This study found
that there was an overall response rate of 14% (Labrie et al, 1999), however, a recent
multicentre phase III trial with EM-800 was terminated early due to inferior
responses with EM-800 compared to tamoxifen.
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1. 3. 5. 2. 2. 1. Faslodex (ICI182,780, Fulvestrant)
Faslodex® (ICI 182, 780, fulvestrant) is a selective ER downregulator which was
developed by Wakeling et al (1991) and retains pure oestrogen antagonist activity. It
was the first in a new class of novel, steroidal, 'pure' antioestrogen which down
regulates the ER and stimulates the degradation of ER preventing receptor
dimerisation, inhibiting estrogen-dependent gene transcription (Mckeage et al, 2004;
Piccart et al, 2003). It has significant anti-tumour activity in patients with advanced
breast cancer (Howell et al, 1996). The absence of partial agonist activity and the
novel mechanism of action made the agent an ideal candidate for the treatment of
advanced breast cancer in both pre- and postmenopausal women (Robertson, 2001)
and in patients where tamoxifen resistance has developed (Martin et al, 2005;
Mckeage et al, 2004).
Faslodex has a similar effectiveness in patients with tamoxifen-resistant disease to
that of the aromatase inhibitor anastrozole. A number of clinical trials have reported
that Faslodex may be a suitable alternative to nonsteroidal antiestrogens and
aromatase inhibitors as a first-line endocrine treatment (Vergote and Robertson,
2004). Faslodex is not linked with an increased risk of endometrial cancer which has
been associated with tamoxifen (Wakeling and Bowler, 1988).
However, it has been shown that MCF-7 cells were able to develop resistance and
proliferate in the presence of ICI 182, 780 through enhanced erbB signaling after
long-term culture in the presence of the pure antiestrogen ICI 182,780 (McClelland et
al, 2001). Shaw et al (2006) also recently developed an ICI 182, 780-resistant
MCF-7 cell line, and indicated this was due to a mechanism other than ERa
alteration. These studies suggest that resistance may develop in clinical situations.
The current and future roles of Faslodex in the management of breast cancer are
discussed by Howell (2006).
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1. 3. 5. 2. 3. Aromatase Inhibitors
Aromatase inhibitors (AIs) such as anastrozole are being considered as alternative
first-line agents of choice in the treatment of postmenopausal women with ER-
positive advanced breast cancer to tamoxifen (Cuzick, 2005). The previous AIs of
choice such as aminoglutethimide and 4-OH androstenedione have now been
superseded by the newer non-steroidal AIs anastrozole and letrozole and the steroidal
inhibitor exemextane (figure 1. 6) due to their greater therapeutic ratio (Iveson et al,
1993; Plourde et al, 1995; Gershanovich et al, 1998; Zilembo et al, 1995). The newer
AIs are more potent and have a lower profile of side effects than the older AIs.
Anastrozole (Arimidex®) has been reported to completely down-regulate the ER,
which subsequently prevents the agonist activity of the drug (Howell et al, 2001). In
clinical trials, anastrozole has been shown to be superior to tamoxifen in first-line
therapy for advanced breast cancer in post-menopausal women (Nabholtz et al,
2000). The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) clinical trial,
where the Al was tested alone and in combination with tamoxifen versus tamoxifen
alone found that there was a significant improvement in disease-free survival with
anastrozole compared to tamoxifen alone (Smith et al, 2005).
CH;
Figure 1. 6. The structures of three aromatase inhibitors, letrozole, anastrozole and
exemestane (reproduced from Choueri et al, 2004).
Letr«ete Anastrosote
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It was hypothesised that the Immediate Preoperative Anastrozole, Tamoxifen, or
Combined With Tamoxifen (IMPACT) trial would predict the long-term outcome in
adjuvant therapy of the ATAC trial. The IMPACT trial predicted the negative effect
of the combination treatment and suggested the benefit of anastrozole. However, the
IMPACT Trial did not confirm this result, perhaps because the end-points and size of
study were such that the study was underpowered to measure the modest additional
benefit of anastrozole. It could only be concluded from this study that neoadjuvant
anastrozole was as effective and well tolerated as tamoxifen in ER-positive operable
breast cancer in postmenopausal women (Smith et al, 2005).
Letrozole (Femara®), the most potent of the new generation of AIs, inhibits
oestrogen biosynthesis by inhibiting the conversion of androgens to oestrogens by the
aromatase enzyme, the last stage in this biosynthetic sequence (Miller et al, 2002). A
diagram of the conversion of androgens is shown in figure 1. 7 and is applicable to all
AIs.
Androstenedlone Testosterone
Figure 1. 7 The mechanism of action of aromatase inhibitors compared with tamoxifen
in post menopausal women (reproduced from Toni et al, 2004).
Letrozole has also proved to have a higher efficacy than tamoxifen as first-line
treatment in post-menopausal women with advanced breast cancer (Smith et al,
2000).
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The International Letrozole Breast Group carried out a clinical trial using adjuvant
treatment with letrozole or tamoxifen in hormone-receptor positive postmenopausal
women, and found that letrozole was significantly efficacious over tamoxifen in
reducing the risk of recurrent disease in these patients (The Breast International
Group (BIG) 1-98 Collaborative Group, 2005). The EORTC trial showed
exemestane also has some promising activity and toxicity data as a first-line
hormonal therapy in metastatic breast cancer patients (Paridaens et al, 2000).
Another class of endocrine therapy is the lutenising-hormone-releasing-hormone
(LHRH) family, of which goserelin (Zoladex®) remains the first-line agonist of
choice for the treatment of pre-menopausal patients with advanced breast cancer
(Howell et al, 2001). Goserelin is rarely used as a single agent as it is more effective
in combination with not only tamoxifen but also an Al as ovarian E2 production is
halted, improving the efficacy of the agents in pre-menopausal women. The pituitary
gland produces leutenising hormone (LH), which stimulates E2 production by the
ovaries. Inhibition of LH production by goserelin, a gonadotropin-releasing hormone
analogue, reduces plasma/serum E2 levels (Cheer et al, 2005) which in turn slow
tumour cell proliferation and may actually shrink the tumour. Improvements in
response and survival and a reduction in time to progression were seen when
goserelin was combined with tamoxifen compared to goserelin alone (reviewed by
Jonat et al, 2006). Side effects of goserelin include the cessation of menstruation, hot
flushes, weight gain, sore joints and perhaps initial tumour enlargement.
1. 3. 5. 3. Radiotherapy
Radiotherapy involves the direct irradiation of breast tumours and perhaps the
surrounding tissues. It is generally used externally although the radioactive material
may be temporarily placed internally (also known as 'brachytherapy' or 'high-dose
intraccavity radiation') in the site where the tumour was removed from at the end of
is used in the treatment (www.breastcancer.org.uk). An important constituent of
therapy for a large proportion of women with early stage breast cancer is adjuvant
radiotherapy (Patt et al, 2005). The supplementary treatment of women post-surgery
with radiotherapy allows the patient to retain their breast whilst improving their
chances to those of women who have had a mastectomy initially (Fisher et al, 1995;
Fisher et al, 2002). The application of radiotherapy after mastectomy also reduces
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the risk of local recurrence of the disease and may also improve overall survival
(Overgaard et al, 1997; Ragaz et al, 1997). Both these applications of radiotherapy
post surgery reduce breast cancer mortality (Early Breast Cancer Trialists'
Collaborative Group, 2000), although radiotherapy has been associated with an
increased risk of cardiovascular mortality with long-term treatment, particularly of
tumours of left breast (Patt et al, 2005).
1. 3. 5. 4. Chemotherapy
Chemotherapy is a systemic drug treatment and usually involves the combination of
several agents. Chemotherapy is a treatment option for a large number of patients
with metastatic breast cancer (O'Shaughnessy, 2005). It is always used where there
is lymph node involvement and is recommended in pre-menopausal women with
invasive tumours, as these tend to be more aggressive. It is used in the treatment of
patients classified as ER-negative, or where endocrine therapy resistance has
occurred. It is not recommended for the treatment of non-invasive breast cancer.
Chemotherapy can also be used prior to surgery in order to shrink the tumour.
There are several agents which have been found to have single-agent activity,
including the anthracyclines and taxanes, which are considered to have the most
activity. Agents such as capecitabine (Xeloda®), gemcitabine (Gemzar®), and
vinorelbine (Navelbine®) have also demonstrated substantial activity in the
metastatic setting (Gralow, 2005). Single agent survival rates are generally improved
when a second agent is administered as a follow-on agent, for example Paclitaxel
median response rate of 34% was increased to 47% upon the addition of doxorubicin,
which had a median response rate of 36% alone (Sledge et al, 2003).
Other combinatorial studies have confirmed this improvement. A recent 5-year
study found that for women with early-stage, node-positive breast cancer, treatment
with docetaxel (Taxotere®) was more effective than 5-fluorouracil in combination
with adriamycin and cyclophosphamide at reducing the risk of recurrence. Other
studies have shown that not all combinations are effective as current treatments in
use. For example, in a study of the treatment of women with metastatic cancer with
the GET combination, Gemzar (gemcitabine), epirubicin, and Taxol (paclitaxel),
there was no significant improvement compared to the FEC combination of 5-
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fluorouracil, epirubicin, and cyclophosphamide. This was important as the women
who received the GET combination had more deleterious side effects (Musib et al,
2003; Zielinski et al, 2003).
Recent trials have also seen improvements in survival and other benefits of a
combination of not only chemotherapeutic agents, but also in conjunction with
targeted therapies such as Herceptin (see later section for further detail on herceptin)
(Slamon et al, 2001; Marty et al, 2005).
1. 3. 5. 5. Monoclonal antibodies
The role of the cell membrane receptors in the balance between cell proliferation and
programmed cell death (apoptosis) has widely been investigated. Angiogenesis and
cell migration also play crucial roles in the spread of cancer and the investigation into
these areas as a whole imparted the development of novel targeted cancer therapies
(Mass, 2004). The epidermal growth factor family of receptors (erbB, EGFR, or
HER family) is one such group of cell membrane receptors, which have been widely
implicated in the development ofmany cancers, including breast cancer.
1. 3. 5. 5. 1. Anti-ErbB2 monoclonal antibodies
1. 3. 5. 5. 1. 1. Herceptin (trastuzumab)
Herceptin (trastuzumab) is a humanised monoclonal antibody against a membrane-
proximal epitope in the extracellular region of erbB2 (Nagy et al, 2005). It binds
competitively to the extracellular domain of the erbB2 receptor and blocks
intracellular signalling (Bianco, 2004). Herceptin was originally developed by Axel
Ullrich and co-workers at Genetech Inc. in 1990. Herceptin comprises of the antigen-
binding loops from a murine monoclonal antibody against the extracellular domain of
the erbB2R and the human variable region framework residues plus the IgGl constant
domains (Carter et al, 2002).
The mechanism of action of herceptin has yet to be entirely elucidated, with several
possible theories speculated to date. A proposed mechanism is the enhancement of
erbB2 degradation (Molina et al, 2001), while Artega et al (2001) found herceptin to
act in part by inducing receptor endocytosis. Le et al (2003) and Jackson et al (2004)
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speculated that the activity of herceptin arose as a result of the inhibition of cell cycle
progression via inhibition of the MAPK pathway while Yakes et al (2002) and
Mohsin et al (2005) suggested that the suppression of the anti-apoptotic PI3-K/Akt
pathway was responsible.
There are also reports of the action of herceptin in mediating antibody-dependent
cellular toxicity (ADCC) (Cooley et al, 1999; Clynes et al, 2000; Carson et al, 2001;
Repka et al, 2003; Gennari et al, 2004). However, the mechanisms are not
necessarily confirmed when comparing in vitro data from cells with erbB2
overexpression, to in vivo studies (Mohsin et al, 2005). The most recent study by
Fujita et al (2006) has suggested that PTEN activity may play a significant and major
role in the antitumour effect of herceptin via the erbB2/PI3-K/Akt pathway.
Therefore, the group suggested that PTEN could be a useful biomarker for predicting
the efficacy of herceptin in the treatment ofbreast cancer.
Herceptin was the first monoclonal antibody to be licensed for targeted therapy
(Mass, 2004) and can effectively treat tumours with amplification of the erbB2-gene
in 25% of patients as a monotherapy (Vogel et al, 2003). 50% of patients can
effectively be treated with herceptin with a combination treatment such as taxane or
other chemotherapy (Slamon et al, 2001), although tumour cells become resistant
after 1-2 years of remission to any herceptin treatment (Ross and Gray, 2003; Slamon
et al, 2001).
Herceptin is well tolerated in erbB2-positive patients with metastatic breast cancer
when received as first line treatment (Vogel et al, 2002) and in combination with
chemotherapy in patients with disease progression (Cobleigh et al, 1999). Herceptin
treatment in combination with chemotherapy prolonged survival from a median of
20.3 to 25.1 months, and increased the objective response rate from 32% to 50%.
The time to progression in women with erbB2-positive metastatic breast cancer was
also extended from 4.6 to 7.4 months when used as a first line agent combined with
an anthracycline plus cyclophosamide or paclitaxel (Slamon et al, 2001). The
survival duration (26.8 months) and response rate (56%) were greatest in patients
who received herceptin in combination with an anthracycline and cyclophosamide,
the former of which being doxorubicin in the majority of cases. Herceptin has been
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linked with the increased incidence of cardiac toxicity in the form of congestive heart
failure (Slamon et al, 2001; Tan Chiu et al, 2005). The use of anthracyclines such as
liposomal doxorubicin and epirubicin are hoped to reduce this higher than expected
incidence of cardiotoxicity seen with the use of other anthracyclines (Gianni, 2002).
Other studies have shown similar responses, however, no tumour regression was
observed in the remainder of patients who did not respond to single or combination
treatment. Interestingly, the erbB2 gene was found to be amplified and the protein
overexpressed in the primary tumour and metastases of these patients, indicating
erbB2-positive status is not the sole contributor when determining herceptin
sensitivity (Tanner et al, 2002). This has lead to the study of various other
combination treatments. Herceptin in combination with tamoxifen has also provided
positive inhibitory results, with strong synergistic growth inhibition, inhibition of
erbB2 activity, enhancement of G(0)-G(1) cell cycle accumulation, and a cytostatic
effect without cell death (Wang et al, 2005). Ropero et al (2004) reported reduction
in BT 474 cell proliferation of 44% compared to 24% and 31% with herceptin and
tamoxifen alone respectively. However, these data are dependent on the order in
which each agent was added, as an antagonism of the agents was seen with an
inhibitory concentration of 30% (IC30) when cells were treated with herceptin first.
Herceptin has also been tested in combination with Tarceva as mentioned previously
(Totpal et al, 2002), and a recent study by Nakamura et al (2005) found the
combination of herceptin plus Iressa to be additive or synergistic in their anti-tumour
activity in NSCLC.
Currently, herceptin is licensed at a second-/third-line monotherapy and first line with
paclitaxel in metastatic breast cancer with erbB2 overexpression. There are also four
Phase III trials in combination with chemotherapy and/or radiotherapy as adjuvant
therapy taking place (Mass, 2004), and a Phase IV trial where patients with metastatic
breast cancer are selected by FISH for treatment with docetaxel or paclitaxel post
herceptin treatment.
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1. 3. 5. 5. 1. 2. RhuMab2C4 (Pertuzumab, Omnitarg™, 2C4)
Humanised anti-erbB2 monoclonal antibody 2C4 (2C4) was first developed by
Fendly et al (1990) and is a novel agent that has shown particular promise in in vitro
studies against MCF-7 cells (Agus et al, 2002). 2C4 binds to and sterically hinders
the signalling action of erbB2 (figure 1. 8), inhibiting ligand-stimulated signalling in
tumour cells that express both low and high erbB2 levels (Agus et al, 2002; Albanell
et al, 2003). This is significant as previously only tumours with high erbB2 levels
were able to be effectively targeted with the anti-erbB2 antibody Herceptin (Albanell
et al, 2003). 2C4 will be used as a tool to investigate the role, if any, of erbB2 in the
development of endocrine resistance in this model of resistance.
2C4
Figure 1. 8 A model for the proposed mechanism of 2C4 activity (reproduced from Agus et
at, 2002). HRG binds to erbB3 which heterodimerises with erbB2. This dimerisation step is
blocked by 2C4.
2C4 is produced in Chinese hamster ovary cells and is based on the human
immunoglobulin (Ig) G1 (k) framework sequences, consisting of two light chains
(214 residues) and two heavy chains (449 residues) (Agus et al, 2005). The antibody
binds to the dimerisation domain of erbB2 (Franklin et al, 2004), which sterically
inhibits its ability to form dinners with other erbB receptors (Agus et al, 2002;
Sliwkowski et al, 1994; Schaefer et al, 1997; Fitzpatrick et al, 1998; Liu et al, 2002;
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Mendoza et al, 2002). 2C4 blocks both homo- and heterodimerisation of erbB2 and
represents one of a new group of agents known as 'dimerisation inhibitors' (Agus et
al, 2005). 2C4 has a distinct mechanism of action to Iressa and Tarceva, and
represents a new class of targeted therapies known as erbB dimerisation inhibitors
(Mass, 2004). 2C4 also has a separate binding site in domain II to that of herceptin
which does not overlap with the epitope on erbB2 which herceptin recognises (Fendly
et al, 1990; Cho et al, 2003).
A clinical study by Agus et al (2005) has found that 2C4 is well tolerated, has a
pharmacokinetic profile which supports a 3-week dosing regime and is clinically
active. 2C4 is currently in Phase II trials for second-/third-line monotherapy in
advanced ovarian cancer, hormone-resistant prostate cancer and advanced NSCLC.
1. 3. 5. 5. 2. Inhibitors of the EGFR (erbB1)
1. 3. 5. 5. 2. 1. Iressa (gefitinib, ZD1839)
Iressa is a small molecule selective quinazoline derivative and is a reversible tyrosine
kinase inhibitor which blocks the erbBl receptor (Mass, 2004). Iressa (and Tarceva,
see next section) binds competitively to the intracellular adenosine triphosphate
binding site of erbBl (Ciardiello and Tortora, 2001). The antitumour activity of
Iressa is not dependent on the expression of erbBl, and conversely resistance to
Iressa is not dependent on the expression levels either (Moasser et al, 2001). This
indicates that receptor level expression is not an indicator of the sensitivity to Iressa.
Interestingly, high levels of the erbB2 are also highly sensitive to Iressa, and erbBl
and erbB2 receptor phosphorylation occurs upon treatment with the inhibitor
(Moasser et al, 2001). However, it has been reported that the erbBl is required for
this effect to take place and thus mediates the action of erbB2 phosphorylation
induced by Iressa (Moulder et al, 2001 ). There is also evidence of activation of the
PI3-K/Akt pathway via erbB3 interactions when cells are treated with Iressa
(Moulder et al, 2001).
Iressa is orally active and has demonstrated cytostatic growth inhibitory properties in
breast cancer cell lines expressing functional erbBlRs. The agent also caused marked
reductions in growth in a variety of tumours including breast and ovarian cancer
36
Kate Moore Chapter 1: Introduction
(reviewed by Ciardiello and De Vita, 2005 and Dowsett et al, 2005). Iressa is
currently in the late phase of clinical development in several cancers (Mass, 2004)
and has already been approved by the United States Food and Drug Administration
(FDA) for pre-treated patients with advanced non-small cell lung carcinoma
(NSCLC). This as a result of the phase III INTACT 1 and 2 and the IDEAL 1 and 2
trials with Iressa administered in combination with chemotherapy and as a
monotherapy respectively (Mass, 2004). Phase II trials are currently taking place in
various tumour types including glioma, where trials are ongoing as monotherapy, in
combination with chemotherapy and/or radiotherapy, and other targeted agents.
1. 3. 5. 5. 2. 2. Tarceva (erlotinib, OSI-774)
Tarceva is also an inhibitor of erbBl. It is potent and highly selective and inhibits the
activity of the isolated tyrosine kinase and erbBl autophosphorylation at very low
concentrations in vitro (Moyer et al, 1997). Tarceva also inhibits various
downstream signalling molecules (Hidalgo et al, 2001; Akita et al, 2002), but a much
higher concentration is required than for receptor phosphorylation. Tarceva operates
via several mechanisms which include the inhibition of proliferation via cell arrest
and induction of apoptosis (Moyer et al, 1997). The anti-tumour effects of Tarceva
are likely to arise from the fact that inhibition of EGFR will subsequently inhibit
angiogenesis, invasion, cell motility and the ability of the cell to recover from
radiation and chemotherapy damage (Artega, 2001; Elessami et al, 2000; Woodburn,
1999). Tarceva has also been shown to inhibit the EGFRvIII (Iwata et al, 2002),
which is expressed in what is believed to be the more aggressive phenotype, hence
this may be of some clinical significance (Lai et al, 2002). Tarceva is well tolerated
and responses have been observed in breast cancer, NSCLC and ovarian cancer
(Mass, 2004), with dose-dependent inhibition of human head-and-neck carcinomas
with EGFR overexpression (Pollack et al, 1999). The only side effects noted were
diarrhoea and acneiform skin rash from the maximum tolerated dose of 150mg/day
(uninterrupted schedule) (Hidalgo et al, 2001).
It has been hypothesised that the targeting of multiple pathways will produce an
additive and perhaps synergistic effect due to the inhibition of 1, 2 or more pathways
at once. This theory is supported by preclinical studies such as a study by Totpal et al
(2002), who found the combination of Tarceva and the anti-erbB2 monoclonal
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antibody 2C4 to have an additive effect on apoptosis. Further Phase I/I I trials are
being carried out in metastatic erbB2-positive breast cancer to investigate the
potential benefits of combining Tarceva with Herceptin, which would target erbBl
and erbB2 respectively, thus inhibiting a significant proportion of the erbB receptor
signalling network (Mass, 2004). A recent study by Friess et al (2005) has also
reported promising additive and 'more than additive' anti-tumour effects of
combining Tarceva with 2C4 in breast tumour xenografts.
1. 3. 5. 6. Tyrosine kinase inhibitors in development
There are currently a number of tyrosine kinase inhibitors in development, including
Tarceva and Iressa discussed earlier. Other such inhibitors are the EGFR/erbB2
inhibitor, Lapatinib, which is in Phase II trials in many tumour types including
metastatic breast and colorectal cancers, the former under second-/third line studies in
combination with Herceptin. Another agent targeting metastatic breast cancer is the
pan erbBR irreversible inhibitor CI-1033. PD153035 is in preclinical studies and
targets erbBl and erbB2.
1. 3. 5. 7. Current opinion of treatment of breast cancer
The International Consensus Guidelines from the St. Gallens conference (2005)
reviews the general opinion of European experts for the treatment of breast cancer
(http://www.breastcancersource.com). The focus of the consensus shifted from
initially considering risk factors such as tumour size in previous years to endocrine
responsiveness. Breast cancer was categorised into endocrine responsive, responsive
uncertain and non-responsive and then further classified according to low,
intermediate or high risk, and whether the patient was pre- or postmenopausal. The
risk factor was dependent on the tumour size, node status, age, whether the tumour
was invasive and the erbB2 gene status. For example, individuals with I -3 nodes
involved and amplified erbB2 expression or 4 or more nodes involved were deemed
to be 'high risk'. The combination of factors presented at diagnosis identified which
particular treatment would be the most efficacious for that individual postoperatively.
For example, an endocrine responsive, intermediate risk postmenopausal breast
cancer patient would be recommended tamoxifen, an Al, chemotherapy followed by
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tamoxifen or chemotherapy with adjuvant AI therapy. There is also an indication for
a switch to an AI (exemestane or anastrozole after 2-3 years, letrozole after 5 years)
post tamoxifen therapy.
1. 4. Ovarian Cancer
1. 4. 1. Incidence and Survival Rates
Almost 7,000 ovarian cancer cases are diagnosed annually in the UK, making it the
4th most common female cancer after breast, bowel and lung cancer
(http://www.cancerhelp.org,uk/help/default.asp?page=l43). Ovarian cancer arises in
l in 100 women within their lifetime in the UK, with survival rates of 54.8% &
26.3% for post-menopausal women 1 & 5 years post diagnosis respectively (CGS,
Cancer Surveillance Group). Early diagnosis provides survival rates as high as 90%,
although the vast majority of cases of ovarian carcinoma are not identified until late
stage, where survival falls to 30-40% (Connolly et aI, 2003). Women with no family
of ovarian cancer have an average lifetime risk of developing the disease of
approximately 1.5%. Thus, on average 1 in 70 women will develop the disease
during their lifetime in the U.S. (www.ricancercouncil.org/ facts/ovafacts.php).
1. 4. 2. Epidemiology
The epidemiology of ovarian cancer is reviewed at www.ricancercouncil.org/
facts/ovafacts.php. Figure 1.9 shows the sites of origin of ovarian cancer. It arises
from epithelial, germ or stromal cells which have been subjected to deregulation of
normal cellular processes. There are three forms of ovarian cancer. Epithelial
carcinoma is the most common form and arises in the epithelial cells lining the
ovaries. Germ cell cancer comprises approximately 5% of the total number of
ovarian cancers cases annually. It occurs in the cells that develop into the egg cells
and is generally found in younger women. Stromal cell cancer also constitutes only
about 5% of ovarian cancer cases and arises in the cells that form the tissues holding
the ovary together.
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Figure 1.9 The points of origin of ovarian cancer (reproduced from Langdon et al, 1997).
1. 4. 3. Stages of ovarian cancer
Ovarian cancer can also be identified and diagnosed, as for breast cancer, by a series
of stages. Stage I ovarian cancer may be located in one or both ovaries, but has not
metastasised to any other organs. Stage II ovarian cancer is diagnosed where the
tumour cells have metastasised to the other reproductive organs such as the uterus or
fallopian tubes and/or has extended through the pelvis. Ovarian cancer which has
spread to the abdomen above the pelvis, liver surface, lymph nodes and/or small
bowel regions is classified as Stage 111. Stage IV is advanced ovarian cancer which
classifies carcinomas which have metastasised to organs outside the abdomen and the
liver, for example the lungs.
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1. 4. 4. Diagnosis
Ovarian cancer is diagnosed through a combination of methods such as a pelvic
exam, a CA-125 blood test, transvaginal ultrasound, biopsy and perhaps via a CT
scan (http://www.cancerhelp.org.uk/help/default.asp?page=143). Symptoms
indicative of ovarian cancer include abdominal bloating and discomfort, fluid around
the lungs/shortness of breath, indigestion and nausea, loss of appetite/sudden weight
loss and vaginal bleeding not during menstruation.
1. 4. 5. Causes and risk factors
There are several known risk factors which may affect the relative risk of developing
ovarian cancer. The most significant risk factor of developing the disease is a family
history of the disease. The risk increases 3-fold if the woman has one or more
primary relatives (mother/sister/daughter) who have had ovarian cancer
(www.ricancercouncil.org/ facts/ovafacts.php). The known mutations can be tested
for and occur in the BRCA1 and BRCA2 genes, although the presence of a mutation in
either gene does not necessarily lead to the development of ovarian cancer. Women
in the 'high risk' group may choose to register on the UK Familial Ovarian Cancer
Registry, and subsequently take part in the UK Familial Ovarian Cancer Screening
Study (UKFOCSS) which is currently taking place.
Age is also a key risk factor, with ovarian cancer developing in women between the
40 and 70 years of age. The larger the number of menstrual cycles in a woman's
lifetime also increases the risk. For example, a woman who has her first cycle before
the age of 12 and/or begins the menopause after 50 years has an increased risk of
ovarian cancer. A high-fat diet has been indicated to elevate the risk of ovarian
cancer as excess fat can cause Ea-retention and the conversion of other hormones into
a form of E2. Ethnicity also plays a role in the risk of ovarian cancer, with studies in
the U.S. reporting Caucasians and Hawaiians to have the highest risk and Native
Americans to have the lowest risk (American Cancer Society Cancer Facts & Figures
2006).
Lifestyle changes can reduce the risk of developing ovarian cancer, including
exercise, a low-fat diet, being a non-smoker and having a yearly gynaecological
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and/or pelvic exam. Other factors which reduce the risk of ovarian cancer include
breastfeeding, having more than one child and/or a child below the age of 30 years.
Alternatively, a woman who has taken birth control medication for a period ofmore
than 5 years may have a reduced risk of ovarian cancer, although studies have been
inconclusive (http://www.cancerhelp.org.uk/help).
1. 4. 6. Current treatment of ovarian cancer
The current strategy for the treatment of ovarian cancer is dependent on the stage of
the disease. It usually involves the surgical removal of the ovaries and womb
followed by chemotherapy in the form of a platinum compound in combination with
Taxol (The Advanced Ovarian Cancer Trialists Group, 1999). The Advanced
Ovarian Cancer Trialists Group (1999) reviewed the advantages of platinum versus
non-platinum agents in chemotherapy of advanced ovarian cancer. Surgery may not
be necessary if the tumour grade is very low or borderline, but this is not generally
the case. Post-surgery of stage I ovarian cancer, biopsies of the lymph nodes,
diaphragm and tissue lining the abdomen and pelvis are taken to assess the extent of
the spread of the disease. Adjuvant chemotherapy usually takes the form of cisplatin
or carboplatin. The National Institute of Clinical Excellence (NICE) recommended a
treatment choice of either Paclitaxel (Taxol) and a platinum agent, or a platinum drug
alone in 2003.
Radiotherapy is rarely used in the treatment of ovarian cancer, but may be applied in
the therapy of stage Ic or stage II cancers post-surgery where there is little or no sign
of cancer in the abdomen or pelvis.
The majority of ovarian cancers are antioestrogen resistant, with a response rate of
only approximately 15% (reviewed in Slotman and Rao, 1988). However, a distinct
subset of patients do respond to endocrine therapy, while studies performed tended to
be in small groups of patients in whom other therapies had proved unsuccessful
(Clinton and Hua, 1997). Therefore, there is a rationale for hormonal therapy in this
subset, particularly as abnormal oestrogenic signalling has a well known association
with ovarian cancer (Pujol et al, 1998). In addition, as a result of the endocrine
associations with ovarian cancer, the few deleterious side effects of hormonal therapy
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and the established efficacy of these therapies in other endocrine organ-associated
cancers, the role of endocrine therapy in ovarian cancer merits further investigation
(Rao and Miller, 2006).
Endocrine therapy may be used in the treatment of ovarian cancer patients who have
developed resistance to chemotherapy, while combination treatment with tamoxifen
and goserelin has also been reported to be an active regimen in platinum-resistant
ovarian cancer patients (Hasan et al, 2005). Trials currently underway involving
endocrine therapy includes a Phase III trial performed by the Gynecologic Oncology
Group of the efficacy of tamoxifen versus thalidomide in patients with recurrent
ovarian epithelial cancer after first-line chemotherapy (www.c 1 inicaltrials.gov).
1. 5. The oestrogen receptor (ER) and breast and ovarian
cancer
As previously stated, the approximately a third of breast cancer cells are ERa-positive
and proliferate in response to oestrogen, which has led to the conclusion that ERa
plays a pivotal role in the development of breast cancer (Murphy et al, 1997; Schmitt
et al, 1995). ERa are also expressed in the ovaries. ERa and oestrogen have been
implicated in ovarian cancer and are perhaps related to its causation (Rao and Miller,
2006). Rao and Miller (2006) suggested that additional research was required into
hormonal therapies as a treatment for ovarian cancer as discussed in the previous
section. Therefore, ERa may play a crucial role not only in breast cancer, but also
ovarian cancer.
ER mediate most biological effects of the hormone oestrogen including development
& maintenance of female reproductive organs & lipid metabolism. 17(3-oestradiol is
the most abundant circulating form of the ovarian hormone oestrogen (Gianni, 2002;
Santen, 1986). ERs belong to a steroid/thyroid hormone superfamily of receptors,
which act as transcription factors when specific ligands are bound to them (Joel et al,
1995). The ER was first identified by Toft and Gorski (1966), and isolated from
several species including human (Gorski et al, 1968). Two groups eventually cloned
the ER, now termed ERa (Walter et al, 1985; Green et al, 1986; Greene et al, 1986;
Green et al, 1986a). The discovery of a second ER, ERf), was not made until the mid-
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1990s (Kuiper et al, 1996). The cloning of the full-length 530 amino acid ERp
molecule was performed by Ogawa et al (1998) and confirmed by Moore et al
(1998), along with a collection of other isoforms.
ER signalling plays a role in sexual maturation (male and female), fertility, bone
formation, cardiovascular and angiogenesis effects, and behaviour (McCauley et al,
2003; Windahl et al, 2002; Iafrati et al, 1997; Wersinger et al, 1997; Korach et al,
1996). ERa is the predominant receptor involved in mammary gland development
(Herynk and Fuqua, 2004). It has been shown extensively that ERa overexpression is
associated with breast and ovarian cancer, and ERP has also been linked with the
development of these diseases (Rutherford et al, 2000; Speirs et al, 1999a and 6;
Pujol et al, 1998). ERP is expressed in breast cancer but the exact role it plays
remains controversial (Platet et al, 2004; Gustafsson and Warner, 2000), hence this
study will mainly focus on the role ofERa in breast and ovarian cancer.
1. 5. 1. ERa structure
Figure 1.10 shows the functional domains of ERa with ERp for comparison. ERa
has six domains termed A-F (Green et al, 1986) including a variable N-terminal
domain, which contains activation function-1 (AF-1), a moderately conserved C-
terminal ligand binding domain, which contains activation function-2 and 2a (AF-2
and AF-2a) and a highly conserved DNA-binding domain. AF-1 and AF-2 mediate
transcriptional activation. ERp has a very homologous DNA and ligand binding
domain to that of ERa, and is also activated by oestrogen and inhibited by anti-
oestrogens including tamoxifen (Ali and Coombes, 2002). Ogawa et al (1998)
predicted a 96% homology in the DNA binding domain (C), and a 53% homology
between the E/F domains, while the A, B, and hinge (D) domains are not well
conserved between the two receptors.
44
Kate Moore Chapter 1: Introduction
N ucleoUdcs 233 345
ERa protein




























A B C D E/F
530
Figure 1.10. The ERa and ERp protein domains (A & B respectively). A-F, nucleotide
numbers corresponding to the start of each domain are above, with amino acid numbers
shown below. The solid bars beneath the ER schematic represent some of the known
functional domains and their relative positions, with the binding domain indicated by BD
(reproduced from Herynk and Fuqua, 2004)
ERs also contain functional domains alongside their structural domains (AF-1 and 2
mentioned previously). AF-1 is located within the amino-terminal A and B domains
and contains ligand-independent activation function (Ribeiro et al, 1995; Metzger et
al, 1995; Berry et al, 1990; Kumar et al, 1987). The A/B region contains a
coregulatory domain, which binds a variety of ER coactivators and corepressors that
modulate ER-mediated transcription (see later in section for further details). The C
domain encodes the DNA binding domain and consists of two zinc finger motifs.
This binds to the oestrogen responsive elements (EREs) within the promoters of
oestrogen-responsive genes (Ribeiro et al, 1995). The dimerisation domain is
divided between the C and E domains and is vital for the dimerisation of ERs, which
allows them to bind to the entire ERE site (Ribeiro et al, 1995). ERa and ER(3 can
both form homo- and heterodimers. The hinge region, a section of the ER nuclear
localisation signal and a section of the ligand-dependent AF-2a domain are located in
the structural D domain (Norris et al, 1990). The E and F regions at the carboxyl
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terminal contain the ligand binding domain and the AF-2 domain as previously
mentioned. The carboxy-terminal region is also involved in the formation of receptor
dimers, the binding of chaperone proteins, including heat shock proteins 70 and 90
and the binding of coregulatory proteins (Scherrer et al, 1993; Chambraud et al,
1990).
1. 5. 2. ER transcription
Both ERa and ER0 bind as dimers to short inverted palindromic repeat DNA motifs
in the promoters of oestrogen regulated genes. Specifically, the ER dimer binds
through the action of a pair of zinc fingers (Schwabe et al, 1993). The sequences
surrounding these regions are also involved in the affinity for ER-DNA binding
(Chen et al, 1999; Chen et al, 2000; Joel et al, 1995). ERs initiate gene transcription
and expression by inducing the recruitment of the general transcription machinery
to the start site of transcription via the activation domains (reviewed by Ali and
Coombes, 2002 and summarised in figure 1.11).
The ER may either interact directly with the general transcription components
(Sadovsky et al, 1995) or more recent studies have indicated trans-activation by
nuclear receptors to occur via co-activator complexes. The co-activator complexes
interact directly to recruit the transcription machinery, and more significantly the
complexes mediate chromatin remodelling (reviewed by Glass and Rosenfeld, 2000
and McKenna and O'Malley, 2000). Such complexes include the
TRAP/DRIP/SMCC complex, which is linked to polymerase II (Ito and Roeder,
2001), CREB-binding protein (CBP) and p300/CBP-associated factor (PCAF). These
are histone acetyltransferase (HAT) complexes, where hyperacetylation rather than
hypoacetylation of histones appears to be associated with regions of the genome
which are more actively transcribed. HAT recruitment may be vital in negating the
repressive effects of chromatin on transcription (Strahl and Allis, 2000).
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Figure 1.11 ER activation mechanisms (reproduced from Ali and Coombes, 2002). ER has
three domains: AF1 and AF2 regulated by phosphorylation and the binding of E2 respectively
and a DNA-binding domain (DBD). In the inactivated state, ER is bound to corepressor
(CoR) complexes, which recruit HDACs. HDACs maintain histones in a deacetylated state,
favouring chromatin condensation. A conformational change occurs on E2 binding in AF2
which facilitates interaction with co-activators (CoA), binding histone HATs. Histone
acetylation by HATs results in chromatin decondensation, enabling transcriptional activation.
SERMs modulate ER activity probably by balancing CoA and CoR complex recruitment to
AF2, which is dependent on the SERM-induced conformation and other factors including
tissue-specific differences in the availability of CoA/CoR. Cyclin D1 and growth factor-
induced AF1 phosphorylation may also facilitate the recruitment of CoAs via ligand-
independent mechanisms. ERE, oestrogen response element; H12, helix 12.
There is a group of three related co-factors which are known as the pi 60 co-
activators that induce the activity of the ER after the binding of a ligand such as
oestrogen via AF-2 (reviewed by McKenna et al, 1999 and Leo and Chen, 2000).
The three proteins are called nuclear-receptor co-activator 1 (NCOA1, SRC1),
NCOA2 (TIF2, GR1P1) and NCOA3 (P/CIP, ACTR, A1B-1 or TRAM1) and
facilitate histone acetylation by associating with the transcription factor CBP
(Bannister and Kouzarides, 1996; Ogryzko et al, 1996). NCOA1 and 3 also acetylate
histones directly (Spencer et al, 1997;Chen et al, 1997). The ERa undergoes a
conformational change in AF-2 to form a surface at which co-activators interact, and
bind histone acetyltransferases (HATs). The shape of this surface determines if a
ligand acts as an agonist or antagonist (Russo and Russo, 1987). HAT histone
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acetylation results in chromatin decondensation which facilitates transcriptional
activation. Ligands such as IGF and TGFa activate the ligand-independent AF-1
domain (Webb et al, 1998; Arnold et al, 1995), and this is closely related to the
phosphorylation status of the domain (Gayther et al, 2000; Smith et al, 1997). The
ligand independent and non-genomic signalling pathways involving ERa
phosphorylation will be discussed in a later section.
The inactive ER is bound to corepressor complexes, which recruit histone
deacetylases (HDACs). These molecules maintain the histone deacetylation state
that is aligned with chromatin condensation. Repression of gene expression by a
number of unliganded nuclear receptors can be mediated by the recruitment of
HDACs via the interaction of the receptors with nuclear-receptor corepressor 1
(NCOR1) or NCOR2 (SMRT) (Nagy et al, 1997; Chen and Evans, 1995). AF-2
mediates NCOR recruitment without the need for a ligand, hence ligand binding leads
to the dissociation of these complexes and the recruitment of co-activators. For the
ER specifically, other histone-modifying proteins, including arginine
methyltransferases, act as co-activators either through association with co-activators
(Stallcup, 2001) or by directly interacting with the LBD (Koh et al, 2001). Ligand
binding to the hydrophobic pocket of the carboxy-terminal of both the ERs induces
the movement of helix 12 to position itself over the pocket (Steinmetz et al, 2001)
thus stabilising the helix and allowing the recruitment of coactivators. These steps
are required for full agonist action (Feng et al, 1998; Moras et al, 1998), while the
bulky side chains of partial agonists or antagonists including tamoxifen, raloxifene or
faslodex prevent the helix from aligning in the full agonist position.
This results in the blockade of co-activator binding to the ER (Pike et al, 2000).
ERa-bound-tamoxifen represses gene expression by recruiting corepressors NCoRl
and 2 (Shang et al, 2000), which contrasts with ERp, which has been reported to
recruit these corepressors not in the presence of antagonists but agonists (Webb et al,
2003). Decreased expression of NCoR and SMRT have both been correlated with
tamoxifen resistance in breast tumours (Shang et al, 2000; Graham et al, 2000;
Jackson et al, 1997).
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ERp appears to have a greater affinity for phytoestrogens than ER (Kuiper et al,
1997), while ERP also displays reduced transactivation in the majority of cells in
direct comparison with ERa. This is possibly due to the reduced ERp AF-1 activity
(Kuiper et al, 1997). Contrastingly, the AF-2 activity for both ERa and ERp is
similar, although this is dependent on the cell type (Cowley and Parker, 1999).
ERa and ERP differentially regulate transactivation of heterologous promoters
(Kushner et al, 2000). ERa activating protein (AP)-l activity is upregulated by
oestrogens, in contrast to ERp AP-1 which is reduced. Tamoxifen and raloxifene both
increase AP-1 activity of ERa and ERp. Herynk and Fuqua (2004) have reviewed the
mutations of the ER which lead to alterations within the protein sequence,
predominantly those affecting the function of AF-1 or AF-2. The review discusses
the numerous ER mRNA splice variants which have been found and the subsequent
variant forms of the ER proteins.
1. 5. 3. ER expression and breast cancer
Approximately 7-10% of normal human breast epithelial cells are thought to express
ERa (Herynk and Fuqua, 2004), which fluctuates during the menstrual cycle
(Battersby et al, 1992; Ricketts et al, 1991; Markopoulos et al, 1987). Normal cells
which express ERa are not the same as those which are proliferating (Russo et al,
2000; Russo et al, 1999). Contrastingly, ERp expression is markedly higher at 80-
85%, which is also unrelated to cellular proliferation (Palmieri et al, 2002) and does
not alter during the menstrual cycle (Shaw et al, 2002). ER signalling is required for
normal development of the mammary gland and it thought that deregulation of this
signalling facilitates irregular cell proliferation possibly results in the breast cancer
development and its progression (Herynk and Fuqua, 2004).
Low grade DCIS has been shown to express high levels of ERa in approximately
75% of its cells, which is similar to invasive breast cancer. However, high grade
DCIS has a reduced expression of ERa in approximately 30% of its cells (Leal et al,
1995). DCIS have also been reported to have reduced expression of ERp in
comparison to normal epithelial cells, while high grade DCIS displays the most
dramatic decrease in ERp expression (Shaw et al, 2002). Herynk and Fuqua (2004)
report that at present, there is an absence of large studies analysing ERP protein
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expression in early lesions, invasive cancers and in normal breast tissue. The review
concluded that ERa levels fluctuated while ERP expression levels rose during tumour
progression.
1. 5. 4. ERa signalling & 'cross-talk'
It was previously thought that ligand binding was required in order to activate ERa,
however it has been shown that growth factors can stimulate ERa. AF-l activity is
regulated by phosphorylation while AF-2 requires E2 to bind to the ligand-binding
domain. It is possible that AF-l and AF-2 may act independently and/or
synergistically to activate transcription (Gianni, 2002) (figure 1.12). Phosphorylation
is a common covalent modification of proteins that provides an important mechanism
by which the activity of transcription factors is regulated (Chen et al, 1999).
Indirect evidence has shown that phosphorylation is involved in receptor function, for
example, E2 causes a rapid increase in phosphorylation by several fold, and TGFa is
able to elicit ligand-independent ERa activation (Bunone et al, 1996; Joel et al,
1995).
to response 1o estradiol binding:
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Figure 1.12 Schematic diagram of ERa domains. Phosphorylation of ERa is enhanced
upon E2 binding or activation of second messenger signalling pathways, via TGFa
stimulation, for example. TGFa & other ligands of EGFR family are thought to stimulate the
kinases shown (image reproduced from Lannigan, 2003).
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Events subsequent to this initiate ERE-mediated gene expression. Oestrogens and
anti-oestrogens, such as tamoxifen, and protein kinase activators also increase
phosphorylation of the ER and/or proteins in the ER signalling cascade. Specifically,
AF-1 of the ERa contains phosphorylation sites for a number of kinases including
MAPK and cyclin A/ Cdk2 (Katzenellenbogen et al, 1995).
There are two signalling pathways involved in normal cellular proliferation via ERa.
The two pathways are believed to interact with one another leading to the
development of endocrine therapy-resistance in ERa-positive cancers. The two
pathways are termed the ligand-dependent and the ligand-independent pathways.
Previous studies have shown that phosphorylation of serine residues on ERa at
positions 104 and/or 106, serine 118 and serine 167 cause activation and that
mutation of these residues reduces ERa activation, gene transcription and eventually
cell proliferation. There is also evidence of the involvement of serine 236 and
tyrosine 537 residues, however this is inconclusive (Lannigan, 2003). Figure 1.13 is
a summary diagram of 'cross-talk' between the two pathways.
1. 5. 4. 1. The Ligand-Dependent Pathway
The ligand-dependent pathway requires the direct binding of hormones, such as
oestrogen, to stimulate the growth of mainly epithelial cells via the AF-2 domain of
ERa. Oestrogen binds to ERa inducing a conformational change (dimerisation),
which triggers gene transcription & cell proliferation (Atanaskova et al, 2002). In the
ligand-dependent pathway the highly conserved serine residues 104, 106 and 118 are
involved in ERa activation. Serine 104 and/or 106 are believed to be phosphorylated
by the cyclin-A-cyclin dependent kinase 2 (Cdk2) complex (Rogatsky et al, 1999).
Chen et al (1994) (Chen et al, 2000) found that oestrogen treatment of the breast
cancer cell line MCF-7 stimulated cell growth and transcription via serine 118
phosphorylation, located on AF-1 of ERa. Evidence has shown that phosphorylation
of serine 118 is mediated through cdk7, which is a cyclin-dependent kinase associated
with basal transcription factor TFIIH (Chen et al, 2000). Chen et al (1994) concluded
that serine 118 was a major oestrogen-inducible phosphorylation site of the ER. It
was observed that oestrogen enhanced serine 1 18 phosphorylation to a greater extent
compared with serine 104 or 106 phosphorylation (Le Goff et al, 1994).
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Figure 1.13 Schematic diagram of the 'cross-talk' between the ligand dependent and
independent pathways of ERa. The ligand-dependent pathway: oestrogen (E2) binds
directly to and stimulates gene expression via activation function-2 (AF-2) of the ERa. E2
also activates transcription via serine (S) 118 phosphorylation of activation function-1 (AF-1).
The ligand-independent pathway: the erbBR pathway is shown as an example of ligand-
independent signalling, where a ligand of the erbBR family such as TGFa (shown as an
example here) binds to the erbBRs triggering receptor homo or heterodimerisation (erbB1/2
as one possible combination for TGFa), signal cascades and gene transcription via AF-1.
These signals are mediated by at least two pathways including the PI3-K/Akt and MEK/ERK
pathways, phosphorylating ERa residues S118 and S167, and S167 and S104/6 respectively.
ERa activation via AF-1 and/or AF-2 results in ERa binding to the oestrogen response
element (ERE) of the promoter region of genes stimulating gene transcription and ultimately a
cellular response, dependent on ligand stimulation. The anti-oestrogen tamoxifen and a
selection of inhibitors used in this study are shown at their various targets. Tamoxifen
competes with E2 at AF-2 of ERa.
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1. 5. 4. 2. Non-genomic ER signalling; the Ligand-lndependent
Pathway and the Epidermal Growth Factor Receptor Family
The ligand-independent pathway refers to signalling which does not involve
stimulation of ER by a hormone such as oestrogen. One such ligand-independent
pathway operates via members of the Receptor Tyrosine Kinase (RTK) I family or
erbB family of receptors (HER/ EGFR/ erbB family), which eventually enhance the
phosphorylation of various ERa residues including serine 118 and 167. This family
of receptors play an important role in the developmental processes and have been
implicated in the development of breast cancer. These and other breast cancer
markers are reviewed by Giancotti (2006).
The erbB family consists of four closely related receptors: EGFR (erbBl), erbB2,
erbB3 and erbB4 (Sweeney and Carraway, 2000; Muthuswamy et al, 1999; Riese and
Stern, 1998; Schlessinger and Ullrich, 1992) (figure 1.14). Ligands of the erbB
family such as epidermal factor (EGF), transforming growth factor-a (TGFa) and
heregulin-P (HRGP) bind to and activate erbB family members. This causes the
receptors to undergo a conformational change, which leads to dimerisation and the
formation of either a monomer or heterodimer (Sweeney and Carraway, 2000;
Muthuswamy et al, 1999). This leads to phosphorylation of a specific set of tyrosine
residues in the Src-homology 2 (SH2) domains of the receptors. These domains act
as docking sites for adaptor proteins including She, Grb2, and Sos resulting in the
activation of the Ras/Raf/MEK/ERK and PI3K/Akt pathways and ultimately
transactivation, cell growth, proliferation and survival (Yarden et al, 2001; Tzahar et
al, 1998).
ErbB2 is the preferred heterodimerisation partner for other members of the family
(Vinolas et al, 1997). In non-cancerous cells erbB2 is involved in activating
signalling pathways, which eventually result in cell growth and division (Nichols et
al, 1998). ErbB2 adopts an open formation which is constitutively active and is
similar to erbBl when a ligand is bound (Humphreys and Hennighausen, 2000;
Keski-Oja et al, 1988). This is an active conformation, and may be indicative of why
other family members preferentially bind to erbB2 (Atanaskova et al, 2002).
Experiments in vitro and in vivo have shown that erbB2 heterodimers induce a greater
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mitogenic response than homodimers of the other receptors of the family. It was
therefore hypothesised that Iigand-induced activation of erbBl or erbB3 receptors
that formed heterodimers with the erbB2 receptor were important in tumour growth



























Figure 1.14 The erbB family of receptors and their associated ligands. ErbB receptors
contain an extracellular ligand-binding domain, an intrinsic tyrosine kinase cytoplasmic
domain and a single hydrophobic transmembrane domain (Sweeney and Carraway
Sweeney, 2000; Riese and Stern, 1998; Schlessinger and Ullrich, 1992).
TGFa plays an important role in the normal and neoplastic development of the
mammary gland (Humphreys and Hennighausen, 2000) and oncogenesis in a number
of tissues (Humphreys and Hennighausen, 2000; Keski-Oja et al, 1988; Sporn and
Roberts, 1985). It acts as a mitogen in most cells and initiates intracellular signalling
pathways upon binding to erbBRs. TGFa stimulates erbB2 and the ERK/MAPK and
the phosphatidylinositol 3-kinase (PI3-K)/ protein kinase B (PKB/Akt) pathways
(Datta et al, 1999) which potentially leads to the phosphorylation of serine residues
118 and/or 167, followed by ERa activation and gene transcription (see figures 8 and
9). Serine 118 is phosphorylated via the E2-independent pathway by mitogen-
activated kinases (MAPK) ERKI & II (Kato et al, 1995) and via PI3-K. Serine 167 is
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also phosphorylated through this pathway via PI3-K and Akt and the 90kDa
ribosomal S6 kinase RSK (Joel et al, 1998).
HRGp is a member of a polypeptide family of growth factors and is also known as a
neu differentiation factor (Holmes et al, 1992) and regulates cell proliferation and
differentiation (Plowman et al, 1993). HRG is often expressed in breast cancer
tissues (Dunn et al, 2004) and is able to bind to erbB3 and erbB4, inducing
heterodimerisation with erbB2. This in turn stimulates receptor tyrosine
phosphorylation and induction of signal transduction pathways downstream (Fiddes
et al, 1998; Sliwkowski et al, 1994; Plowman et al, 1993; King et al, 1988). HRG
activates a number of signalling pathways in various systems, including activation of
PI3-K, ERK and c-Jun N-terminal kinase (Bacus et al, 1996; Karunagaran et al,
1996; Ram et al, 2000).
HRG has mitogenic actions in a selection of various human mammary epithelial cells
which co-express erbB2 and erbB3 receptors, and PI3-K is constitutively activated by
erbB2 /erbB3 in breast carcinoma cells that overexpress the erbB2 receptor (Ram et
al, 2000). Observations of breast cancer cell lines have shown that HRG has diverse
effects which are cell-dependent (Marte et al, 1995; Peles et al, 1992). It is believed
that the growth factor may be involved in regulating several biological effects of
cancerous cells, for example adhesion, migration, invasion (Staebler et al, 1994;
Bacus et al, 1993) and apoptosis (Daly et al, 1997). Further studies are needed to
elucidate the integration of HRG-activated signals which lead to various biological
effects as the overall picture remains unclear (Tan et al, 1999), although accumulating
evidence suggests HRG increases breast cancer cell proliferation and promotes
aggressive and invasive phenotypes as well as tumorigenesis (Atlas et al, 2003; Falls,
2003). This is supported by evidence where the inhibition of HRG expression
suppressed breast cancer cell metastasis and tumorigenicity (Tsai et al, 2003).
1. 5. 4. 2. 1. 'Cross-talk' and Endocrine Therapy Resistance
Hua et al (1995) reported that ERa-positive ovarian cancer is often refractile to anti-
oestrogen therapy, while approximately 30% of ERa-positive breast cancers are
unresponsive to anti-oestrogen treatment and the majority of those which respond
initially eventually become resistant (Ali and Coombes, 2002). Anti-oestrogen-
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resistant growth of ERa-positive ovarian & breast tumours remains a significant
clinical problem. It is believed that resistance to endocrine therapy arises through one
of the following scenarios, or combination of scenarios; ERa activation in the absence
of oestrogen, hypersensitivity to low levels of circulating oestrogen or activation as
opposed to inhibition by oestrogen antagonists (Ali and Coombes, 2002).
Overexpression or alteration of a component of the ERa signalling pathways is
believed to lead to the pathways interacting with one another increasing
transcription and deregulating cellular proliferation.
In ovarian cancers erbBl is present in 33% to 75% of cases (Owens et al, 1991;
Battaglia et al, 1989) and is implicated in the progression and growth of the disease
(Simpson et al, 1999). TGFa is often co-expressed with erbBl, is expressed in
multiple breast cancer cell lines (Vyhlidal et al, 2000) and stimulates growth of
ovarian cancer cells in culture (Crew et al, 1992; Morishige et al, 1991) supporting
this theory. TGFa operating through overexpressed erbBl and the ligand-
independent pathway may account for the null effect of tamoxifen and the
development of endocrine therapy resistance as TGFa operates via AF-1 as opposed
to AF-2 which tamoxifen targets. TGFa has been shown to be induced by oestrogen
treatment in ER-positive cell lines (Gong et al, 1992; Clarke et al, 1989).
The c-erbB2 oncogene is overexpressed in 20-30% of many cancer types including
breast and ovarian cancer (Gottesman et al, 2002; Yu and Hung, 2000; Hengstler et
al, 1999; Revillion et al, 1998; Hynes and Stern, 1994) and is associated with
malignant transformation, poor overall survival and oncogenesis (Yu and Hung,
2000; Hudziak et al, 1987). Pietras et al (1995) found that the erbB2 pathway
targeted the ERa and promoted hormone-independent growth in human breast cancer
cells. Overexpression of erbB3 or erbB4 is less frequent in breast cancer and does
not appear to affect prognosis (Travis et al, 1996). However, more recent studies by
Tovey et al (2004) and Witton et al (2003) have reported that overexpression of
erbB4 may predict, surprisingly, for increased survival and lower proliferation indices
in breast cancer.
Over expression of several elements downstream of the erbB family also leads to the
development of cancer, for example, Ras, Raf, extracellular signal-regulated kinases I
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and II (ERKI/II), mitogen-activated protein kinase (MAPK) and protein kinase C
(PKC). PI3-K and Akt amplification is also seen in breast and ovarian cancer
(Murray et al, 2005; Kirkegaard et al, 2005; deGraffenried et al, 2004; Nakatani et al,
1999; Shayesteh et al, 1999; Bellacosa et al, 1995). Suppression of ERa activation
via ligand stimulation using protein kinase inhibitors has been used to show that ER
bioactivity through the oestrogen-independent pathway involves protein kinases (Cho
and Katzenellenbogen, 1993; Aronica and Katzenellenbogen, 1993). It is believed
that the final proteins of the MEK/ERK and PI3-K/Akt signalling pathways
phosphorylate various residues located on AF-1 of ERa. There is substantial
evidence that ERa is activated via phosphorylation of only one or more of serine
residues located on AF-1. Specifically, serine residues 104/6, 118 and 167 have been
indicated as three potential sites. The exception to serine residue phosphorylation is
the low level of phosphorylation found at tyrosine position 537 on the ERa.
32
["'P] phosphopeptide tryptic map comparison suggested serine residues 104 & 6
(SI04/6) as major sites of phosphorylation in MCF-7 mammary carcinoma cells
which was confirmed using point mutation (Le Goff et al, 1994). Serine 118 (SI 18)
was identified as a probable site of phosphorylation within AF-1 of ERa through
point mutation (Le Goff et al, 1994; Ali et al, 1993). Kato et al (1995) found that
SI 18 was phosphorylated by MAPK in vitro and in vivo in a ligand independent
manner, while Joel et al (1995) also used point mutation to definitively identify SI 18
as a major site of phosphorylation in cells treated with oestrogen or phorbol ester. In
a later paper Joel et al (1998) stated that SI 18 phosphorylation of the human ERa
(hERa) enhanced ER-mediated transcription and this was induced by oestrogen
stimulation and activation of the MAPK (oestrogen-independent) pathway.
The latest research has shown that bidirectional cross talk between ERa and the erbB
receptor family signalling pathways regulates tamoxifen-resistant growth where
amphiregulin (AR) increased SI 18 phosphorylation (Britton et al, 2005). Britton et
al (2005) indicated that the function of ERa in tamoxifen-resistant cells was
maintained as a result of erbBR/MAPK-mediated SI 18 phosphorylation, and that this
subsequently generated a self-propogating autocrine growth-regulatory loop through
the ERa-mediated production of AR.
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Campbell et al (2001) and Martin et al (2000) both support the theory that ERa
phosphorylation by Akt occurs at serine 167 (SI67), resulting in oestrogen-
independent activation of ERa. However, serine residue phosphorylation is cell
specific, with no SI67 involvement in COS-1 cells, although phosphorylation of
SI04/6, SI 18 and SI67 of hERa does occur in MCF-7 cells, which were used in this
investigation. Nicholson et al (2004) and Shou et al, (2004) showed that increased
nuclear ERa phosphorylation at SI 18 and 167 occurred as a result of increase
erbBlR/erbB2R/lGF-lR-regulated MAPK and Akt activity in cells with acquired
tamoxifen resistance. This promoted proliferation via stimulation of the
transcriptional activity of the tamoxifen-ERa complex. Nicholson et al (2004)
hypothesised that these kinases, among others, may be able to promote
phosphorylation of the nuclear ERa, with subsequent ligand independent
transcriptional activity, enabling ERa to act as a transcription factor in an oestrogen-
depleted environment. Martin et al (2003) also implicated this genomic ERa
mechanism in the development of oestrogen hypersensitivity.
The phosphorylation of serine residues on ERa is significant as it is a mechanism by
which the activation of the ERa and ultimately cell growth and proliferation occurs.
The ligand dependent mechanism provides a new aspect by which to study the
activation of ER-positive endocrine therapy resistant cancer cell lines versus
oestrogen-sensitive cancer cell lines. From this it may be possible to determine
which pathways are involved in the progression from anti-oestrogen-responsive
cancer to endocrine therapy resistant cancer.
1. 5. 4. 2. 1. 1. PI3-K/Akt pathway
The Akt signalling pathway is activated in cells subject to diverse stimuli such as
growth factors, hormones and extracellular matrix components (Tsai et al, 2001; Gu
et al, 2002). Activation ofAkt has been reported by Sun et al (2001) to be present in
-40% of breast carcinomas and Jordan et al (2004) has suggested that the PI3-K
pathway plays a role in the proliferation of their particular tamoxifen resistant cell
lines. Akt activation has also been shown to predict the outcome of breast cancer
patients treated with tamoxifen (Kirkegaard et al, 2005).
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It has been inferred that increased expression of IGFR-I and increased levels of Akt
and PI3-K, as well as IRS-1, may confer resistance to anti-oestrogens (Wiseman et al,
1993; Ahmad et al, 1999; Salerno et al, 1999; Campbell et al, 2001; Vivanco et al,
2002). Further to these studies, Frogne et al (2005) also found that elevated P-Akt
levels were present in both tamoxifen and ICI 182, 780 resistant cell lines compared
to the parental MCF-7 cell line from which they were derived. The cell lines with
elevated levels of P-Akt were more sensitive than the parental cell line to wortmannin
and SH-6, inhibitors of PI3-K and Akt respectively, therefore suggesting that Akt
signalling was required for cell proliferation in anti-oestrogen resistant cell lines.
Expression and activity of PTEN, a tumour suppressor protein, remained unaffected
in the resistant cell lines with elevated P-Akt. PTEN dephosphorylates
phosphatidylinositol 3, 4, 5-triphosphate (PIP-3), which in turn acts as a second
messenger involved in Akt activation (Li et al, 1998). These data implicate Akt and
signalling via Akt as a potential site and pathway for targeted therapy in resistant
breast cancer.
A downstream component of the PI3-K/Akt pathway, mammalian target of
rapamycin (mTOR), has been associated with tamoxifen resistance in breast cancer.
mTOR is a serine-threonine kinse responsible for the function of transcriptional
regulators p70s6 kinase and 4E-BP1 (reviewed by Hildaldo and Rowinsky, 2000) and
is activated by Akt. Signalling via mTOR is therefore partly responsible for the
regulation of cell cycle control, apoptosis and enhancement of growth factor
production among other processes (reviewed by Nicholson et al, 2002). These
functions are key to the oncogenic transformation of mammalian cells (deGraffenried
et al, 2004). The PI3K/AKT/mTOR pathway has been correlated with the relapse
and death of ERa-positive breast cancer patients post tamoxifen treatment. This
concurs with in vitro evidence where Akt was demonstrated to mediate tamoxifen
resistance (Kirkegaard et al, 2005; deGraffenried et al, 2004).
mTOR is actively being investigated as a potential therapeutic target with various
inhibitors in clinical trials. Everolimus (RAD-001) is in a Phase III randomised
clinical trial in the presence and absence of endocrine therapy for the treatment of
metastatic breast cancer. Temsirolimus (CCI-779) is also in a Phase II trial in the
presence and absence of endocrine therapy and is also in a Phase II clinical trial for
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the treatment of metastatic breast cancer as a single agent. The progress of
combining mTOR antagonists with endocrine therapy in the treatment of breast
cancer is reviewed by Johnston (2006).
Akt activation has also been associated with NFkB translocation and transactivation
(Meng et al, 2002; Sizemore et al, 1999), inhibition of substrates linked positively
with apoptosis and endothelial nitric oxide synthase activation. Bad and caspase 9
are substrates related to apoptosis which are inhibited by Akt (Ivanov et al, 2002).
1. 5. 4. 2. 1. 2. MEK/ERK pathway
Previous studies have suggested that P-ERKI/II is elevated in long term oestrogen
deprived (LTED), tamoxifen-resistant and gefitinib-resistant MCF-7 cells under
control conditions (Martin et al, 2005; Santen et al, 2005; Yue et al, 2002; Britton et
al, 2005; Knowlden et al, 2003; Normanno et al, 2006). The elevated levels of P-
ERK, and potentially PI3-K, were hypothesised to be due to residual oestrogens
binding to ERs in the cytoplasm which then interacted and phosphorylated SHC via
Src. This rapid 'non-genomic' mechanism of'cross-talk' was put forward by Santen
et al (2004) and was linked with cells adapting to long term oestrogen deprivation.
This was associated with the conversion of their cell model to an oestrogen
hypersensitive model. Santen et al (2004) and Song et al (2004) proposed that in
breast cancer the activated insulin-like growth factor (IGFR-I) (discussed in section 1.
6) recruited the SHC/ER complex to the plasma membrane, upstream of MEK
activation. The results suggested this form of kinase signalling eventually converged
on cell cycle components which promoted proliferation (Staka et al, 2005). Santen et
al (2004) suggested this was independent of a direct ER transcriptional effect as even
though oestrogen growth hypersensitive, this hypersensitivity was not mirrored at the
ERE-regulated transcriptional level. Thus, an alternative genomic model was
implicated for kinase/ER 'cross-talk' taking place at the nuclear ER level which must
directly affect the transcriptional activity.
Cell proliferation after LTED was suggested to arise as a result of growth factor
signalling, and various LTED models implicated not only erbB2, but also IGFR-1 and
downstream activation of ERK and P13-K/Akt, which were implicated to interact
with ER (Stephen et al, 2001; Martin et al, 2003; Santen et al, 2004).
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1. 6. Vascular endothelial growth factor receptor (VEGFR)
The vascular endothelial growth factor (VEGF) (Brunner et al, 1993) gene is a major
angiogenic factor which is stimulated by oestrogen and is involved in the progression
of breast cancer (Hyder et al, 1999; Losordo et al, 2001). Breast cancer cells produce
VEGF, which stimulates angiogenesis via a paracrine mechanism in the endothelial
cells of tumours (Ferrara, 1999). VEGF also promotes cell growth via an autocrine
pathway in tumour cells (Miralem et al, 2001; Bachelder et al, 2001). VEGF12] and
VEGF165 are the predominant of the six alternatively spliced human isoforms of
VEGF that exist (Ferrara, 1999). VEGF operates via VEGF receptors (VEGFRs), of
which three are known; VEGFR-1, VEGF-2 and the VEGF156 receptor, NRP-1 (Guo
et al, 2003). VEGFRs are located in breast cancer cells and research has shown that
oestrogen and VEGF regulate a related group of genes in inducing breast cancer
progression (Losordo et al, 2001). Guo et al (2003) showed that the overexpression
of VEGF isoforms VEGF]2i and VEGF165 in oestrogen-dependent MCF-7 cells
stimulated breast tumour formation and that this occurred in an oestrogen-
independent manner (no oestrogen treatment). VEGF also enhanced oestrogen-
dependent breast cancer tumour formation in mice. The data provided by Guo et al
(2003) suggest that VEGF up-regulation in oestrogen-dependent breast cancers
contributes to the development of an oestrogen-independent phenotype by stimulating
tumour progression and angiogenesis via both paracrine and autocrine mechanisms.
Interestingly, VEGF is increased in tumours and cancers with erbB2 overexpression,
while VEGF overexpression itself is significantly correlated with higher levels ofAkt
and mTOR phosphorylation (Klos et al, 2006). Therefore, it appears that there are
multi-faceted associations between many of the signalling proteins involved in breast
cancer development and progression.
1. 7. Insulin-like Growth Factor receptor (IGFR) signalling
The type l IGF surface receptor (IGFR-I) was reported by Stewart et al (1990) to be
an oestrogen-inducible protein, with several groups reporting the importance of the
IGFR-I and ligands of the IGFR-I, insulin-like growth factor I and II (IGF-I/II), in the
growth and survival of breast cancer cells (Arteaga and Osborne, 1989; Baserga et al,
1997; Jerome et al, 2003). It has long been established that IGF-l acts as a mitogen in
human breast cancer cells including the MCF-7 cell line (Ullrich et al, 1986; Huff et
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al, 1986). 1GF-1 binds to, activates and signals via the IGFR-I, which comprises of
two extracellular a-subunits and p-subunits (Ullrich et al, 1986). IGFR-I acts as a
tyrosine kinase upon IGF-I binding. IGFR-I activation leads to extensive
phosphorylation of the 185kDa insulin receptor substrate 1 (IRS-1), an important
substrate of the IGFR-I. The phosphorylated residues of IRS-1 bind to numerous
SH2 domain-containing proteins, thus IRS-1 acts as a 'multisite docking protein'
(Dufournay et al, 1997). Proteins which bind to IRS-1 include PI3-K, via its p85
regulatory subunit, and the guanine-nucleotide exchange factor Grb2/SOS (Backer et
al, 1993; Skolnik et al, 1993). Potential downstream targets of PI3-K include the Rho
family polypeptides Rac and Cdc42 (Chou and Blenis, 1996) and Akt (Burgering and
Coffer, 1995). The former results in activation of the p21ias and raf oncogenes and
MEK1, which activates ERK. The latter kinases are primarily activated in response
to proliferative stimuli (Marshall, 1995). Other kinases such as c-Jun N-terminal
kinases (JNKs) and the p38 kinases respond to cell stresses (Kyriakis and Avruch,
1996). IGF-I (Monno et al, 2000) and growth factors such EGF have been shown to
activate the JNKs (Logan et al, 1997).
The IGF-I growth stimulatory action occurs via the P13-kinase/Akt pathway in cells
adherent to the culture substratum (Dufournay et al, 1997). Dufournay et al (1997)
suggested that PI3-K activity, but not that of MAPK is required for IGF-1 signal
transduction in the MCF-7 cell line, implying the MAPK signal transduction cascade
does not play a role in IGF-I-enhanced growth induction. A further study by Suzuki
and Takahashi (2000) reported that the IGF-I signal, which led to the stimulation of
MCF-7 cell DNA synthesis, occurred via ERK through PI3-K only when the cells
were anchorage-deficient. Upstream signalling kinases Raf-1, MEK and ERK were
also activated by IGF-I in floating MCF-7 cells.
There is also considerable evidence of cross-talk between erbBl and IGFR-I in breast
cancer cells, with Knowlden et al (2005) suggesting a unidirectional IGFR-1/erbBl
cross-talk mechanism where the IGF-I I ligand, operating via 1GFR-I, controls ligand-
activated and basal erbBl signalling in conjunction with cell proliferation. This is
believed to occur in a Src-dependent manner in cells which are tamoxifen resistant.
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1. 8. Origin of cell lines
Breast and ovarian cancer cell models are being used in this investigation to study
growth effects and serine phosphorylation of the ERa. The human breast cancer cell
line MCF-7 was utilised in this study for this purpose in order to study breast cancer
and was originally isolated from a malignant pleural effusion in a postmenopausal
breast cancer patient (Soule et al, 1973). MCF-7 cells are widely used in studies as
they are sensitive to the effects of oestrogen and thus susceptible to tamoxifen
therapy. Several sublines of MCF-7 cells have been systematically isolated,
including the Mill cell line, which was developed by prolonged withdrawal from
potent oestrogenic stimuli in vivo in the nude mouse (Clarke et al, 1989). A
schematic representation of the derivation of MCF-7 variant cell lines can be seen in
Figure 1.15. The stepwise development of resistance in the MCF-7 derived cells is a
clinically relevant model as it reflects what occurs in patients treated with tamoxifen
followed by an Al, who may receive Faslodex on relapse. The current benefits and
limitations of endocrine therapy are discussed by Nicholson and Johnston (2005).
For example, some patients receive tamoxifen followed by an Al, and then may
receive Faslodex on relapse (Nicholson and Johnston, 2005). Alternatively, patients
may be treated with tamoxifen followed by an Al on relapse. Again, these cells are
good models of stepwise induction of resistance which are a result of current
treatment regimes.
Mill cells were originally isolated from tumours growing in ovariectomised mice and
are E2-independent. Their growth is inhibited by all major antioestrogen therapies in
vitro (Brunner et al, 1993a). MCF7/FCC1 (FCC1) cells were obtained after a further
in vivo selection of Mill cells, and display a shorter lag period from inoculation of
tumour cells to the appearance of proliferating tumours (Yano et al, 1992). FCC1
cells are similar to Mill cells as they have acquired a hormone-independent
phenotype and do not require E2 for growth (Thompson et al, 1993). However, both
cell lines respond mitogenically to E2-supplementation in vivo, and have been found
to retain sensitivity to anti-oestrogens and FH-RH antagonists (Clarke et al, 1989;
Yano et al, 1992; Brunner et al, 1993a).
The MCF7/LCC2 (LCC2) cell line was derived from the LCC1 cell line. The cell
line is a 4-hydroxytamoxifen resistant human breast cancer variant, which retains
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sensitivity to the steroidal antioestrogen ICI 182, 780 (Brunner et al, 19936), a
characteristic often observed in patients with acquired tamoxifen resistance. LCC2
cells are E2-independent when growing in vitro or in vivo (Brunner et al, 1993b).
Brunner et al (1993a, b) demonstrated that by continuous sequential selection of
MCF-7 cells in a stepwise manner a model could be produced to study endocrine
resistance. A stable ICI 182, 780-resistant variant, MCF7/LCC9 (LCC9) was
obtained using stepwise selections in vitro from lOpM to lpM ICI 182, 780 against
LCC1 cells (Brunner et al, 1997). The cells are also resistant to the nonsteroidal
antioestrogen tamoxifen. Table 1. 2. shows a summary of characteristics of the cell
lines used.
The human ovarian carcinoma cell line PEOl was established and characterised by
Langdon et al (1988) as E2-insensitive. The SKOV-3 human ovarian carcinoma cell
line is not responsive to E2 and is not inhibited by antioestrogens OFI-tamoxifen and
ICI 164, 384 (Hua et al, 1995). They express ER at a level equivalent to the apparent
Kd for E2 binding. However, their E2 resistance is believed to arise through a loss of
E2 regulation of selected growth regulatory gene products as opposed to defective
transcriptional activation of ER by E2. PEOl cells were used as a model of E2 and
anti-oestrogen sensitive ovarian carcinoma and SKOV-3 cells were used as an in vitro
model for E2 and anti-oestrogen resistant ovarian cancer.
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Figure 1.15 Schematic representation of the derivation of MCF-7 variant breast cancer cell
lines and their relationship to the MCF-7 parental line (reproduced from Brunner et al, 1997).
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Table 1. 2. E2-sensitivity and ERg expression levels of ovarian and breast cancer cell lines.
Cell line Phenotype ERa Expression (sites/cell) Reference
SKOV-3 E2-sensitive Less than MCF-7 Imai et al, 2005
PE01 E2-sensitive More than or = MCF-7 Langdon et al, 1988,90
MCF-7 E2-dependent
Tam-, ICI 182, 780
&ICI 164, 384-
sensitive
120,540 ±20,000 Soule et al, 1973
Mill E2-independent &
responsive
ICI 182, 780 & ICI
164, 384-sensitive


















54, 076 ± 15, 066 Bronzed et al, 1985
Clarke et al, 1989
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1. 9. Aims & Objectives
ERa activation via serine residue phosphorylation provides a new aspect by which to
study the activation ofER-positive endocrine therapy resistant cancer cell lines versus
E2-sensitive cancer cell lines. The signalling pathways involved in the development
of endocrine therapy resistance were investigated by comparing the E2-sensitive cell
line MCF-7 to lines with varying degrees of E2-sensitivity (Mill, LCC1, LCC2,
LCC9 & LY2). LY2 cells are resistant to tamoxifen and other antioestrogens. The
LCCl and LCC2 cell lines retain tamoxifen sensitivity and are fully sensitive to ICI
182 780 and yet their growth is hormone-independent, while remaining E2-
responsive. These cell lines represent an intermediate situation between hormone-
sensitive and hormone-independent but hormone-responsive cells with increased
metastatic potential. The cell lines provide a useful model to determine the molecular
events associated with malignant progression to a hormone-independent and
metastatic phenotype (Thompson et al, 1993) and changes associated with endocrine
therapy resistance. The objectives were achieved by using two model systems, a
breast cancer oestrogen-resistant model with MCF-7 variant lines and an ER-positive
ovarian cancer model comparing an E2-sensitive cell line, PEOl, with SKOV-3, an
E2-insensitive cell line.
The initial aim of this study was to confirm the growth responses elicited by E2 and
anti-E2s in the breast cancer cell lines and also to characterise the effect of growth
factors in the resistant cell lines, and to compare this characterisation with the
characterisation of growth responses in MCF-7 variant cell lines. This
characterisation also took place in the ovarian cell lines using E2 and TGFa.
A secondary objective was to characterise ERa levels and activation through ERa
phosphorylation of serine residues 118 and 167 (P-S118/167) using western blotting
after oestrogen, antioestrogen and growth factor treatment of all breast cell lines. The
novel aspect of the study was the characterisation of the same phosphorylation sites in
the resistant cells and to compare these data with MCF-7 cell characteristics and
observe any modifications which may have occurred between them. Studies into
P-Sl 18 and P-S 167 expression were also performed in the ovarian cell lines.
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The signalling pathways involved in the development of breast cancer resistance
development were then investigated. This was achieved by using western blotting to
investigate the total and activated levels of various signalling proteins in the
PI3-K/Akt and MEK/ERK pathways. The effect of a panel of tyrosine kinase
inhibitors on these pathways (via protein expression levels) and the cellular
proliferation of the breast cancer cell lines in this model were then studied. The
inhibitors were used to investigate the role of each signalling molecule.
A further aim of the study was to confirm the effect of E2 and characterise the effect
of TGFa on mRNA expression levels in a series of oestrogen-responsive genes (ER,
progesterone receptor (PR), pS2, cathepsin D (CTD)) in the breast cancer model. The
effect of tyrosine kinase inhibitors on these expression levels was also documented.
The inhibitors were used to investigate the affect, if any, the blockade of these
proteins has on mRNA expression.
The cell cycle distribution and apoptosis of the breast cancer cells was
characterised after E2, growth factor and anti-E2 treatment. The effect of novel anti-
erbB2 agent 2C4 on the proliferation, cell cycle distribution and apoptosis in the
breast cancer cell lines was also characterised to investigate the role of erbB2 in this
model.
It is hypothesised that a combination of several factors are involved in the
development ofE2 and anti-E2 insensitivity ranging from elevated levels ofsignalling
molecules such as Akt and ERK, mRNA expression to increased number of cells
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2. 1. Materials
Chemicals and reagents were obtained from Sigma unless otherwise stated. Materials
used are listed according to technique and antibody information is detailed in the
Western blot section.
2. 1. 1. Cell culture
2. 1. 1. 1. Cell lines
MCF-7 cells were provided by Professor W. Miller (Edinburgh Breast Unit) and were
routinely maintained in Dulbecco's minimal essential medium (DMEM) containing
phenol red (PR) supplemented with 10% foetal calf serum (FCS), O.lmg/ml
penicillin/streptomycin (P/S). MCF-7 variant cell lines LCC1, LCC2, LCC9 and
LY2 were kindly provided by Professor Robert Clarke (Cancer Centre, Georgetown
University, Washington). The human ovarian carcinoma cell line PEOl was
provided by Dr. Simon Langdon and was derived from the ascites of a patient with a
poorly differentiated serous adenocarcinoma at the Edinburgh Oncology Unit. The
SK.OV-3 ovarian cell line was obtained from the European Collection of Animal Cell
Cultures, Porton Down, UK.
2. 1. 1. 2. Tissue culture reagents
Product Manufacturer/Supplier
Cryovials - Nuncleon, Invitrogen
Dulbecco's minimal essential medium + phenol red - Invitrogen
Foetal calf serum - Harlan Sera Lab
Penicillin/streptomycin - Invitrogen
Phosphate buffered solution - Invitrogen
RPMI 1640 growth media + phenol red - Invitrogen
Trypsin/ EDTA - Invitrogen
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Inhibitors were reconstituted in DMSO according to manufacturers' instructions to
• • . 2initial stock solutions of 1CCM, from which dilutions were made. Inhibitors were
aliquoted out in small volumes and stored at -20°C, with the exception of U0126
which was reconstituted just prior to use to avoid degradation and tamoxifen which
was stored at 4°C. Light sensitive inhibitors were stored in the dark.
2. 1. 2. Protein protocols
Product
Chemiluminescence Western Blotting Kit
Gel apparatus







2. 1. 3. Molecular protocols
All molecular biology kits - Qiagen
Protein sequences were originally obtained from the SwissProt website
(ww w.ebi.ac.uk/swissprot/j. These sequences were then used to design primer pairs
using the Primer3 database (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer 3www.cgi). The primer design allowed for differentiation
between the amplified product of cDNA and any amplified product derived from
contaminating genomic DNA. Primer pairs were manufactured by Sigma.
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CTD: fwd CCCGAGGTGCTCAAGAACTA/ rev TCACGTAGGTGCTGGACTTG
ER: fwdCCACCAACCAGTGCACCATT/rev GTCTTTCCGTATCCCACCTTTC
PR: fwd GTCAGTGGGCAGATGCTGTA/ rev AGCCCTTCCAAAGGA ATTGT
pS2: fwd TTGTGGTTTTCCTGGTGTCA/ rev CCGAGCTCTGGGACTAATCA
2. 2. Methods
2. 2. 1. Cell culture
2. 2. 1. 1. Routine cell line culture
All MCF-7 variant cells were routinely cultured as monolayers in phenol red (PR)-
free DMEM supplemented with 5% double charcoal stripped serum (DCSS),
O.lmg/ml penicillin/streptomycin and 2mM L-glutamine. Both ovarian cell lines
were routinely cultured in RPMI 1640 media containing PR supplemented with 10%
FCS, O.lmg/ml P/S and 2mM L-glutamine. All cell lines were grown at 37°C in a
humidified atmosphere of 5% CO2/ 95% O2.
2. 2. 1. 2. Harvesting of cells
All cells were harvested at 70% confluence, with the exception of cells for RT-PCR,
where -50-60% confluence was required for initial seeding. In order to harvest cells
for continued growth or for seeding for experiments, all cell lines were washed twice
in PBS and trypsinised using trypsin/EDTA (IX) at 37°C for 5 min. The
trypsin/EDTA was neutralised upon the addition of normal growth medium and the
cell suspension was then centrifuged at 2,000 rpm for 5 min. Trypsin/EDTA
containing media was discarded and the cell pellet resuspended in medium for growth
or seeding at the appropriate cell density.
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2. 2. 1. 3. Cell recovery from liquid nitrogen and
cryopreserva tion
Cells were removed from liquid nitrogen storage and defrosted rapidly by the
addition of warm medium. Cells were resuspended in a 10ml volume before
centrifugation at 2,000 rpm for 5 min, whereupon the supernatant was replaced with
fresh medium and cells seeded into 25cm2 flasks. Cells were cryopreserved by
harvesting and centrifuging as before, with the exception that cell pellets were
resuspended in l-2ml freezing media (10% DMSO in FC-S) and transferred to
cryopreservation vials for initial freezing at -70°C. Vials were transferred to liquid
nitrogen storage tanks after 24h.
2. 2. 1. 4. Cell counting
Different experimental conditions required different concentrations of cells, thus cells
were harvested as previously described, resuspended in 10ml of growth medium and
cell number determined using a haemocytometer. The appropriate cell concentration
was then achieved through dilution with media. Cells were grown in 24-well trays.
Cells to be counted were washed twice with warm PBS and 300pl of trypsin/EDTA
was added per well. The plates were then incubated at 37°C for 15-20 min, or until
cells became detached from the wells. Once detached from the well surface, 200pl of
10% FCS DMEM was added to each well to stop any further trypsinisation. The
plates were then kept on ice until cells were counted. The contents of each well were
mixed using a 1ml BD Plastipak syringe with a gauge 3 BD Microlance needle.
200pl from each well was added to 1,8ml of 0.9% NaCl in a coulter pot. A Beckman
Z2 Coulter particle counter and size analyser was used to count the number of cells
present.
2. 2. 1. 5. Dextran-charcoal stripping of FCS
To study the functionality of the cell lines, it was necessary to grow the cells in
medium containing charcoal-stripped FCS in order to remove endogenous stimuli that
may have altered signalling. These endogenous steroids were stripped from FCS
using dextran-coated charcoal and type IV sulphatase (EC 3.1.6.1). After thawing for
lh at room temperature, 1L of serum was heat inactivated at 56°C for 30 min, at
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which point 2000U sulphatase was added and incubated for a further 2h at 37°C. The
serum was pH adjusted to 4.2 using 2M HC1. A charcoal mix prepared prior to this
stage was added and agitated overnight at 4°C. The charcoal mix consisted of 5g
charcoal and 25mg dextran T70 in 50ml dFLO, which was stirred overnight. The
charcoal was removed from the serum via centrifugation at 10,000 rpm (30 min,
4°C), the pH was readjusted to 4.2 and then a second charcoal mix was added for
further 24h agitation at 4°C. The serum was again centrifuged and a further spin
required to remove any residual charcoal traces. 2M NaOH was used to return the
serum to pH 7.2. The serum was then filter sterilised before aliquoting and storage at
-20°C.
2. 2. 2 Functional assays
2. 2. 2. 1. Morphological study
Log-phase cells were seeded into 6-well tissue culture plates (optimised between
2-5 x 104 cells/ml). MCF-7 cells were seeded in 10% FCS DMEM (designated day -
2). After 24h cells were washed twice in PBS and media was replaced with 5%
DCSS DMEM for 24h prior to treatment (day -1). As variant cell lines were
routinely cultured in charcoal-stripped DMEM, these cell lines only required seeding
24h prior to treatment (day -1). On day 0, cells were treated with E2 (InM), TGFa
(InM), Tarn (lpM) or E2+Tam (InM & lpM respectively) for 48h before images of
each cell line were taken using a Kodak MDS120 camera. These images were
focused and processed using PhotoshoprM software.
2. 2. 2. 2. Growth assay
Log-phase cells were seeded into 24-well tissue culture plates (optimised between
2-5 x 104 cells/ml as before). Cells were seeded as previously described for the
morphological study. Plates were treated for 0, 3, 5 and 7 days for each cell line.
The day 0 plate only required cells seeding in the 2 outside columns to act as controls
(no treatment). Plates for all other days were seeded in all 24 wells. A different
treatment was added to each of the 4 middle columns to provide 4 wells and thus 4
cell counts for each treatment. After 48h charcoal stripping for MCF-7 and 24h post-
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seeding for variant cells, day 0 plates were counted and plates for days 3, 5, and 7
were subjected to E2 (InM), TGFa (InM), Tam (lpM) or E2+Tam (InM & lpM).
Ovarian lines were treated with E2 and TGFa and a combination of the two ligands
only. Cells were then counted and re-treated on days 3, 5 and 7.
2. 2. 2. 3. Inhibitor studies using the sulphorhodamine B
assay
Log-phase cells were seeded into 96-well tissue culture plates (optimised between
2-5 x 104 cells/ml) and treated with E2, TGFa, HRGpi (all InM), Tam (lpM) or a
combination of inhibitor and ligand for 72h. Control wells contained 0.05% DMSO
as all inhibitors were reconstituted in DMSO. Specific inhibitor concentrations were
determined through literature review and initial growth assays and were applied to
western blotting for protein analysis (see Table 2.1 for inhibitor information). The
treatment was halted by the addition of 50pl/well 25% trichloroacetic acid for lh at
4°C. Plates were then washed 5 times in tap water and left to dry. Once dry,
50pFwell 0.4% SRB solution in 1% acetic acid was added and left for 30 min at room
temperature prior to washing the plates 5 times in 1% acetic acid. Plates were again
allowed to dry and then 150pl/well of lOmM Tris-Base (pH 10.5) was added for lh at
room temperature. The optical densities of each plate were ascertained at 540nm
using a Biohit BP800 plate reader. Data were plotted as a percentage of control
growth.
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Table 2. 1 Inhibitor information















U0126 MEK 1, 4-diamino-2, 3-dicyano-1, 4-bis (2-
aminophenylthio) butadiene
0-60pM
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2. 2. 2. 3. 1. SRB method development to determine correct
seeding density
To determine the optimal seeding density for each cell line, cells were set up over a
range of densities. Cells were trypsinised and counted on day l. MCF-7 and resistant
cell lines were seeded 72h and 24h prior to experimentation and MCF-7 cells exposed
to charcoal-stripped FCS medium as previously described. SI and S2 cell
suspensions were prepared, SI containing 250,000 cells/ml and S2 containing 25,000
cells/ml. Cell suspensions were counted after dilution to control the accuracy of
dilution and altered with medium to reach the exact cell count. The difference from
the theoretical number should be <20%. The different cell dilutions were prepared
according to table 2. 2, with I50(il/well of each dilution from columns 2 to 11 in 7
96-well plates. The dilutions according to table 2. 3 were then prepared and
150(lFwell of each plated from columns 2 to 11 in l plate. The calibration plate was
precipitated the following day. After precipitation of the plates on days 1-7 the entire
set of plates were stained according to the SRB protocol.
2. 2. 2. 3. 1. 1. Growth curves
The calibration plate was used to plot a graph with OD according to cell density. This
is expected to be linear. The equation parameters were then calculated. The growth
curves for each cell density were then plotted from the other plates (figures 2.1-3A).
The calibration equation was used to calculate the number of cells/well on the day 2
plate. The latency, the time for the OD to increase by more than 20%, and the
doubling times were also calculated (taken from data in figures 2.1-3C and D).
Exponential growth implies that Y= No.e k*, so the doubling time X\a — ln2/ k. This
converted the optical densities (OD) to cell numbers, where upon a graph with cell
number according to time using a logarithmic scale on the Y-axis was plotted (figure
2.1-3C). The optimal cell density for cytotoxicity studies was determined, which is
the cell density that gives an OD>l .5 when cells are allowed to grow least 3 doubling
times (figure 2.1-3D). It was observed that LCC9 and LY2 cell lines grew more
slowly at lower densities than the other resistant cell lines, and proliferation only
mirrored that of the other cell lines once cells reached 3-4 x Kfcells/ml. This may
account for the non-linear aspect of the relationships between OD and cell number in
these cell lines. LCC9 and LY2 cell lines were therefore seeded at 3-4 x l(fcells/ml.
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Tables 2. 2 & 2. 3 Seeding for plates for SRB assay: stop one plate/day & calibration plate
(lower table).
Cells/









500 2500 0.02 0.18 56 1.12 10.08 11.2
1000 5000 0.04 0.16 56 2.24 8.96 11.2
1500 7500 0.06 0.14 56 3.36 7.84 11.2
2000 10000 0.08 0.12 56 4.48 6.72 11.2
2500 12500 0.1 0.1 56 5.6 5.6 11.2
3000 15000 0.12 0.08 56 6.72 4.48 11.2
3500 17500 0.14 0.06 56 7.84 3.36 11.2
4000 20000 0.16 0.04 56 8.96 2.24 11.2
4500 22500 0.18 0.02 56 10.08 1.12 11.2
5000 25000 0.2 0 56 11.2 0 11.2
S2 61.6 (prepare 70ml)
500 2500 0.02 0.18 8 0.16 1.44 1.6
1000 5000 0.04 0.16 8 0.32 1.28 1.6
2000 10000 0.08 0.12 8 0.64 0.96 1.6
3000 15000 0.12 0.08 8 0.96 0.64 1.6
5000 25000 0.02 0.2 0 8 1.6 0 1.6
10000 50000 0.04 0.16 8 0.32 1.28 1.6
20000 100000 0.08 0.12 8 0.64 0.96 1.6
30000 150000 0.12 0.08 8 0.96 0.64 1.6
40000 200000 0.16 0.04 8 1.28 0.32 1.6
50000 250000 0.2 0 8 1.6 0 1.6
51 11.328 (prepare 15 ml)
52 3.68
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Figure 2. 1 Determination of the optimum seeding density of MCF-7 and LCC1 cells for
the SRB assay in cytotoxicity and growth studies. Cells were seeded according to tables
2.2 and 2.3 and charcoal stripped 48h prior to the measurement of OD. ODs were obtained
on days 1-7 and this could be directly related to cell number (A). B, proliferation, represented
as OD values, according to seeding density over time (♦ =500, ■ =1000, ▲ =1500, x =2000,
x =2500, • =3000, + =3500, - =4000, - =4500, =5000 cells/ml). C, cell number according to
time and (D) doubling times of each cell density. The final graph allows for the estimation of
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Figure 2. 2 Determination of the optimum seeding density of LCC2 and LCC9 cells for
the SRB assay in cytotoxicity and growth studies. Cells were seeded according to tables
2.2 and 2.3 and charcoal stripped 48h prior to the measurement of OD. ODs were obtained
on days 1-7 and this could be directly related to cell number (A). B, proliferation, represented
as OD values, according to seeding density over time (♦ =500, ■ =1000, =1500, x =2000,
x =2500, • =3000, + =3500, - =4000, - =4500, =5000 cells/ml). C, cell number according to
time and (D) doubling times of each cell density. The final graph allows for the estimation of
the optimum seeding density for subsequent SRB studies.
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Figure 2. 3 Determination of the optimum seeding density of LY2 cells for the SRB
assay in cytotoxicity and growth studies. Cells were seeded according to tables 2.2 and
2.3 and charcoal stripped 48h prior to the measurement of OD. ODs were obtained on days
1-7 and this could be directly related to cell number (A). B, proliferation, represented as OD
values, according to seeding density over time (♦ =500, ■ =1000, =1500, x =2000, x
=2500, • =3000, + =3500, - =4000, - =4500, =5000 cells/ml). C, cell number according to
time and (D) doubling times of each cell density. The final graph allows for the estimation of
the optimum seeding density for subsequent SRB studies.
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2. 3. Protein detection
2. 3. 1. Protein extraction
All cell lines were trypsinised at 70% confluence and seeded into 10cm diameter petri
dishes (Nunclon) at a density of 8 x 104cells/ml, with the exception of LCC9 and LY2
cell lines, which were seeded at l x lO^cells/ml due to a slower growth rate. MCF-7
cells were grown for 24h in 10% FCS DMEM before being washed twice with PBS
and then grown in 5% DCSS DMEM for a further 48h. Variant cell lines were
seeded in 5% DCSS DMEM 24h before treatment. Cells were treated with E2 (InM),
TGFa (InM), Tarn (lpM) or E2+Tam (InM & lpM) for either 15 or 30 min or at
various time points spanning 0-24h. All agents used were diluted from stock to
working solution using 5% DCSS DMEM. After the desired treatment time had
elapsed the treatment solution was aspirated and cells washed twice with ice cold
PBS. 1ml of ice cold PBS was added to each plate and the cells scraped into
eppendorf tubes. Cell suspensions were centrifuged at 13,000 rpm at 4°C for 30s and
PBS removed using a pipette. The remaining cell pellets were lysed in TNN lysis
buffer for 30 min on ice. Following lysis, lOpl of the protein solution was used to
perform a Bradford assay to obtain the protein concentration. Bradford protein assay
dye reagent concentrate was obtained from Bio-Rad Laboratories GmbH (Munchen,
Germany). All samples were made up to either 0.5mg/ml or lmg/ml depending on
relative expression of ERa using lysis buffer. 5X loading buffer containing SDS and
mercaptoethanol was added to each sample to give a final dilution of IX SDS loading
buffer. Aliquots were then stored at -20°C until required.
2. 3. 2. Western blotting
Stacking gels were poured onto 10% polyacrylamide running gels set up in Bio-Rad
Mini Protean 3 cells. lOpg of each protein sample (including loading buffer) to be
investigated was denatured at 95 °C for 5 min, cooled on ice for 5min and then
centrifuged for a further 5 min at 13,000 rpm at 4°C. Samples were loaded in
individual wells of the stacking gel and run alongside a lkb prestained protein marker
broad range (premixed) (New England Biolabs inc.). Gels were run in IX running
buffer at 80V using a Power Pac 200 (Bio-Rad) for 15 min to allow all samples
loaded to reach a similar level at the top of the running gel. The voltage was then
increased to 200V for lh, or until the loading buffer was run off the running gel.
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Once run, gels were removed from the Mini Protean cells and placed in transfer tanks
sandwiched next to nitrocellulose membrane at 4°C and subjected to 200mA/tank for
1.5h. After the wet transfer, nitrocellulose membranes were incubated in ponceau
solution for 1 min to allow protein bands to become visible. Membranes were cut
into the sections desired for separate antibody incubations, and then washed in water
followed by IX TBS for 5 min to remove the ponceau staining. Membranes were
then incubated in 5% non-fat milk (Marvel) or 0.5% blocking solution (Roche) in
0.1% TBS-tween for lh at room temperature to prevent non-specific binding.
Following the lh incubation, membranes were subjected to 3 x 5 min washes in IX
TBS-tween (0.1%). The membranes were then incubated in the appropriate primary
antibody at 4°C overnight (optimum conditions for a phospho-antibody). The
membranes were washed 3 times for 5 min each in IX TBS-tween as before and then
incubated in secondary antibody for lh at room temperature. Post secondary
antibody incubation, membranes were washed three times for 5 min each in IX TBS-
tween and then twice in IX TBS for a further 10 min each wash to remove any
detergent which may affect chemiluminescent detection.
Phospho-serine proteins were visualised by incubating the nitrocellulose membranes
in a solution of equal parts of SuperSignal West Femto Maximum Sensitivity
Substrate solutions (Pierce) at a 1:2 with H2O. Stronger protein signals (ERKI/II etc)
were detected using SuperSignal west pico stable solution and luminol/enhancer
solution (Pierce) at a 1:2 with FI20. Membranes were then sandwiched between 2
pieces of transparency in a photographic cassette where upon a piece of film was
subjected to an initial exposure of 10s before being developed. Further film
exposures for various lengths of time were then carried out on the basis of the
strength of this initial signal.
2. 3. 3. Solutions
Running buffer (10X) consisted of 30g Trizma-Base, 144g glycine and lOg SDS
(lauryl sulfate) made up in dH20, with transfer buffer (1 OX) containing Trizma-Base
and glycine only. All solution components were supplied by Sigma as before. TBS
(10X) comprised of 24.2g Trizma-Base and 80g NaCl (BDH Laboratory Supplies)
and was reconstituted in dH20 and titrated to pH 7.6. 10% Running gel comprised of
30% acrylamide/ bisacrylamide stock solution (Severn Biotech Ltd.), 1.5M tris (pH
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8.8), 10% SDS, 25% ammonium persulfate and N, N, N', N'-
tetramethylethylenediamine. These were all supplied by Sigma.
Human recombinant TGFa (0.1mg) was also provided by Sigma, with the initial
stock solution being made up in 1ml PBS containing 0.5% BSA (1.67 x 10"5M). E2
and tamoxifen stock solutions (10 2M) were made up in ethanol (BDH Laboratory
Supplies). Lysis (TNN) buffer contained 150mM NaCl (BDH Laboratory Supplies),
0.5% NP-40 detergent (New England Biolabs inc.), a Mini complete protease
inhibitor cocktail tablet (Roche), ImM sodium fluoride, ImM sodium orthovanadate,
50mM tris pH7.5 and 5mM EGTA.
2. 3. 4. Antibodies
ERa was detected using the primary ERa mouse monoclonal antibody clone and
probed with secondary antibody goat anti-mouse IgG HRP conjugate. Phospho-
oestrogen receptor a Ser 104/6, 118 and 167 were detected using the relevant specific
primary antibodies made up in lxTBS-tween with 0.5% blocking solution. All
phospho-signals were probed for with the secondary goat anti-rabbit IgG HRP
conjugate also made up in IX TBS-tween with 0.5% blocking solution.
Protein loading was verified using actin ascites primary antibody and probed with the
secondary antibody anti-mouse IgM, H & L Ch. (Goat) peroxidase conjugate. A
summary of antibodies and antibody conditions is provided in tables 2.4 and 2.5.
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Table 2. 4 Primary antibodies used in western blotting technique
Primary antibody Dilution Source Type Supplier details
Actin (a, (3 & y) clone CP01 1: 50,000 Mouse igM Calbiochem
Akt 1: 1000 Rabbit igG NEB:# 9272
EGFR 1:1000 Rabbit igG NEB:# 2232
ERa F-10 1: 200 Mouse IgG (mAb) sc-8002
ErbB2 1:1000 Rabbit IgG NEB:# 2242
ERKI/II 1:1000 Rabbit igG NEB:# 9102
MEK 1:1000 Rabbit IgG NEB:# 9122
P-Akt (Ser473) 1:1000 Rabbit igG NEB:# 9271
P-p44/42 MAPK (Thr202/ Tyr204) 1:1000 Rabbit igG
(polyclonal)
NEB:# 9101
P-MEK (Ser 217/221) 1:1000 Rabbit IgG NEB:# 9121
P-ERa Ser 118 16J4 1:1000 Mouse IgG (mAb) NEB:# 2511
P-ERa Ser 167 1: 500 Rabbit igG NEB:# 2514
P-EGFR (Tyr845) 1:1000 Rabbit igG NEB:# 2231
P-ErbB2 (Tyr1248) 1:1000 Rabbit IgG NEB:# 2247
New England Biotechnology (NEB) distributed by Cell Signaling technology; s-c- Santa Cruz
Biotechnology Inc.
Table 2. 5 Secondary antibodies used in western blotting technique
Secondary antibody Dilution Supplier details
Anti-Mouse IgM, H & L Ch.
(Goat) peroxidase conjugate
1: 500 (6ul in 30ml) Calbiochem
Anti-rabbit IgG, HRP-linked 1:1000 NEB:# 7074
Goat anti-mouse IgG HRP
conjugate
1: 5000 Upstate, Cell Signaling
Solutions
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2. 3. 4. 1. Antibody Optimisation
During this investigation, it was necessary to optimise the conditions when using
certain antibodies as following manufacturer's instructions did not necessarily
produce western blots with clear bands and low background. Figure 2.4 illustrates the
various conditions western blots were performed with using the phospho-ERa serine
118 antibody as an example. MCF-7 cells were treated with Et for 30 min as a
positive control and harvested. Once transferred to nitrocellulose membrane, the
membrane was cut into strips and different incubation conditions applied to each
section. The optimum conditions found were a 1:1000 dilution of the antibody (as
per manufacturer's instructions) in 5% blocking solution (Roche) in IX TBS. 5% IX
TBS containing 5% non-fat milk (NFM) also produced bands of a similar standard.
Incubating the strips in IX TBS without NFM or bovine serum albumin (BSA) or IX
TBS containing 5% BSA produced blots with a high background, making bands
difficult to distinguish. Similar optimisation was performed for the phospho-ERa
serine 167 antibody and any other antibodies where high background or multiple
indistinguishable bands were observed.
P-S118 P-S118
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Figure 2. 4. Optimisation western blot of phospho-ERa serine 118 antibody (P-S118).
MCF-7 cells were subjected to control media or media containing E2 (1nM) for 30 min.
Nitrocellulose membrane strips were incubated separately with P-S118 (1:1000) in 1X TBS
without non-fat milk (NFM) or bovine serum albumin (BSA), 5% BSA or 5% blocking solution.
Optimum conditions were found to be incubations performed in blocking solution.
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2. 4. Flowcytometric analysis
For each culture condition, 5 x 105 cells were plated into 25mm' petri dishes. Cells
were seeded and charcoal stripped for 48h as previously described and then treated
for 72h with control media, E2 (InM), HRGp (InM), tamoxifen (lpM) and 2C4
(lOOnM) and various combinations of these treatments.
2. 4. 1. Cell cycle
After 72h the petri dishes were washed twice with 2ml PBS, 2ml of trypsin was then
added per dish, taking care not to allow the cells to lyse. The trypsin was neutralised
quickly with 2ml 10% FCS DMEM and the cells transferred to FACS tubes with
individual syringes per treatment. The samples were centrifuged at 1600rpm for 5
min. Once centrifuged, the rims of the tubes were then blotted dry the pellets
resuspended in 200ul vindelov citrate buffer at 4°C and vortexed gently. Samples
were then stored at -20°C until time for analysis. Solutions A, B and C were thawed
prior to use, with Solution C kept on ice after defrosting. Cell samples were thawed
at room temperature and then 450pl of trypsin Solution A added per tube, briefly
whirlimixed and incubated for 3 min. After 3 min 375pl of a trypsin inhibitor
Solution B was added to neutralise the initial solution for 10 min. 250pl of Solution
C containing propidium iodide was then added per tube and the tubes were then
incubated on ice in the dark for a further 10 min. Stained cells were then immediately
analyzed with a FACScalibur (Becton Dickinson) and data were obtained with the
CellQuest 1.2.2 and the ModFit LT 1.01 software (Becton Dickinson).
2. 4. 2. Apoptosis
Annexin V can be utilized to detect apoptotic cells. Annexin V belongs to a family of
calcium-dependent phospholipid-binding proteins which definitively belong to a
family of ubiquitous cytoplasmic proteins involved in signal transduction. Annexin
V binds preferentially with high affinity to phosphatidylserine (PS). PS is mainly
located in membrane leaflets, facing the cytosol. During apoptosis, molecular
machinery exposes PS at the cell surface, where it displays procoagulant and
proinflammatory activity. Annexin V binds to the PS-exposing apoptotic cell, where
its function is to inhibit the proinflammatory and procoagulant activities of a dying
cell. Labelling with F1TC permits direct detection by FACS analysis, and
counterstaining with propidium iodide allows the discrimination of apoptotic cells.
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Thus, the Annexin V-FITC Kit can be utilised to detect PS on the outer leaflet of the
cell membrane using flow cytometry. Figure 2. 5 is a schematic diagram of the
flipping of phospholipids during apoptosis and the subsequent binding of annexin V
molecules to the surface of the cell.
Annexin V . Annexin V bindingAPOPTOSIS
Ca2+ Ca2+ Ca2+
ffTTTTTTTfffT ytfrTn^fiTi^
Normal cell Apoptotic cell
^ Phosphatidylserine
Figure 2. 5. Schematic diagram depicting the flipping of phospholipids during apoptosis and
the subsequent binding of annexin V molecules to the surface of the cell.
Cells were treated with ligand or ligand in combination with inhibitor or vehicle for
48 hours as previously described for cell cycle analysis. Cells floating in the media
were harvested into labeled FACS tubes and centrifuged at 1700rpm for 4 min.
Supernatant was discarded and the pellets produced were pooled with cells
trypsinised from the petri dishes (trypsinisation described in previous section 2. 4. 1.,
with the exception only 1,5ml 10% FCS DMEM was added to neutralize the trypsin).
Samples were centrifuged at 1700rpm for 4 min. Supernatant was discarded as
before and pellets resuspended in 1ml 10% FCS DMEM and incubated at 37°C for 5
min. Samples were further centrifuged at 1700rpm for 4 min. Cell pellets were
resuspended in 1ml ice cold PBS and centrifuged as before. Cell pellets were then
resuspended in lOOpl ice cold annexin-v buffer (R&D Systems, 1:10 dilution in
dH20). lOpl of propidium iodide (PI) and lpl FITC were added per tube and
incubated in the dark for 15 min. Three control tubes were also set up, one with only
PI, another with FITC and the third containing neither agent. After 15 min 400pl
annexin-v buffer was added per tube. Cytofluorometric analysis was performed
(FACScalibur cytometer) within the hour and the background and experimental
fluorescence intensities were evaluated by the CellQuest 1.2.2. software on 10,000
acquired events.
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2. 4. 3. FACS Solutions
Citrate buffer contained 85.5g sucrose and 11,76g trisodium citrate (BDH Laboratory
Supplies) in 800ml dFLO. 50ml DMSO (BDH Laboratory Supplies) was then added
and adjusted to pH 7.6. The solution was then made up to 1L with dHiO. Stock
Solution consisted of 200mg trisodium citrate (BDH Laboratory Supplies), 121mg
Tris, 1044mg spermine tetrahydrochloride and 2ml Nonidet NP40 in 1,8L dH20. The
solution was adjusted to pH 7.6 and made up to 2L with dH20. Solution A comprised
of 15mg trypsin in 500ml Stock Solution (pH 7.6), aliquoted into 20ml volumes and
stored at -20°C. Solution B contained 250mg trypsin inhibitor (Fluka Chemicals) and
50mg RNAse A in 500ml Stock Solution (pH 7.6), aliquoted again into 20ml volumes
and stored at -20°C. Solution C comprised of 208mg propidium iodide (Fluka
Chemicals) and 500mg spermine tetrahydrochloride in 500ml Stock Solution (pH 7.6)
aliquoted and stored as described for Solutions A and B. All chemicals were
provided by Sigma unless otherwise stated.
2. 4. 4. Analysis of apoptosis results produced using the
annexin-v assay and FACS analysis
A representative example of an apoptosis experiment produced using the annexin-v
assay and FACS analysis with MCF-7 cells in the presence and absence of tamoxifen
is shown in figure 2. 6. All cells were charcoal stripped for 48h as previously
described and were then treated with control media (A) or tamoxifen (lpM) (B) for
72h. The graphs in A and B on the left hand side of the figure illustrate the area of
scatter of cells selected for analysis (represented by forward and side scatter of cells).
The graphs on the right hand side of the figure show the distribution of cells
according to their apoptotic status dictated by the fluorescence produced. This
example illustrates that the majority of MCF-7 cells in DCSS media are not
undergoing apoptosis (Lower Left (LL) quadrant). Early apoptosis is represented in
the Lower Right (LR) quadrant from which the apoptosis data were recorded. The
Upper Right (UR) and Upper Left (UL) quadrants represent late stage
apoptosis/necrosis and necrotic cells respectively. These processes were not under
investigation here. The example in figure 2. 6 shows tamoxifen produced a small
increase in the percentage of cells in the LR quadrant, and thus undergoing apoptosis.
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Figure 2. 5. Representative example of an apoptosis experiment produced using the
annexin-v assay and FACS analysis with MCF-7 cells. Cells were charcoal stripped for
48h as previously described and were then treated with control media (A) or tamoxifen (1pM)
(B) for 72h. The graphs in A and B on the left hand side of the figure illustrate the area of
scatter of cells selected for analysis (represented by forward and side scatter of cells). The
graphs on the right hand side of the figure show the distribution of cells according to their
apoptotic status dictated by the fluorescence produced. This example illustrates that the
majority of MCF-7 cells in DCSS media are not undergoing apoptosis (Lower Left (LL)
quadrant). Early apoptosis is represented in the Lower Right (LR) quadrant from which the
apoptosis data were recorded. The Upper Right (UR) and Upper Left (UL) quadrants
represent late stage apoptosis/necrosis and necrotic cells respectively. These processes
were not under investigation here. This example shows tamoxifen produced a small increase
in the percentage of cells in the LR quadrant, and thus undergoing apoptosis.
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2. 5. Inhibitor studies using quantitative Reverse-
Transcriptase Polymerase Chain Reaction (qRT-PCR)
Log-phase MCF-7 cells were seeded into 75cm" flasks and charcoal-stripped 24h
later and incubated for 48h prior to treatment. Resistant cell lines were seeded into
75cm" flasks 24h prior to treatment. Control times 0 and 24h flasks were set up
alongside flasks treated with E2 (InM), TGFa (InM), LY 294002 (lOpM), U0126
(lOpM), U71322 (5pM) and combinations of each ligand plus each inhibitor. Cells
were pre-treated with U71322 for lh while LY294002 and U0126 were added 30
min prior to ligand treatment. Control and treated flasks were harvested at 0 and 24h
where appropriate.
2. 5. 1. Sample collection and RNA isolation
2. 5. 1. 1. RNA extraction
Cells were harvested into polypropylene tubes (Sarstedt) by the addition of 7.5ml TRl
reagent per flask (lml TRI reagent/lOcm2 of culture plate surface area). Once added,
the cell lysate was passed through a pipette several times to form a homogenous
lysate. Samples were left to stand for 5 min at room temperature to allow for
complete dissociation of nucleoprotein complexes. l.5ml chloroform was added per
tube, the mixture shaken vigorously and the samples then left to stand for
approximately 5 min at room temperature to allow for separation of the sample into
layers. The samples were then centrifuged at IOK rpm for 15 min (SS34 rotor, Sorval
RC5B centrifuge), 4°C, in order to separate the mixture into 3 phases (a red organic
protein phase; a DNA interphase and a colourless RNA containing upper aqueous
phase). The aqueous phase was transferred to a fresh tube and 3.75ml/sample of
isopropanol was added and the tube inverted. This mixture was then centrifuged at
10K rpm for 10 min, 4°C. Supernatant was poured off and the pellet washed by
adding 5ml 75% ethanoFtube, vortexing and centrifuging the sample at 13K rpm,
5min, 4°C. The sample was then briefly centrifuged again under the same conditions
and the last few drops of ethanol removed. The pellets were briefly air-dried (in
sterile hood) and 50pl dFLO added and pipetted up and down before heating at 60°C
for 10 min to aid dissolution.
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2. 5. 1. 2. DNase treatment
2jal DNase 1 (RNase free) lOU/pl, 1 p.1 RNasin 40U/jj,1 and 5.8pl 10X buffer (all
agents supplied by Boehringer Mannheim) were added to the 50pl volume of each
sample and vortexed. Samples were then incubated at 37°C for 60 min. 60pl phenol:
chloroform (50:50) was added to each sample, vortexed and centrifuged at 13K rpm,
15 min, 4°C. 55jul of the top layer was put in a separate tube to which 55pl of
chloroform was added and vortexed for 5 s. Samples were centrifuged for 15 min at
13K rpm, 4°C. Approximately 55pl of the top layer was transferred to a new tube on
ice. Samples were then precipitated using 5.5pl 3M sodium acetate pH5.6 and 1 20jli1
ice cold 100% ethanol and stored overnight at -70°C. After a maximum of 24h
samples were pelleted at 13K rpm, 15 min, supernatant removed and washed in 1ml
75% ethanol. Samples were centrifuged at 13,000 rpm (15 min, 4°C), supernatant
removed and pellets centrifuged again to remove excess ethanol. RNA pellets were
then resuspended in 50pl DEPC treated water and the concentration determined from
the optical density (OD) at 260nm using a Unicam UV2 u.v. spectrophotometer.
2. 5. 1. 3. qRT-PCR
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) allows for
the quantitative detection and analysis of specific genes from small amounts of RNA
using double-stranded DNA fluorescent dyes such as SYBR Green. RT-PCR
amplification of a particular mRNA sequence requires a pair of primers which are
specific for that mRNA sequence. The reverse transcriptase transcribes the RNA to
cDNA, by extension from a primer complementary to the RNA sequence, where upon
the PCR process immediately takes place. PCR amplification can be
compartmentalised into three sections; an early background phase (little product
accumulation), an exponential phase (or log linear phase, rapid product accumulation)
and a plateau phase (no further product is amplified). The principle of RT-PCR is
based on measuring fluorescence signals at the end of the extension phase of each
PCR cycle that are generated following SYBR Green I (a double stranded (ds) DNA-
binding dye) binding to PCR products. During the exponential phase of PCR
theoretically the amount of DNA doubles at every cycle, and therefore during this
phase the fluorescent signal increase should be directly proportional to the PCR
product amount. The fluorescence signal increases as the product increases, resulting
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in a sigmoidal-shaped curve. SYBR Green I dye is not specific therefore the reaction
is made specific using "hot-start" PCR and by empirically determining annealing and
signal acquisition temperatures for each gene-specific primer pair. Relative
expression levels are quantified by constructing a standard curve using serial dilutions
of a cDNA template to monitor the expression of a highly expressed gene. Any
given piece of dsDNA will melt at a specific temperature which is mainly determined
by the length and base content of the dsDNA. As temperature increases during PCR,
the PCR product will denature and hence release any associated SYBR Green,
causing a sharp decline in fluorscence. A good indication of the purity of the PCR
product can be ascertained from construction of a melt curve, which is obtained by
plotting the negative first derivatives values of the fluorescence intensity as a function
of the temperature, resulting a peak. A single narrow peak is the optimal result.
p-Actin was used as the housekeeping gene in order to confirm initial equal mRNA
concentration, i.e. the housekeeping gene acts as a loading control, where all test
cDNA products were divided through by the amount of P-actin cDNA produced from
the same sample. This gene was used to monitor loading as levels are equal and
constant irrespective of treatment, unlike other genes whose expression may be up or
downregulated.
qRT-PCR was carried out according to manufacturers instructions (QuantiTect™
SYBR® Green RT-PCR handbook), with the exception that the reaction mix per
sample comprised of 7.5 pi 2x Quantitect SYBR green, 0.375pl 20pM mix of
primers, 0.15pl Quantitect RT Mix, 2.975pl RNase-free water and 4pl template RNA
to give a final reaction volume of 15pl/sample. The Real Time cycler (Rotorgene
RG-3000, Corbett Research) conditions were RT: 50°C for 30min (for primer
annealing); PCR: initial activation 95°C for 15 min; followed by 40 cycles of
denaturation 94°C for 15 sec, annealing 57°C for 30 sec, extension 72°C for 30 sec;
and a final extension of 72°C for 60 sec. Details of primers used are detailed in the
Materials section.
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2. 5. 1. 3. 1. Confirmation of PCR products
The primers were confirmed to detect the correct cDNA (genes) via entering the
forward and reverse primer sequences into the Blast database
(http://www.ncbi.nlm.nih.gov/Blast). The database provides any sequences to which
the primers could bind to and subsequently amplify. All primer pairs were found to
only bind to and amplify the gene of interest for which they were designed. The
specificity of the PCR products was determined by running all the products on an
agarose gel (as well as referring to the melt curve produced during qRT-PCR).
Positive control treated (E2 (InM), 24h) MCF-7 cell PCR product samples were run
against a lOObp ladder (Invitrogen) 011 a 2% agarose gel (2g agarose heat dissolved in
100ml IX TAE buffer (1L 50X TAE buffer consisting of 242g Tris-base, 57.1ml
glacial acetic acid and 100ml 0.5M EDTA, titrated to pH 8), plus lpl ethidium
bromide post-heating). 9pl of each qRT-PCR sample plus lpl 10X DNA loading
buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in dbfO)
were loaded and run at 60V for approximately lh, or until the bands of the ladder had
spread sufficiently to distinguish between molecular weights. Bands were visualised
using a dual intensity ultraviolet transilluminator (Ultra-Violet Products) and a
picture produced using GDS Imagestore 7500 Version 7.12 software. Single bands
were produced from each sample indicating only cDNA product of that size was
produced per PCR reaction, and these band sizes each corresponded to their relevant
sequence designed to be amplified by the primer pairs (gel shown in Figure 2. 7).
This indicates the primers were gene-specific and the absence of multiple bands
indicates the PCR products were not contaminated with products of different sizes.
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Figure 2. 7 Confirmation of PCR products. The PCR products of MCF-7 cells treated
with E2 (1nM) for 24h after RT-PCR with CTD, ERa, pS2 and PR primers were run on a
2% agarose gel in order to confirm their molecular weights corresponded with the
relevant sequence designed to be amplified by the primer pairs. All PCR products were
of the correct molecular weight (ERa 107bp; pS2 209bp; PR 193bp; CTD 196bp).
2. 6. Statistical Analysis
One-way ANOVA with Tukey-Kramer post test was performed using GraphPad
In-Stat version 3.06, for Windows 95 (GraphPad Software, San Diego California,
USA, www.graphpad.com), where any changes which were considered
statistically significant were allocated P values of P<0.05 (*, significant), PO.Ol
(**, highly significant) and P<0.001 (***, extremely significant).
Analysis of variance (ANOVA) permits comparison of population means, and if
the null hypothesis is rejected, the Tukey-Kramer procedure can be utilised to
determine any statistically significant differences between pairs of means, which
is not possible with the ANOVA procedure. This provides an advantage over
ANOVA alone as it specifies which treatment means have a statistically
significant difference. Both simultaneously test for equality of all the mean
values. The Tukey-Kramer test involves numerous statistics already computed in
ANOVA, thus the former test is often used as a supplement to ANOVA rather
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than as a replacement. It should be noted that ANOVA and the Tukey-Kramer
tests both rely on data with a normal distribution, departure from which may
cause errors. The robustness of the ANOVA and Tukey-Kramer statistical tests is
discussed by Driscoll (1996).
The tests were utilised in conjunction to ascertain if cells treated with various
agents such as TGFa, induced a significant change in growth, mRNA expression
and phospho-signal expression for example, compared to not only untreated cells,
but also to other treatments. Therefore it was possible to evaluate the effect of a
treatment versus several others, including combination treatments. For example,
HRGP and TGFa both enhanced phospho-Akt (P-Akt) expression compared to
basal levels and statistical analysis of 3 replicate independent experiments
provided information that not only were both growth factors able to elicit
extremely significant increases in P-Akt compared to control untreated cells, but
that HRGp enhanced P-Akt to a significantly greater extent than TGFa.
2. 7. Consistency ofData
In order to confirm the reproducibility and reliability of the data shown in
representative individual experiments shown in each results chapter a summary
table of some key data is shown in table 2. 3. The table is a summary of the
consistency of some of the key results including percentage change in
proliferation (reached by day 7, compared to day 7 control, with the exception of
day 7 control, which was compared to the day 0 control), signalling
characteristics (P-S118 and P-Akt shown as examples) and gene expression (ERa
and pS2 shown as examples).
The data shown are final values from three independent replicate experiments.
Each value was analysed using the ANOVA Tukey-Kramer test in relation to the
other treatments performed in that experiment (for example, control compared to
E2, TGFa and HRGP treatments and also each treatment with one another).
ANOVA & Tukey-Kramer were used to compare across treatments in each cell
line, while control values were compared between cell lines to ascertain any
significance between the parental & resistant phenotype. The mean of the three
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values from the three independent experiments were then analysed in comparison
with the means of all the other treatments using the ANOVA procedure to give a
final significance value. This value is given in each box of the table. For
example, although a modest increase in percentage cell proliferation was observed
in the MCF-7 cell line under control conditions (as shown by the numbers being
red in colour), the final value of 31.7 ± 26.5% (P>0.05) was not a significant
increase compared to the 2992.3 ± 1252.8%, 1339.8 ± 606.1% or 1614.4 ±
771.7% increases observed with E2, TGFa and HRGp treatment respectively
(PO.OOl). Values shown in blue represent a decrease in percentage proliferation
or gene expression for example. Numbers in black indicate either no change, or
that the change is not significant.
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Table 2. 3 Summary of the consistency of some of the study key results;
Percentage Change in Proliferation, Relative P-S118 and P-Akt Expression and Relative
ERa and pS2 Expression. Values shown in red and blue represent an increase or
decrease respectively in proliferation for example. Values in black indicate either no
change, or that the change was not found to be statistically significant using the ANOVA
and Tukey-Kramer tests where * = P<0.05 and is significant, ** = P<0.01 and is deemed
highly significant and *** = P<0.001 and is considered to be extremely significant.
ANOVA & Tukey-Kramer were used to compare across treatments in each cell line, while
control values were compared between cell lines to ascertain any significance between
the parental & resistant phenotype. (Tx = treatment)
Assay/Cell MCF-7 LCC1 LCC9
%ChangeiProliferation-day7Txcf.d yC ntl/c llliconts
Cont
60.4 + 26.7+ 8.1
= 31.7 + 26.5%
(P>0.05)
2120 + 2813 + 4629.4
=3187.511295.9%
(p<0.001)
3138.4 + 2992 + 5450.5




= 2992.3 + 1252.8%
(p<0.001)
152.6 + 20.4 + 91.2
=88.1 1 66.2%
(p<0.01)
0.7 + 33.8 + 20.2






17.2 + 0.94 + 9.5
= 2.9 113.5%
(P>0.05)
12.5 + 11 + 12.1
= 4.3 1 27.3%
(P>0.05)
HRGp
813 + 2352.5 + 1614.4
= 1614.4 1771.7%
(p<0.001)
6.7 + 12.2 + 41.1






0 + 0 + 50.2
= 16.7 1 29% (P>0.05)
2.7 + 8.6 + 13.9
= 2.7 111.25% (P>0.05)
11.32 + 13 + 5.9
= 10.1 1 3.7% (P>0.05)
e2
+Tam
90.1 + 70.3 + 63.5
= 74.6113.8%
(P<0.001)
12.6 + 39+ 27.9
= 26.51 13.3%
(P>0.05)
4.2 + 0.2 + x









0.28 +0.26 + 0.18
= 0.241 0.05 (P>0.05)
0.31 + 0.13 + 0.51
= 0.3210.19 (P>0.05)
0.06 + 0.11 + 0.08
= 0.0810.03 (P>0.05)
1.08 +0.88 + 1.03
= 1 1 0.1 (p<0.001)
1.42 + 1.28 + 1.55
= 1.42 + 0.14 (pc0.001)
0.02 + 0.06 + 0.07
= 0.05 1 0.03 (P>0.05)
0.29 + 0.45 + 0.56
= 0.4310.14 (P>0.05)
0.3 + 0.71 + 0.5
= x 1 y (P<0.001)
0.04 + 0.1 + 0.06
= 0.07 1 0.03 (P>0.05)
0.48 +0.52 + 0.33
= 0.441 0.1 (P>0.05)
0.87 + 0.6 + 0.59
= 0.691 0.16 (P>0.05)
0.03 + 0.05 + 0.1
= 0.061 0.04 (P>0.05)
0.48 +0.67 + 0.55
= 0.5710.1 (P<0.001)
1.14 +1.08 + 0.86
= 1.031 0.15 (p<0.001)
0.07 +0.07 + 0.07
= 0.07 10 (P>0.05)
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= 0.16 ± 0.02 (P>0.05) =1.94 ± 0.7 (P<0.001) =1.3 ±0.11 (P<0.001)
+
*♦»"











1+1 + 1 (+ve control) 2.79 + 3.2 + 2.07 2.2 + 2.9 + 1.92






HRGP 5.09 + 7.78 + 4.42 6.5 + 5.24 + 5.74 3.34 + 6.17 + 4.2
=5.76 ± 0.02 (P<0.001) =5.83 + 0.63 (P<0.001) =4.57 ± 1.45 (P<0.001)
<«■*
c 2.26 + 1.96 + 1.48 3.86 + 3.66 + 4.31 2.03 + 3.82 + 2.93










1.49 + 1.24 + 1.21
= 1.31 + 0.15
2.32 + 3.79 + 2
=2.7 + 0.95
1.82 + 1.72 + 3
=2.18 ± 0.7 (P>0.05)
p:Ul (P<0.05) (P<0.01)
c 0.1 + 0.28 + 0.06 1.01 + 1.2 + 1.85 0.66 + 0.58 + 0.92
o










1.04 + 1.53 + 1.27
= 1.28 + 0.25%
3.4 + 5.2 + 3.18
= 3.93 ±1.11 %
2.15 + 2.72 + 3.96
= 2.94 ± 0.93%
CO
Q. (P<0.001) (P<0.01) (P<0.01)
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Chapter 3
Characterisation of oestrogen and
growth factor regulated responses in
resistant breast cancer cell lines.
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3. 1. Growth characterisation
A selection of ovarian and breast cancer cell lines were chosen as models of
oestrogen sensitivity and resistance. The cell lines were first characterised in
response to the SERMs 17P-oestradiol (E2) and tamoxifen (Tamox, Tarn) and the
growth factors TGFa and HRGp. The breast cancer cell lines were characterised
further in order to determine whether any differences in the mRNA expression of
oestrogen-responsive genes, cell cycle distribution or apoptosis were present and if
there were links to the development of endocrine-therapy resistance.
3. 1 .1. Breast cancer cell lines
3. 1. 1. 1. Growth responses
Breast cancer cell lines Mill, LCCl, LCC2, LCC9 and LY2 were characterised in
conjunction with their parental breast cancer cell line MCF-7 in response to
treatment with a concentration range of E2 (figure 3. I). The endocrine sensitivity of
each cell line was then characterised by treating the cells with E2 in the presence and
absence of tamoxifen (figure 3. 2). The panel of cell lines was narrowed for growth
characterisation with TGFa and HRGp (figure 3. 3). Mill and LCC2 cell lines were
excluded from more detailed studies as their growth phenotypes were similar to those
of other lines in the panel and thus deemed superfluous. The morphology of the cells
was observed after treatment with E2, TGFa, Tamox, E2 + TGFa and E2 + Tamox
(figure 3. 4A-C).
In order to ascertain if any concentration of E2 would stimulate the resistant cell lines
and to determine the optimum E2 concentration for further studies, cells were treated
with O.l-lOOnM F2. Control media used was phenol red-free DMEM containing 5%
charcoal stripped FCS (DCSS). The relative E2 sensitivity of the cell lines using a
InM concentration after 7 days, was MCF-7 > Mill > LCCl - / > LCC2 > LCC9 =
LY2 (figure 3. I). InM E2 was used as this concentration induced the optimum
increase in cell number in the majority of oestrogen-responsive cells lines and was
used for further studies. The relative E2-sensitivity of the cell lines was determined
by comparing the fold changes induced in proliferation of each cell line by a set
concentration of E2 on a set day.
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Figure 3. 1 The effect of various E2 concentrations on the growth of resistant breast
cancer cell lines versus the sensitive parental MCF-7 breast cell line. All cell lines were
charcoal stripped 24h prior to treatment and were then treated with control media (♦) or
0.1 nM (. ), 1nM (■), 10nM (x) or 100nM (■) E2. Cells were treated and counted on days 0, 3
& 5 and a final count took place on day 7. Data were plotted as a mean of quadruplicate cell
counts +/- SD for treated values and as a mean of 8 cell counts +/- SD for untreated cells.
Results are representative of 1 of 3 independent experiments.
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For example, 1 nM E2 produced a significant increase in MCF-7 cell proliferation of
~63-fold (day 7, P<0.()01 compared with day 7 control). The fold increase fell to —2-
fold for the Mill cell line (P<0.001), and ~1.3-fold in both the LCC1 and LCC2 cell
lines by day 7. The fold increase in the Mill cell line was still considered significant
as the cell counts were very similar. In contrast, the cell counts for the LCC1, LCC2,
LCC9 and LY2 cell lines varied somewhat, producing larger standard deviations and
therefore even the increases of ~1.3 and ~1.6-fold for LCC9 and LY2 cell lines
respectively were not found to be statistically significant (1 nM E2, day 7 compared to
day 7 control, P>0.05). The LCC1 and LCC2 cell lines displayed some E2-
sensitivity at InM, but this was only significant at day 5 (-1.4 and -1.5-fold
increases respectively, P<0.001 compared to day 5 control). In contrast to
observations here, Bronzert et al (1985) previously reported the LY2 cell line to be
E2-sensitive. However, the statistical increases noted by this author were observed
after a minimum of 8 days in the presence of IO11M E2, or 10 days in the presence of
a range of concentrations compared to a maximum of 7 days in this experiment. The
shorter incubation period in these studies may account for the absence of a
significant increase in response to E2 treatment. Also, DMEM media was used in
this study in comparison to IMEM media utilised by Bronzert et al (1985), although
this should not produce dissimilar results. As the growth of the LY2 cell line was not
found to be significantly increased by InM E2 after 0-7days incubation in these
studies, and InM was used in further experiments, the cell line was considered to be
E2-insensitive under these conditions for the remainder of the study.
A similar E2-responsive pattern to that seen with a 1 nM concentration was also seen
with O.lnM E2 on day 7, where the MCF-7 cell line was increased by ~62-fold
(P<0.001), the Mill cell line by -2-fold (PO.OOl) and LCC1 and LCC2 cells by
-1.2-fold, values similar to those produced with 1 nM E2. Fold increases in the LCC1
and LCC2 cells were found to be significant on day 5 (only LCC1 cells were
stimulated on day 3, and insignificant at this concentration on day 7. Any increase in
growth in the LCC9 and LY2 cell lines was statistically insignificant (P>0.05, days
3, 5 and 7). Interestingly, the maximum concentration of E2 used did not cause the
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greatest increase in growth. lOOnM increased growth by ~60-fold in MCF-7 cells
compared to a ~63-fold increase with the lesser concentration of 1 nM. This suggests
the effect of E2 stimulation plateaus between lnM and lOOnM in the MCF-7 cell line.
This plateau effect may also occur in the Mill cell line, or possibly a loss of growth
stimulation is occurring, although all E2-induced fold increases in growth remain
significant compared to control conditions. For example, lOnM and lOOnM
concentrations produced smaller fold growth increases compared to lower
concentrations, with ~1.6-fold and —1.5-fold increases respectively (P<0.01)
LCC1 cells were significantly stimulated by all concentrations by day 3, with the
greatest increase produced with lnM E2 (~1.8-fold, P<0.01). By day 5, E2
concentrations of lnM and lOnM significantly increased LCC1 cell proliferation by
~1.4 and -1.5-fold respectively (P<0.01-0.001). By day 7 only lOnM significantly
enhanced proliferation beyond the control level of proliferation, and only by —1.2-
fold (P<0.05). No significant growth increase was observed in LCC2 cells by day 7.
Therefore, a higher E2 concentration did not necessarily produce the greatest growth
response in this panel of cell lines. 1 nM E2 was selected for use as firstly it produced
a similar growth response to that of higher concentrations tested and secondly, it is a
physiologically relevant dose at the upper end of the normal range for a
premenopausal woman.
MCF-7 cells did not grow significantly in charcoal-stripped media in the absence of
E2 treatment, which contrasted with the resistant cell lines, which continued to
proliferate in the absence of E2 (a minimum 10-fold increase in proliferation from
day 0 to day 7 control, P<0.001). The MCF-7 cell line was the most sensitive to all
treatments (figures 3. 2 & 3. 3), with a cell growth increases of ~25-fold & -11-fold
(both P<0.001) with E2 & TGFa treatments respectively (day 7). The slight
discrepancy in size of the E2-fold induction in the MCF-7 cells in the separate
experiments is likely to be due to a difference in the initial seeding density.
Figure 3.2 shows that tamoxifen almost completely abrogated E2-induced cell
proliferation in MCF-7 cells, with a reduction in growth of -10-fold (P<0.001) by
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day 7 in the presence of E2 + tamoxifen compared to E2 alone. The resistant cells
proliferated in the absence of any ligand stimulation (control) and this was observed
in all growth experiments (figures 3. 1,3. 2, 3. 3). Mill cells were sensitive to E2
(InM) and there was between a ~3 and ~2-fold (P<0.05 and P<0.()01) induction in
growth compared to control (figures 3. 1 and 3. 2 respectively).
LCC1 and LCC2 cells proliferated in response to E2 (~2.5-fold increase by day 7,
P<0.001) and tamoxifen significantly reduced this E2-induced growth but not to
control level (P<0.001, day 7). Tamoxifen alone had no effect on growth in either
the LCC1 or LCC2 cell line (P>0.05). LCC9 and LY2 cells were also insensitive to
all treatments and grew in a similar manner irrespective of treatment (P>0.05).
105































Figure 3. 2 The effect of endocrine agents on the growth of resistant breast cancer cell
lines versus the sensitive parental MCF-7 breast cell line. All cell lines were charcoal
stripped 24h prior to treatment and were then treated with control media (♦), E2 (1nM) (■),
tamoxifen (1pM) (A) or E2 + tamoxifen (1nM + 1pM) (x). Cells were treated and counted on
days 0, 3 & 5 and counted on day 7. Data were plotted as a mean of quadruplicate cell
counts +/- SD for treated values and as a mean of 8 cell counts +/- SD for untreated cells.
Results are representative of 1 of 3 independent experiments.
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Figure 3.3 shows the effect of growth factor stimulation on the growth of the parental
MCF-7 cell line in comparison to the resistant LCC1, LCC9 and LY2 cell lines. As
previously observed, control growth is minimal in MCF-7, compared to all resistant
cell lines, which increased in growth by -59, -70 and ~80-fold for LCC1, LCC9 and
LY2 cells respectively (day 7 compared to day 0, P<0.0()1). TGFa and HRGp
elicited an increase in cell proliferation of approximately the same size in MCF-7
cells (-11 and -9-fold increases respectively, day 7), but to a lesser extent than E2
(~23-fold increase by day 7, P>0.001). The growth factors had no stimulatory effect
in the resistant cell lines. Flowever, initial observations indicated that HRGp
treatment caused 'clumping' of the cells, perhaps more so in the resistant lines,
which made them more adherent to each other and less adherent to the dish, hence
the stimulatory effect may be slightly greater than recorded in the MCF-7 cell line.
Thus, although no increase in resistant proliferation was observed with growth factor
stimulation, there may be alterations in the extent of cell aggregation and cell-cell
adhesion in the resistant cell lines.
These data suggest the resistant cell lines are not only increasingly insensitive to E2
as previously documented, but also that the cells are insensitive to stimulation by
other growth factors. It has been previously postulated that in some instances,
endocrine resistance arises through initial stimulation by other growth factors,
therefore further studies were carried out to determine the point at which the growth
factors become ineffective in this model system.
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Figure 3. 3 The effects of growth factors on the growth of resistant breast cancer cell
lines versus the sensitive parental MCF-7 breast cell line. All cells were charcoal
stripped 24h prior to treatment and were then treated with control media (♦), E2 (1nM) (■),
TGFa (1nM) ( ) or HRGp (1nM) (A). Cells were treated and counted on days 0, 3 & 5 and
a final count took place on day 7. Data were plotted as a mean of quadruplicate cell counts
+/- SD for treated values and as a mean of 8 cell counts +/- SD for untreated cells. Results
are representative of 1 of 3 independent experiments.
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3. 1. 1. 2. Cell morphology
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The morphology of the panel of breast cell lines (excluding Mill at this stage) was
observed after 3 days treatment with control medium, E2 (InM), tamoxifen (lpM),
TGFa (InM), E2 + TGFa (both InM) and E2 + tamoxifen (InM + lpM).
MCF-7 cells settled into a monolayer under control conditions with cell-matrix
adhesions creating a 'cobblestone' effect. Treatment with E2 caused the cells to form
cell-cell adhesions as opposed to the cell-matrix adhesions, producing clumps of
cells growing together with larger spaces in between. TGFa did not appear to alter
the monolayer 'cobblestone' growth of the cells under control conditions. When
grown in the presence of both ligands, the cells took upon an appearance somewhere
between that of E2 and control conditions. Tamoxifen treatment did not change the
appearance of the cells when administered alone. The combination of E2 plus
tamoxifen also appeared to partially reverse the morphology change caused by E2
alone. All resistant cell lines grew in monolayers under control conditions. There
were a greater number of resistant cells under control conditions compared to the
MCF-7 cells.
The morphology of the resistant cell lines was similar to that of MCF-7 cells treated
with E2, where cell-cell adhesions occurred. E2-treatment caused clumping of the
cells creating larger spaces than that observed in MCF-7 cells under the same
conditions. TGFa and tamoxifen had no effect on the resistant cell morphology in
any combination here.
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Figure 3. 4 The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell line. (A) MCF-
7 cells were charcoal stripped 24h prior to treatment and all cell lines were then treated with
control media, E2 (1nM), tamoxifen (1pM), E2 + TGFa (both 1nM) or E2 + tamoxifen (1nM +
1pM) (figure continued A-E). Magnification x 100.
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Figure 3. 4 The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell line. (B) LCC1
cells were charcoal stripped 24h prior to treatment and all cell lines were then treated with
control media, E2 (1nM), tamoxifen (1pM), E2 + TGFa (both 1nM) or E2 + tamoxifen (1nM +
1pM) (figure continued A-E). Magnification x 100






Figure 3. 4 The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell line. (C) LCC2
cells were charcoal stripped 24h prior to treatment and all cell lines were then treated with
control media, E2 (1nM), tamoxifen (1pM), E2 + TGFa (both 1nM) or E2 + tamoxifen (1nM +
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Control
Figure 3. 4 The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell line. (D) LCC9
cells were charcoal stripped 24h prior to treatment and all cell lines were then treated with
control media, E2 (1nM), tamoxifen (1pM), E2 + TGFa (both 1nM) or E2 + tamoxifen (1nM +













Figure 3. 4 The effect of various treatments on the cellular morphology of resistant
breast cancer cell lines versus the sensitive parental MCF-7 breast cell line. (E) LY2
cells were charcoal stripped 24h prior to treatment and all cell lines were then treated with
control media, E2 (1nM), tamoxifen (1pM), E2 + TGFa (both 1nM) or E2 + tamoxifen (1nM +
1pM) (figure continued A-E). Magnification x 100.
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3. 1. 2. Ovarian cancer cell lines
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ERa and oestrogen have been implicated in ovarian cancer and are perhaps related to
its causation (Rao and Miller, 2006). Rao and Miller (2006) suggested that
additional research was required into hormonal therapies as a treatment for ovarian
cancer as discussed in the introduction. Therefore, ERa may play a crucial role not
only in breast cancer, but also ovarian cancer. Hence, ovarian cancer cell lines PEOl
and SKOV-3 were characterised in conjunction with the breast cancer cell line
MCF-7 in response to treatment with E2 and TGFa. The cell lines were subjected to
increasing concentrations of E2 and TGFa varying from 0.1 to lOOnM for E2 and
0.01 nM to lOnM for TGFa (figures 3.4 and 3.5 respectively).
Figure 3.5 shows the effect of increasing E2 concentrations on PEOl and SKOV-3
cells. MCF-7 data are as previously described, where a higher E2 concentration did
not necessarily produce the greatest growth response in the cell line (figure 3.5A).
E2 did not effect the cell counts in SKOV-3 cells at any concentration (no fold
change, P>0.05) and only a small increase in cell number was observed in PEOl
cells treated with the 0.1 nM E2 treatment (~1 .■4-fold increase, P<0.05, day 7) (figure
3.5C). Figure 3.6 shows that TGFa produced an increase in cell number in both
SKOV-3 and PEOl lines as with MCF-7 cells. InM TGFa increased MCF-7 cell
numbers to the greatest extent, with a ~22.5-fold increase by day 7 (P<0.()01). The
higher concentration of growth factor did not increase growth to the same degree
(~16-fold increase) although this was still considered extremely significant
(P<0.001). This is in agreement with earlier E2 data (figures 3.2 and 3.4).
PEOl cells were more responsive to TGFa treatment than the SKOV-3 cell line.
InM and lOnM TGFa produced similar fold increases of ~1.7-fold (P<0.001) in
SKOV-3 cells, while both InM and lOnM TGFa produced a ~6-fold increase in
PEOl cell number (P<0.0()1) by day 7. O.OlnM and O.lnM TGFa concentrations
stimulated cell proliferation by ~3-fold and ~5-fold in PEOl cells (day 7 data), which
were considered extremely significant inductions (figure 3.5C). In contrast, O.OlnM
TGFa did not significantly increase SKOV-3 cell proliferation by day 7 (P>0.05).
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Figure 3. 5 The effect of various E2 concentrations on the growth of resistant ovarian
cancer cell lines versus the sensitive parental MCF-7 breast cell line. MCF-7 cells were
charcoal stripped 24h prior to treatment and all cell lines were then treated with control
media (♦) or 0.1nM ( ), 1nM (■), 10nM (x) or 100nM (■) E2. Cells were treated and
counted on days 0, 3 & 5 and a final count took place on day 7. Data were plotted as a
mean of quadruplicate cell counts +/- SD for treated values and as a mean of 8 cell counts
+/- SD for untreated cells. Results are representative of 1 of 3 independent experiments.
However, in contrast to MCF-7 and PEOI cell lines, SKOV-3 cells were able to
proliferate profusely in charcoal stripped media (between a -5.5 and a —11 -fold
increase, P<0.001, figures 3.5B and 3.6B respectively), compared to a nominal
increase in MCF-7 cell number between a zero value and a -1.3-fold increase
(P>0.05-<0.05, figures 3.5A and 3.6A). PEOI cells proliferated to small degree
under control conditions, but only by between -1.3 and ~3-fold (P<0.05-0.001)
between days 0 and 7.
116




























Figure 3. 6 The effect of various TGFa concentrations on the growth of resistant
ovarian cancer cell lines versus the sensitive parental MCF-7 breast cell line. MCF-7
(A), SKOV-3 (B) and PEOI (C) cell lines were charcoal stripped 24h prior to treatment and
were then treated with control media (♦) or 0.01 nM (■), 0.1 nM (A), 1nM ( .) or 10nM (■)
TGFa. Cells were treated and counted on days 0, 3 & 5 and a final count took place on day
7. Data were plotted as a mean of quadruplicate cell counts +/- SD for treated values and as
a mean of 8 cell counts +/- SD for untreated cells. Results are representative of 1 of 3
independent experiments.
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3. 2. Expression profiling of a panel of breast cancer cell lines
The expression profiles of a panel of known oestrogen-responsive genes were
investigated in the MCF-7, LCC1, LCC9 and LY2 breast cancer cell lines. mRNA
expression levels of the pS2, ERa, PR and CTD genes were monitored in the
presence and absence of E2 and TGFa stimulation after 24h incubation.
Basal ERa mRNA levels were elevated in all three resistant cell lines compared to
MCF-7 cells, with increases of ~4.3-fold (PO.OOl), ~2.2-fold (P<0.05) and -2.5-
fold (P<0.01) in LCC1, LCC9 and LY2 cell lines (figure 3.7A). E2 treatment
reduced ERa mRNA expression by approximately a third (-31.6%, P=0.0105) in
MCF-7 cells, -two-thirds (-63.3%, PO.OOl 5) in LCC1 cells and an extremely
significant reduction was noted in the LY2 cell line (74.2%, PO.OOOl) (figure
3. 7B). In contrast, no significant change in ERa mRNA levels was observed in the
LCC9 cell line (-10.7% reduction, P=0.4883). The reductions in the resistant cell
lines compared to the MCF-7 cell line (as indicated by red asterices) were deemed
very significant in the LCC1 cell line (PO.Ol) and extremely significant in the LY2
cell line (P<0.001). The increase in ERa mRNA due to E2 treatment was considered
to be significant in the LCC9 cells compared to the MCF-7 cell line (P<0.05).
TGFa also reduced ERa mRNA expression (—37.3%, PO.021) in MCF-7 cells. The
ERa mRNA levels of LCC1 and LY2 cell lines remained insignificantly affected by
TGFa (P>0.05, -6.3% reduction in LCC1 and —18.5% increase in LY2 cell line
respectively), although ERa mRNA levels were increased by -1.5-fold in LCC9 cells
(P=0.005). The various reductions and increases in the ERa mRNA levels post
TGFa treatment in the three resistant cell lines led to significant differences between
these lines and the MCF-7 cell line. Values of P<0.05, PO.OOl and PO.Ol were
recorded for the differences between the MCF-7 cell line and LCC1, LCC9 and LY2
cell lines respectively.
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Figure 3. 7 The effect of E2 and TGFa stimulation on ERa expression in resistant
breast cancer cell lines versus MCF-7 cell line. MCF-7 (■), LCC1 (■), LCC9 ( ) and LY2
( ) cell lines were treated with (A) control media to determine basal levels, (B) E2 (1nM) or
(C) TGFa (1nM) for 72h. Data were plotted as the mean of triplicates +/- SD relative to
MCF-7 E2 positive control. ANOVA test: * = P<0.05, ** = P<0.01 and *** = P<0.001.
Asterisks in black represent statistically significant changes between MCF-7 and the
resistant cell lines and those in red represent any statistically significant changes post-
treatment with E2 or TGFa compared to control. Results are representative of 1 of 3
independent experiments.
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Figure 3.8A shows that basal levels of pS2 mRNA were significantly elevated in all
the resistant cell lines compared to MCF-7 cells (~19-fold (P<0.0002), ~21-fold
(PO.OOOl) and ~3.7-fold (P<0.00()1) higher in LCC1, LCC9 and LY2 cells
respectively). LY2 cell pS2 mRNA was not elevated as dramatically in control
conditions compared to the LCC1 and LCC9 cell lines. E2 significantly increased
pS2 mRNA to a similar extent in MCF-7 and LY2 cell lines, with ~16-fold
(P=0.0003) and ~ 14-fold (P=0.0017) increases in these lines respectively. E2 also
significantly increased pS2 mRNA levels in LCC1 and LCC9 cell lines by ~2.8-fold
(P=0.0()15) and ~2.3-fold (P=0.0071), but the increases were not as pronounced
compared to the MCF-7 or LY2 cells (-5.5- and ~6.7-fold higher in the parental cell
line compared to LCC1 and LCC9 respectively, both P<0.()1). TGFa significantly
enhanced pS2 in MCF-7 cells, but to a much lesser extent than E2 (~1.7-fold,
P=0.0096). No significant changes in pS2 levels were observed with TGFa
treatment of any of the resistant cells (P>0.05). MCF-7 cells were significantly
different in their percentage response to E2 compared to LCC1 and LCC9 cells
(P<0.001), and to all the resistant cell lines in response to TGFa treatment (P<0.01).
Basal PR mRNA levels were similar in the MCF-7 and LCC1 cell lines, while LCC9
PR mRNA were vastly elevated compared to MCF-7 cells (~5-fold increase,
P<0.001) (figure 3.9A). Contrastingly, PR mRNA levels in the LY2 cell line were
reduced by ~6.2-fold (P<0.01) compared to MCF-7 cells. PR expression was
induced by 24h treatment with E2 by ~12-fold (P=0.0013) in MCF-7 cells (figure
3.9B). PR mRNA levels were also significantly elevated in LCC1 and LCC9 cells
(~5-fold, P=0.0005) and ~1.7-fold increases, but this was not found to be significant
for the latter cell line. Interestingly, PR mRNA expression levels were increased
significantly by ~19-fold in the LY2 cells with E2 treatment compared to control
cells (P=0.0005).
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Figure 3. 8 The effect of E2 and TGFa stimulation on pS2 expression in resistant
breast cancer cell lines versus sensitive parental MCF-7 breast cell. MCF-7 (■), LCC1
(■), LCC9 ( ) and LY2 ( ) cell lines were treated with (A) control media to determine basal
levels, (B) E2 (1nM) or (C) TGFa (1nM) for 72h. Data were plotted as the mean of triplicate
samples +/- SD relative to MCF-7 E2 positive control. ANOVA test: * = P<0.05, ** = P<0.01
and *** = P<0.001. Asterisks in black represent statistically significant changes between
MCF-7 and the resistant cell lines and those in red represent any statistically significant
changes post-treatment with E2 or TGFa compared to control. Results are representative of
1 of 3 independent experiments.
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Figure 3. 9 The effect of ligand stimulation on PR expression in resistant breast
cancer cell lines versus sensitive parental MCF-7 breast cell. MCF-7 (■), LCC1 (■),
LCC9 ( ) and LY2 ( ) cell lines were treated with (A) control media to determine basal
levels, (B) E2 (1nM) or (C) TGFa (1nM) for 72h. Data were plotted as the mean of triplicate
samples +/- SD. ANOVA test: * = P<0.05, ** = P<0.01 and *** = P0.001. Asterisks in black
represent statistically significant changes between MCF-7 and the resistant cell lines and
those in red represent any statistically significant changes post-treatment with E2 or TGFa
compared to control. Results are representative of 1 of 3 independent experiments.
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In contrast to E2, figure 3.9C shows that TGFa reduced the PR mRNA expression
levels in MCF-7 cells by —2.6-fold to -38% (P=0.0034). TGFa elevated PR mRNA
in both the LCC9 and LY2 cell lines, with increases of -88% (P=0.0063) and -69%
respectively (P^O.OSd, considered not quite significant). There was no alteration in
the level of PR expression upon treatment with TGFa in LCC1 cells (P=0.805, not
significant). This is consistent with growth data where proliferation remained
unchanged compared to that of untreated cells. MCF-7 cells were significantly
different in their PR mRNA response to E2 compared to LCC9 cells (P<0.05), and to
all the resistant cell lines in response to TGFa treatment (P<0.001).
Figure 3.1 OA depicts a histogram of CTD mRNA basal levels in the panel of breast
cancer cell lines. LCC1 cells have -1.5-fold less mRNA expressed than MCF-7 cells
(P<0.05, significant), while the most notable reduction was observed in the LY2 cell
line where a -2.8-fold reduction in mRNA was reported compared to MCF-7 cells
(P<0.001, extremely significant). LCC9 cells expressed a similar level of CTD
mRNA relative to positive control compared to the MCF-7 cell line (P>0.05). Figure
3.10B shows E2 induced a -75% increase in MCF-7 CTD expression (P=0.017).
CTD expression was not increased significantly in the resistant LCC1 cell line by E2
(-1.2-fold). Basal CTD was inconsistently elevated in LCC9 cells to the level of
MCF-7 treated with E2 (24h), but the gene was shown to remain as E2-regulated and
active as E2 elevated the higher basal level by 1.4-fold (P<0.05, figure 3.9B). Basal
LCC9 CTD expression was however elevated compared to that of LCC1 basal CTD
expression (P=0.0024). The most notable CTD mRNA changes were again observed
in the LY2 cell line. LY2 CTD mRNA levels were extremely significantly elevated
by E2 treatment, with an increase of -3.4-fold (P=0.0002) compared to basal LY2
CTD levels and relative to the positive control (figure 3.9B). Figure 3.IOC illustrates
that TGFa only induced minor changes to CTD expression, with varying degrees of
significance. CTD mRNA levels were elevated marginally in the LCC1 cell line by
—1.3-fold (P=0.034), while MCF-7 and LCC9 cell lines remained unaltered after
TGFa treatment (P>0.05). The LY2 cell line was also increased by -1.3-fold with
TGFa treatment, but this was insignificant.
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Figure 3. 10 The effect of ligand stimulation on cathepsin D (CTD) expression in
resistant breast cancer cell lines versus sensitive parental MCF-7 breast cell. MCF-7
(■), LCC1 (■), LCC9 (ss) and LY2 ( ) cell lines were treated with (A) control media to
determine basal levels, (B) E2 (1nM) or (C) TGFa (1nM) for 72h. Data were plotted as the
mean of triplicates +/- SD. ANOVA test: * = P<0.05, ** = P<0.01 and *** = P<0.001.
Asterisks in black represent statistically significant changes between MCF-7 and the
resistant cell lines and those in red represent any statistically significant changes post-
treatment with E2 or TGFa compared to control. Results are representative of 1 of 3
independent experiments
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3. 3. Cell cycle characterisation
In order to identify any cell cycle changes associated with the stepwise development
of endocrine resistance seen in this system, the cell cycle distribution of MCF-7 cells
was studied in comparison to the LCC1 and LCC9 cell lines. The three cell lines
were treated with E2, TGFa and HRGp to specifically activate the ERa ligand-
dependent and independent pathways respectively. In addition, the effect of
tamoxifen anti-oestrogen treatment on the cell cycle was assessed in order to identify
changes in association with the development of resistance.
Figure 3.11 shows the effect of E2 and growth factors on the cell cycle distribution of
the three cell lines. All three ligands initiated cell cycle entry of the MCF-7 cell line
(figure 3.11A). E2 produced an increase in S-phase from -3% to -33% (P<0.001).
TGFa and HRGp produced similar increases from this -3% to -30% and —34% in
the S-phase respectively (both P<0.001). It is interesting to note that a higher
percentage of cells of both of the resistant cell lines are in the S-phase of cell cycle
under control conditions than the MCF-7 cell line (-30% and -14% of LCC1 and
LCC9 cells respectively are in the S-phase compared to only -3% of MCF-7 cells
(P<0.001 for comparisons between all cell lines)). In discord with the MCF-7 cell
line, E2, TGFa and HRGp all appear to reduce the proportion of LCC1 and LCC9
cells in the S-phase of the cell cycle (all P<0.001, with the exception of LCC9 TGFa
treated cells, P<0.01) (figures 3.1 IB and C).
Figure 3.12 shows the effect of E2 in combination with anti-hormonal therapy on
the cell cycle distribution of MCF-7, LCC1 and LCC9 cell lines. In MCF-7 cells E2
produced a dramatic phase distribution change as before, with a reduction from
-85% of cells in G1/G0 to -44% (P<0.001), leading to corresponding increases from
-7% to -37% in S-phase and -7% to -18% in G2/M phases respectively (both
P<().0()1) (figure 3.12A). Tamoxifen alone did not significantly increase the number
of cells in Gi/Go-phase (P>0.05). This may be explained by the fact that a large
percentage of MCF-7 cells are already in G1/G0 arrest as the cells are subject to
charcoal stripped conditions.
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Figure 3. 11 The effect of ligand stimulation on the cell cycle of resistant breast cancer
cell lines versus sensitive parental MCF-7 breast cell. All 3 cell lines were charcoal
stripped 48h prior to treatment with control media, E2 (1nM), TGFa (1nM) or HRG(3 (1nM) for
72h. The percentage of cells in G0/G1 (■), S-( ) and G2/M (■) phases of the cell cycle were
plotted as the mean of triplicate samples +/- SD as a percentage of the cell cycle. ANOVA
test: * = P<0.05, ** = P<0.01 and *** = P<0.001. Asterisks represent statistically significant
changes between control and a treatment. Results are representative of 1 of 3 independent
experiments.
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Treatment
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Figure 3. 12 The effect of endocrine therapy on the cell cycle of resistant breast
cancer cell lines versus sensitive parental MCF-7 breast cell. All 3 cell lines were
charcoal stripped 48h prior to treatment with control media, E2 (1nM), tamoxifen (Tamox)
(1pM) or E2+Tamoxifen (Tarn) (1nM+1pM) (a) for 72h. The percentage of cells in G0/1 (■), S
( ) and G2/M (B)-phases of the cell cycle were plotted as the mean of triplicate samples +/-
SD as a percentage of the cell cycle. ANOVA test: * = P<0.05, ** = P<0.01 and
***
= p<0.001. Black asterisks represent statistical significance between the same cell cycle
phase with each treatment, while red asterices represent statistical significance between the
same phase post-treatment with tamoxifen compared to E2 alone. Results are
representative of 1 of 3 independent experiments.
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Tamoxifen in combination with E2 reduced the extent of the phase progression
caused by E2 treatment alone, increasing the percentage of cells in G0/1 phase from
-44% to —56% (P<0.05) and reducing the proportion of MCF-7 cells in the S-phase
from -38% to -31% and from -18% to -14% in G2/M phase (P<0.01).
In figures 3.12B and C, the percentage of cells in S-phase in the resistant lines was
reduced by approximately half with E2 treatment as before. In both cell lines this
corresponded with an increase in cells in the G1/G0 phase. Figure 3.12B is the cell
cycle distribution for the LCC1 cell line. Tamoxifen also reduced this value in LCC1
cells, but to a lesser extent than E2 (from -29% to -20% (P<0.001) with tamoxifen
treatment versus a reduction to -15% with E2 treatment). The combination of E2
plus tamoxifen did in fact increase the number of cells in G1/G0 arrest to a value in
between the two treatments (-16%, PO.OOl compared to control treated cells).
Figure 3.12C is a histogram of the LCC9 cell cycle distribution which display a very
similar trend to that of the LCC1 cell line, with the exception that the percentage of
LCC9 cells in S and G2/M phases are approximately half those in the LCC1 cell line.
3. 4. Characterisation of the apoptotic nature of the panel of
breast cancer cell lines
The effects of various ligands and the anti-oestrogen tamoxifen on apoptosis were
monitored via annexin-v staining in the MCF-7, LCC1 and LCC9 cell lines. Figures
3.13 and 3.14 show the effects of E2 and HRGp in the presence and absence of
tamoxifen respectively. The data in figure 3.13A shows a non-significant reduction
of -1.4-fold occurs with E2 treatment in MCF-7 cells. Tamoxifen increased the
percentage of cells with positive annexin-v staining and thus apoptosis in MCF-7
cells, but not to a significant degree (-1.2-fold increase), however in combination
with E2 there was a significant increase in staining and hence this implicated an
increase in early apoptosis of ~4-fold compared to E2 alone (P<0.001).
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Treatment
Figure 3. 13 The effect of endocrine agents on apoptosis of resistant breast cancer
cell line LCC1 versus sensitive parental MCF-7 breast cell. Both cell lines were charcoal
stripped 48h prior to treatment with control media (■), E2 (1nM) (■), tamoxifen (Tamox)
(1pM) (■), or E2 + tamoxifen (Tarn) (1nM + 1pM) (a) for 72h. Early apoptosis was monitored
and data were plotted as the mean of triplicate samples +/- SD as a percentage of cells
stained with annexin-v. ANOVA test: * = P<0.05, ** = P<0.01 and *** = P<0.001. Asterisks
in black represent statistically significant changes between control and a treatment and those
in red represent any statistically significant changes post-treatment with tamoxifen compared
to E2 alone. Results are representative of 1 of 3 independent experiments.
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The apoptotic levels of the LCC1 cell line, as for the MCF-7 cell line, remained
significantly unaffected by E2, although a ~1.3-fold reduction was observed in
positive staining, which supports the growth phenotype of the LCC1 cell line.
Tamoxifen did not significantly induce cell death via apoptosis (only a -1.8%
increase with tamoxifen treatment compared to control) and was unable to prevent
any anti-apoptotic effect caused by E2 (no change to the ~1.3-fold reduction with E2
alone).
Figure 3.14 illustrates the effect of HRGp in the presence and absence of tamoxifen
on the apoptosis of MCF-7, LCC1 and LCC9 cells via observation of the annexin-v
stained cells. HRGp treatment had an anti-apoptotic effect on MCF-7 cells, with a
reduction in early stage apoptosis of -57% (P<0.001). Tamoxifen did not
significantly affect annexin-v staining and thus apoptosis, while the addition of
tamoxifen to HRGP significantly reduced the annexin-v staining and thus the number
of cells identified as in the early stages of apoptosis by -1.8-fold (P<0.05). HRGp
and tamoxifen had no effect on apoptosis in LCC1 or LCC9 cells (figures 3.14B and
C). This contrasts with the HRGp plus tamoxifen treatment, where a reduction in the
annexin-v staining was observed in the LCC1 cell line (P<0.05). The LCC9 cell
actually saw an increase in the annexin-v staining of-1.3-fold (P<0.05).
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Figure 3. 14 The effect of HRGp and tamoxifen treatment on apoptosis of resistant
breast cancer cell lines versus sensitive parental MCF-7 breast cell. MCF-7 cells were
charcoal stripped 48h prior to treatment. All 3 cell lines were treated with control media,
HRGp (1nM), tamoxifen (1pM), or HRGP + tamoxifen (1nM + 1pM) for 72h. Early apoptosis
was monitored and data were plotted as the mean of triplicate samples +/- SD as a
percentage of cells stained with annexin-v. ANOVA test: * = P<0.05, ** = P<0.01 and
***
= p<0.001. Asterisks in black represent statistically significant changes between control
and a treatment and those in red represent any statistically significant changes post-







Chapter 3: Cell Line Characterisation
This section will discuss the characteristics defined by this chapter in order to
ascertain the relevance of this panel of cell lines and whether the panel may be useful
as a model of oestrogen and endocrine therapy insensitivity.
3. 5. 1. Growth characteristics
3. 5. 1. 1. Breast cancer cell lines
The breast cell line growth responses were characterised and the results were
consistent with published data (Soule et al, 1973; Thompson et al, 1993; Brunner et
al, 1993; Brunner et al, 1997). The following section will detail the findings for each
cell line.
The parental MCF-7 cell line was sensitive to growth stimulatory actions of E2,
TGFa and HRG(3. E2 has been well documented as having a proliferative effect on
breast cancer cells including MCF-7 cells (Thomas et al, 2005; Power and
Thompson, 2003). Growth factors, including TGFa and HRGP have also been
reported to enhance the proliferation of MCF-7 cells (Normanno and Ciardiello,
1997; Keshamouni et al, 2002; Larsen et al, 1999). Tamoxifen alone did not elicit a
positive or inhibitory growth response in this cell line, however the cells were found
to be sensitive to the anti-oestrogenic actions of the drug when combined with E2,
which is agreement with many published articles (Lippman et al, 1979; Kallio et al,
2005; Seeger et al, 2003).
Morphology studies showed MCF-7 cells had a flat 'cobblestone' appearance when
untreated and that cell appearance changed only if treated with E2, or E2 in
combination with TGFa or tamoxifen. These observations are in agreement with
previous findings where MCF-7 cultured cells were observed to be flat adherent
epithelial-like cells (Thomas et al, 2005; Srivastava et al, 2004) which are sensitive
to the proliferative and antiproliferative actions of E2 and tamoxifen respectively
(Palmari et al, 2000). MCF-7 cells have been reported to have protrusions of the
plasma membrane (Thomas et al, 2005) and these were visible in all treatments. E2
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treatment increased the number of MCF-7 cells and altered their appearance from
cell-matrix adhesions to cell-cell adhesions in agreement with a study by Srivastava
et al (2004), who found E2 to up regulate the cells morphologically and numerically.
Tamoxifen did not alter the appearance of MCF-7 cells which is consistent with
observations by Srivastava et al (2004) who noted no cytotoxic effect on the cell line
post tamoxifen treatment. The morphology of treated MCF-7 cells agreed with the
growth studies, where tamoxifen reversed E2-induced growth. TGFa did not appear
to alter the morphology from that of control treated cells, although it did increase cell
number in agreement with proliferation studies here and published data (Stewart et
al, 1992).
The Mill and LCC1 cell lines were characterised as having acquired a 'hormone-
independent but hormone-responsive phenotype' by Thompson et al (1993). This
statement is in agreement with the growth curves produced in this chapter. The Mill
breast cancer cell line was therefore less sensitive to the proliferative effects of E2
than the MCF-7 cell line as it proliferated in charcoal stripped media. LCC1 cells
displayed a limited sensitivity to the proliferative effects of E2. The cell lines retain
sensitivity to antioestrogens and LH-RH antagonists (Artega et al, 1999; Clarke et al,
1989; Brunner et al, 1993a; Yano et al, 1992), which explains the reversal of the
effect of E2 in the presence of tamoxifen. Neither of the growth factors were able to
stimulate proliferation in any of the resistant cell lines tested. These are novel
results.
The LCC2 cell line also proliferated in a hormone-independent manner. LCC2 cells
displayed limited sensitivity to E2. Unlike the closely related LCC1 cell line, the
LCC2 cell line was insensitive to the anti-proliferative effects of tamoxifen. These
results are in agreement with a report on this cell line by Brunner et al (1993b). The
LCC2 cell line was found to be insensitive to TGFa and HRGp as previously
mentioned.
The LCC9 and LY2 cell lines were found to be completely insensitive to all ligands
and also to the anti-oestrogenic properties of tamoxifen when combined with E2.
The data on E2 and tamoxifen are corroborated by Brunner et al (1997) and Clarke et
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al (1987), and although as previously discussed in this chapter, Bronzert et al (1985)
reported LY2 cells to be E2-sensitive, this was after a longer incubation period
compared to this study. The panel of resistant breast cancer cell lines had a less
structured morphology than the MCF-7 cell line, perhaps reflecting their more
chaotic, uncontrolled and profuse proliferation.
It was hypothesised that the resistant cell lines would behave in a manner similar to
that of long term oestrogen deprived cells (LTED) as the cells proliferate in the
absence of stimuli. Several studies have implicated that hypersensitivity occurs in
LTED breast cancer cells (Santen et al, 2004), where extremely low residual
concentrations of hormones are able to stimulate cell proliferation. In a study by Yue
et al (2002), LTED MCF-7 cells responded in a 'nearly identical' manner to E2.
These studies both contrast with data here, where E2 response was progressively lost.
In another study, increasing concentrations of E2 reduced the proliferation of another
model of LTED (Song et al, 2001), which also contrasts with data obtained here.
There are some similarities, however, to a study by Staka et al (2005). This group
found that their LTED MCF-7 cells, MCF-7X, were not oestrogen hypersensitive,
and retained some degree of E2 sensitivity. This is consistent with Mill and LCC1
data, which were both elevated by E2 and proliferated in charcoal stripped media.
However, the remainder of the resistant cell lines were unresponsive to E2. The
divergence in pathways implicated in the published studies will be investigated in the
following chapters, including, the PI3-K/Akt and MEK/ERK pathways, with ERa
serine phosphorylation also being considered.
3. 5. 1. 2. Ovarian cancer cell lines
Growth data for the PEOl and SKOV-3 ovarian cancer cell lines was also consistent
with published studies, where both cell lines were sensitive to the proliferative
effects of TGFa, but only the PEOl cell line was found to be sensitive to E2.
(Langdon et al, 1988; Langdon et al, 1990; Hua et al, 1995; Doraiswamy et al,
2000).
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3. 5. 2. Expression profiles
The expression profiles of this model of resistance were monitored to assess whether
acquisition of hormone-independence and endocrine therapy resistance were related
to alterations in oestrogen-responsive genes.
LCC1 cells were reported to retain ERa levels equivalent to the parental MCF-7
cells (Brunner et al, 1993), however, this is in discord with data reported here where
LCC1, LCC9 and LY2 cells lines had elevated ERa mRNA expression compared to
the MCF-7 cell line. Later data published by de Cremoux et al (2003) contradicts
this earlier study and finds in favour of the LCC1 data here, where LCC1 basal levels
are higher than the parental line. This study did not confirm the LCC9 data reported
here, and instead stated there was a 19-fold reduction in ERa levels compared to the
LCC1 cell line, which was not observed here. It may be that differences in the time
point at which the mRNA changes were measured (48h as opposed to 24h time point
in this study), the primers used and/or the standard curve may account for these
changes. Also, differences in confluency of the cell lines may affect the mRNA
detected. All cell line ERa levels, with the exception of LCC9 cells, were reduced
with E2 treatment, with the greatest reduction observed in the LY2 cells. The
reduction was previously been reported by de Cremoux et al (2003) in the MCF-7
cell line.
The effects of growth factors on all the mRNA levels measured of the resistant cell
lines have yet to be reported, hence data reported here are novel. The elevated
expression levels of ERa in LCC1 and LCC9 cell lines may account for the elevation
in expression with TGFa treatment. This theory may also apply to the basal PR level
in the LCC9 cell line which is elevated even further with TGFa treatment. LCC1 PR
levels are similar to MCF-7 cell levels, but there is no reduction with growth factor
addition. This suggests the insensitivity of these cells to the proliferative effects of
TGFa may arise as a result of the insensitivity at the mRNA level. LY2 cells
generally reacted in a similar manner to MCF-7 cell lines, with perhaps only
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increased levels rather than reductions, again suggesting some form of resistance is
visible at the mRNA level in this cell line.
Basal levels of pS2 expression were significantly elevated in LCC1 and LCC9 cells
compared to MCF-7 cells, which is consistent with data published by Brunner et al
(1993) in these cell lines specifically, and also by Cho et al (1991) in two E2-
insensitive sublines, also derived from the MCF-7 cell line. LY2 cell pS2 mRNA
was not elevated as dramatically in control conditions compared to the LCC1 and
LCC9 cell lines, suggesting a different mechanism of resistance to these cells. E2
induced an extremely significant increase in pS2 mRNA in MCF-7 cells, which is
consistent with published data (Sun et al, 2005; Cho et al, 1991). Cho et al (1991)
showed that while ERa and PR mRNA expression remained the same in all lines, as
shown in this study, pS2 expression was higher in the E2-insensitive sublines. In
agreement with these earlier findings, these data suggest that the alteration of the pS2
gene in the resistant cell lines is probably not due to a defective ER regulation or ER
itself.
TGFa also enhanced pS2 in MCF-7 cells, in agreement with a study by El-Tanani
and Green (1997), but to a lesser extent than E2. pS2 expression remained unaltered
by TGFa in all the resistant cell lines. Again, the effects of growth factors on all the
mRNA levels of the resistant cell lines have yet to be reported, hence data here is
novel. This null effect may contribute to the growth factor insensitive phenotype of
the resistant cell lines.
Basal expression levels of PR mRNA were low in both MCF-7 and LCC1 cells,
which is supported by studies by de Cremoux et al (2003) and Brunner et al (1993),
while a study by Brunner et al (1997) found the LCC9 cell line to have an elevated
PR expression, in agreement with levels reported in this study. LY2 cells had a
reduced PR expression compared to MCF-7 cells. The LY2 cell line responded in a
similar manner to the MCF-7 with E2 treatment. PR expression was induced by E2 in
MCF-7 cells (Fritah et al, 2005; Cho et al, 1994), which was observed in these
findings. Studies by de Cremoux et al (2003) and Brunner et al (1997) also reported
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MCF-7 PR tnRNA, unlike that of the LCC9 cell line, was still oestrogen-inducible.
This statement again confirms findings here. PR expression was also elevated in
LCC1 cells, but to a lesser degree. Interestingly, PR mRNA expression levels were
increased significantly in the LY2 cells with E2 treatment compared to control cells.
This indicates that PR is still responsive to hormonal stimulation in all resistant cell
lines at the mRNA level, but to a much lesser extent in the LCC1 and LCC9 cells
than the completely E2-sensitive MCF-7 cell line. PR mRNA also appears to be
highly E2-responsive in the LY2 cell line, although this did not translate to the
proliferation data.
However, the resistant cell line mRNA levels behaved in a dissimilar manner to the
parental line when treated with TGFa. MCF-7 cell PR mRNA levels were reduced
upon TGFa treatment, while the levels remained unchanged in the LCC1 and LY2
cells (perhaps a slight, although insignificant, increase in the latter). The MCF-7
data contrasted with the LCC9 cell line mRNA levels which were increased with
TGFa treatment. The unchanged response to TGFa in LCC1 and LY2 cells and the
growth factor up regulation of PR levels in the LCC9 resistant cell line may be a
possible contributing factor to the development of resistance in these cell lines.
Expression profiling here showed that ERa, PR and pS2 genes all responded to E2 as
expected in MCF-7 cells, and that the resistant cell lines had elevated levels of pS2,
suggesting that the alteration of the pS2 gene in the resistant cell lines is probably not
due to a defective ERa regulation or ERa itself (Cho et al, 1991). TGFa, in general,
did not affect any of the resistant gene expression profiles, with the exception of the
LCC9 cell ERa and PR mRNA levels, where increases were observed, and an
increase in CTD expression in the LCC1 cells. This implies that there is a
disjunction between growth stimulation and the effects on E2-regulated gene
expression in the resistant cell lines. The majority of the stimulatory actions of
growth factors are ineffective at gene transcription level in E2-regulated genes in the
resistant cell lines and yet the genes themselves remain responsive to E2.
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MCF-7 basal CTD expression was not reduced in comparison to the resistant cell
lines contrasts with reports of increased levels of the cathepsin D enzyme in the
LCC1 cell line (Thompson et al, 1993). CTD has been shown to be elevated ~5-fold
between LCC1 and LCC9 cell lines (Gu et al, 2002b), which reflects the data here
where the LCC9 cell line had the highest relative CTD expression of any of the cell
lines. CTD has also been documented as an oestrogen-responsive gene (Chalbos et
al, 1993; Sun et al, 2004), which supports data reported here, where E2 induced a
significant increase in MCF-7 CTD expression. Basal CTD was inconsistently (and
insignificantly) elevated in LCC9 cells to the level of MCF-7 treated with E2 (24h),
but the gene was shown to remain as E2-responsive and active as E2 still elevated the
basal level significantly. These data are in agreement with studies mentioned earlier
in other oestrogen-regulated genes where the mRNA of the resistant cell lines
remains oestrogen-inducible.
CTD expression was unaltered in all cell lines treated with TGFa, with the exception
of slight increases in the LCC1 and perhaps the LY2 cell line. Previous studies by
Wang et al (2000) and Chalbos et al (1993) have shown an increase in the CTD gene
in the MCF-7 cell line with EGF and 1GF-1 growth factors. This disagrees with data
here, where no significant change was observed. The absence ofCTD induction may
be due to the lower concentration used (5 to 10-fold) while the study by Chalbos et al
(1993) used EGF, which although possesses very similar properties to TGFa, is not
identical to TGFa and therefore may not be directly comparable.
In conclusion, the development of a hormone-independent phenotype with varying
degrees of endocrine therapy resistance in human breast cancer may be associated
with disruption in the expression of specific oestrogen-regulated genes. In
particular, elevated expression ofER, pS2 and PR, but not CTD, mRNA occurs in the
resistant cell lines.
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3. 5. 3. Cell cycle characteristics
The cell cycle machinery is known to be under the direct control of oestrogen in
breast cancer expressing ERa (Prall et al, 1997; Planas-Silva and Weinberg, 1997).
Thus, to explore the causes of hormone independent growth, resistance to the
antiproliferative effects of tamoxifen and the proliferative effects of growth factors
cells were stained with propidium iodide and cell cycle analysis was performed using
flow cytometry.
MCF-7 cells arrest in the Go/Gi phase of the cell cycle when subjected to reduced
serum conditions (Dufournay et al, 1997), which supports the data obtained here.
All three ligands stimulated MCF-7 cells in the cell cycle, observed as significant
increases in the percentage of cells in S-phase of the cell cycle, which is consistent
with earlier research (Thomas & Thomas, 1994; Foster & Wimalasena, 1996; Lewis
et al, 1996; Prall et al, 1997; Abdelrahim et al, 2002). Tamoxifen alone did not
stimulate MCF-7 cells to enter the cell cycle. This is consistent with published
studies by Hodges et al (2003), Planas-Silva and Weinberg (1997) and Osborne et al
(1983). Tamoxifen significantly reduced the amount of E2 treated MCF-7 cells
progressing through the cell cycle compared to those treated with E2 alone which is
in agreement with published studies (Watts et al, 1994).
In contrast to the parental cell line, LCC1 and LCC9 resistant cell lines both
displayed a constitutive increase in the number of cells in the S-phase of cell cycle.
This is indicative of an increased number of cells proliferating in the absence of
ligand and supports cell proliferation studies. Wilcken et al (1997) demonstrated that
overexpression and induction of cyclin D1 stimulated cells which were previously
arrested in G1 to enter S-phase which supports results in this chapter. Wilcken et al
(1997) postulated that this occurred by the formation of active cyclin Dl/Cdk4
complexes and hyperphosphorylation of the retinoblastoma protein.
In contrast to the MCF-7 cell line, the resistant cell lines did not show an increased
progression of cells into the S-phase of cell cycle post treatment with E2 or either
139
Kate Moore Chapter 3: Cell Line Characterisation
growth factor. These cells had in fact a reduced number of cells in the S-phase post-
treatment. Oestrogen has been shown to induce Gi-progression via the activation of
Cdk4 and Cdk2 mediated through increased cyclin D1 expression, its regulatory
subunit (Prall et al, 1997). It may be that the resistant cell lines do not possess or
express these molecules to the same extent as MCF-7 cells, or more likely, the
molecules are overexpressed and automatically drive the cell cycle in the absence of
ligand stimulation. This is supported by Murray et al (2005), who reported that
upregulated expression of cyclin D1 was found in tumours in comparison to normal
mammary glands. Importantly, over expression of cyclin D1 was also reported by
Hodges et al (2003) to be present in cell lines with tamoxifen resistance.
Recent studies by Riggins et al (2005) and Gu et al (2002) have provided evidence of
the overexpression of an alternative molecule to support the cell cycle oestrogen-
insensitivity of the LCC9 cell line. The LCC9 cell line was found to have elevated
expression of the p65 NFkB subunit and IkB kinase essential modulator, the
upstream regulator of NFkB. NFkB and other members of this family regulate
inhibitors of apoptosis and the pro-proliferative affects of c-myc among many factors
(Chen and Greene, 2004). The constitutive activation of NFkB has been implicated
in breast cancer, and has been shown to be linked with resistance to agents which
promote apoptosis (Baldwin, 2001). However, overexpression of the p65 NFkB
subunit and IkB kinase was only found in the LCC9 cell line and not in the LCC1
cell line, suggesting a different mode of oestrogen-independent signalling in the
LCC1 cell line. Perhaps the overexpression of a different molecule may play a role
in the LCC1 cell line. The slight downward trend in the number of resistant cells in
S-phase post ligand treatment may be as a result of superfluous ligand interfering
with the over expressed molecules or other parts of the cell cycle machinery.
Tamoxifen and E2 + tamoxifen had the same effect as E2 alone on cell cycle
regression in both the resistant cell lines. This reversal of the resistant cell lines into
arrest may act as a protective mechanism, reducing the number of cells that can be
targeted by a pro-apoptotic caspase or BcI-2 family member.
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3. 5. 4. Apoptotic profile
The regulation of apoptosis and proliferation are together thought to determine the
response to radiotherapy, chemotherapy, and endocrine therapy response (Dowsett et
al, 1999) the latter being of particular interest in this investigation. Deregulation or
an imbalance of these factors has been implicated in the development of cancer
(Wyllie, 1997). The annexin staining of each cell line pre and post treatment enabled
the assessment of the extent of apoptosis of the resistant cell lines in comparison to
the sensitive MCF-7 cells. Any differences noted at this downstream point may
reflect changes in an upstream signalling molecule which led to the development of
insensitivity.
In charcoal stripped serum under control conditions the MCF-7 cell line was found
to display a certain amount of apoptosis and this is supported by data provided by
Rodrick et al (2005) who found that in the absence of growth factors, the MCF-7 cell
line underwent apoptosis. This study and others also report that E2 has an anti-
apoptotic action in MCF-7 cells deprived of serum (Rodrick et al, 2005; Somai et al,
2003). This supports the results recorded here where a marginal reduction in
apoptosis was observed with E2 treatment, although this was not found to be
significant. Rodrick et al (2005) suggested that the action of E2 may occur in breast
cancer cells via the promotion of survival signals through an mTOR-dependent
elevation of Myc expression. The group also hypothesised that an increase in
phospholipase D (PLD) expression, which is prevalent in breast cancer, may result in
oestrogen independence.
Tamoxifen has been shown to inhibit the proliferation of breast cancer cells and
induce apoptosis of these cells by ERa-dependent modulation of gene expression
(Kallio et al, 2005). Autophagic cell death has also been implicated in MCF-7 cells
when treated with tamoxifen (Bursch et al, 1996). The established apoptotic model
consists of intiator caspases 8 and 9 and executioner caspases 3, 6 and 7, although
MCF-7 cells do not contain caspase-3 (Janicke et al, 1998). Different caspases are
probably still involved in tamoxifen-induced MCF-7 cell death however, as the cells
have been shown to undergo caspase-dependent cell death when subject to etoposide
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or doxorubicin treatment (Janicke et al, 1998). The absence of caspase-3 activation
in MCF-7 cells has led to speculation that tamoxifen operates via a caspase-
independent mechanism to induce cell death. Apoptosis and alternative mechanisms
of cell death are reviewed by Guimares and Linden (2004), and may involve the
downregulation of Bcl-2, as reported in breast cancer cell lines.
A study by Kallio et al (2005) suggested that there are several mechanisms by which
tamoxifen causes breast cancer cell death. A possible mode of action is the rapid
induction of cell death by mitochondrial mechanisms, which can be modulated by
ERs, but are not solely dependent on these receptors. The group also demonstrated
that the susceptibility of breast cancer cells to cell death induced by tamoxifen may
be elevated by oestrogen withdrawal, or by pre-treating the cells with another anti-
oestrogen. This theory may be consistent with the LCC1 and LCC9 cell lines which
were developed in a similar manner.
lgM Tamoxifen has been documented as being able to inhibit proliferation and
induce apoptosis of MCF-7 cells (Kallio et al, 2005), but under these charcoal
stripped specific conditions in this study tamoxifen was unable to reduce cell
proliferation further than control conditions thus it is unsurprising apoptosis was not
increased significantly further than control levels. This is consistent with the cell and
proliferation data provided here. The absence of tamoxifen-induced apoptosis under
charcoal stripped conditions may be explained by a theory proposed by Evan and
Littlewood (1998). These authors theorised that apoptosis could not occur unless
cells could also proliferate. This suggests that cell proliferation is a requirement in
order for apoptosis to occur, and that perhaps the withdrawal of a growth signal such
as E2 and/or the addition of an inhibitor of that signal (tamoxifen) disrupts cells
trying to grow down an apoptotic pathway. Tamoxifen has also been shown to
induce apoptosis in a time- and dose-dependent manner by modulating bcl-2 levels in
breast cancer cells. The tamoxifen-induced downregulation of bcl-2 was not
accompanied by alterations in p53 levels (Zhang et al, 1999).
HRGp treatment had an anti-apoptotic effect on MCF-7 cells, with a significant
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reduction in early stage apoptosis, which is supported by earlier studies with growth
factors (Guerra-Vladusic et al, 1999).
E2 appeared to reduce the apoptosis taking place in the LCC1 cell line, which is
consistent with the growth phenotype. Both resistant cell lines were insensitive to the
anti-apoptotic affect of HRGp, again consistent with the growth data. A possible
mechanism for the reduced rate of apoptosis of the LCC9 cell line was documented
by Bouker et al (2004). The group indicated that the development of anti-oestrogen
resistance present in the LCC9 cell line was mediated by a reduction in ER-mediated
apoptosis by a loss of IRF-1 and IRF-1 regulation. Bouker et al (2004) also
indicated that this reduction in apoptosis was responsible for resistance rather than a
variation in cell cycle distribution. However, the reduction in IRF-1 was not
observed in LCC1 cells, indicating again the progression of resistance in this model
is also occurring at the molecular level.
Treeck et al (2004) observed that MCF-7 cells subjected to long term tamoxifen
treatment displayed a significantly reduced apoptotic response to tamoxifen. This
supports the data acquired in this study, where tamoxifen was unable to increase
apoptosis in either the LCC1 or LCC9 cell lines. A summary of the characteristics of
the cell lines are listed in Table 1. 2.
In conclusion the absence ofcell cycle progression in response to ligand stimulation
and a general reduction in the number of apoptotic resistant cells suggest
insensitivity and resistance occurs in a pathway upstream of these processes. The
next chapter will investigate the activation of these upstream pathways, in the form
of the PIS-K/Akt and MEK/ERK, in order to ascertain whether the loss of growth
factor activity and Ej-insensitivity developed here.
This panel ofcell lines is a useful model ofnot only oestrogen and endocrine therapy
resistance but also growth factor insensitivity at several levels. The cell lines were
originally derived from one source and show a gradual development of insensitivity,
which is extremely relevant as this mirrors the clinical progression of breast cancer
and how resistance develops.
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Table 3.1. Summary table of the characteristics of the panel of breast and ovarian cell lines.
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Chapter 4: Signalling Pathway Characterisation
Differential expression and activation
of ERa and upstream signalling
pathways in resistant breast cancer
cell lines
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4. 1. Functionality and activation of ERa
Chapter 3 showed the resistant cell lines to be insensitive to not only oestrogen but
also growth factor stimulation. In order to ascertain where this insensitivity arose
from, the signalling pathways upstream of ERa were investigated. ERa itself was
also probed at the protein level to assess whether it could be activated, or was
functional at this stage in the cell proliferation pathway.
Previous studies have shown that phosphorylation of serine residues on ERa at
positions 104 and/or 106, serine 118 and serine 167 cause activation of ERa and that
mutation of these residues reduces ERa activation, gene transcription and eventually
cell proliferation (reviewed by Lannigan, 2003). Indirect evidence has shown that
phosphorylation is involved in receptor function, for example, oestrogen causes a
rapid increase in phosphorylation by several fold, and TGFa is able to elicit ligand-
independent ERa activation (Joel et al, 1995; Bunone et al, 1996). Events
subsequent to this initiate ERE-mediated gene expression. Oestrogens and
antioestrogens, such as tamoxifen, and protein kinase activators also increase
phosphorylation of the ER and/or proteins in the ER signalling cascade
(Katzenellenbogen et al, 1995), hence the effect of growth factors and oestrogen and
tamoxifen were used to investigate the effect on the ligand independent and
dependent pathways respectively.
4. 1. 1. Is the ERa still present and functional in resistant
breast cancer?
The ERa protein expression levels in the resistant and parental breast cancer cell
lines were investigated. The cells were treated with oestrogen in the form of 17(3-
oestradiol (E2) (InM) to observe if the receptors were 'turned over' and thus protein
levels reduced by degradation. Turnover of ERa occurs when E2 binds activating
transcription and removing ERa from further E2 activation and reducing the amount
of protein detectable by western blotting (El Khissin and Leclercq, 1999; Nawaz et
al, 1999; Lonard et al, 2000). The relative ERa expression was determined in the
panel of cell lines. Initial studies of ERa and ER(3 were performed in all the breast
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cancer cell lines, but the Mill cell line was excluded later as it was considered to
have a very similar phenotype to the LCC1 cell line. The more significantly altered
phenotypes of the LCC1 and LCC9 cell lines were deemed more suitable for further
investigation. ERa protein levels were higher in the Mill, LCC1 and LCC2 resistant
cell lines in comparison to the MCF-7, LCC9 and LY2 cell lines (figure 4. 1A).
The lower panel of ERa expression shows LCC1 and LCC2 ERa protein levels were
-1.8 and ~1.6-fold higher than the parental cell line. ERa levels were reduced by
-0.5-fold in MCF-7 cells upon E2 treatment and LCC9 and LY2 cell lines were
reduced by -0.7-fold. The ERa protein levels were also reduced in LCC1 and LCC2
cell lines, but to a lesser degree (-0.3 and -0.2-fold reductions). These reductions
were all seen at only 30 min, which is an early time point. Time course studies were
also performed to investigate the effects of E2 over a longer time period (see figure
4. 2). The reduction in protein expression suggests the ERa of the resistant cell lines
are all able to bind E2, however, this may not necessarily translate to the expression
of functionally active ERa. ERp expression in the panel of cell lines was also
investigated. There was no clear difference between the resistant and MCF-7 cell
lines (figure 4.IB), although these studies do not show whether the ERa:ERp ratio is
equivalent across the panel of cell lines.
Figure 4.2 shows the effects of E2 (InM), tamoxifen (lpM) and E2 + tamoxifen (InM
+ lpM) over a 24h time course (0-1440 min). These studies, and subsequent more
in-depth profiles, were performed in MCF-7, LCC1 and LCC9 cell lines as these
lines displayed a clear progression in antioestrogen resistance and oestrogen
independence. The western blots of the ERa protein expression levels are shown in
the left hand panel with their corresponding p-actins beneath each blot as loading
controls. The histograms in the right hand panel represent the optical density (OD)
values taken from the western blots relative to each other using MCF-7 cells treated
with E2 for 30 min as a positive control (+). The maximum reduction was observed
after 1440 min (24h) in all cells, with reductions of -7, -47 and ~63-fold for MCF-7,
LCC1 and LCC9 cell lines respectively after E2 treatment. Tamoxifen did not affect
the levels of MCF-7 ERa as the values wavered around those of control treated cells.
E2 + tamoxifen did not induce or reduce ERa expression in this cell line.
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Figure 4. 1 ERa and ERp protein expression levels. A, ERa expression levels in the panel
of breast cancer cell lines. The effect of E2 was assessed in a reduced panel of cells, where
ERa levels decreased in the presence of E2 in parental and resistant breast cancer cell lines
alike. MCF-7 cells were charcoal-stripped for 24h and then the cell lines were treated with
E2 (1nM) for 30 min.; B, ERp protein expression levels, where levels were similar across the
panel of cell lines. Protein lysates were run on a 10% SDS-gel and membranes probed with
ERa (F10, 1:200) or ERp (H-150, 1:200) primary antibody. Results are representative of 1 of
3 independent experiments.
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Figure 4. 2 ERa protein expression levels decreased in the presence of E2 over time in
parental and resistant breast cancer cell lines. MCF-7 cells were charcoal-stripped for
24h and then all cell lines were treated with control media (♦), E2 (1nM) (■), tamoxifen
(1pM) (A) or E2 + tamoxifen (1nM + 1pM) (▼), for 0-1440 min. Protein lysates were run on
a 10% SDS-gel and membranes probed with ERa primary antibody (F10, 1:200).
Histograms represent the western blots in the left hand panel. The positive control (+) was
MCF-7 E2 30 min treatment, which was used to calculate relative ERa expression (OD units
standardised to actins & + control) in the histograms of each western blot. Results are
representative of 1 of 3 independent experiments.
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In the LCC1 cell line the ERa levels were reduced over time with all treatments
except control. Interestingly, tamoxifen appeared to reduce the level of protein by
~4-fold, which could be explained by the mild oestrogenic activity of tamoxifen.
The trend of ERa expression after E2 + tamoxifen treatment is similar to that of
tamoxifen alone, where a ~4-fold reduction is observed. This is supported by
previous growth data and published research, where the LCC1 cells were shown to
be tamoxifen-resistant (Brunner et al, 1993a). The ERa protein levels in the LCC9
cell line were only reduced by E2. Tamoxifen alone and E2 + tamoxifen treatment
produced ERa trends similar to that of the untreated cells.
4. 1. 2. Is the ERa still activated in resistant breast cancer?
4. 1. 2. 1. P-S118 30 min single time point
As the ERa was shown to be turned over, phosphorylation of the ERa was then
studied to determine any differences in the activation of resistant breast cancers
compared to the parental MCF-7 cell line. The activation of the ERa via
phosphorylation of serine residue 118 was investigated by treating the panel of breast
cancer cell lines with E2 (InM), TGFa (InM), tamoxifen (lpM) or E2 + tamoxifen
(InM + 1 pM), for 30 min. Lysates were run on 10% SDS gels and once transferred,
membranes were probed with a P-Sl 18 antibody. Figure 4.3A is a representative
western blot and shows the antibody binds to the ERa P-S118 (at ~66kDa) and
produced a number of bands at and around that position, depending on treatment.
Control treatment produced relatively little or no P-Sl 18 in all cell lines, while E2
produced a significant increase in P-Sl 18 in all cell lines (seen as a doublet, or a
single band where the two bands merge together), with the exception of LCC9 cells.
Figure 4.3B shows a histogram of western blot OD values of the MCF-7 and two
chosen resistant lines (LCC1 and LCC9). Statistical analyses were performed on
these data only. The small differences in control levels between the cell lines were
statistically insignificant. There were, however, increases in P-Sl 18 of ~5-fold for
MCF-7 (P<0.001) and Mill cells with 30 min E2 treatment compared to control
levels, and of~22-fold (P<0.001) compared to control in LCC1 cells.
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Figure 4.3 Effect of various treatment on the level of ERa P-S118 in resistant versus
parental breast cancer cell lines. A, Western blot showing the panel of breast cancer cell
lines were charcoal stripped for 24h then treated with control media, E2 (1nM), TGFa (1nM),
tamoxifen (1pM) and E2 + tamoxifen (1nM + 1pM) for 30 min. Lysates were run on a 10%
SDS gel and membranes probed with ERa P-S118 antibody (1:1000). Actins are shown as
loading controls. B, Histogram representing optical densities (OD) from triplicate western
blots, where cells were treated with control media(«), E2(«), TGFa ( ), tamoxifen ■) and E2 +
tamoxifen (■), where the positive control used was MCF-7 E2. ANOVA test: * = P<0.05,
**
= PO.01 and *** = P<0.001. Black asterisks represent statistical significance between
control and each treatment in each cell line, those in green represent statistical significance
between cells treated with E2 and E2+Tamox in each cell line, while those in red represent
statistical significance between MCF-7 and resistant cell lines treated with E2. Western blots
are representative of 1 of 3 independent experiments which are amalgamated in the
histogram (B).
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There was a similarly large induction of P-S118 in LCC2 cells, although the fold
increase could not be determined due to the zero optical density reading of the
control value (~1.3 OD units post E2 treatment compared to zero units with control
media alone). E2 enhanced P-S 118 by -6.5-fold in the LY2 cell line. TGFa
enhanced P-S 118 after 30 min in the Mill cell line only (~3-fold compared to
control). Tamoxifen enhanced P-Sl 18 in MCF-7, Mill and LCC1 by approximately
2, 6 and 2.5-fold (P>0.05, not statistically significant) respectively and an increase of
0.2 OD units was noted in the LCC2 cell line. Tamoxifen reversed E2-induced
P-S 118 in MCF-7 cells (~4-fold reduction, P<0.01, as indicated by the green
asterices on figure 4.3B), but to a lesser degree in LCC1 (-0.1-fold reduction,
P>0.05) and LCC2 cells (-0.25-fold reduction).
No reversal of E2 enhanced P-S 118 was observed in Mill cells with tamoxifen
treatment (-0.1-fold increase). Tamoxifen reversed E2-enhanced P-Sl 18 by ~3-fold
in the LY2 cell line. LCC9 P-Sl 18 levels were low compared to all other cell lines
and irrespective of treatment (P>0.05).
4. 1. 2. 2. P-S118 24h time course
The effect of E2 (InM), tamoxifen (lpM) and E2 + tamoxifen (InM + lpM) on ERa
P-Sl 18 over a 24h time period (0-1440 min) in MCF-7, LCC1 and LCC9 cell lines
was investigated (Figure 4.4). ERa P-Sl 18 was detected using western blotting with
a phospho-specific antibody as before. A representative western blot and histogram
for MCF-7 cells are shown in figure 4.4A and B respectively. The only marked
induction in ERa P-Sl 18 was seen with E2 treatment. E2 treatment enhanced P-S 118
after 5 min and this continued up to and including the 240 min time point. The
maximum increase in P-Sl 18 was observed between the 30 and 60 min treatments
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Figure 4.4 Effect of E2 and tamoxifen on the level of ERa P-S118 in MCF-7 parental
breast cancer cell line over a 24h time course. A, western blot showing the MCF-7 cell
line was charcoal stripped for 24h then treated with control media, E2 (1nM), tamoxifen
(1pM) and E2 + tamoxifen (1nM + 1pM) over a 24h time period (0-1440 min). Lysates were
run on a 10% SDS gel and membranes probed with ERa P-S118 antibody (1:1000). Actins
are shown as loading controls. B, Graphical representation of optical densities (OD) from the
western blot shown in A, where cells were treated with control media (■), E2 (■), tamoxifen
(■) and E2 + tamoxifen (■) and ODs were actin corrected and standardised to time 0. Results
are representative of 1 of 3 independent experiments
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Figures 4.5A and B show the western blot and histogram for the time course
treatments of the LCC1 cell line. There is a massive induction in P-S118 with E2
treatment after 5 min, which remained above control level up to and including the 60
min time point. P-S 118 levels return to basal level after 240 min E2 treatment.
Tamoxifen enhanced P-Sl 18 markedly after 5 min, and this remained the case for the
duration of the time course, with the exception of the 30 min time point where the
increase was only minor.
After 240 min exposure to E2, the level of P-Sl 18 returned to a level similar to that
of control. Tamoxifen was able to almost completely abrogate E2-induced P-Sl 18
(95% reversal after 5 min), reducing P-Sl 18 to just above that of control treated
cells, and interestingly below that of tamoxifen treatment alone for the duration of
the experiment.
The LCC9 cell line was treated as described for MCF-7 and LCC1 cell lines and is
shown in figure 4.6A and B (representative western blot and histogram respectively).
There was no obvious change in P-Sl 18 levels irrespective of treatment at any time
point, although a small increase was observed with tamoxifen alone and E2 plus
tamoxifen treatments after 24h (1440 min).
Chapter 3 reported the resistant cell lines to be growth insensitive to treatment with
TGFa hence this ligand was further investigated for the potential to enhance P-Sl 18
over time to see if the ligand had lost its ability to activate ERa. Figures 4.7A and B
are the data for the MCF-7 cell line. Control levels were low as before. E2
treatment, as previously described, induced a dramatic increase in P-Sl 18 after 5 min
to 240 min treatment, whilst TGFa also enhanced P-Sl 18, but to a lesser degree.
The greater area under the curve shows that E2 enhanced P-Sl 18 for a more
prolonged time period, with the greatest increase around 30 min as before (~9-fold
increase), compared to a smaller peak also seen after 30 min TGFa treatment (~6-
fold increase).
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Figure 4.5 Effect of E2 and tamoxifen on the level of ERa P-S118 in the LCC1 breast
cancer cell line over a 24h time course. A, western blot showing the LCC1 cell line was
charcoal stripped for 24h then treated with control media, E2 (1nM), tamoxifen (1pM) and E2
+ tamoxifen (1nM + 1pM) over a 24h time period (0-1440 min). Lysates were run on a 10%
SDS gel and membranes probed with ERa P-S118 antibody (1:1000). Actins are shown as
loading controls. B, Graphical representation of optical densities (OD) from the western blot
shown in A, where cells were treated with control media (■), E2 (■), tamoxifen (■) and E2 +
tamoxifen (■) and ODs were actin corrected and standardised to time 0. Results are
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Figure 4.6 Effect of E2 and tamoxifen on the level of ERa P-S118 in the LCC9 breast
cancer cell line over a 24h time course. A, western blot showing the LCC9 cell line was
charcoal stripped for 24h then treated with control media, E2 (1nM), tamoxifen (1pM) and E2
+ tamoxifen (1nM + 1pM) over a 24h time period (0-1440 min). Lysates were run on a 10%
SDS gel and membranes probed with ERa P-S118 antibody (1:1000). Actins are shown as
loading controls. B, Graphical representation of optical densities (OD) from the western blot
shown in A, where cells were treated with control media (■), E2 (■), tamoxifen (■) and E2 +
tamoxifen (■) and ODs were actin corrected and standardised to time 0. Results are
representative of 1 of 3 independent experiments.
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Figure 4.7 Effect of E2 versus TGFa on the level of ERa P-S118 in the parental MCF-7
breast cancer cell line over a 24h time course. A, western blot showing the MCF-7 cell
line was charcoal stripped for 24h then treated with control media, E2 (1nM), and TGFa
(1nM) over a 24h time period (0-1440 min). Lysates were run on a 10% SDS gel and
membranes probed with ERa P-S118 antibody (1:1000). Actins are shown as loading
controls. B, Graphical representation of optical densities (OD) from the western blot shown in
A, where cells were treated with control media (■), E2 (■), and TGF a ( ) and ODs were actin
corrected and standardised to time 0. Results are representative of 1 of 3 independent
experiments.
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Figure 4.8 Effect of E2 versus TGFa on the level of ERa P-S118 in the LCC1 breast
cancer cell line over a 24h time course. A, western blot showing the LCC1 cell line was
charcoal stripped for 24h then treated with control media, E2 (1nM), and TGFa (1nM) over a
24h time period (0-1440 min). Lysates were run on a 10% SDS gel and membranes probed
with ERa P-S118 antibody (1:1000). Actins are shown as loading controls. B, Graphical
representation of optical densities (OD) from the western blot shown in A, where cells were
treated with control media (■), E2 (■), and TGF a ( ) and ODs were actin corrected and
standardised to time 0. Results are representative of 1 of 3 independent experiments.
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TGFa treatment of LCC1 cells increased P-Sl 18 levels after approximately 30 min
compared to that of control treated cells (figure 4.8A and B) with levels returning to
near basal level after 120 min. E2 treatment enhanced P-Sl 18 to greater extent than
TGFa (~2-fold difference between peak values).
Exposure to E2 or TGFa did not alter P-Sl 18 expression in LCC9 cells (figures 4.9A
and B). The LCC9 data was compared to a positive control (MCF-7 cells treated
with E2 for 30 min) to highlight the extremely low levels of expression in
comparison to the MCF-7 cell line and also to confirm the activity of the antibody.
As with figure 4.6, there was a minor increase in P-Sl 18 after 1440 min (24h) with
E2 treatment. This also occurred with TGFa treatment.
E2 enhanced P-Sl 18 in resistant LCC1 and LCC2 cell lines to a greater extent than
MCF-7 cells and Mill cells. These data are consistent with the elevated levels of
ERa in these cell lines, which may account for this elevated P-Sl 18, and are also
consistent with the growth data. Exploratory analysis into the ratio of T-ER to P-
S118 supports the elevated T-ER in resistant cell line hypothesis, with the LCC1 cell
line having a larger proportion of T-ER than the parental cell line. The LCC1 cell
line had a ratio of -5.7:1 (T-ER: P-Sl 18) compared to -0.15:1 in the MCF-7 cell line
after 5 min E2 treatment, where maximum P-Sl 18 enhancement was reported in the
LCC1 cell line. The ratio remained in favour of a greater T-ER content in the LCC1
cell line even at the maximum P-Sl 18 enhancement in the MCF-7 cell line after 30
min E2 treatment, with ratios of 1.7:1 and 0.7:1 in the LCC1 and MCF-7 cell lines
respectively. Initial exploratory analysis of this ratio in the LCC9 cell line produced
a ratio of—0.4:1 after 5 and 30 min of E2 treatment. The ratio may not be as great as
that between the LCC1 and MCF-7 cell lines, but the LCC9 cell line still has a
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Figure 4.9 Effect of E2 versus TGFa on the level of ERa P-S118 in the LCC9 breast
cancer cell line over a 24h time course. A, western blot showing the LCC9 cell line was
charcoal stripped for 24h then treated with control media, E2 (1nM), and TGFa (1nM) over a
24h time period (0-1440 min). Lysates were run on a 10% SDS gel and membranes probed
with ERa P-S118 antibody (1:1000). Actins are shown as loading controls. B, Graphical
representation of optical densities (OD) from the western blot shown in A, where cells were
treated with control media (■), E2 (■), and TGF a ( ) and ODs were actin corrected and
standardised to time 0. Results are representative of 1 of 3 independent experiments.
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4. 1. 2. 3. ERa P-S167
ERa activation was also monitored at serine residue 167 (SI67) as this residue has
been shown to be phosphorylated in MCF-7 cells as a result of stimulation via the
Pl3-K/Akt pathway and has been implicated in tamoxifen-resistance (Campbell et al,
2001). It was therefore hypothesised, as for P-Sl 18 expression, that the resistant cell
lines would be constitutively activated at SI67; however this was not found to be the
case.
The relative level of P-S167 in MCF-7 cells in comparison to LCC1 and LCC9 cell
lines is shown in figure 4.1 OA. MCF-7 cells treated with HRGp for 15 min were
used as a positive control. A clear band was observed in this lane, but no other,
showing the MCF-7 and the resistant cells alike were not constitutively activated at
this position. Figure 4.1 OB illustrates the activation of ERa at SI67 in all three cell
lines as bands are visible with HRGP treatment in the second column of all cell lines.
























Figure 4.10. Basal levels and HRGp activation of ERa P-S167 in MCF-7 versus
resistant breast cancer cell lines. A, western blot showing MCF-7, LCC1 and LCC9
breast cancer cell lines were charcoal stripped for 48h then treated with control media for 15
min. MCF-7 cells were also treated separately with HRGp (1nM) for 15 min to act as a
positive control (+). B, Cells were treated as in (A), with control media and HRGp (1nM) for
15 min. Lysates were run on a 10% SDS gel and membranes probed with ERa P-S167
antibody (1:1000). Actins are shown as loading controls. Results are representative of 1 of
3 independent experiments.
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4. 2. ERa expression and activation in ovarian cancer
4. 2. 1. ERa expression in ovarian cancer
The relative expression of ERa was confirmed in the ovarian PEOl and SKOV-3 cell
lines in comparison to the MCF-7 breast cancer cell line (figure 4.11). The western
blot showed that the greatest ERa expression was found in MCF-7 cells, with PEOl
and SKOV-3 cells expressing dramatically reduced levels of this protein. PEOl cells
expressed approximately a third of the amount of protein, while SKOV-3 expression
was relatively low compared to the other cell lines (at least ~20-fold reduced
expression compared to MCF-7 and PEOl cell lines).
4. 2. 2. ERa activation in ovarian cancer
The reduced expression of ERa in the ovarian cell lines was hypothesised to reduce
the activation observed through phosphorylation. Figure 4.12 shows that the effect
of E2 and TGFa on P-Sl 18 in MCF-7 cells in comparison to the PEOl and SKOV-3
cell lines. MCF-7 cells treated with E2 and TGFa for 30 min were used as positive
controls for P-S118 and P-S167 respectively. PEOl cells displayed no detectable
P-Sl 18 while E2 induced a low level of P-Sl 18 in SKOV-3 cells. There appeared to
be some background P-Sl 18 in the SKOV-3 cell line. No P-S167 was detected in
either ovarian cell line with either E2 or TGFa treatment.
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Figure 4.11. ERa expression levels in the MCF-7 breast cancer cell line compared to
ovarian cancer cell lines. All cells were charcoal stripped for 24h and protein lysates were
run on a 10% SDS-gel and membranes probed with ERa F10 antibody (1:200). Actins are




















Figure 4.12. Effect of various treatments on the level of ERa P-S118 and P-S167 in
MCF-7 breast cancer cell line in comparison to ovarian cancer cell lines. Western blots
showing P-S118 and P-S167 expression in MCF-7 breast cancer in comparison with PEOI
and SKOV-3 ovarian cancer cell lines. All cells were charcoal stripped for 24h then treated
with control media, E2 and TGFa (both 1nM) for 30 min. MCF-7 cells treated with E2 and
TGFa for 30 min were used as positive controls for P-S118 and P-S167 respectively (+).
Lysates were run on a 10% SDS gel and membranes probed with either ERa P-S118 or P-
S167 antibodies (1:1000). Actins are shown as loading controls. Results are representative
of 1 of 3 independent experiments.
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4. 3. Are signalling molecules upstream of ERa involved in
the development of resistant breast cancer?
Signalling molecules upstream of ERa were investigated in the presence and absence
of hormonal and growth factor stimulation to determine their role and importance, if
any, in the development of E2 and endocrine-therapy-insensitivity. In particular, the
activation status, through phosphorylation, of signalling molecules Akt, MEK and
ERKI/II were characterised. These molecules were chosen as they have all
previously been linked with the development of breast cancer.
4. 3. 1. P-Akt
Figure 4.13A shows a representational western blot of the protein expression of
P-Akt in MCF-7, LCC1 and LCC9 cells treated with control media, E2 (InM), TGFa
(InM) or HRGp (InM) for 15 min. Total-Akt levels were used as loading controls.
Figure 4.13B shows a histogram representing triplicates of independent western blots
performed, where P-Akt was significantly constitutively activated in both the LCC1
and LCC9 cells compared to MCF-7 cells (~2.2- (P<0.01) and ~2.1-fold (P<0.05)
increases respectively compared to control treated MCF-7 cells). P-Akt was not
elevated in any cell line with E2 treatment (P>0.05) when compared to the control or
other treatments. TGFa activated Akt through phosphorylation in all cell lines.
TGFa elevated P-Akt ~6-fold in MCF-7 cells (PO.OOl, when considered separately
from HRGp data). Resistant cell lines were activated further than their elevated
basal levels upon TGFa treatment, with inductions of ~1.5-fold for LCC1 cells
(P>0.05) and ~1.8-fold (P<0.05) for LCC9 cells. HRGp significantly increased P-
Akt in MCF-7 by over ~30-fold (PO.OOl), ~3.3-fold in LCC1 cells (PO.OOl) and
~3.5-fold in LCC9 cell lines (P<0.01). The final P-Akt expression levels were





















































Figure 4. 13. Comparison of the levels of P-Akt and the effect of ligand stimulation on
levels of P-Akt in resistant versus parental breast cancer cell lines. A, Western blot of
P-Akt levels, where MCF-7 cells were charcoal stripped for 48h before all cell lines were
treated with control media, E2 (1nM), TGFa (1nM) or HRG (1nM) for 15 min. Membranes
were probed with P-Akt primary antibody (1:1000). T-Akt levels were used as loading
controls. B, histogram of P-Akt levels of MCF-7, LCC1 and LCC9 cell lines treated with
control media (■), E2 (■), TGFa ( ) or HRG ( ) as before, where data are in triplicate +/-SD.
MCF-7 cells treated with TGFa were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Black asterisks represent statistical significance between
control and each treatment in each cell line. Western blots are representative of 1 of 3
independent experiments which are amalgamated in the histogram (B).
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4. 3. 2. P-MEK
The levels of P-MEK in MCF-7, LCC1 and LCC9 cells were determined after 15
min treatment with control media, E2 (InM), TGFa (InM) and HRGp (InM) (Figure
4.14) as for previous signalling experiments. Figure 4.14A is a representative
western blot of the phospho and total levels of MEK protein found in each cell line.
T-MEK levels were used as loading controls. Figure 4.14B is a histogram of
triplicate OD values taken from the western blots of separate experiments. The
histogram shows statistical analysis of data including HRGp treatment. Very little
P-MEK was observed, if at all, in any of the three cell lines treated with control
media and there was no significant difference between the basal levels of any of the
cell lines.
Et did not significantly increase P-MEK in any cell line as the SD values were large.
TGFa and HRGP increased P-MEK extremely significantly in MCF-7 cells (mean
OD values of 1 and 5+/-0.2 arbitary units compared to a control value of zero,
P<0.001). TGFa significantly elevated the P-MEK in LCC1 cells by ~300-fold
(P<0.001, when considered separately from HRGp data), and P-MEK expression was
elevated by ~3000-fold with HRGP treatment, which was also found to be extremely
significant (P<0.001). LCC9 cells were also subject to an increase in P-MEK with
TGFa (~43-fold) (P<0.001, when considered separately from HRGp data). HRGP
increased P-MEK expression by ~1500-fold in the LCC9 cell line (P<0.01). Figure
4.14B shows the differences in P-MEK expression between the MCF-7 and the
resistant cell lines when subjected to TGFa treatment to be extremely significant
(P<0.001). P-MEK levels were also significantly higher in the parental line in
comparison to the resistant lines when treated with HRGp (P<0.05 and P<0.001 for
LCC1 and LCC9 cells respectively). LCC1 P-MEK expression was also elevated
significantly when compared to the LCC9 cell line (P<0.01).
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Figure 4. 14. Comparison of the levels of P-MEK and the effect of ligand stimulation on
levels of P-MEK in resistant versus parental breast cancer cell lines. A, Western blot
analysis of P-MEK levels, where MCF-7 cells were charcoal stripped for 48h before all cell
lines were treated with control media, E2 (1nM) or TGFa (1nM) for 15 min. Membranes were
probed with P-MEK primary antibody (1:1000). T-MEK levels were used as loading controls.
B, histogram of P-MEK levels of MCF-7, LCC1 and LCC9 cell lines treated with control
media (■), E2 (■), TGFa ( ) or HRG ( ) as before, where data are in triplicate +/-SD.
MCF-7 cells treated with TGFa were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistical significance between
control treated cells and another treatment and those in red represent statistical significance
between MCF-7 and the resistant cell lines when treated with TGFa. Western blots are




4. 3. 3. P-ERKI/II
Chapter 4: Signalling Pathway Characterisation
Figure 4.15 shows the effects of 15 min E2, TGFa and HRGf3 (all InM) treatment on
the levels of P-ERKI/II in MCF-7, LCC1 and LCC9 cells. Total-ERK/11 levels were
used as loading controls. There were no significant differences between the basal
levels of P-ERKI/II in any of the three cell lines (P>0.05). E2 did not increase
P-ERKI/II in MCF-7 or LCC9 cell lines. There was a marginal increase in
P-ERKI/II with E2 in LCC1 cells (~1.4-fold), but this was not significant (P>0.05).
TGFa activated P-ERKI and II significantly and equally in all three cell lines, with
the production of bands at 44 and 42kDa respectively (figure 4.15A). Inductions of
~6, ~3.7 and ~6.5-fold were reported in MCF-7 (PO.OOl), LCC1 (P<0.05) and
LCC9 (P<0.001) cell lines respectively with TGFa (figure 4.15B). HRGp also
enhanced P-ERKI/II in all cells, with increases of ~6, ~4.5 and ~6.8-fold in MCF-7,
LCC1 and LCC9 cells respectively (all P<0.001). The histogram in figure 4.15B
shows statistical analysis of data including HRGP treatment (n = 3).
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Figure 4. 15. Comparison of the levels of P-ERKI/II and the effect of ligand stimulation
on levels of P-ERKI/II in resistant versus parental breast cancer cell lines. Western blot
analysis of P-ERKI/II levels, where all cells were charcoal stripped for 48h before all cell lines
were treated with control media, E2 (1nM) or TGFa (1nM) for 15 min. Membranes were
probed with P-ERKI/II primary antibody (1:1000). T-ERKI/II levels were used as loading
controls. B, histogram of P-ERKI/II levels of MCF-7, LCC1 and LCC9 cell lines treated with
control media (■), E2 (■), TGFa ( ) or HRG ( ) as before, where data are in triplicate +/-SD.
MCF-7 cells treated with TGFa were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistical significance between
control treated cells and another treatment. Western blots are representative of 1 of 3
independent experiments which are amalgamated in the histogram (B).
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4. 4. Does signalling differ in other MCF-7-derived resistant
cells?
In addition to the LCC1 and LCC9 resistant cell lines, the expression and activation
of Akt, MEK and ERKI/II were assessed in the LY2 cell line. LY2 cells are resistant
to tamoxifen and LY 117018, but were derived separately to the LCC- cell lines.
The LY2 cell line was investigated to ascertain if P-Akt was constitutively activated
in this cell line also and perhaps indicate other changes which would account for
differential growth responses between the LCC- and LY2 cell lines.
Figure 4.16 is a western blot of P-Akt expression in LY2 cells run in parallel with
MCF-7, LCC1 and LCC9 cell lines. The cells were treated with TGFa and HRGp as
these growth factors were previously shown to enhance MCF-7, LCC1 and LCC9
cells earlier in this chapter. Figure 4.16 shows that LY2 cells did indeed possess
constitutively activated Akt under control conditions, which appeared to be to a
similar level to that of LCC1 and LCC9 cell lines. TGFa marginally increased P-Akt
expression in the LY2 cell line and was enhanced markedly by HRG(3. These data
are similar to the pattern already observed in the LCC- cell lines. The reduced level
of T-Akt, and thus loading, in LCC9 cells treated with TGFa may account for a
slight reduction in signal in comparison to data already recorded.
Figure 4.17 shows the effect of growth factors on P-MEK expression in the same
panel of cell lines. The growth factors enhanced P-MEK in MCF-7 and LCC- cell
lines as before, where HRGp produced a greater intensity of signal which diminished
as resistance progressed. That is, P-MEK expression was less in the LCC1 cell line
compared to the MCF-7 cell line, and reduced again in the LCC9 cell line compared
to the LCC1 cell line when treated with either growth factor. HRGp enhanced P-Akt
to a similar extent in the LY2 cell line as the LCC9 cell line. However, no






















Figure 4.16. The effect of growth factors on P-Akt expression in the LY2 breast cancer cell
line compared to the MCF-7 and LCC- cell lines. Western blot analysis of P-Akt levels, where
all cells were charcoal stripped for 48h before all cell lines were treated with control media,
TGFa or HRGp (both 1nM) for 15 min. Membranes were probed with P-Akt primary antibody
(1:1000). T-Akt levels were used as loading controls. Western blots are representative of 1
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Figure 4.17. The effect of growth factors on P-MEK expression in the LY2 breast cancer cell
line compared to the MCF-7 and LCC- cell lines. Western blot analysis of P-MEK levels,
where all cells were charcoal stripped for 48h before all cell lines were treated with control
media, TGFa or HRGp (both 1nM) for 15 min. Membranes were probed with P-MEK primary
antibody (1:1000). T-MEK levels were used as loading controls. Western blots are
representative of 1 of 3 independent experiments.
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The effect of HRGp on P-ERK1/11 expression in the LY2 cell line compared to the
MCF-7 and LCC- cell lines is shown in figure 4.18. TGFa failed quality control
tests performed by the manufacturer/supplier hence this ligand could not be used in
this experiment. Figure 4.18 illustrates the expression of P-ERKI/II was elevated by
HRGp in FY2 cells to a similar extent as in MCF-7, LCC1 and FCC9 cells, which is
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Figure 4.18. The effect of HRGP on P-ERKI/II expression in the LY2 breast cancer cell line
compared to the MCF-7 and LCC- cell lines. Western blot analysis of P-ERKI/II levels, where
all cells were charcoal stripped for 48h before all cell lines were treated with control media or
HRGp (1nM) for 15 min. Membranes were probed with P-ERKI/II primary antibody (1:1000).
T-ERKI/II levels were used as loading controls. Western blots are representative of 1 of 3
independent experiments.
4. 5. The effect of serum-free conditions
The effects of E2, TGFa and HRGp on P-Akt and P-ERKI/II expression were
observed under serum-free conditions. This was to replicate the conditions of similar
studies by Stoica et al (2003) to observe if the absence of E2 effects on P-Akt and the
absence of constitutively activated ERK1/1I was due to experimental conditions or
was a true differential response. Figure 4.19 shows that P-Akt expression under
serum-free conditions did not differ to that of expression levels of cells treated in 5%
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double charcoal stripped serum (DCSS). P-ERKI/I1 expression in the resistant cells
under serum-free conditions was consistent with that produced under DCSS
conditions. In contrast, MCF-7 P-ERKI/II expression did show some variation, but
only when treated with E2, where an elevated level of P-ERKI/II was observed
compared to that of basal expression. The level of expression induced was not
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Figure 4. 19 Comparison of the levels of P-Akt and P-ERKI/II and the effect of various
ligand stimulation on these levels in serum-free conditions in resistant versus
parental breast cancer cell lines. Western blot analysis of P-Akt and P-ERKI/II levels,
where all cells were charcoal stripped for 48h before all cell lines were treated with control
media, E2, TGFa or HRGp (all 1nM) for 15 min. Membranes were probed with either P-Akt or





Chapter 4: Signalling Pathway Characterisation
This chapter investigated the role of ERa expression and activation in the
development of resistance in breast and ovarian cancer. ERa has been well
documented to play a critical role in the normal mammary gland development and
also the development and progression of breast and ovarian cancer (Platet et al,
2004; Rao and Miller, 2006). Overexpression and constitutive activation of ER has
been implicated in tamoxifen-resistance (Britton et al, 2005).
4. 6. 1. Breast cancer ERa expression and activation
4. 6. 1. 1. Loss of signalling via ERa is unlikely to confer
tamoxifen resistance in endocrine resistant cell lines
The LCC1 and LCC9 cell lines were originally derived from MCF-7 cells through
exposure to low levels of E2 and anti-oestrogens (Brunner et al, 1993). The Mill and
LCCl cell lines and the similar LCC2 cells expressed slightly elevated levels of ERa
protein compared to the parental cell line. This is supported by published data where
long-term oestrogen-deprived (LTED) cells were shown to have higher ERa levels
than the wild type MCF-7 cells (Martin et al, 2005; Staka et al, 2005). The elevated
ERa expression may explain the elevated basal rate of cellular proliferation in the
Mill, LCCl and LCC2 cell lines. However, the LCC9 cells were also developed in
this manner but the level of ERa remained similar to that of the parental line. This
may be explained by the further exposure of the LCC9 cell line to low levels of
oestrogens and anti-oestrogens. The LY2 cell line also expressed a relatively
unaltered level of ERa compared to MCF-7 cells, which may also be explained by
the different manner in which this cell line was derived.
The down-regulation of ERa expression by E2 has been previously reported by Lee
et al (2005), Hurd et al (1995) and Saceda et al (1988), and hence supports the
reduction in ERa levels in MCF-7 cells with E2 (InM) treatment. Lee et al (2005)
reported that the reduction in ERa was also time dependent which is in agreement
with the time course data provided here. The reduction in ERa levels in the resistant
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lines after E2 treatment is supported by these previous works which suggest E2 is
perhaps binding to and degrading ERa, and further suggests ERa are remaining
functional in tamoxifen resistant cell lines. Tamoxifen-resistant tumours and breast
cancer cell lines have repeatedly been reported to remain responsive to pure
antioestrogens and hormone therapies (Lykkesfeldt et al, 1994; Brunner et al, 1993;
Encarnacion et al, 1993) where it was concluded that it is unlikely that loss of
signalling via ERa confers tamoxifen resistance (Nabha et al, 2005). However, this
theory may only be applicable to resistant cell lines that retain sensitivity to pure
antioestrogens, such as the LCC1 and LCC2 lines, and not the LCC9 cell line as
LCC9 cells are insensitive to pure antioestrogens.
4. 6. 1. 2. 1. Changes in ERa P-S118 expression may
contribute to the progression of resistance and insensitivity
from the parental MCF-7 cell line to and between the resistant
cell lines.
Basal levels of P-Sl 18 MCF-7 were low as expected (Joel et al, 1995). P-Sl 18 was
hypothesised to be constitutively phosphorylated in the resistant cell lines of this
model. This was found not to be the case and contrasts with other studies which
have reported elevated basal expression of P-Sl 18 in tamoxifen-resistant MCF-7 cell
lines (Tam-R) (Britton et al, 2005). Britton et al (2005) routinely cultured the
MCF-7 cell line in 5% DCSS medium rather than 5% FCS medium used here. 5%
DCSS medium was utilised in the MCF-7 cell line only for experiments in this
investigation. The reduction in serum may trigger the Tam-R cell line to use an
alternative signalling pathway which is not utilised or available to the MCF-7 cells
and may account for the elevation in ERa and subsequently P-Sl 18 and P-ERK1/1I
levels.
E2 enhanced P-Sl 18 in MCF-7 cells, in agreement with many published studies (Joel
et al, 1995) and reviewed by Lannigan (2003). The time course data showed rapid
enhancement of P-Sl 18 upon E2 treatment after approximately 30 min in MCF-7
cells which is consistent with a study by Joel et al (1998) and time courses by Chen
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et al (2002) and Martin et al (2005). Chen et al (2002) produced a time course
which was consistent to that reported in this chapter, where P-Sl 18 also peaked at 30
min and was reduced after 180 min. E2 also enhanced P-S118 in Mill cells,
indicating this cell line is activated by this ligand. This is consistent with growth
data, where E2 increased proliferation. However, P-Sl 18 was enhanced to a similar
extent in Mill compared to the parental cell line, indicating the overexpression of
ERa did not correspond with elevated P-Sl 18 expression in this cell line.
E2 enhanced P-Sl 18 in resistant LCC1 and LCC2 cell lines to a greater extent than
MCF-7 cells and Mill cells. These data are consistent with the elevated levels of
ERa in these cell lines, which may account for this elevated P-S 118, and are also
consistent with the growth data. This is also consistent with the study of LTED
MCF-7 cells by Martin et al (2005), which reported their tamoxifen-resistance LTED
cells overexpressed P-Sl 18 compared to MCF-7 cells in line which also had elevated
ERa expression. The ratio of T-ER to P-Sl 18 supports this hypothesis, with the
LCC1 cell line having a larger proportion of T-ER than the parental cell line. The
hypothesis may also explain the reduction of P-Sl 18 as T-ER levels also decline over
time. The LCC9 cell line also had a higher ratio of T-ER: P-Sl 18 than the MCF-7
cell line, although only after 5 min rather than 30 min, suggesting the level of T-ER
changes over time.
The LY2 cell line differed to Mill, LCC1 and LCC2 cell lines as the ERa expression
was not elevated and yet P-S 118 was enhanced by E2 and this was not reduced by
tamoxifen. The level of P-Sl 18 expression was similar to that of MCF-7 cells, in
keeping with the similar ERa expression observed in the two cell lines. However,
LY2 cells are generally E2-growth insensitive, hence, as for the LCC2 cell line,
activation of ERa at SI 18 may be redundant downstream.
Growth factors have been shown to enhance P-Sl 18 in MCF-7 cells (Kato et al,
1995, 1998) which reflected the TGFa-enhanced P-Sl 18 observed in MCF-7 cells.
The time course showing a sharp peak with TGFa at 30 min closely reflected that
produced by Chen et al (2002). Growth factor stimulation was not observed at SI 18
in the resistant cell lines after 30 min, but was seen at a later time point in the LCC1
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cells, but this was diminished compared to E2-enhanced P-S118. The absence of
growth factor stimulation in the resistant cells is in discord with the expected
elevated P-Sl 18 levels which occur in other tamoxifen-resistant cells (Britton et al,
2005). The absence or reduced levels of P-Sl 18 suggest the cells in this model are
behaving in a manner consistent with a study by Fowler et al (2004). Fowler et al
(2004) found ERa levels were elevated and this was thought to result in the
activation of receptor transcriptional function via non-classical pathways which may
not require ligand binding or growth factor phosphorylation. This supports the
general absence of growth factor stimulated cellular proliferation reported in the
resistant cell lines in this investigation. Fowler et al (2004) demonstrated this
mechanism using a tetracycline-inducible ERa expression model of the MCF-7 cell
line. Fowler et al (2004) reported that increased ERa activity was via AF-1 and was
independent of P-Sl 18. The elevated levels of ERa observed in the Mill, LCC1 and
LCC2 cell lines (and perhaps a slight increase in the LCC9 cell line) are consistent
with this study and also with the heightened levels reported by Staka et al (2005).
However, Fowler et al (2004) also suggested this mechanism was independent of
P-Sl 18 which may partially explain the absence of P-Sl 18 observed in the LCC9
cell line, but does not account for the elevated levels observed in the other three
resistant cell lines upon ligand stimulation. In addition, Fowler et al (2004)
demonstrated that P-ERKI/II levels were growth factor activated and not enhanced
by oestrogen but were not elevated with elevated ERa expression. The group
therefore concluded that the elevated transcriptional activity ofERa in the absence of
ligand did not involve the MEK/ERK pathway. This is in agreement with results
obtained in the LCC- and LY2 cell lines.
Tamoxifen slightly enhanced P-Sl 18 in MCF-7 which is in agreement with the
partial agonist action of the SERM. Tamoxifen also enhanced P-Sl 18 in Mill, LCC1
and LCC2 cell lines. The increases in P-S 118 expression were expected in the
tamoxifen-sensitive MCF-7 cell line and perhaps even in the Mill and LCC1 cell
lines which do retain some tamoxifen sensitivity. These results are consistent with a
studies performed by Chen et al (2002) and Ali et al (1993) where tamoxifen was
shown to increase P-Sl 18. However, the increase in P-Sl 18 in LCC2 cells was
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surprising as LCC2 cells are growth insensitive to both oestrogen and tamoxifen.
Tamoxifen significantly reduced E2-enhanced P-Sl 18 in MCF-7 and Mill cell lines,
in accordance with the anti-oestrogenic properties of this agent (Bunone et al, 1996).
E2-enhanced P-S118 was only reduced marginally in LCC1 and LCC2 cells lines.
The LCC1 data are consistent with the growth data. These data are consistent with
the theory that tamoxifen is acting via both AF-1 to enhance P-Sl 18 and via AF-2 to
inhibit P-Sl 18 and proliferation (Chen et al, 2002). Also, the reduction in the E2-
enhanced reversal by tamoxifen in the LCCl and LCC2 cell lines is consistent with a
recent study by Rayala et al (2006), although this study assessed the affect of
tamoxifen resistance on ERE Luc activity rather than directly by P-Sl 18 western
blotting. Data from the Rayala et al (2006) study showed tamoxifen was unable to
significantly reverse the E2-enhanced ERE Luc activity in Tam-R cells, in contrast to
MCF-7 cells where tamoxifen significantly reduced this activity.
The most interesting P-Sl 18 expression pattern was produced in the LCC9 cell line.
The cells expressed comparatively low levels of P-Sl 18 which remained relatively
unchanged irrespective of treatment. The absence of ligand stimulation shows the
LCC9 cells differ to the remaining resistant cell lines and that ERa P-Sl 18 may not
be significant in the proliferation of this cell line.
It appears that ERa P-SI18 is involved in the progression of resistance in Mill,
LCCl, LCC2 and LY2 cell lines, but may be of less importance in the LCC9 cell line
as indicated by a reduction or absence ofP-Sl 18 with ligand stimulation.
4. 6. 1. 2. 2. Changes in ERa P-S167 expression do not
appear to contribute to the development of resistance
ERa SI67 expression, as for SI 18, was also hypothesised to be constitutively
phosphorylated in the resistant cell lines as activation of SI67 has been linked with
tamoxifen-resistance in breast cancer (Glaros et al, 2006; Campbell et al, 2001).
Again, this was not found to occur, with basal levels remaining low in MCF-7, LCCl
and LCC9 cell lines alike. P-S 167 was elevated with growth factor treatment in all
cell lines consistent with published data (phosphorylation reviewed by Lannigan,
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2003; Joel et al, 1998). This suggests phosphorylation of S167 may play a role in the
activation of ERa in resistant cell lines, which has already been documented in
MCF-7 cells, but this may not be directly associated with resistant cellular
proliferation.
4. 6. 2. Ovarian cancer ER expression and activation
ERa expression was low in SKOV-3 cells compared to MCF-7 cells which is
consistent with published data (Imai et al, 2005; Lau et al, 1999; Hau et al, 1995).
Neither PEOl nor SKOV-3 cells were constitutively phosphorylated at SI67,
suggesting these residues are not responsible for the elevated basal proliferation of
the SKOV-3 cell line. P-S118 was not elevated in the PEOl cell line either.
However, there did appear to be some constitutive P-Sl 18 under control conditions
in the SKOV-3 cell line, suggesting this may account for the elevated basal rate of
proliferation in this cell line. However, studies have shown that the SKOV-3 cell
line expresses non-functional and E2-unresponsive ERa (Imai et al, 2005); therefore
the E2-activation of ERa by phosphorylation of SI 18 appears to be irrelevant to the
mechanism which drives proliferation of this cell line.
In contrast, the PEOl ovarian cell line expressed a moderate level of ERa, consistent
with published studies (Langdon et al, 1990), and expressed more ERa than SKOV-
3. It was expected the increase in ERa in the PEOl cell line would elevate P-Sl 18 in
response to E2, especially as the cells proliferate upon E2 addition, but surprisingly
no activation at SI 18 or SI67 was seen. These results imply ERa activation via
SI 18 and SI67 phosphorylation may not be crucial to PEOl cellular proliferation.
Due to the absence of any detectable P-Sl 18 and P-S 167 in the PEOl cell line it was
decided to limit further studies into the breast cancer cell model of resistance.
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4. 6. 3. Changes in signalling molecule activation may
contribute to the progression of resistance and insensitivity
in the MCF-7 model
The signalling molecules Akt, ERK and MEK have all been previously implicated in
breast cancer. Activation of Akt was reported by Sun et al (2001) to be present in
-40% of breast carcinomas and Navolanic et al (2003) reported MEK and ERK to
implicated in the development and progression of human breast cancer. A study by
Campbell et al (2001) also reported Akt to play a role in the development of anti-
oestrogen resistance. The contribution of the MEK/ERK signalling pathway was
investigated as this has a documented bifunctional role in proliferation and apoptosis
(Cobb, 1999) and has also been implicated in the development and progression of
breast cancer (Martin et al, 2005).
4. 6. 3. 1. Constitutive P-Akt expression in the resistant cell
lines
Overexpression of the Akt signalling molecule has been implicated in breast cancer
(Murray et al, 2005) and has been demonstrated to mediate tamoxifen resistance
(Kirkegaard et al, 2005; deGraffenried et al, 2004). Activated Akt has a variety of
biological effects, which include the suppression of apoptosis by phosphorylation
and the inactivation of some members of the pro-apoptotic pathway, for instance
caspase-9 (Cardone et al, 1998) or Bad, a member of the Bcl-2 family (Datta et al,
1997; del Peso et al, 1997). Therefore it was hypothesised that this upstream
signalling molecule may be involved in tamoxifen-resistance observed in this model.
P-Akt was constitutively activated in LCC1, LCC9 and LY2 resistant cell lines.
These data are consistent with published findings, where a tamoxifen-resistant
MCF-7 cell line and other tamoxifen-resistant cells were found to have elevated
basal levels of P-Akt compared to those of the parental MCF-7 cell line (Jordan et al,
2004; Frogne et al, 2004; Lin et al, 2005). A study by Campbell et al (2001) also
supports this and showed that MCF-7 cells transfected with Akt were less sensitive to
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tamoxifen. Jordan et al (2004) suggested that the PI3-kinase pathway played a role
in the proliferation of their particular tamoxifen resistant cell lines, which will further
be investigated in this model with the use of the inhibitor LY 294002 in the
following chapter. Baccus et al (2002) also reported overexpression of the c-erbB2
oncogene correlated with overexpression of Akt2 and P-Akt. This may be a potential
mechanism by which the cells in this model develop resistance.
Opinion is divided as to the effect of E2 on Akt activation. A recent study by
Rodrick et al (2005) found that E2 did not enhance Akt in MCF-7 cells, which is in
agreement with data reported in this chapter. Contrastingly, a previous study by
Stoica et al (2003) described the rapid activation of Akt by E2. This occurred after
10 min of treatment and used a similar design to that of this report, although their
study was carried out in MCF-7 cells stably transfected with Akt rather than the
LCC- model. Their experimental design also involved a 2-day incubation period in
medium containing charcoal-stripped serum before the medium was changed into
serum-free medium. The absence of this additional step may account for the
corresponding absence of E2 stimulation of P-Akt in this instance. A further study by
Lee et al (2005) reported that E2 only enhanced P-Akt after 24h, 48h and 72h, which
are later time points indicating that the effects of E2 on P-Akt are not as rapid as
those suggested by Stoica et al (2003) which is consistent with data accrued.
In contrast to studies reporting elevated P-Akt expression and the data found here,
Santen et al (2005) did not report an elevated level of P-Akt in their LTED cell line.
The discrepancy between this finding and this published data may be due to the
variations in the cell lines due to the manner in which they were derived, and the
experimental conditions used.
Growth factors enhanced P-Akt in MCF-7 cells in this investigation, supported by
Rodrick et al (2005), Jordan et al (2004) and Martin et al (2000). Jordan et al (2004)
found P-Akt to be constitutively activated in Tarn-R MCF-7 cells as previously
mentioned, and the group also reported growth factor activation of this cell line.
This concurs with P-Akt enhancement documented in the LCC- and LY2 cell lines.
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However, Jordan et al (2004) noted that the Tam-R cells were enhanced to a greater
extent than the parental MCF-7 cell line, which differs to the enhancement between
the MCF-7 and LCC- and LY2 cell lines. The discrepancy is more than likely due to
the differences between the cell lines being characterised. It is interesting to note
that HRGP enhanced P-Akt to a greater extent than TGFa. This indicates the cell
lines may preferentially express erbB heterodimers which have a higher HRGP
binding affinity such as erbB2/3 or erbB2/4 rather than those with affinity for TGFa
(erbB 1/1 or erbB 1/2 heterodimers). This may be in agreement with a theory
proposed by Takai et al (2005) who hypothesised that ovarian cells may
preferentially form certain heterodimers.
4. 6. 3. 2. P-MEK expression is altered with progression in
resistance
P-MEK basal levels were relatively low and equal in MCF-7, LCC1 and LCC9 cell
lines. This was also the case for E2 treated cells. Basal levels of MEK activation
were low in MCF-7 cells in agreement with studies by Martin et al (2003), although
in contrast to this investigation, Martin et al (2003) reported elevated basal levels of
P-MEK in their LTED cell line. This group also reported increased expression of
ERa and P-ERK, the latter increase being inconsistent with data reported here. The
discrepancies are more than likely due to the different models being tested as well as
slight variations in experimental conditions where the addition of IGF-I appeared to
'super-sensitise' the cells to residual oestrogen and perhaps promote the tamoxifen-
resistance (Staka et al, 2005).
Differences in P-MEK expression appeared upon treatment with growth factors,
where expression fell as resistance occurred from MCF-7 to LCC1 cells and then
progressed from the LCC1 to LCC9 cell line. This is consistent with the study by
Glaros et al (2006), who reported that transfection of MCF-7 with MEK led to the
maintenance of tamoxifen sensitivity. The study by Glaros et al (2006) also reported
this increased P-S118, which would be consistent with data produced in the LCC9
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cell line. The overexpression of Akt and oestrogen ERa activation via a non-
genomic pathway may account for elevated P-Sl 18 in the LCC1 cell line.
Moelling et al (2002) documented that Akt suppressed Raf kinase activity when
activated by high concentrations of growth factor IGF-I, while lower doses still
stimulated proliferation but do not repress Rafl activity in the MCF-7 cell line.
PMA, a ligand known to induce differentiation in this cell line, markedly activated
the Raf/MEK/ERK pathway but only weakly stimulated the P13-K/Akt pathway and
did not induce crosstalk. This report would support the theory that the elevated
levels of Akt in the LCC1, LCC9 and LY2 resistant cell lines suppressed MEK
activation, via Akt-Raf crosstalk, to a greater extent than in the MCF-7 cell line. It
also suggests that MEK activity is suppressed further in the LCC9 cell line than
LCC1 cells.
4. 6. 3. 3. ERKI/II activation is unaltered in this model of
tamoxifen resistance
Previous studies have suggested that P-ERKI/II is elevated in LTED and tamoxifen-
resistant MCF-7 cells under control conditions (Martin et al, 2005; Santen et al,
2005; Yue et al, 2002; Britton et al, 2005; Knowlden et al, 2003). This is in
disagreement with data here where basal P-ERKI/II levels were found to be low in
parental and resistant cell lines alike. Martin et al (2005) reported the rapid P-Sl 18
stimulated by E2 was not associated with an elevation in P-ERKI/II expression. This
supports the expression profile seen in all the breast cancer cells. Joel et al (1998)
and Keshamouni et al (2002) both saw an increase in P-ERK expression with growth
factors, but not with E2 after 15 min which supports data here. Gaben et al (2004)
and Keshamouni et al (2002) reported an increase in P-ERKI/II with E2 only after a
prolonged time period (approximately 6h and 2h treatment respectively), which is
again consistent with the absence of signal observed at the 15 min time point in this
investigation. TGFa and HRG(3 activated P-ERKI/II in MCF-7 cells in agreement
with published data (Fowler et al, 2004; Thottassery et al, 2004). The growth factors
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also enhanced P-ERKI/1I in all the resistant cell lines to a similar extent. A study by
Britton et al (2005) supports growth factor activation of P-ERK1/I1 in Tam-R cells.
Moreover, TGFa activated P-ERK/I1 significantly and equally in all three cell lines,
suggesting the point of divergence did not occur at this signalling molecule and that
P-ERKI/II is not the point of origin for the development of resistance in this model.
Any differences that were observed upstream of P-ERKI/II at P-MEK were not
observed here, indicating P-MEK differences are insignificant alone, 'cancelled out'
or the ligand signals via another pathway such as the PI3-K/Akt or IGFR-I pathways.
A study by Zimmerman and Moelling (1999) showed that growth factor Akt
activation was adequate to surmount the growth inhibitory action of prolonged ERK
activation in breast cancer cells. Campbell et al (2001) hypothesised that growth
factors may activate ERa via the PI3-K/Akt pathway, thus conferring hormone-
independent growth. This may be the rationale behind the elevated basal
proliferation in the resistant cell lines.
This chapter shows that ERa, P-Sl 18, P-Akt and P-MEK expression varies between
MCE-7 cells and cell lines possessing a resistant phenotype. The impact of the
PI3-K/Akt and MEK/ERK signalling pathways will be assessed further in the
following chapter using specific tyrosine kinase inhibitors, while a novel anti-erbB2
inhibitor will be utilised to ascertain the importance of erbB2 in this model in
Chapter 6.
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Chapter 5
The roles of Akt and ERK signalling
pathways in resistant breast cancer
cell lines
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5. 1. Do tyrosine kinase inhibitors block non-genomic
signalling pathways, inhibit cell line proliferation and
produce changes in expression profiles differentially
in this model of resistance?
Breast cancer cells have been reported to proliferate in response to ligand stimuli via
several pathways including the ligand dependent pathway, the IGFR-I pathway and
this ligand independent pathway. Elements of 'cross-talk' between the former two
pathways have widely been published (reviewed by Lannigan, 2003), whilst more
recently, evidence has come to light of interactions between the latter two pathways
(Dudek et al, 1997; Kauffmann-Evan et al, 1997; Gee et al, 2005). These pathways
and interactions are fully discussed in chapter 1. This chapter will mainly focus on
the ligand dependent and ligand independent erbB pathways.
The ligand dependent pathway requires the direct binding of E2 to ERa, and the
ligand-independent pathway requires the stimuli, for example by growth factors
TGFa and HRG(3, upstream of ERa. The ligand-independent pathway can signal via
the erbB receptor family of tyrosine kinases. ErbB receptors play a pivotal role in the
growth and differentiation of cells and irregular erbB activity and overexpression has
been implicated in several human cancers including breast cancer (Slamon et al,
1987; Slamon et al, 1989; Blume-Jensen and Hunter, 2001). TGFa acts as a mitogen
in most cells and initiates intracellular signalling pathways upon binding to erbB
receptors (Derynck, 1988). It can stimulate erbB2 and the MEK/ERK and the PI3-
K/AKT pathways (Datta et al, 1999) which potentially lead to the phosphorylation of
serine residues 118 and/or 167 of ERa, followed by ERa activation and gene
transcription. Growth factor signalling via the erbB receptors has been implicated in
the development of acquired antioestrogen resistance (Nicholson et al, 2004).
Previous studies have reported that the involvement of components of the PI3-K/Akt
and MEK/ERK signalling pathways can be determined by the use of specific
inhibitors such as LY 294002 and U0126 (Marks et al, 2000; Stoica et al, 2003;
Staka et al, 2005). The specificity of these agents for their targets provides a
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powerful tool for the investigation of the physiological role of these signalling
pathways. Several inhibitors were initially used to detect any differences in a range
of targets, with further studies being continued with LY 294002 and U0126 (and
U-73122 in expression profiling) only as Akt and MEK had previously been
implicated in the development of antioestrogen resistance in tamoxifen resistant cell
lines (Britton et al, 2005; Campbell et al, 2001).
To assess the potential role of Akt, MEK and ERKI/I1 in the development of
resistance to anti-hormonal therapies these tyrosine kinases in the erbB receptor
pathway, and other relevant pathways which may 'cross-talk' with this pathway, were
targeted with a series of specific tyrosine kinase inhibitors (TKI) and these will be
discussed individually. The inhibitors used were LY 294002, NL-71-101, U-71322
and SB 203580. Proliferation assays were performed to determine the effect of these
tyrosine kinase inhibitors on cell proliferation. Protein expression levels of the
molecules within the relevant signalling pathways were then examined to verify the
specificity of the inhibitors. Any changes between the MCF-7 and resistant cell lines
LCC1, LCC9 and LY2 were monitored. All four cell lines were subjected to a
suitable concentration range of inhibitor determined from previous publications in the
presence and absence of E2, TGFa and HRG|3 (all InM). LY2 cell line was excluded
from protein expression studies as this cell line possessed features similar to those of
the other resistant lines. Protein expression studies were performed using three
appropriate concentrations selected from the proliferation assay studies to explore any
reduction produced in a dose-dependent manner. The selection of inhibitors was
narrowed in order to monitor their downstream effects via the mRNA expression
levels of several E2-responsive genes in the presence and absence of E2 and TGFa.
This was to discover if the inhibition of a second messenger could be directly linked
to specific gene expression as well as cell proliferation. The reasons for the selection
of LY 294002, U0126 and U-73122 in this study will be discussed further later in the
chapter.
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5. 1. 1. The effect of LY294002 and NL-71-101 on elevated
P-Akt in this model of resistance
5. 1. 1. 1. Proliferation Studies
5. 1. 1. 1. 1. LY294002
LY 294002 is a competitive inhibitor for the ATP binding site of PI3-kinase and is
specific for PI3-kinase even at a dose of 50pM (Vlahos et al, 1994). NL-71-101 is a
specific Akt inhibitor (Reuveni et al, 2002) which operates just downstream of
LY 294002. LY 294002, and NL-71-101 initially, were used to assess the importance
of the elevated basal levels of Akt in the development of resistance in the LCC1,
LCC9 and LY2 resistant cell lines compared to the parental MCF-7 cell line. Aktl, 2
and 3 were detected as the investigation used a pan-Akt antibody.
Under normal conditions, such as in the MCF-7 cell line, day 0 and day 3 control
values are both approximately equal (100%). Any differences in inhibitor
concentration required to inhibit cellular proliferation occurring between cell lines
were noted as this may be indicative of altered signalling pathways in the
development of resistance in this model. Figure 5.1 shows the effect of a
concentration range of LY 294002 on cell number in the presence and absence of E2,
TGFa and HRG(3 (all InM) in resistant cell lines compared to the parental MCF-7
cell line. LY 294002 alone inhibited proliferation in all four cell lines, but was
unable to reduce the cell number of the resistant cell lines to that of the MCF-7 cells.
LY 294002 was able to significantly inhibit MCF-7 cell proliferation with the lowest
concentration of 5pM (P<0.001). LY 294002 concentrations between 20pM and
70pM did not significantly reduce MCF-7 cell proliferation beyond that achieved
with 20pM. LY 294002 significantly reversed the growth stimulation induced by E2
and TGFa in MCF-7 cells in a similar manner. However, the ligand stimulated cell
proliferation was not fully reversed to that of control level with 5pM LY 294002, and
proliferation was only reduced to that of basal growth with concentrations of ~7pM,
~8pM and ~23pM for E2, TGFa and HRGp treatments respectively. The elevated
LY 294002 concentration required to inhibit HRGP-induced growth to the same
188
Kate Moore Chapter 5: Akt & ERK signalling in resistant breast cancer cell lines
extent as the other treatments suggests HRGp treatment appears to prevent
LY 294002 induced growth reversal in MCF-7 cells.
LY 294002 also reversed the growth proliferation induced by E2 in LCC1 cells, with
significant reductions occurring with every concentration used (5-70pM, P<0.001).
LCC1 cells treated with 5pM LY 294002 alone were reduced from -316% day 3
growth to -183%. E2, TGFa and HRGp elevated the concentration required to reduce
proliferation to this level from 5pM to ~6pM, ~8pM and -llpM respectively.
LY 294002 reduced cell proliferation when cells were treated with TGFa and HRGp,
but the growth factors appeared protective to the effect of LY 294002, as for the
MCF-7 cell line, with HRGP preventing LY 294002 growth inhibition to the greatest
extent. The fact that the growth factors still prevent LY 294002 induced growth
inhibition in LCC1 cells compared to LY 294002 treatment alone is surprising as the
resistant cell lines did not proliferation in response to the growth factors. The shape
of the curves for all the cell lines were very similar, implying the cells are inhibited
by LY 294002 in a similar manner.
LY 294002 in combination with E2 required concentrations similar to those required
to inhibit control growth to a similar extent, with values of ~9.5pM, ~43pM, ~69pM
and ~55.5pM for MCF-7, LCC1, LCC9 and LY2 cell lines respectively to reduce
growth to approximately 50% of day 0. Slightly elevated concentrations of ~18pM,
~70pM and ~68pM were recorded to inhibit proliferation to the same extent in MCF-
7, LCC1 and LY2 cells respectively treated with LY 294002 and TGFa. A
corresponding concentration was not obtained for LCC9 cells treated with LY 94002
and TGFa.
HRGP was reported to 'protect' all cell lines to a greater extent at lOpM, a
therapeutically suitable concentration, than cells treated with E2, TGFa or control
conditions. There are statistically significant differences of -60% with control and E2
treatments, and -52% with TGFa treatment compared to HRGp treatment in MCF-7
cells. This effect is mirrored in the LCC1 and LCC9 cell lines, with HRGP
'protecting' cells by -17%, -9% and -6.5% with control, (P0.001), E2 (P<0.01) and
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Figure 5.1 Growth inhibitory effect of LY 294002 in MCF-7 cells versus resistant breast
cancer cell lines.. All cells were charcoal stripped 24h prior to treatment and were then
treated with a concentration range of LY 294002 spanning 0-70pM plus control media (♦), E2
(1nM) (■), TGFa (1nM) ( ) or HRGp (1nM) (A). Cells were treated on day 0 and treatment
halted on day 3. Data were plotted as a mean of 6 OD values +/- SD for treated values and
as a mean of 12 OD values +/- SD for untreated cells. Graphs are representative of 1 of 3
replicate experiments.
TGFa treatments respectively in the LCC1 cell line, although this difference was not
statistically significant in the latter treatment. In the LCC9 cell line HRG[3
'protected' cells by ~18% (P<0.0()1), -14.5% (P<0.001) and -9% (P<0.01) compared
to cells subject to control, E2, and TGFa treatment. 70pM LY 294002 reduced day 3
growth in the resistant cell lines treated with HRGp to -79%, -60% and -63% in
LCC1, LCC9 and LY2 cells respectively, in keeping with the growth factor having a
'protective' effect in the resistant cell lines as well as in the MCF-7 cell line.
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All ligands increased proliferation in MCF-7 cells as previously described (chapter
3), E2, TGFa and HRGp treatment increasing proliferation by -240%, -68% and
-192% respectively (all P<0.001). HRGp increased MCF-7 cell number to a greater
extent in this chapter compared to the increase noted in chapter 3. The discrepancy is
probably due to the differences in experimental protocol between growth curves
produced via 24-well plates with washes (chapter 3) versus the SRB technique where
cells were grown in 96-well plates without media changes or certain wash steps.
Cells grown in 24-well plates were observed to be less adherent once treated with
HRGP, in agreement with published studies indicating HRGP to be involved in the
invasion and metastases of breast cancer (Tsai et al, 2003). This effect was abolished
in the SRB technique as cells were fixed to the plate surface post-treatment. This
increase A higher concentration of LY 294002 was required to inhibit day 3 growth
back to 50% when cells were treated with HRGp (69pM) in comparison to E2 which
produced approximately the same increase in proliferation but required only -9.5pM
to produce the same proliferation inhibition. TGFa and control treatments only
required concentrations of ~18pM and -1 lpM respectively to reduce proliferation to
the same degree.
TGFa did not increase cell number in LCC1 cells, while E2 and HRGp increased cell
number by -47% (P<0.001) and -9% (P>0.05, not significant) respectively. 5pM
LY 294002 significantly reduced LCC1 cell proliferation in the presence of E2, TGFa
and HRGP by -161%, -83% and -109% respectively and by -133% in untreated
cells. The maximum concentration of 70pM reduced growth to -51% and -79% day
3 growth compared to day 0 with TGFa and HRGp treatment respectively in the
LCC1 cell line.
Figure 5.1 shows LY 294002 also inhibited growth in LY2 cells irrespective of ligand
treatment, with the exception of HRGp as before, while both growth factors increased
the concentration of LY 294002 required to achieve a similar level of inhibition as
control and E2 treatments in LCC9 cells. 70pM LY 294002 reduced growth to only
-70% when LCC9 cells were treated with either growth factor, compared to -43% in
cells treated with control media or E2 with the same LY 294002 concentration.
Neither LCC9 nor LY2 cells were significantly growth stimulated by any ligand in
agreement with previous data (chapter 3). LY 294002 concentrations of ~47pM,
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~55.5pM and ~68pM were recorded for inhibition to 50% of day 0 proliferation in
LY2 cells when untreated and when treated with Eo and TGFa respectively. In
contrast, LY 294002 was unable to produce 50% inhibition of LY2 cells relative to
day 0 incubated with HRGp.
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5. 1. 1. 1. 2. NL-71-101
The inhibitory action of NL-71-101 on the Akt signalling pathway was investigated
using the SRB assay to study the effect of increasing NL-71-lOl concentration on
cellular proliferation. NL-71-lOl studies were performed in the MCF-7, LCCl and
LCC9 cell lines only. All cell lines used were charcoal stripped 48h prior to
treatment and were then treated with a concentration range of NL-71-lOl spanning 0-
20pM plus control media, E2 (InM), TGFa (InM) or HRGp (InM). Cells were
treated on day 0 and treatment halted on day 3. Data were plotted as a mean of 6 OD
values +/- SD for treated values and as a mean of 12 OD values +/- SD for untreated
cells. All three cell lines responded to E2, TGFa and HRGP treatment as previously
described (chapter 3), where MCF-7 proliferated in response to all three ligands,
while LCCl cells only increased in cell number with E2 treatment. LCC9 cell
proliferation was not significantly altered compared to that of control treated cells
irrespective of ligand treatment.
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Figure 5.2. Growth inhibitory effect of
NL-71-101 in MCF-7 cells versus resistant
breast cancer cell lines. All cells were charcoal
stripped 48h prior to treatment and were then
treated with a concentration range of NL-71-101
spanning 0-20pM plus control media (♦), E2
(1 nM) (■), TGFa (1nM) ( ) or HRGp (1nM) (A).
Cells were treated on day 0 and treatment halted
on day 3. Data were plotted as a mean of 6 OD
values +/- SD for treated values and as a mean
of 12 cell counts +/- SD for untreated cells.
Graphs are representative of 1 of 3 replicate
experiments.
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NL-71-101 inhibited day 3 proliferation relative to day 0 control in MCF-7, LCC1
and LCC9 cell lines (figure 5.2). The maximum concentration of~20pM NL-71-101
reduced proliferation to approximately 50% of day 0 in the parental cell line only
under control conditions and TGFa treatment. The maximum concentration of 20pM
reduced day 3 growth relative to day 0 control growth of MCF-7 cells in the presence
of E2 and HRGP to -53% and -59% respectively. NL-71-101 reduced proliferation
to -76%, -94%, -61% and -96% in LCC1 cells treated with NL-71-101 alone and in
combination with E2, TGFa and HRGP respectively. LCC9 cell proliferation was
also decreased with NL-71-101 alone and in combination with E2, TGFa and HRGP
to -113.5%, -90%, -92.5% and -101% respectively.
In general, NL-71-101 inhibited proliferation according to the ligand stimulation,
with E2, TGFa and HRGP all elevating the concentration required to inhibit growth
by the same extent as NL-71-101 alone in MCF-7 cells. Only E2 elevated this
concentration in the LCC1 cells, although this was not statistically significant, while
the concentrations were approximately equal irrespective of treatment in the LCC9
cell line in accordance with the resistant cell line growth responses.
Relatively few studies have been performed with NL-71-101, hence due to the novel
nature of NL-71-101 and the incomplete pharmacokinetic profile of this inhibitor it
was decided to continue further studies with LY 294002 only. The novel aspect of
NL-71-101, and the lack of evidence that there was a profound difference in the
sensitivity of the inhibitor between the sensitive and resistant cell lines would demand
substantial additional work to see if the data were informative.
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5. 1. 1. 2. The effect of LY 294002 on P-Akt protein levels
enhanced by TGFa
Figure 5.3 shows the inhibitory effect of LY 294002 in the presence and absence of
TGFa on the Akt signalling pathway in MCF-7 cells versus resistant breast cancer
cell lines. Figure 5.3A shows a representational western blot of P-Akt levels, where
all cells were charcoal stripped 48h prior to treatment and were then pre-treated with
lpM, 5pM or 30pM LY 294002 for 30 min then the cells were treated with control
media or TGFa (l nM) for 15 min.
Membranes were probed with P-Akt primary antibody (1:1000). T-Akt levels were
used as loading controls. Figure 5.3B is a histogram of P-Akt OD values of all cell
lines treated with control media, 5pM LY 294002, TGFa (InM) or TGFa+ 5pM
LY 294002 (InM + 5pM), where data are in triplicate +/-SD. MCF-7 cells treated
with TGFa were used as the positive control. LCC1 and LCC9 cell lines were
significantly constitutively phosphorylated at the Akt position (P<0.05) compared to
the parental MCF-7 cell line as previously described in chapter 4. TGFa significantly
enhanced P-Akt in all three cell lines (P<0.001). The basal levels of P-Akt in MCF-7
cells treated with increasing concentrations of LY 294002 alone remained constant,
while these levels were reduced with increasing concentrations in both resistant cell
lines (P<0.05 with 5pM concentration, figure 5.3B).
The western blot in figure 5.3A shows that TGFa-enhanced P-Akt levels were
reduced with increasing LY 294002 concentrations in all three cell lines, with the
greatest reduction taking place with 30pM LY 294002. lpM LY 294002 noticeably
reduced P-Akt levels increased by TGFa treatment in MCF-7 and LCC1 cell lines,
but less so in LCC9 cells. The clearest reductions in bands were visible at 5pM and
reductions were further investigated at this concentration (figure 5.3B).
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Figure 5.3 Inhibitory effect of LY 294002 in the presence and absence of TGFa on the
Akt signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A,
Western blot of P-Akt levels, where all cells were charcoal stripped 48h prior to treatment and
were then pre-treated with 1pM, 5pM or 30pM LY 294002 for 30 min then the cells were
treated with control media or TGFa (1nM) for 15 min. Membranes were probed with P-Akt
primary antibody (1:1000). T-Akt levels were used as loading controls. B, histogram of P-Akt
OD values of all cell lines treated with control media (■), 5pM LY 294002 (■), TGFa ( ) or
TGFa+ 5pM LY 294002 (■), where data are in triplicate +/-SD. MCF-7 cells treated with
TGFa were used as the positive control. ANOVA test: * = P<0.05, ** = P<0.01 and
***
= p<o.001. Asterisks in black represent statistically significant changes between control
and a treatment, those in green represent statistical significance between control treated
MCF-7 and resistant cell lines and those in red represent any statistical significant changes
between TGFa pre and post LY 294002. Western blots are representative of 1 of 3
independent experiments which are amalgamated in the histogram (B).
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Figure 5.3B shows 5pM LY 294002 reduced constitutively phosphorylated Akt in the
resistant cell lines as described above (P<0.05), with MCF-7 low basal levels
remaining unaffected by any concentration of LY 294002 alone. 5pM LY 294002
significantly reduced P-Akt enhanced by TGFa in all three cell lines (P<0.001), with
the greater reductions occurring in the resistant cell lines (-7.5 and -8.7-fold
reductions in LCC1 and LCC9 cell lines compared to -3-fold reduction in MCF-7
cells).
5. 1. 1. 3. The effect of LY 294002 on the MEK/ERK/IIpathway
5. 1. 1. 3. 1. The effect of LY 294002 on P-MEK protein levels
enhanced by TGFa
The effect of LY 294002 on the MEK/ERKI/II was subsequently investigated in
order to ascertain consequences of PI3-kinase inhibition on downstream pathways.
Figure 5.4 shows the effects of LY 294002 on the MEK signalling molecule. Figure
5.4A shows a representative western blot of P-MEK protein levels subjected to
LY 294002 treatment, where cells were treated as previously described for figure 5.3,
with the exception that membranes were probed with P-MEK and T-MEK antibodies
for phospho- and total levels. TGFa significantly enhanced P-MEK in MCF-7
(PO.OOl) and LCC1 (P<0.05) cell lines. Any increase in P-MEK in the LCC9 cell
line was small in agreement with previously described data (chapter 4).
P-MEK levels were not significantly inhibited in the MCF-7 cell line at the two lower
concentrations of lpM and 5pM LY 294002 (figure 5.4A and B). P-MEK levels
were inhibited by —13.6-fold in the parental cell line with 30pM LY 294002. The
western blot in figure 5.4A depicts a decline in TGFa-enhanced P-MEK signal in
LCC1 and LCC9 cell lines when treated with lpM and 5pM LY 294002. This
reduction was found to be significant at 5pM in the LCCl cell line (P<0.05). The





Chapter 5: Akt & ERK signalling in resistant breast cancer cell lines
P-MEK T-MEK
LY294002 LY294002(pM) LY294002 LY294002(pM)
(MM) +TGFa(1nM) -5 (|JM) +TGFa (1 nM)
g » 1 5 30 1 5 30 g 0 1 5 30 1 5 30
MCF-7 LCC1 LCC9
Cell Line
Figure 5.4 Inhibitory effect of LY 294002 in the presence and absence of TGFa on the
MEK signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A,
Western blot of P-MEK levels, where all cells were charcoal stripped 48h prior to treatment
and were then pre-treated with 1pM, 5pM or 30pM LY 294002 for 30 min then the cells were
treated with control media or TGFa (1nM) for 15 min. Membranes were probed with P-MEK
primary antibody (1:1000). T-MEK levels were used as loading controls. B, histogram of
P-MEK OD values of all cell lines treated with control media (■), 5pM LY 294002 (■), TGFa
( ) or TGFa+ 5pM LY 294002 (■) as before, where data are in triplicate +/-SD. MCF-7 cells
treated with TGFa were used as the positive control. ANOVA test: * = P<0.05, ** = PO.01
and *** = P<0.001. Asterisks in black represent statistically significant changes between
control and a treatment and those in red represent any statistical significant changes between
TGFa pre and post-treatment with LY 294002. Western blots are representative of 1 of 3
independent experiments which are amalgamated in the histogram (B).
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5. 1. 1. 3. 2. The effect of LY 294002 on P-ERKI/II protein levels
enhanced by TGFa
The effects of LY 294002 on TGFa-enhanced P-ERK/II levels are shown in figure
5.5. Figure 5.5A is a representational western blot of this experiment, where basal
P-ERKI/II levels were comparably low in MCF-7, LCC1 and LCC9 cell lines. TGFa
(InM) significantly elevated P-ERKi/II in all three cell lines (P<0.00l) compared to
basal levels treated with control media. LY 294002 did not significantly affect
P-ERKI/II levels in the presence or absence of TGFa stimulation at any concentration
used in any of the cell lines tested.
5. 1. 1. 4. The effect of LY 294002 on signalling in cells treated
with E2
The role of E2 in the Akt and MEK/ERKI/II signalling pathways in the possible
development of resistance in this model was investigated using the PI3-kinase
inhibitor LY 294002 in the presence and absence of E2 (figure 5.6). Figure 5.6A and
B are western blots of P-Akt and P-ERKI/II levels respectively, where all cells were
charcoal stripped 48h prior to treatment and were then pre-treated with lpM, 5pM or
30pM LY 294002 for 30 min then the cells were treated with control media or E2
(InM) for 15 min. Membranes were probed with P-Akt and P-ERKI/II primary
antibodies (1:1000). T-Akt and T-ERKI/I1 levels were used as loading controls.
MCF-7 cells treated with TGFa were used as the positive control.
Figure 5.6A depicts the P-Akt levels of MCF-7, LCC1 and LCC9 cell lines. LCC1
and LCC9 cell lines were significantly constitutively phosphorylated at the Akt
position (P<0.05) compared to the parental MCF-7 cell line as previously described in
chapter 4 and in figure 5.3. P-Akt levels were not significantly altered by E2
treatment of any cell line. In agreement with figure 5.3B, the basal levels of P-Akt in
MCF-7 cells treated with increasing concentrations of LY 294002 alone remained
constant, while these levels were reduced with increasing concentrations in both
resistant cell lines (P<0.05 with 5pM concentration for LCC1 and LCC9 cells, figure
5.3B).
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Figure 5.5 The effect of LY 294002 in the presence and absence of TGFa on the ERKI/II
signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A, Western
blot of P-ERKI/II levels, where all cells were charcoal stripped 48h prior to treatment and
were then pre-treated with 1pM, 5pM or 30pM LY 294002 for 30 min then the cells were
treated with control media or TGFa (1nM) for 15 min. Membranes were probed with
P-ERKI/II primary antibody (1:1000). T-ERKI/II levels were used as loading controls. B,
histogram of P-ERKI/II OD values of all cell lines treated with control media (■), 5pM LY
294002 (■), TGFa ( ) or TGFa+ 5pM LY 294002 (■) as before, where data are in triplicate +/-
SD. MCF-7 cells treated with TGFa were used as the positive control. ANOVA test:
*
= P<0.05, ** = P<0.01 and *** = P<0.001. Asterisks in black represent statistically significant
changes between control and a treatment and those in red represent any statistically
significant changes between TGFa pre and post-treatment with LY 294002. Western blots
are representative of 1 of 3 independent experiments which are amalgamated in the
histogram (B).
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Figure 5.6 The effect of LY 294002 in the presence and absence of E2 on the Akt and
ERKI/II signalling pathways in MCF-7 cells versus resistant breast cancer cell lines. A
and B, Western blots of P-Akt and P-ERKI/II levels respectively, where all cells were charcoal
stripped 48h prior to treatment and were then pre-treated with 1pM, 5pM or 30pM LY 294002
for 30 min then the cells were treated with control media or E2 (1nM) for 15 min. Membranes
were probed with P-Akt and P-ERKI/II primary antibodies (1:1000). T-Akt and T-ERKI/II levels
were used as loading controls. Western blots are representative of 1 of 3 independent
experiments.
E2 was unable to increase or significantly alter the levels of P-ERK/ll protein
expression in MCF-7, LCC1 or LCC9 cell lines, which remained comparatively low
irrespective of treatment or cell line (figure 5.6B).
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5. 1. 1. 5. The effect of LY 294002 on mRNA expression levels
of E2-responsive genes in this model of resistance
The 'protective' nature of the growth factors in the resistant cell lines in the presence
of the inhibitor LY 294002 was an interesting observation, given their inability to
stimulate proliferation in the same cell lines. Gu et a! (2002) reported that one of the
mechanisms by which breast cancer cells become resistant is via alterations to gene
networks controlling cell proliferation and apoptosis. Therefore, the effect of the
growth factors, run in conjunction with E2, was assessed downstream of ERa at the
mRNA level.
5. 1. 1. 5. 1. E2 response
The effects of LY 294002 in the presence and absence of E2 on mRNA expression
levels of E2-responsive genes are illustrated in figure 5.7. Histograms representing
the effect of ER (A), pS2 (B), PR (C) and CTD (D) expression levels of all cell lines
were obtained. All cells were charcoal stripped 48h prior to treatment and were then
pre-treated with lOpM LY 294002 for 30 min and then treated with control media or
E2 (InM) or E2 + 5pM LY 294002 (InM + lOpM) for 24h. Data are in triplicate +/-
SD and MCF-7 cells treated with E2 were used as the positive control.
The ER mRNA basal expression levels of MCF-7, LCC9 and LY2 cell lines were
found to be similar (—l .5, -2 and -2.4 relative expression units for MCF-7, LCC9 and
LY2 cell lines), while the control expression of LCCl cells was significantly elevated
to a value of -6.3 relative expression units (P<0.00l, figure 5.7A, supported by data
in chapter 3) (figure 5.7A). This is in agreement with the ERa protein expression
levels observed in chapter 4. E2 significantly decreased ER mRNA expression
compared to basal levels in MCF-7 cells (P<0.05), LCCl cells (P<0.0l) and LY2
cells (P<0.0l), but not in the LCC9 cell line (in agreement with data in chapter 3).
lOpM LY 294002 alone did not significantly alter the ER mRNA expression levels of
any cell line. lOpM LY 294002 was unable to significantly reverse or alter the affect
of E2 on ER mRNA expression in any of the four cell lines tested in this model.
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Figure 5.7 The effect of LY 294002 in the presence and absence of E2 on mRNA
expression levels of E2-responsive genes. Histograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and were then pre-treated with 10pM LY 294002 for 30 min and then treated with
control media or E2 (1nM). Cells were treated with control media(B), 5pM LY 294002(b), E2(b)
or E2 + 10pM LY 294002(b) for 24h, where data are in triplicate +/-SD. MCF-7 cells treated
with E2 were used as the positive control. ANOVA test: * = P<0.05, ** = P<0.01 and
***
= p<0.001. Asterisks in black represent statistically significant changes between control
and a treatment, those in green represent statistical significance between MCF-7 cells and
the resistant cell lines and those in red represent any statistical significant changes between
E2 pre and post-treatment with LY 294002. Histograms are representative of 1 of 3
independent experiments.
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The mRNA expression levels of the E2-responsive pS2 gene are depicted in figure
5.7B relative to the positive control (MCF-7 treated with E2). Basal pS2 mRNA
levels were elevated significantly in LCC1 and LCC9 resistant cell lines compared to
the MCF-7 parental cell line (P<0.001), with values of -1.2 and -0.9 relative
expression units versus -0.06 relative expression units. The basal pS2 mRNA level in
the LY2 cell line was insignificantly different to that of MCF-7 cells (P>0.05). pS2
mRNA levels were elevated significantly with E2 treatment in all four cell lines. The
most significant increases were observed in the MCF-7, LCC1 and LY2 cell lines
(PO.OOl) compared to P<0.05 significance value for the LCC9 cell line. These data
are supported by results presented in chapter 3. 5pM LY 294002 treatment alone did
not statistically significantly alter basal pS2 levels and 5pM LY 294002 was unable
to significantly reverse the increase in pS2 expression produced with InM E2 in any
cell line.
As previously discussed in chapter 3 basal PR mRNA expression levels were
elevated in LCC9 cells by -5.4-fold (PO.OOl) and reduced in LY2 cells by —5.8-fold
(P<0.01) in comparison to MCF-7 cells (figure 5.7C). LCC1 basal PR expression
was not significantly different to that of MCF-7 cells. PR mRNA expression was
increased by E2 treatment in MCF-7 (PO.OOL), LCC1 (PO.OOl) and LY2 cells
(PO.01) but not in LCC9 cells. LY 294002 did not alter the PR expression of any
cell line when administered as a single agent. LY 294002 significantly increased PR
expression over and above that achieved by E2 alone in the MCF-7 and LCC9 cell
lines (P<0.05). PR expression remained relatively unaltered in LCC1 and LY2 cell
lines when treated with LY 294002 and E2 in combination (P>0.05).
Figure 5.7D shows the basal CTD mRNA expression levels were reduced in LCC1
and LY2 cells (PO.05 and PO.OOl respectively) compared to MCF-7 cells as
previously discussed. Basal LCC9 CTD expression was not significantly changed to
that of control treated MCF-7 cells. LCC1 CTD expression levels were significantly
reduced in general to those of MCF-7 cells (PO.05). The CTD mRNA levels of
MCF-7 and LCC1 cells were unaltered by E2, lOpM LY 294002 alone or lOpM
LY 294002 + InM E2 (P>0.05) treatments. E2 increased CTD expression by
-1.4-fold (PO.05) in LCC9 cells, which was subject to some reversal by pre-
treatment with lOpM LY 294002 (P<0.05). LY 294002 did not alter the basal LCC9
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CTD expression levels. The mRNA expression levels of the LY2 cell line responded
in a similar manner to LCC9 cells. The level was significantly increased by E2 by
~3.4-fold (PO.OOl), which was again reduced by LY 294002 by ~0.5-fold (PO.OOl).
The reversals observed in the LCC9 and LY2 cells lines require confirmation in the
form of dose-response data as these may be false positive results if one considers that
measuring changes between three cells lines multiplied by four markers incurs a
>50% chance that one result will be 5% significant despite no real changes occurring.
5. 1. 1. 5. 2 TGFa response
The effects of LY 294002 in the presence and absence of TGFa on mRNA expression
levels of E2-responsive genes are illustrated in figure 5.8. Histograms representing
the effect of ER (A), pS2 (B), PR (C) and CTD (D) expression levels of all cell lines
were obtained. All cells were charcoal stripped 48h prior to treatment and were then
pre-treated with lOpM LY 294002 for 30 min and then treated with control media or
TGFa (InM) or TGFa + LY 294002 (InM + lOpM) for 24h. Data are in triplicate +/-
SD and MCF-7 cells treated with E2 were used as the positive control.
Basal ER mRNA expression levels were as per described for E2 treated cells in
section 5. I. I. 5. 1. Figure 5.8A shows TGFa treatment reduced MCF-7 ER
expression by ~1.6-fold (P>0.05). LY 294002 did not affect MCF-7 cells when
administered alone. LY 294002 in combination with TGFa significantly reduced ER
mRNA levels relative to control (P<0.01), but this reduction was insignificant
compared to TGFa treatment alone. TGFa did not alter ER expression in LCC1 or
LY2 cells, however the ligand did increase ER expression in LCC9 cells by ~1.7-fold
(P<0.01). LY 294002 did not significantly alter ER expression in LCC1 cells, but
interestingly reduced ER mRNA levels in combination with TGFa compared to
control and TGFa alone (PO.01). LY 294002 alone increased ER expression in
LCC9 and LY2 cells significantly (P<0.01 and P<0.05 respectively).
Figure 5.8B shows the basal pS2 mRNA expression levels were as per described for
E2 treated cells in section 5.1.1.5.1. Generally the pS2 mRNA levels were elevated
irrespective of treatment in LCC1 and LCC9 cell lines compared to MCF-7 and LY2
cell lines. TGFa increased pS2 mRNA levels by 0.7-fold (P<0.05) in MCF-7 cells,
which was not reduced by LY 294002. Treatment of this cell line with LY 294002
alone did not change pS2 mRNA expression from that of control treated cells.
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Figure 5.8 The effect of LY 294002 in the presence and absence of TGFa on mRNA
expression levels of E2-responsive genes. Histograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and were then pre-treated with 10pM LY 294002 for 30 min and then treated with
control media or TGFa (1nM). Cells were treated with control media(b), 10pM LY
294002(b),TGFa ( ) or TGFa+ 10pM LY 294002(b) for 24h, where data are in triplicate +/-
SD. MCF-7 cells treated with E2 were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistically significant changes
between control and a treatment, those in green represent statistical significance between
MCF-7 cells and the resistant cell lines and those in red represent any statistically significant
changes post-treatment with LY 294002. Histograms are representative of 1 of 3 independent
experiments.
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TGFa did not affect pS2 expression in any of the resistant cell lines compared to
basal levels. pS2 mRNA levels in LCC1 cells were also unaffected by LY 294002
alone and in combination with TGFa (P>0.05). The pS2 expression levels of the
LCC9 cell line were, however increased by ~1.5-fold with LY 294002 alone
compared to control and by ~1.6-fold when LY 294002 was combined with TGFa
compared to control. pS2 levels were also elevated in the combined treatment in
LCC9 cells when compared to cells treated with TGFa alone (-1.1-fold increase,
P<0.01). The pS2 mRNA levels of LY2 cells remained unaffected irrespective of
conditions.
Figure 5.8C illustrates the effect of LY 294002 and TGFa on the PR mRNA
expression levels in the panel of cell lines. TGFa produced a significant decrease in
PR expression in the MCF-7 cell line (P<0.01), while an increase was seen in the
LCC9 cell line (P<0.01) compared to levels recorded in untreated control cells.
TGFa did not significantly change PR expression in LCC1 or LY2 cells. LY 294002
did not alter PR expression in the MCF-7 cells alone, but the combination of inhibitor
plus growth factor raised the reduced mRNA value, although not significantly
compared to the combination treatment. No changes were observed in the resistant
cell lines treated with LY 294002 alone. There were no significant differences in PR
mRNA post-treatment with LY 294002 compared to TGFa alone in MCF-7 and
LCC9 cells, however, the combination treatment appeared to be less significantly
elevated in these cell lines compared to control than when the inhibitor was
administered alone (P<0.01 reduced to P<0.05 and P<0.001 lessened in significance
to P<0.01 in MCF-7 and LCC9 cells respectively). Also the combination treatment
did not produce significant changes in LCC1 and LY2 cell lines compared to TGFa
alone, but the mRNA value produced was considered significant compared to control
treated cells.
CTD mRNA levels fluctuated around basal level irrespective of treatment in all four
cell lines (figure 5.8D). LCC1 and LY2 basal levels were significantly lower than
that of MCF-7 and LCC9 cell lines (P<0.05). The CTD mRNA levels of LCC9
control treated cells were slightly elevated compared to MCF-7 cell control
expression levels but this was not found to be significant (~1.04-fold increase).
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TGFa did not affect pS2 expression in any of the resistant cell lines compared to
basal levels. pS2 mRNA levels in LCC1 cells were also unaffected by LY 294002
alone and in combination with TGFa (P>0.05). The pS2 expression levels of the
LCC9 cell line were, however increased by ~1.5-fold with LY 294002 alone
compared to control and by ~1.6-fold when LY 294002 was combined with TGFa
compared to control. pS2 levels were also elevated in the combined treatment in
LCC9 cells when compared to cells treated with TGFa alone (~l.l-fold increase,
P<0.01). The pS2 mRNA levels of LY2 cells remained unaffected irrespective of
conditions.
Figure 5.8C illustrates the effect of LY 294002 and TGFa on the PR mRNA
expression levels in the panel of cell lines. TGFa produced a significant decrease in
PR expression in the MCF-7 cell line (P<0.01), while an increase was seen in the
LCC9 cell line (PO.Ol). TGFa did not significantly change PR expression in LCC1
or LY2 cells. LY 294002 did not alter PR expression in the MCF-7 cells alone, but
the combination of inhibitor plus growth factor raised the reduced mRNA value,
although not significantly compared to the combination treatment. No changes were
observed in the resistant cell lines treated with LY 294002 alone. There were no
significant differences in PR mRNA post-treatment with LY 294002 compared to
TGFa alone in MCF-7 and LCC9 cells, however, the combination treatment appeared
To be les significantly elevated in these cell lines compared to control then when the
inhibitor was administered alone (P<0.01 reduced to P<0.05 and P<0.001 lessened in
significance to P<0.01 in MCF-7 and LCC9 cells respectively). Also the combination
treatment did not produce significant changes in LCC1 and LY2 cell lines compared
to TGFa alone, but the mRNA value produced was considered significant compared
to control treated cells.
CTD mRNA levels fluctuated around basal level irrespective of treatment in all four
cell lines (figure 5.8D). LCC1 and LY2 basal levels were significantly lower than
that of MCF-7 and LCC9 cell lines (P<0.05). The CTD mRNA levels of LCC9
control treated cells were slightly elevated compared to MCF-7 cell control
expression levels but this was not found to be significant (~0.04-fold increase).
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5. 1. 2. The effect of MEK inhibitor U0126 on reduced growth
factor stimulated P-MEK in LCC1, LCC9 and LY2 cell lines
U0126 was identified as an AP-l transactivation inhibitor, with specific action
against MEK-l and MEK-2 superior to that obtained against protein kinase C, ERK
and several other kinases (Favata et al, 1998). This inhibitor was used to investigate
the role of the MEK/ERKI/Il pathway in the resistant cell lines as MEK was
previously shown to be differentially phosphorylated in the resistant cell lines
compared to MCF-7 cells upon growth factor stimulation (see chapter 4). These data
showed that growth factor-enhanced P-MEK expression significantly decreased from
the MCF-7 cell line to the LCCl cell line (P<0.00l), and this further diminished
between the LCCl and LCC9 cell line (Figure 4.14). In contrast E2 did not
significantly alter P-MEK due to large standard deviation between experiments
(P>0.05). These alterations in expression may or may not be relevant in the
development of resistance in this model, therefore, if inhibition was altered in the
resistant cell lines showing reduced levels, this would support the theory that the
MEK/ERK pathway may be a contributing factor to resistance.
5. 1. 2. 1 Growth inhibitory response
Figure 5.9 illustrates the growth effect of 0-60pM U0126 in MCF-7, LCCl, LCC9
and LY2 cell lines in the presence and absence E2, TGFa and FlRGp. Proliferation
assays were performed as detailed in earlier inhibitor studies, where cells where
treated on day 0 and treatment halted on day 3. Data were plotted as a mean of 6 OD
values +/- SD for treated values and as a mean of 12 OD values +/- SD for untreated
cells.
All cell lines proliferated in response to ligand treatment as reported earlier (chapter
3, figures 5.1 and 5.2). 60pM U0126 reduced control growth by ~2.4-fold in MCF-7
cells from 125% to 53% day 3 growth relative to day 0 control with U0126
(P<0.001). 60pM U0126 inhibited proliferation by -3.6, -3 and ~4-fold with E2,
TGFa and HRGP treatment respectively in the parental cell line (P<0.001). The
growth stimulation was inhibited by 50% of day 0 growth with U0126 concentrations
of ~27.5pM for E2, ~45pM for TGFa and ~36pM for HRGP treatment in MCF-7
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cells. Interestingly, HRGp proliferation was reduced significantly even with lpM
U0126 (P<0.001) while the increase in proliferation due to E2 was not significantly
reduced with lpM U0126. This also contrasts with control treated MCF-7 cells
which were significantly reduced with this concentration (PO.Ol). However, this did
not occur at higher concentrations and in general the shape of the curves indicate that
E2 stimulation was more easily reversed than HRGp. Also, TGFa increased growth
was not significantly reduced until MCF-7 cells were treated with lOpM U0126.
60pM U0126 inhibited proliferation by -2.9, -2.6, -2.7 and -2.5-fold in LCC1 cells
subject to control, E2, TGFa and HRGp conditions (P<0.001). However, as these
cells proliferated in the absence of any stimulation (control conditions), the final
percentage proliferation of cells on day 3 was elevated compared to the MCF-7 cell
line, with values of-150%, -155, - 101.5% and -113% for LCC1 cells treated with
control media, E2, TGFa and HRGp respectively.
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Figure 5.9 Growth inhibitory effect of U0126 in MCF-7 cells versus resistant breast
cancer cell lines. All cells were charcoal stripped 24h prior to treatment and were then
treated with a concentration range of U0126 spanning 0-60pM plus control media (♦), E2
(1nM) (■), TGFa (1nM) ( ) or HRGp (1nM) (A). Cells were treated on day 0 and treatment
halted on day 3. Data were plotted as a mean of 6 OD values +/- SD for treated values and
as a mean of 12 OD values +/- SD for untreated cells. Graphs are representative of 1 of 3
independent replicate experiments.
The lowest concentration of lpM U0126 used significantly inhibited control and E2
treated LCC1 cells (PO.OOl), but higher concentrations of 5pM and lOpM U0126
were required to significantly inhibit cells treated with TGFa and HRG(3 respectively.
LCC9 cells were inhibited by -2.2, -2.9, -2.9 and -2.7-fold when treated with 60pM
U0126 alone, E2, TGFa and HRG[3 respectively.
The LY2 cell line was inhibited by -3-fold with 60pM U0126 irrespective of
treatment. lpM U0126 significantly inhibited proliferation treated with control
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media, E2 and HRGp. TGFa treatment required 5pM U0126 to be inhibited
significantly. 60pM U0126 inhibited proliferation to —103% in control conditions,
-105% with E2, -104% with TGFa and -125% with HRGP treatment.
It is interesting to note that at lower U0126 concentrations, in particular 10-20pM,
HRGP is again 'protecting' MCF-7, LCC1 and LY2 cells in comparison to all other
treatments. Moreover, in contrast to LY 294002 data, E2 and TGFa are both
'protective' against U0126 in not only MCF-7 cells as for LY 294002, but in the
LCC1 cell line also. The LCC9 cell line behaved differently to the other cell lines,
where proliferation was inhibited by U0126 to a similar extent irrespective of
treatments.
5. 1. 2. 2 The effect of MEK inhibitor U0126 on the MEK/ERK
pathway in LCC1 and LCC9 cells versus MCF-7 cells
The role of MEK/ERK signalling was investigated in resistance by using the MEK
inhibitor U0126 to abrogate signalling via this pathway.
5. 1. 2. 2. 1 The effect of U0126 on P-ERKJU in cells treated
with TGFa
Figure 5.10 shows the inhibitory effect of U0126 in the presence and absence of
TGFa on the ERKl/II signalling pathway in MCF-7, LCCl and LCC9 cell lines.
Figure 5.10A is a representational western blot of P-ERKl/Il levels, where all cells
were charcoal stripped 48h prior to treatment and were then pre-treated with lpM,
20pM or 60pM U0126 for 30 min; the cells were then treated with control media or
TGFa (InM) for 15 min. Membranes were probed with P-ERKI/11 primary antibody
(1:1000). T-ERKI/I1 levels were used as loading controls. The western blot illustrates
the low and similar levels of P-ERKI/II in MCF-7, LCCl and LCC9 cells. There were
significant increases in P-ERKI/II with TGFa (InM) in all cell lines, with the
production of doublets at 44 and 42kDa respectively, as previously documented in
chapter 4 and in figure 5.5 (P<0.001, comparison between control and TGFa
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Figure 5.10 Inhibitory effect of U0126 in the presence and absence of TGFa on the
ERKI/II signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A,
Western blot of P-ERKI/II levels, where all cells were charcoal stripped 48h prior to treatment
and were then pre-treated with 1pM, 20pM or 60pM U0126 for 30 min then the cells were
treated with control media or TGFa (1nM) for 15 min. Membranes were probed with P-
ERKI/II primary antibody (1:1000). T-ERKI/II levels were used as loading controls. B,
histogram of P-ERKI/II OD values of all cell lines treated with control media (■), 20pM
U0126 ( ), TGFa ( ) or TGFa (1nM) + 20pM U0126 (■) as before, where data are in
triplicate +/-SD. MCF-7 cells treated with TGFa were used as the positive control. ANOVA
test: * (P<0.05), ** (P<0.01) and *** (P<0.001) represent significant, highly significant and
extremely significant changes. Asterisks in black represent significant changes between
control and a treatment and those in red represent significance between TGFa pre and post-
treatment with U0126. Western blots are representative of 1 of 3 independent experiments
which are amalgamated in the histogram (B).
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Analysis of multiple western blots using OD values of cells treated with a single
concentration of 20pM (figure 5.1 OB) showed the reduction in P-ERK1/II signal to be
most significant in LCC9 cell line (~6.4-fold reduction, P<0.001) rather than MCF-7
cells (~0.3-fold reduction, P<0.05) or LCC1 cell line (~0.7-fold reduction, P<0.01).
5. 1. 2. 2. 2 The effect of U0126 on P-MEK in cells treated with
TGFa
Figure 5.11 illustrates the effect of U0126 in the presence and absence of TGFa on
the MEK signalling pathway in MCF-7 cells versus resistant breast cancer cell lines.
A representational western blot of P-MEK levels is shown in figure 5.11 A, where all
cells were charcoal stripped 48h prior to treatment and were then pre-treated with
lpM, 20pM or 60pM U0126 for 30 min. The cells were then treated with control
media or TGFa (InM) for 15 min. Membranes were probed with P-MEK primary
antibody (1:1000). T-MEK levels were used as loading controls.
TGFa significantly enhanced P-MEK in MCF-7 (PO.OOl) and LCC1 (P<0.01) cell
lines. Any increase in P-MEK in the FCC9 cell line was small in agreement with
previously described data (chapter 4). The western blot shows that P-MEK increased
in signal strength with increasing U0126 concentration from lpM to 20pM to 60pM
in all cell lines. The histogram in figure 5.1 IB allows statistical analysis of the 20pM
combinations as data was in triplicate.
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Figure 5.11 The effect of U0126 in the presence and absence of TGFa on the MEK
signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A, Western
blot of P-MEK levels, where all cells were charcoal stripped 48h prior to treatment and were
then pre-treated with 1pM, 20pM or 60pM U0126 for 30 min then the cells were treated with
control media or TGFa (1nM) for 15 min. Membranes were probed with P-MEK primary
antibody (1:1000). T-MEK levels were used as loading controls. B, histogram of P-MEK OD
values of all cell lines treated with control media (■), 20pM U0126 ( ), TGFa ( ) or TGFa+
20pM U0126 (■) (columns 1-4 respectively) as before, where data are in triplicate +/-SD.
MCF-7 cells treated with TGFa were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistically significant changes
between control and a treatment and those in red represent statistical significance between
TGFa pre and post-treatment with U0126 in each cell line. Western blots are representative
of 1 of 3 independent experiments which are amalgamated in the histogram (B).
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The combination of 20pM U0126 and TGFa (InM) enhanced P-MEK significantly
in all three cell lines with increases from ~1 to -2.9 arbitrary units (P<0.01) in MCF-
7 cells, -0.08 to -1.3 units (P<0.01) in LCC1 cells and -0.002 to -1.12 units
(P0.001) in the LCC9 cell line. The increase in P-MEK produced from the
combination of 20g,M U0126 and TGFa was significantly greater in the parental
MCF-7 cell line compared to both LCC1 and LCC9 resistant cell lines (P<0.01).
There was no significant difference between the LCC1 and LCC9 cell lines
themselves when subjected to this combination (P>0.05).
5. 1. 2. 2. 3.The effect of U0126 on P-Akt in TGFa-treated cells
The effect of U0126 in the presence and absence of TGFa on the Akt signalling
pathway in MCF-7 cells versus resistant breast cancer cell lines is shown in figure
5.12. All cells were charcoal stripped 48h prior to treatment and were then pre-
treated with lpM, 20pM or 60pM U0126 for 30 min then the cells were treated with
control media or TGFa (InM) for 15 min. Membranes were probed with P-Akt
primary antibody (1:1000). T-Akt levels were used as loading controls.
The western blot in figure 5.12A shows TGFa enhanced P-Akt levels were
significantly increased further with increasing U0126 concentrations in all cell lines,
with what appears to be the greatest enhancement occurring with 60pM (P<0.001
with 20pM concentration in all cells compared to TGFa treatment alone, figure
5.12B). The basal levels of P-Akt in MCF-7 cells treated with increasing
concentrations of U0126 were increased, but not significantly compared to control
treated cells. In contrast, U0126 increased LCC1 and LCC9 cell line elevated
constitutive P-Akt levels (P<0.01 and P<0.001 respectively).
Figure 5.12B is a histogram of P-Akt OD values of all cell lines treated with control
media, 20pM U0126, TGFa (InM) or TGFa + U0126 (InM + 20pM), where data
are in triplicate +/-SD. MCF-7 cells treated with TGFa were used as the positive
control. LCC1 and LCC9 cell lines were significantly constitutively phosphorylated
at the Akt position (P<0.05) compared to the parental MCF-7 cell line as previously
described in chapter 4 and in figure 5.3.
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Figure 5.12 The effect of U0126 in the presence and absence of TGFa on the Akt
signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. A, Western
blot of P-Akt levels, where all cells were charcoal stripped 48h prior to treatment and were
then pre-treated with 1pM, 20pM or 60pM U0126 for 30 min then the cells were treated with
control media or TGFa (1nM) for 15 min. Membranes were probed with P-Akt primary
antibody (1:1000). T-Akt levels were used as loading controls. B, histogram of P-Akt OD
values of all cell lines treated with control media (■), 20pM U0126 ( ), TGFa ( ) or TGFa
(1nM) + 20pM U0126 (■) as before, where data are in triplicate +/-SD. MCF-7 cells treated
with TGFa were used as the positive control. ANOVA test: * = P<0.05, ** = P<0.01 and *** =
P<0.001. Asterisks in black represent statistically significant changes between control and a
treatment and those in red represent statistical significance between TGFa pre and post-
treatment with U0126 in each cell line. Western blots are representative of 1 of 3
independent experiments which are amalgamated in the histogram (B).
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TGFa significantly enhanced P-Akt in all three cell lines (P<0.001 in MCF-7 and
P<0.01 for the resistant cell lines) also as previously described. U0126 potentiated
TGFot-enhanced P-Akt from ~1 to ~3 relative expression units in MCF-7 cells, from
-1.6 to ~5 relative expression units in LCC1 cells and from -2 to ~4.3 relative
expression units in LCC9 cells (all P<0.001). As for U0126 alone, the resistant cell
line P-Akt levels were elevated further than the MCF-7 cell line. However, there was
no difference between LCC1 and LCC9 cells lines, indicating P-Akt stimulation has
peaked at the same level in both cell lines.
5. 1. 2. 3. The effect of MEK inhibitor U0126 on signalling
pathways in cells treated with E2
5. 1. 2. 3. 1. P-ERK/II
The effect of U0126 on P-ERK.I/II was observed in the cell model when cells were
treated with E2 (figure 5.13A). Basal P-ERK/II levels were low and relatively equal
in all three cell lines and were not enhanced by treatment with E2 (InM). U0126
appeared to reduce the low basal levels even further with reductions of -3, ~5 and
~12-fold in MCF-7, LCC1 and LCC9 cell lines with a concentration of lpM. E2
appears to prevent this reduction in the basal level of P-ERKI/II in the MCF-7 cell
line, but only at the lowest concentration of lpM of U0126. 20pM and 60pM
U0126 abolished any basal signal remaining.
5. 1. 2. 3. 2. P-Akt
The effect of UOl26 on P-Akt was observed in the cell model when cells were
treated with E2 (figure 5.13B). Basal and TGFa-treated P-Akt levels were as
previously described in chapter 4 and in figures 5.3 and 5.12. The pattern of P-Akt
treated with U0126 alone reflects that of figure 5.12, where U0126 increased P-Akt
in all cell lines with increasing concentration. Interestingly, the addition of E2 further
increased U0126 (lpM) enhanced P-Akt from ~2-4-fold in all cell lines. The increase
in P-Akt appears to plateau at 20pM U0126 + E2 and does not increase any further
with 60pM U0126 in combination with E2. This also occurs in the absence of E2.
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Figure 5.13 The effect of U0126 in the presence and absence of E2 on the Akt and
ERKI/II signalling pathways in MCF-7 cells versus resistant breast cancer cell lines. A
and B, Western blots of P-Akt and P-ERKI/II levels respectively, where all cells were charcoal
stripped 48h prior to treatment and were then pre-treated with 1pM, 20pM or 600pM U0126
for 30 min then the cells were treated with control media or E2 (1nM) for 15 min. Membranes
were probed with P-Akt and P-ERKI/II primary antibodies (1:1000). T-Akt and T-ERKI/II levels
were used as loading controls. Western blots are representative of 1 of 3 independent
experiments.
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5. 1. 2. 4 The effect of MEK inhibitor U0126 on mRNA
expression levels of E2-responsive genes in this model of
resistance
As previously reported, one of the proposed mechanisms by which breast cancer cells
become resistant is via alterations to gene networks controlling cell proliferation and
apoptosis (Gu et al, 2002). Therefore, the effect of the growth factors, run in
conjunction with E2, was assessed downstream on E2-regulated gene expression in the
presence and absence ofMEK inhibitor U0126.
5. 1. 2. 4. 1 E2 response
The effects of UOl26 in the presence and absence of E2 on mRNA expression levels
of E2-responsive genes are illustrated in figure 5.14. Histograms representing the
effect of ER (A), pS2 (B), PR (C) and CTD (D) expression levels of all cell lines
were obtained. All cells were charcoal stripped 48h prior to treatment and were then
pre-treated with lOpM U0126 for 30 min and then treated with control media or E2
(InM) or E2 + U0126 (InM + lOpM) for 24h. Data are in triplicate +/-SD and
MCF-7 cells treated with E2 were used as the positive control.
The basal and E2-treated mRNA levels in all four genes tested are described in
section 5. 1. 1. 5. ER mRNA expression levels were reduced significantly in MCF-7
cells treated with lOpM U0126 alone (P<0.01) (figure 5.14A). U0126 was unable to
significantly reverse the reduction in mRNA levels caused by E2, although combined
treatment produced less of a reduction in ER mRNA than treatment with E2 alone
(P>0.05). lOpM U0126 did not significantly alter LCC1 cells treated with control
media or E2, although a slight reduction of ~0.5-fold was recorded P>0.05). U0126
significantly reduced LCC9 ER mRNA expression when combined with E2 from ~1.7
to ~1 arbitrary expression units (P<0.05). LY2 cell ER mRNA levels were again
significantly reduced with E2 treatment from -2.2 to -0.6 arbitrary expression units
(P<0.001), which was significantly reduced to -1 unit by pre-treatment with lOpM
U0126 (P<0.01). U0126 did not significantly change LY2 ER mRNA expression
when administered alone. Figure 5.14B depicts the effect of U0126 on pS2 mRNA
expression levels in this cell model.
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Figure 5.14 The effect of U0126 in the presence and absence of E2 on mRNA
expression levels of E2-responsive genes. Histograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and were then pre-treated with 10pM U0126 for 30 min and then treated with
control media or E2 (1nM). Cells were treated with control media (■), 5pM U0126 ( ), E2(«)
or E2+ 5pM U0216 (■) for 24h, where data are in triplicate +/-SD. MCF-7 cells treated with E2
were used as the positive control. ANOVA test: * = P<0.05, ** = P<0.01 and *** = P<0.001.
Asterisks in black represent statistically significant changes between control and a treatment
in that cell line, those in green represent statistical significance between MCF-7 cells and the
resistant cell lines and those in red represent any statistical significant changes post-
treatment with U0126 in combination with E2 compared to E2 alone in each cell line.
Histograms are representative of 1 of 3 independent replicate experiments.
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U0126 significantly reversed the elevated pS2 expression induced by E2 by ~2-fold
(P<0.05), but was unable to fully abolish the induction in the MCF-7 cell line.
U0126 did not affect pS2 expression relative to control levels in the parental cell line.
U0126 reversed control pS2 expression by ~0.6-fold (P<0.05) in LCC1 cells and
almost completely abolished E2-induced pS2 mRNA expression, with an extremely
significant reversal of ~2.6-fold (P<0.001). U0126 also reversed the E2-elevated pS2
levels in the LCC9 cell line by —1.7-fold (P<0.01). U0126 reduced LY2 cell mRNA
expression elevated by E2, although this was not found to be statistically significant.
U0126 did not significantly affect the pS2 mRNA levels of LY2 control treated cells
(-0.2-fold reduction, P>0.05).
Figure 5.14C shows the PR mRNA expression levels of this model when subjected to
lOpM U0126 in the presence and absence of E2 (InM). PR mRNA expression
remained unchanged by pre-treatment with U0126 alone in all cell lines compared to
that of control, whilst U0126 combined with E2 elevated PR mRNA levels
significantly in MCF-7 cells (-1.4-fold increase, P<0.05). Interestingly, E2-enhanced
PR expression was reduced significantly in the LCC1 cell line by -0.9-fold
(P<0.001), and to a minor extent in LCC9 cells (-1.2-fold reduction, P>0.05).
U0126 plus E2 PR mRNA expression was elevated compared to E2 alone in LY2 cell
lines (-1.7-fold), but this change was not found to be significant.
The CTD mRNA expression of all four cell lines treated with lOpM U0126 in the
presence and absence of E2 (InM) are illustrated in figure 5.14D. U0126 reduced
basal CTD expression in MCF-7 cells by ~0.5-fold, but this was not considered
significant (P>0.05). CTD expression was elevated in MCF-7 cells when treated with
U0126 and E2 (P<0.05). LCC1 cell line PR mRNA expression did not significantly
differ irrespective of treatment. E2-enhanced CTD expression in the LCC9 cell line
was significantly reduced by pre-treatment with lOpM U0126 from —1.6 to —1.1
relative arbitrary expression units (P<0.05). U0126 did not significantly modify
CTD mRNA of LY2 cells compared to basal levels or E2-enhanced CTD levels. CTD
mRNA values remained significantly elevated in the presence of U0126 (P<0.001
compared to control).
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5. 1. 2. 4. 2 TGFa response
The effects of U0126 in the presence and absence of TGFa on mRNA expression
levels of E2-responsive genes are illustrated in figure 5.15. Histograms representing
the effect of ER (A), pS2 (B), PR (C) and CTD (D) expression levels of all cell lines
were obtained. All cells were charcoal stripped 48h prior to treatment and were then
pre-treated with lOpM U0126 for 30 min and then treated with control media or
TGFa (InM) or TGFa+ U0126 (InM + lOpM) for 24h. Data are in triplicate +/-SD
and MCF-7 cells treated with E2 were used as the positive control.
Basal and TGFa treated ER mRNA expression levels were as described in sections 5.
1. 1. 5. 1 and 5. 1. 1. 5. 2 respectively, although TGFa produced what was considered
an even more significant reduction in ER mRNA expression in MCF-7 cells in figure
5.15A (P<0.001 compared to P<0.05 in figure 5.8A). Figure 5.15A shows U0126
reduced the ER mRNA value relative to control by -1.3-fold (PO.OOl), but the
combined U0126 plus TGFa treatment did not affect the reduction in ER expression
induced by TGFa treatment alone. U0126 also reduced LCC1 cell line values of ER
mRNA expression by -0.4-fold (P<0.05), which was reduced even further in the
presence of TGFa (-2-fold compared to control, P<0.01). U0126 reduced ER
mRNA expression when combined with TGFa from ~1.2 versus —0.8 relative
arbitrary units (P<0.05) in LCC9 cells and from -0.26 to -0.16 units (P<0.01) in LY2
cells compared to TGFa alone. U0126 did not decrease ER mRNA expression when
administered alone in either LCC9 or LY2 cell lines.
pS2 expression was significantly decreased by U0126 alone in MCF-7 (PO.Ol),
LCC1 (P<0.05) and LCC9 cell lines (PO.OOl) (figure 5.15B). U0126 alone did not
significantly change the pS2 expression in LY2 cells. TGFa-enhanced pS2
expression was reduced with U0126 in MCF-7 (-2.2-fold reduction), LCCl (-0.7-
fold reduction) and LCC9 (-1.5-fold reduction) cell lines (PO.OOl, PO.05 and
PO.OOl respectively).
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Figure 5.15 The effect of U0126 in the presence and absence of TGFa on mRNA
expression levels of E2-responsive genes. Histograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and were then pre-treated with 10pM U0126 for 30 min and then treated with
control media or TGFa (1nM). Cells were treated with control media (■), 10pM U0126 ( ),
TGFa ( ) or TGFa+ 10pM U0216 (■) for 24h, where data are in triplicate +/-SD. MCF-7 cells
treated with E2 were used as the positive control. ANOVA test: * = P<0.05, ** = P<0.01 and
***
= p<0.001. Asterisks in black represent statistically significant changes between control
and a treatment in that cell line, those in green represent statistical significance between
MCF-7 cells and the resistant cell lines and those in red represent any statistical significant
changes post-treatment with U0126 in each cell line. Histograms are representative of 1 of 3
independent experiments.
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Figure 5.15C shows the relative PR mRNA expression of MCF-7, LCC1, LCC9 and
LY2 cell lines post treatment with U0126 in the presence and absence of TGFa.
U0126 alone elevated PR mRNA values in the MCF-7 and LY2 cell lines, with
significance values of P<0.05 and P<0.01 respectively. The reduction in PR mRNA
expression was elevated from 0.08 to 0.1 arbitrary expression units when MCF-7
cells were treated with U0126 combined with TGFa compared to U0126 alone
(~1.5-fold increase, P<0.05). U0126 reduced PR expression treated with TGFa in
LCC1 cells by —1.3-fold (P<0.05). TGFa combined with U0126 did not differ from
TGFa treatment alone in LCC1 or LY2 cells. As previously observed in chapter 3,
PR expression was significantly elevated in control LCC9 cells compared to MCF-7
cells (P<0.01). TGFa increased LCC9 PR expression by ~1.9-fold (P<0.01), which
was significantly reduced by U0126 pre-treatment by ~1.5-fold (P<0.05). This
reversal was not complete, and remained above the elevated control PR expression.
Figure 5.15D shows the effect of U0126 in the presence and absence of TGFa on
CTD mRNA expression in this model of resistance. All cell lines were unaffected by
U0126 or TGFa alone or combination of U0126 plus TGFa, with the exception of
the MCF-7 and LY2 cell lines which had elevated CTD expression of ~1.6-fold
(P<0.01) and ~1.8-fold (P<0.05) respectively in the presence of U0126 alone.
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5. 1. 3. The effect of PLCy inhibitor U-73122 in resistant cell
lines versus parental MCF-7 cell lines
U-73122 is an amino steroid PLCy inhibitor which in turn inhibits PLC-dependent
processes (Thompson et al, 1991; Bleasdale et al, 1990; Smith et al, 1990). It has
been used to link the PLCy-mediated motility pathway with tumour invasion in
several cancers, including breast (Kassis et al, 1999) and to elucidate other roles of
PLCy in tumour development and progression. U-73122 was used in cytotoxicity
studies here as PLCy has previously been linked with the erbB receptor pathway
(Anderson et al, 1990) and development of resistance and hence may play a part in
the development of oestrogen and antioestrogen resistance in this particular model
5. 1. 3. 1. Growth inhibitory response
Figure 5.16 illustrates the growth inhibitory effect of 0-20pM U-73122 in MCF-7,
LCC1, LCC9 and LY2 cell lines in the presence and absence of E2, TGFa and HRG(3.
Proliferation assays were performed as detailed in earlier inhibitor studies, where
cells where treated on day 0 and treatment halted on day 3. Data were plotted as a
mean of 6 OD values +/- SD for treated values and as a mean of 12 OD values +/- SD
for untreated cells.
All cell lines proliferated in response to ligand treatment as reported earlier (chapter
3, figures 5.1, 5.2 and 5.9). U-73122 appeared to increase cell proliferation in a
manner similar to that of E2 at lower concentrations, with MCF-7 control (basal)
growth elevated to -203% day 3 growth (relative to day 0 control) from -130% with
lpM (P<0.001). Elevated proliferation was only decreased lower than the initial
untreated control level (-114%) with 7.5pM U-73122. This reduction was significant
compared to the increase produced with lpM U-73122 (P<0.001). Only 15pM and
20pM U-73122 concentrations produced significant reductions of the initial control
growth of MCF-7 cells (PO.OOl). The IC50 values produced by U-73122 were
~16pM and ~18pM for MCF-7 cells treated with control media and E2 in
combination with the inhibitor.
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Figure 5.16 Growth inhibitory effect of U-73122 in MCF-7 cells versus resistant breast
cancer cell lines. All cells were charcoal stripped 24h prior to treatment and were then
treated with a concentration range of U-73122 spanning 0-20pM plus control media (♦), E2
(1nM) (■), TGFa (1nM) ( ) or HRGp (1nM) (A). Cells were treated on day 0 and treatment
halted on day 3. Data were plotted as a mean of 6 OD values +/- SD for treated values and
as a mean of 12 OD values +/- SD for untreated cells. Graphs are representative of 1 of 3
independent experiments.
The maximum concentration of 20pM U-73122 reduced MCF-7 proliferation to
'-80% (day 3 growth relative to day 0 control) for both TGFa and HRG(3 treatments in
contrast to -31% and -33% for control and E2 treated cells. Similar trends were
observed in all three resistant cell lines, with the two growth factors increasing the
concentration of U-73122 required to reduce day 3 proliferation (relative to day 0
control). HRGP was more effective at increasing the concentration required for
equivalent inhibition with U-73122 alone. The concentration required to inhibit
proliferation back to 50% of day 0 growth in LCC1 cells treated with control media
was very similar to that required in MCF-7 cells, with values of ~16pM and ~19pM
respectively. An initial peak was observed with all combinations of treatment
0 5 10 15 20
[U-73127\yM
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involving U-73122 in E2-sensitive MCF-7 and LCC1 cell lines suggesting some
stimulatory effect of this inhibitor, which will be discussed in section 5. 2. 3.
Treatment of the LCC1 cell line with TGFa and HRGP, in agreement with data
obtained for the parental cell line, increased the concentration of U-73122 required to
reduce cell proliferation to the same extent as control. The reductions in proliferation
were to values of -137% and -207% for TGFa and HRGP treated LCC1 cells
respectively, which are elevated values compared to those produced for MCF-7 cells.
FCC9 cells were not growth stimulated by any ligand or U-73122. ~20pM U-73122
alone reduced proliferation in LCC9 cells to 50% of day 0 control growth. FCC9
cells treated with E2, TGFa and HRGP were growth inhibited but 20pM U-73122 was
only able to reduce day 3 proliferation (relative to day 0 control) to -79%, -212%
and -281% for cells treated with E2, TGFa and HRGP respectively. Moreover, these
reductions were still significant compared to untreated cells (all P<0.001). 20pM
U-73122 reduced day 3 growth (relative today 0 control) of LY2 cells treated with
control media to -66%, -79% with E2, -212% with TGFa and -332% with HRGp.
All reductions were significant compared to cells that were not treated with U-73122
(P<0.001).
The combination of U-73122 with either growth factor prevented the fall in cell
proliferation as observed with the same concentration of U-73122 in any cell line
treated with E2 or U-73122 alone. Thus, growth factors 'protected' the cells from the
growth inhibitory action of U-73122, while U-73122 alone acted as an agonist at low
concentrations in E2-sensitive MCF-7 and FCC1 cell lines. The agonist effect of
U-73122 alone was not observed in FCC9 or LY2 cell lines at any concentration.
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5. 1. 3. 2. The effect of U-73122 on mRNA expression levels of
E2-responsive genes in this model of resistance
The proliferation assay data implicated U-73122 increased cell proliferation and thus
acted as an agonist in the E2-sensitive MCF-7 and LCC1 cell lines. MCF-7, LCC1,
LCC9 and LY2 cell lines were treated with U-73122 to investigate any differential
effects on E2-responsive genes.
5. 1. 3. 2. 1. E2 response
Figure 5.17 shows the effect of 5pM U-73122 in the presence and absence of E2 on
mRNA expression of E2-responsive genes. Histograms representing the effect of ER
(A), pS2 (B), PR (C) and CTD (D) expression levels of all cell lines were obtained.
All cells were charcoal stripped 48h prior to treatment and were then pre-treated with
5pM U-73122 for lh and then treated with control media or E2 (lnM) or E2 +
U-73122 (lnM + 5pM) for 24h. Data are in triplicate +/-SD and MCF-7 cells treated
with E2 were used as the positive control.
The basal and E2 treated mRNA levels in all four genes of all four cell lines tested are
described in section 5. 1. 1. 5. MCF-7 cell line ER mRNA expression level remained
unchanged with U-73122 alone compared to control. The reduction in ER expression
was decreased marginally by —1.1 -fold by pre-treatment of MCF-7 cells with
U-71322, but the final value was still deemed significant compared to control treated
cells (P<0.05) (figure 5.17A). U-73122 alone also significantly reduced ER mRNA
expression in LCC1 cells (PO.OOl). LCC1 ER mRNA levels behaved in a similar
manner to the parental line when treated with U-73122 plus E2, with a minor increase
in the ER expression (from -2.3 to -2.6 arbitrary relative expression units) with the
combined treatment, but this remained an extremely significant reduction in ER
mRNA (PO.OOl).
Treatment of LCC9 cells with either E2 or U-73122 alone reduced ER mRNA
expression by 0.5 and O.l-fold respectively, but these reductions were not found to
be significant. However, the expression was further reduced and became significant
when treated with the combination treatment of U-73122 and E2 compared to control
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treated cells (PO.OOl) or LCC9 cells treated with E2 alone (PO.Ol). U-73122
significantly reduced ER mRNA levels in LY2 cells by O.5-fold (PO.OOl). This
reduction was not as great as that produced by E2 (0.75-fold, P<0.001). However,
when combined, U-73122 appeared to significantly reverse some of the reduction
induced by E? back to the level ER mRNA expression achieved with U-73122 alone
(P<0.05).
pS2 mRNA expression profiles are shown in figure 5.17B. E2, U-73122 alone and
the combined treatment significantly elevated pS2 mRNA expression compared to the
basal levels in MCF-7 cells (PO.OOl). The increases in mRNA induced by U-73122
and U-73122 plus E2 were greater than that produced by E2 alone with fold inductions
of ~20-fold in both lines compared to ~16-fold for E2 alone, but not significantly so.
pS2 expression was also elevated in LCC1 cells by E2, U-73122 alone and E2 +
U-73122, with fold inductions of ~2.5-fold (PO.OOl) with all treatments. The
combined E2 + U-73122 treatment increased mRNA levels to a greater extent than
either agent alone, but the value was not significantly different. The pS2 mRNA
profile for the LCC9 and LY2 cell lines showed that again the combined treatment
increased pS2 expression further than either agent alone. E2 increased LCC9 cell
basal pS2 expression by 0.9-fold, U-73122 increased expression by ~1.4-fold and E2
+ U-73122 by ~1.4-fold. Only the latter treatment was found to be a significant
increase (PO.Ol). The pS2 mRNA values of LY2 cells were also increased with E2
and U-73122 alone (both PO.Ol).
PR mRNA expression is shown in figure 5.17C and was elevated with E2, U-73122
alone and E2 + U-73122 in MCF-7 and LC-C1 cells (PO.OOl). The combined
treatment appeared to increase PR mRNA values above and beyond that of either E2
or U-73122 alone in MCF-7 cells, but the increase was not significantly above that of
either agent alone (P>0.05). U-73122 alone was the only treatment which increased
PR mRNA expression in LCC9 cells significantly (PO.05). LY2 cell PR mRNA
expression was elevated by E2, U-73122 (both PO.05) and more so with E2 +
U-73122 treatment (PO.Ol) compared to control.
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Figure 5.17 The effect of U-73122 in the presence and absence of E2 on mRNA
expression levels of E2-responsive genes. Histograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and where applicable were then pre-treated with 5pM U-73122 for 1h and then
treated with control media or E2 (1nM). Cells were treated with control media (■), 5pM
U-73122 (■), E2 (■) or E2 + 5pM U-73122 (■) for 24h, where data are in triplicate +/-SD.
MCF-7 cells treated with E2 were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistically significant changes
between control and a treatment in that cell line, those in green represent statistical
significance between MCF-7 cells and the resistant cell lines and those in red represent any
statistically significant changes post-treatment with U-73122 in each cell line. Histograms are
representative of 1 of 3 independent experiments.
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CTD mRNA expression was not significantly increased in MCF-7 cells irrespective
of treatment (figure 5.17D). E2 + U-73122 did increase CTD expression from ~0.9 to
~1.2 arbitrary relative expression units, but this was not a significant increase. LCC1
cells were also unaffected by any treatment with E2 or U-73122. The CTD
expression was elevated in LCC9 cells with E2 treatment by -0.4-fold (P<0.05),
which was completely abolished by U-73122 pre-treatment (P<0.05). E2 and
U-73122 alone increased CTD expression in LY2 cells by -1.4 and ~2-fold
respectively, which increased to ~5-fold when the inhibitor and ligand were combined
(PO.OOl compared to control, P<0.05 compared to E2 or U-73122 alone).
5. 1. 3. 2. 2. TGFa response
U-73122 was investigated in combination with the growth factor TGFa on the mRNA
expression levels of a panel of E2-responsive genes (figure 5.18). Histograms
representing the effect of ER (A), pS2 (B), PR (C) and CTD (D) expression levels of
all cell lines were obtained. All cells were charcoal stripped 48h prior to treatment
and were then pre-treated with 5pM U-73122 for lh and then treated with control
media or TGFa (InM) or TGFa + U-73122 (InM + 5pM) for 24h. Data are in
triplicate +/-SD and MCF-7 cells treated with E2 were used as the positive control.
The basal and TGFa treated mRNA levels of all four genes in all four cell lines tested
are described in section 5. 1. 1.5. ER mRNA was reduced further upon the addition
of U-73122 prior to TGFa compared to TGFa alone in MCF-7 cells (-0.7 to -0.4
arbitrary relative expression units). This reduction was not found to be any more
significant than TGFa alone (P<0.05). LCC1 cell ER mRNA expression was not
affected by TGFa, but the growth factor reduced ER mRNA expression beyond that
of U-73122 alone (-1-fold reduction (P<0.001) versus -0.5-fold reduction (P<0.01)
respectively). In the LCC9 cell line, ER expression was increased by -0.3-fold with
U-73122 pre-treatment versus control expression (P<0.05). 5pM U-73122 almost
completely abolished any increase observed with TGFa treatment from -1 to -0.64
arbitrary relative expression units.
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Figure 5.18 The effect of U-73122 in the presence and absence of TGFa on mRNA
expression levels of E2-responsive genes. Flistograms of ER (A), pS2 (B), PR (C) and
CTD (D) expression levels of all cell lines where all cells were charcoal stripped 48h prior to
treatment and where applicable were then pre-treated with 5pM U-73122 for 1h and then
treated with control media or TGFa (1nM). Cells were treated with control media (■), 5pM
U-73122 (■), TGFa ( ) or TGFa+ 5pM U-73122 (■) for 24h, where data are in triplicate +/-SD.
MCF-7 cells treated with E2 were used as the positive control. ANOVA test: * = P<0.05,
**
= P<0.01 and *** = P<0.001. Asterisks in black represent statistically significant changes
between control and a treatment in that cell line, those in green represent statistical
significance between MCF-7 cells and the resistant cell lines and those in red represent any
statistical significant changes post-treatment with U-73122 in each cell line. Red bold
asterisks represent statistical significance between U-73122 and U-73122+TGFa in each cell
line. Histograms are representative of 1 of 3 independent experiments.
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U-73122 alone reduced LY2 cell line ER expression compared to basal levels
(P<0.05), while TGFa + U-73122 reduced ER expression further than U-73122 alone
(P<0.01).
Figure 5.18B illustrates the effect of U-73122 in the presence and absence of TGFa
on niRNA expression levels of the pS2 E2-responsive gene. pS2 expression was
elevated significantly in MCF-7 cells treated with U-73122 alone and even further in
combination with TGFa relative to control and TGFa treated cells (both PO.OOl).
U-73122 was unable to significantly increase pS2 expression alone in LCC1 cells
(~0.6-fold increase), but when combined with TGFa this increase was —0.7-fold
which was found to be significant compared to basal and TGFa treated levels. TGFa,
as for the E2 treatment, did not interact with U-73122 in LCC9 cells, and the only
change in pS2 expression was the increase with the inhibitor alone as described in the
previous section. The combined effect of U-73122 + TGFa in the LY2 cell line was a
minor reduction in pS2 mRNA expression compared to U-73122 alone (-1.1 to 0.9
arbitrary relative expression units). The effect of the growth factor and inhibitor
alone are described in the previous sections.
Figure 5.18C shows PR mRNA expression was increased by ~1.6, -1.2 and —1.7-fold
in MCF-7, LCC1 and LCC9 cell lines respectively with 5pM U-73122 pre-treatment
(P<0.001, P<0.01 and P<0.001 respectively). TGFa appeared to reverse some of the
stimulation of PR expression induced by U-73122 alone, with a fold decrease of—1.3-
fold in the MCF-7 cell line (P<0.001), as indicated by the three red asterisks in bold.
Pre-treatment of MCF-7 cells with U-73122 prior to TGFa treatment produced a
statistically significant increase (P<0.01) compared to TGFa alone. LCC1 cell PR
expression was also elevated by -0.9-fold compared to TGFa alone when cells were
pre-treated with U-73122 (P<0.01). The combined treatment did not significantly
differ to that of U-73122 alone. LCC9 cell PR expression was again elevated with
TGFa (InM) (P<0.01). Pre-treatment with U-73122 significantly increased PR
expression in LCC9 as mentioned earlier, and this was abolished with U-73122
treatment to levels similar to those obtained with TGFa alone. Red asterisks in bold
indicate a significant reduction between U-73122 alone and U-73122 plus growth
factor (PO.Ol) in LCC9 cells. The PR mRNA expression of the LY2 cell line was
significantly raised by U-73122 pre-treatment in the presence and absence of TGFa
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(P<0.001 and P<0.01 respectively). TGFa treatment significantly reduced U-73122
elevated PR expression by ~0.6-fold (PO.Ol).
U-73122 elevated CTD mRNA expression in MCF-7 cells by -0.7-fold (PO.05),
~0.8-fold in LCC1 cells (PO.Ol) and -0.9-fold in LY2 cells (PO.Ol). In contrast,
CTD expression was actually decreased in the LCC9 cell line by -0.1 -fold with
U-73122 compared to control treated cells (PO.05), which was marginally reduced
further still by the addition of TGFa (total fold reduction -0.2-fold, ~P<0.01). LY2
cells pre-treated with U-73122 were subject to a raise in CTD mRNA of —1.4-fold
(PO.Ol), which was further increased by TGFa, but not significantly compared to
U-73122 alone (fold change remained -0.9).
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5. 1. 4. The effect of p38 MAPK inhibitor SB 203580 in
resistant cell lines with elevated P-Akt expression
SB 203580 is a p38 MAPK inhibitor that specifically targets this molecule with a
concentration 100-fold less than that required for inhibition of other MAP kinases
(lpM cf. lOOpM) (Cuenda et al, 1995). Gutierrez et al (2005) reported that
tamoxifen resistant growth was associated with an increase in phospho-p38 MAPK.
Therefore, SB 203580 was used to discover if the inhibition of p38 MAPK was
directly related to resistance in this model.
5. 1. 4. 1 Growth inhibitory response
An SB 203580 concentration of just below ~60pM was required for MCF-7 cells to
be inhibited to -50% of day 0 growth under control and TGFa treatment conditions.
E2 increased cell proliferation as previously reported in this chapter and in chapter 3,
and prevented this value being reached in MCF-7 cells. The maximum SB 203580
concentration of 60pM reduced E2 stimulated proliferation (day 3 relative to day 0
control) by -235% to -69%. This reduction was deemed extremely significant
(P<0.001). Reductions from -108% to —50% were observed with SB 203580 alone
and from -190% to -52% with SB 203580 + TGFa (P0.001).
MCF-7 cells treated with control media were only significantly reduced by
SB 203580 concentrations higher than 50pM (P<0.001). Lower SB 203580
concentrations inhibited proliferation induced by E2 and TGFa, although only to a
similar final level as control treated cells in the case of TGFa treatment. 5pM
SB 203580 reduced MCF-7 cell E2 and TGFa-induced proliferation by -40%
(P<0.01) and -30% (P<0.05) respectively. As previously stated, SB 203580 did not
significantly affect MCF-7 control proliferation at this concentration, with a
negligible reduction of only -1%.
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Figure 5.19 Growth inhibitory effect of
SB 203580 in MCF-7 cells versus
resistant breast cancer cell lines. All
cells were charcoal stripped 24h prior to
treatment and were then treated with a
concentration range of SB 203580
spanning 0-60pM plus control media (♦),
E2 (1nM) (■), TGFa or (1nM) ( ). Cells
were treated on day 0 and treatment halted
on day 3. Data were plotted as a mean of 6
OD values +/- SD for treated cells and of
12 OD values +/- SD for untreated cells.
Graphs are representative of 1 of 3
independent experiments.
LCC1 cells proliferated in the absence of stimuli as previously reported in this and
other chapters (-300% day 3 growth relative to day 0 in LCC1 cells compared to
-100% observed in MCF-7 cells on both days 0 and 3). Day 3 growth was not found
to be reduced with 5pM SB 203580 alone, but was found to be reduced from -394%
to 349% in combination with E2 and from -352% and -310% with TGFa. The
LCC1 graph in 5.19 shows the SB 203580 inhibitory curves follow a similar trend,
with E2 having a slightly stimulatory and thus 'protective' effect which is consistent
with the growth data for this cell line.
10 20 30 40
[SB 203580] gM
LCC9 cells proliferated in the absence of growth stimuli as before. E2 treatment did
not significantly alter the inhibitory action of SB 203580 compared to SB 203580
alone between lpM and 5pM, the more therapeutic range of SB 203580. Some
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protective effect was observed at lOpM and with higher concentrations, which is
interesting to note as LCC9 cells are insensitive to the growth stimulatory action of
E2. TGFa did not significantly alter the inhibitory action of SB 203580 at any
concentration of the inhibitor. A higher concentration of ~50pM was required to
inhibit LCC9 proliferation by approximately half of day 3 proliferation compared to
~30pM in LCC1 cells. However, the level to which proliferation was reduced to was
similar in both cell lines (-147% and -140% in LCC1 and LCC9 cell lines). This
suggests the final anti-proliferative effect is similar in both resistant cell lines.
In general, SB 203580 did not appear to be as efficacious as LY 294402 or U0126 at
reducing the proliferation of any of the cell lines. MCF-7 cells treated with
SB 203580 alone were not significantly inhibited at any concentration, while E2 and
TGFa-enhanced cell proliferation was reduced significantly. This suggests
SB 203580 was only effective at reducing stimulated cells, rather than basal levels of
proliferation. The trends of each curve are dissimilar to that of control, implying E2
and TGFa are not 'protecting' MCF-7 cells as for LY 294002 or U0126 inhibitors.
Exceptions did occur at the higher end of the concentrations administered, where E2
did exert some preservative qualities. These were not considered to be relevant
however as these concentrations (50pM and 60pM) are well outside the therapeutic
window (Davies et a/, 2000). Also, neither of the resistant cell line proliferation was
reduced to the initial MCF-7 100% growth, with the growth remaining elevated
compared to that of the resistant cell treated with any of the other inhibitors (-145%
and -140% in LCC1 and LCC9 cells respectively treated with 60pM SB 203580
only).
In contrast to the MCF-7 cell line, basal proliferation of both LCC1 and LCC9 cell
lines was reduced in the presence of SB 203580 alone. This is consistent with the
theory that SB 203580 is only targeting cells which are actively proliferating and not
in a state of quiescence like the MCF-7 cell line. This inhibitor may be useful at
reducing resistant cell proliferation to a certain extent, but the concentrations required
to inhibit resistant cell growth by even -100% are encroaching on the border of non¬
specific effects (60pM). Therefore, p38 MAPK may not be the only kinase inhibited
and the antiproliferative effects of this drug may not be accredited to the blockade of
this protein solely.
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5. 2. Discussion
Oestrogen-independent proliferation has been shown to occur as a result of hyper- or
supersensitivity to oestrogen through the overexpression and/or increased
phosphorylation, and thus activation, of various signalling molecules including Akt
and MEK and ERK (Santen et al, 2005; Yue et al, 2003; Britton et al, 2005;
Campbell et al, 2001; Martin et al, 2005). In particular, P-Akt overexpression has
been associated with oestrogen hypersensitivity (Yue et al, 2003) and resistance to
aromatase inhibitors (and thus oestrogen deprivation) (Tokunaga et al, 2006), while
Jelovac et al (2005) reported that MCF-7 cells with stable expression of aromatase,
conferring resistance to the aromatase inhibitor letrozole, overexpressed P-ERK.
This resistance was reversed with MEK inhibitors. Also of interest are MCF-7 cells
selected for resistance to the pure anti-oestrogen ICI 182,780 which display an
increase dependence on the erbB receptor/ERK signalling pathway (McClelland et al,
2001). This is of particular relevance in the LCC9 cell line, which is ICI 182, 780
resistant (Lykkesfeldt et al, 1997; Brunner et al, 1997).
Therefore, resistance to anti-hormonal therapies such as pure ER antagonists and
aromatase inhibitors remains a significant clinical problem and the signalling
pathways by which it develops are poorly understood. The following section will
discuss the role of differential signalling and the effect inhibiting these proteins has
on cellular proliferation. It was hypothesised that inhibition of molecules which are
overexpressed such as Akt would produce a differential form of inhibition in the
resistant cell lines compared to the parental MCF-7 cell line.
5. 2. 1. Akt and LY294002 inhibition of cell proliferation via
the PI3-Kinase pathway
Elevated levels of P-Akt have been implicated in the development of resistance to
both tamoxifen and ICI 182 780 in breast cancer in vitro (Lykkesfeldt et al, 2005) and
to tamoxifen in clinical breast cancer (Kirkeegaard et al, 2005). Chapter 4 showed
that Akt was constitutively phosphorylated under basal conditions in the resistant cell
lines which is consistent with studies by Clark et al (2002) and Campbell et al (2001).
LY 294002 was utilised to block PI3-K and subsequently Akt, a downstream effector
of PI3-K.
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LY 294002 did not affect the basal P-Akt levels of the parental cell line, consistent
with studies by Gaben et al (2004), but did reduce TGFa-enhanced P-Akt which is in
agreement with studies by Monno et al (2000). LY 294002 reduced TGFa-enhanced
P-Akt in a concentration-dependent manner, which is again consistent with published
results using this inhibitor (Moelling et al, 2002). LY 294002 did not alter P-ERK
expression in MCF-7 or the resistant cell lines, which is consistent with data reported
by Martin et al (2003), showing LY 294002 is specifically inhibiting the PI3-K/Akt
pathway rather than the MEK/ERK pathway.
LY 294002 inhibited P-Akt enhanced by TGFa and elevated P-Akt basal levels to a
greater extent in the resistant cell lines than MCF-7 cells, in particular the LCC9 cell
line, which is consistent with this theory and a published study by Yue et al (2003).
Yue et al (2003) reported that their LTED MCF-7 cell line was more sensitive to the
inhibitory effects of LY 294002 than the parental MCF-7 cell line. This study
confirms the greater reduction in P-Akt expression brought about by LY 294002
treatment observed in the LCC- cells compared to the MCF-7 cell line. The LTED
cell line developed by Yue et al (2003) is valid for comparison as this cell line also
expressed constitutively phosphorylated Akt. A study using other Tam-R MCF-7
cells also supports these observations (Jordan et al, 2004).
The greater inhibition of P-Akt observed in the resistant cell lines led to speculation
that the resistant cell lines would be more sensitive to the anti-proliferative nature of
LY 294002 than in the MCF-7 cell line. This theory is supported by other studies.
For example, Lykkesfeldt et al (2005) reported that inhibition of Akt phosphorylation
by another P13-K inhibitor wortmannin or the Akt inhibitor SH-6 resulted in a more
pronounced growth inhibitory effect on the anti-oestrogen-resistant cells compared
with the parental cells. This implicated Akt signalling was playing a role in their
resistant cell line models. Subsequently, it was hypothesised that elevated levels of
P-Akt would increase the sensitivity of the resistant cell line proliferation in the
model used here to the PI3-kinase inhibitor LY 294002.
However, contrary to this, the resistant cell lines were not more sensitive to
LY 294002 than the parental cell line. LY 294002 was unable to reduce resistant cell
proliferation to the same extent as that of the parental MCF-7 cell line treated with the
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same concentration of inhibitor. Similarly, the reduction in constitutively activated
Akt in the resistant cell lines did not correspond with a reduction in proliferation
beyond that observed in MCF-7 cells treated with the same concentration of
LY 294002. It is interesting to note that both the LCC1 and LCC9 resistant cell lines
were inhibited to a similar degree in the presence of LY 294002. The inhibition of
the latter cell line with LY 294002 is consistent with a study in MCF-7 cells
transfected with AND-34, which also conferred IC1 182, 780 resistance (Felekkis et
al, 2005). These cells also displayed constitutively phosphorylated Akt, which was
seen in the LCC9 cell line. These data are similar to those reported by Zhang el al
(2004). This group reported that an MCF-7 cells overexpressing erbB2, which
proliferated more rapidly than MCF-7 cells, were inhibited back to a similar level as
the MCF-7 cell line in the presence of I ,Y 294002. The slightly elevated
concentration required to inhibit proliferation in this investigation is more than likely
due to the differences between the cell lines and the protocols which were followed in
their derivation.
LY 294002 is a specific competitive inhibitor of PI3-K (Vlahos et al, 1994) and as
such this may account for the 'protective' effect of HRGp. LY 294002 was also
observed to be more efficacious than the MEK inhibitor U0126 at inhibiting cell
proliferation which is also consistent with studies by Hu et al (2001) and Lobenhofer
et a! (2000) in MCF-7 cells. This suggests all the cells, including the resistant cell
lines, are more dependent on the P13-K/Akt than the MEK/ERK signalling pathway
for proliferation.
The expression studies showed that LY 294002 alone did not alter ER, pS2 or PR
mRNA levels in any cell line, which is consistent with a study in MCF-7 cells by
Stoica et al (2003) (expression studies are summarised in Table 5.1). This group
found LY 294002 partly reversed the effects induced by E2 in MCF-7 cells, which
was not observed here. However, the data collected by Stoica et a! (2003) was after
only 6h treatment rather than 24h. Therefore, this indicates any changes induced by
LY 294002 treatment may only be observed at an earlier time point.
The specific Akt inhibitor NL-71-101 also inhibited cellular proliferation in all cell
lines in the presence and absence of growth factors, consistent with published data
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(Qiang et al, 2004). However, the absence of a profound difference between the
MCF-7 and resistant cell lines sensitivity to NL-71-101 indicate that substantial
additional work is required to determine if these data are informative. Qiang et al
(2004) utilised 20pM in their proliferation inhibition studies, a concentration
equivalent to the maximum dose utilised in this investigation. Perhaps an increased
concentration may prove to have a greater anti-proliferative effect in the MCF-7 and
resistant cell lines. Interestingly, this group reported that this inhibitor was unable to
abrogate or reduce the level of P-Akt, but did reduce the activation of the downstream
target ofAkt, FKHRL1, in a concentration-dependent manner.
5. 2. 1. 1. The role of 'Raf-Akt' crosstalk in this model
As previously stated, LY 294002 did not alter P-ERKI/II expression in MCF-7 or the
resistant cell lines, which is consistent with data reported by Gaben et al (2004) and
Martin et al (2003). However, LY 294002 did reduce P-MEK in a concentration-
dependent manner in all cell lines. Growth-factor enhanced P-MEK was reduced to a
greater extent in the LCCl cell line indicating that somehow as P-Akt is reduced so is
P-MEK. Moreover, as LY 294002 specifically targets PI3-K and its downstream
effectors this effect was not expected. Thus, it was hypothesised that some form of
crosstalk may be occurring between the PI3-K/Akt and MEK/ERK pathways in all
cell lines.
Moelling et al (2002) and Zimmerman and Moelling (1999) documented the
existence of this crosstalk between the PI3-K/Akt and Ras/Raf/MEK/ERK pathways
in the MCF-7 cell line. Inactivation of the crosstalk between the pathways in the
MCF-7 cell line was stated to 'switch the biological response from proliferation to
cell cycle arrest'. The 'Raf-Akt' crosstalk involves the inhibition of Raf via Akt
when cells are stimulated with a high dose of growth factor. Low doses of growth
factor did not induce this crosstalk. The presence of elevated levels of Akt in the
resistant cell lines suggests that these cell lines may be able to inhibit cell cycle arrest
activated by the MEK/ERK pathway via Raf-1 inhibition, even in the absence of high
concentrations of growth factor. This would account for the elevated basal
proliferation as the signalling via the MEK/ERK growth arrest pathway is dampened,
allowing more cells to proliferate or survive (figure 5.20). Inhibition of P-Akt with
LY 294002 has been shown to abrogate this crosstalk allowing growth arrest and
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differentiation to resume. As LY 294002 abrogated P-Akt to a greater extent in the
resistant cell lines, this implies any crosstalk occurring due to elevated levels would
also be abolished, again recommencing growth arrest and differentiation.
No elevation in P-ERKI/II expression was seen in any of the cell lines upon
LY 294002 treatment. Moelling et al (2002) did observe an increase in P-ERKI/II
but their studies were performed using a higher concentration of inhibitor (20pM vs
5pM) and the increase was only observed at an earlier time point than the 15 min
monitored here.
/ \




Figure 5.20 Proposed model for the Akt-Raf and MEK-Akt interaction in MCF-7 and
resistant breast cancer cells. In the resistant cell lines constitutively phosphorylated Akt
phosphorylates Raf which may in turn lead to 'cross-talk' and inhibition of the
Ras/Raf/MEK/ERK cascade and proliferation (red bar between Akt and Raf-1). This may
occur in the presence or absence of ligand stimulation (HRG(3 shown as an example with
relevant erbB heterodimer). LY294002 unblocks the 'cross-talk' and allows Raf to induce
growth arrest (blue arrows). Moelling et al (2002) first documented this cross-talk and that low
growth factor concentration did not induce 'cross-talk' in MCF-7 cells thus signalling occurred
via both PI3-K/Akt and Raf/MEK/ERK pathways. Elevated levels of P-MEK occurred in
conjunction with U0126 inhibition and an increase in P-Akt expression suggesting some form
of 'survival' feedback on the PI3-K/Akt pathway (arrow between MEK and Akt). The similar
levels of P-ERKI/II in the resistant cell lines compared to the parental MCF-7 cell line suggest
input from another pathway, perhaps p38 MAPK, which has been implicated in the activated
of other ERK family members (Zimmermann et al, 2001).
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Moelling et al (2002) observed levels were not dissimilar to basal P-ERKI/II
expression at later time points, which would be consistent with data reported in this
chapter. According to the 'Raf-Akt' cross-talk theory, it should follow that P-MEK
and P-ERKI/II expression would be diminished in the resistant cell lines due to the
elevated levels of Akt inhibiting Raf more strongly than in the MCF-7 cell line. This
theory is consistent with the reduced growth factor enhanced P-MEK seen in the
resistant cell lines compared to MCF-7 cells. However, P-ERKI/11 levels in the
resistant cell lines were not diminished when cells were treated with growth factors.
Resistant P-ERKI/II expression levels were in fact very similar to those of the
parental cell line, suggesting perhaps another pathway is feeding into the activation of
P-ERKI/11, such as p38 MAPK, which is known to activate ERK family members,
including ERK3 (Zimmermann et al, 2001) which is very similar in structure to ERK1
(Cheng et al, 1996; Boulton et al, 1991)
Moelling et al (2002) did not document P-MEK expression. The majority of studies
only assess the ability of U0126 to abrogate P-ERKI/11. In contrast to the reduced
P-MEK signal observed in the resistant cell lines when treated with growth factors,
U0126 was observed to increase P-MEK expression. An increase in P-MEK with
U0126 treatment may be due to a blockade of downstream signalling which causes a
build up of P-MEK as it is not being 'turned over' for downstream activation ofERK.
P-Akt was also elevated with U0126 treatment in a concentration-dependent manner.
This implies that some form of feedback may occur at Akt as a result of elevated
P-MEK signalling. This theory is consistent with a review by Chang et al (2003),
who proposed that under a specific set of conditions, elevated Raf signalling resulted
in the inactivation of transcription factors downstream of Raf, such as NF-kB and
c-Myc. This may explain Raf-induced antiproliferative responses which were
observed in a number of studies. A study by Zhang et al (2004b) observed the
opposite effect of high and low concentrations of IGF-I to those reported by Moelling
et al (2002). However, Zhang et al (2004) used Lewis lung carcinoma subline H-59
cells rather than MCF-7 cells, suggesting Raf-Akt 'cross-talk' is cell line specific.
In summary of cross-talk, the mechanisms which are responsible for the stimulation
of one pathway over another at varying ligand concentrations remain unclear. Navab
et al (2001) proposed that any variation in the number of cell surface receptors and/or
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downstream substrate expression may take part in these mechanisms. This is again in
agreement with the theory that elevated P-Akt expression enhances 'Raf-Akt' cross¬
talk in the resistant cell lines. A propose model for the Raf-Akt interaction in MCF-7
and resistant breast cancer cells integrating the possible role of PLCy in cell motility
and survival (Figure 5. 21).
5. 2. 2. U0126 inhibited MEK/ ERK-driven cell proliferation
Chapter 4 showed that P-ERKI/II expression remained unaltered in the resistant cell
lines, which contrasted with the reduction in P-MEK signal observed in the resistant
cell lines. P-ERK overexpression has been implicated in the development of
resistance against aromatase inhibitors which prevent the production of oestrogen,
indicating P-ERK overexpression may be responsible for oestrogen-independent
growth (Jelovac et al, 2005). As previously mentioned, Martin et al (2005) also
implicated elevated P-ERK expression in the development of oestrogen-independent
proliferation. In contrast to these studies, as reported in Chapter 4, P-ERKI/II
overexpression did not occur in the LCC- or LY2 resistant cell lines. However, due
to the growth factor-activation of the MEK/ERK pathway in the resistant cells it was
hypothesised that this pathway still performed some role in their proliferation.
U0126 inhibited MCF-7 cells below the -100% day 0 and 3 value in a concentration-
dependent manner, in agreement with studies published by Yue et al (2003) and
Lobenhofer et al (2000). As previously noted, U0126 was observed to be less
efficacious than LY 294002 which is also consistent with the study by Lobenhofer et
al (2000). The latter group showed that neither E2 nor U0126 affected basal levels of
P-ERKl/Il, which reflected results observed at similar concentrations here.
In general, basal P-ERK1/II expression was reduced by U0126 in all cell lines in
agreement with a published article in MCF-7 cells by Gaben et al (2004). The fact
that P-ERKI/II expression of the resistant cell lines was also slightly reduced
indicates these cells are behaving in the same manner as the parental cells, suggesting
they still signal via the MEK/ERK pathway to some degree.
U0126 blocked the phosphorylation of P-ERKI and 11 in MCF-7 cells which is in
agreement with previously reported data (Gaben et al, 2004; Martin et al, 2003) while
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Keshamouni et al (2002) confirmed U0126 inhibited MCF-7 cell proliferation.
Keshamouni et al (2002) reported that U0126 inhibited MCF-7 cells to a similar
extent irrespective of treatment with E2 or growth factor, but this study was only
performed for 24h, as opposed to 72h. The additional incubation period in the current
investigation may explain the elevated concentration of U0126 required to inhibit
HRG(3-treated cells to the same extent as with the other treatments. Martin et al
(2003) also noted that U0126 abrogated P-ERK1/1I expression in their LTED MCF-7
cells, which proliferated in the absence of E2, and are therefore similar in this respect
to the resistant model here. However, this was a model of LTED which possessed
elevated P-ERK1/II expression rather than P-Akt expression, which is the opposite of
the expression pattern observed here. This could again be due to the differences
between the cell models utilised. However, it is more likely that the data provided by
Martin et al (2003) confirms that the cell lines utilised in this model are not LTED
cells and the behavioural differences imply the mechanism of resistance is therefore
different, which was confirmed by the signalling effects reported here. Thus, these
are in fact two different models of resistance.
In contrast to LY 294002, U0126 significantly reduced basal levels of LCC9 ER
mRNA expression and significantly reduced E2-enhanced pS2 expression in all lines,
except LY2 cells, where only a minor decrease was observed. The effect of U0126
on basal and E2-inducible mRNA levels is partly consistent with published data by
Martin et al (2003). This group found that U0126 significantly reduced basal
transcriptional levels of LTED cell lines. However, no effect on E2-mediated
transcriptional activity was reported. This is probably due to the differential P-Akt
and P-ERK expression profiles of the cell models utilised. The MCF-7 cell line was
less sensitive to U0126 inhibition at a transcriptional level than the LTED cell lines,
supporting their theory that elevated levels of P-ERK were important in the
development of E2-independent growth in the LTED model. This theory of
overexpression was thought to be applicable in terms of P-Akt overexpression
increasing LY 294002 sensitivity in the LCC- and LY2 cell lines at the mRNA level.
This theory was refuted as LY 294002 was in general ineffective in the resistant cell
lines. pS2 is often used, and was used in this investigation, as an indicator of E2-
sensitivity for growth. Human pS2 gene expression is specifically controlled at the
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transciptional level by oestrogens in the MCF-7 cell line (Masiakowski et al, 1982;
Brown et al, 1984).
Rio et al (1987) also established pS2 as an E2-dependent biochemical marker in breast
cancer. This is interesting considering that the concentration of U0126 that
inhibited pS2 did little to affect growth. This suggests that the anti-proliferative
effect of U0126 via blockade of the MEK/ERK pathway and the subsequent
reduction in pS2 expression is not as great as that achieved via the inhibition of Akt
using LY 294002, where the reduction in LY 294002 may occur at an earlier time
point (as observed by Stoica et al, 2003). This indicates the MEK/ERK pathway and
perhaps even pS2 expression regulated by this pathway are not as important as Akt in
terms of cellular proliferation in this model. Therefore, the use of the pS2 gene in
this model may not be an accurate indicator of growth when observing cells treated
with U0126. This supports the conclusions reached by Rio et al (1987), who
reported that screening for pS2 gene expression may provided a basis for establishing
subclasses of ER-containing tumours, but that it remained unclear as to whether the
expression would provide additional information concerning the clinical
unresponsiveness to hormone therapy seen in -40% of ER-positive patients.
The U0126 data contrasts with LY 294002, which altered growth more dramatically
at lower concentrations, but did not alter pS2 mRNA levels. In contrast to this
investigation, Martin et al (2003) found LY 294002 to be similarly effective in
reducing the transcriptional rates of these cell lines as U0126. The differential
results are more than likely due to the increased concentration of LY 294002 utilised
by Martin et al (2003) (50pM versus 5pM in this investigation). This may also
account for the absence of the effect of LY 294002 on pS2 expression.
Observations here showed P-ERK1 and II to be low in the parental MCF-7 and
resistant LCC1 and LCC9 cell lines alike, which disagrees with published data by
Martin et al (2005), who reported P-ERK1/11 to be elevated in LTED cell lines.
However, the model used by Martin et al (2005) also displayed hypersensitivity to
oestrogen and elevated basal P-Sl 18 of ERa, neither of which were observed in the
LCC- and LY2 cell lines. As previously proposed, these differential observations are
more than likely due to the different cell models used.
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Martin et al (2003) combined U0126 and LY 294002 and reported a further decrease
than observed with either inhibitor alone. This suggests a combinatorial approach of
targeting two or more pathways would be more efficacious than a single agent alone.
Other studies, including Yue et al (2003) have implicated combinations of agents to
be of greater benefit than the use of an individual agent alone.
5. 2. 3. Concentration dependent U-73122 oestrogen-like
properties and inhibition of cell proliferation
PLCy has been shown to play a role in motility signalling of several receptors such as
IGFR-I (Bornfeldt et al, 1994) and is activated by many growth factors receptors,
including erbB2 (DiFore et al, 1990; Margolis et al, 1990). PLCy has been
implicated in the development of breast cancer and inhibition of this protein with
U-73122 has been shown to interfere with growth factor-mediated breast cancer
migration and tumour invasion (Price et al, 1999; Xie et al, 1998; Chen et al, 1994).
Therefore, U-73122 was utilised to elucidate if PLCy played a role in the
development of resistance in this model of breast cancer.
U-73122 initially stimulated cell proliferation before inhibiting the growth of all cell
lines. This is consistent with the oestrogen-like actions of the metabolite of U-73122
which was documented by Cenni and Picard (1999). This action was also reflected in
the mRNA expression profiles, with the inhibitor behaving in an extremely similar
manner to oestrogen alone (summarised in Table 5.1). These data are again
consistent with the elevated pS2 expression reported by Cenni and Picard (1999)
upon U-73122 treatment. Any mRNA expression changes are therefore more likely
to be due to the potential oestrogen-like action of U-73122 rather than the
antagonistic properties of the inhibitor at this concentration.
Higher concentrations of U-73122 were able to inhibit proliferation (5-20pM), which
indicates that inhibition of the PLCy has the dominant effect on proliferation, but only
at higher concentrations. All cells were 'protected' from U-73122 inhibition with
growth factor treatment, in particular HRGfL This suggests that perhaps the elevated
levels of P-Akt in the resistant cells are interacting with PLCy, increasing expression
or activation of this protein and thus elevating the concentration of U-73122 required
to inhibit cells to the same extent as in the parental cell line.
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▼ ▼
Survival/ motility Proliferate/ Growth arrest/
survival differentiation
Figure 5.21 Proposed model for the Akt-Raf and MEK-Akt interaction in MCF-7 and
resistant breast cancer cells integrating the possible role of PLCy in cell motility and
survival. Legend as for figure 5.20. The elevated P-Akt in the resistant cell lines may induce
'Raf-Akt' cross-talk (shown by horizontal bar between the aforementioned proteins) which
may subsequently account for the reduction in P-MEK observed in the resistant cell lines
(bold dashed lines). Increased signalling in the resistant cell lines is represented by bold
lines. Fine lines indicate potentially weaker signalling occurring in the parental cell line.
Studies by Wang et al (2006) support the proposed theory that overexpression of Akt in the
resistant cell lines results in increased interaction with PLCy. This increased interaction
potentially increases the activation of PLCy and thus elevates the concentration of U-73122
required to inhibit cells to the same extent as in the parental cell line. Wang et al (2006) also
reported this interaction was growth factor-dependent, which is again consistent with the
'protective' effect of HRGp and TGFa reported in this model. The Akt-PLCy interaction has
been linked with cell survival (Deb et al, 2004) and motility via PIP3, IP3 and DAG
subsequently intracellular calcium release ([Ca2+]') and PKC respectively (pathway as
described by Wang & Wang, 2003).
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This theory is consistent with a study published by Wang et al (2006), who reported
that the SH3 domain of PLCy interacts with the praline rich motifs of Akt and that
this process is dependent on growth factor stimulation. This interaction led to Akt
phosphorylating PLCy at SI248, which stimulated cell motility. The link between the
Akt and PLCy interaction and cell survival has also previously been suggested by
Deb et al (2004).
5. 2. 4. SB 203580 did not differentially inhibit proliferation of
resistant cell lines
p38 MAPK has been implicated in the development of tamoxifen-resistant
proliferation (Gutierrez et al, 2005). p38 MAPK was also associated with the
activation of AIB1 phosphorylation (Wu et al, 2004) which may relate to the
activation of transcription factors such as AP-1 and NFk[3. Gutierrez et al (2005)
proposed that the upregulation of growth factor signalling and subsequent activation
of p38 MAPK may modulate ERa function and that of other transcription factors
resulting in an increased resistance to tamoxifen. It was therefore hypothesised that
this mechanism may also be responsible for the oestrogen-independence observed in
the resistant cell lines. SB 203580 was utilised to investigate the effect of inhibition
of p38 MAPK on the proliferation ofMCF-7, LCC1 and LCC9 cell lines. In contrast
to the parental cell line, basal proliferation of both LCC1 and LCC9 cell lines was
reduced in the presence of SB 203580 alone. This is consistent with the theory that
SB 203580 is only targeting cells which are actively proliferating and not in a state of
quiescence like the MCF-7 cell line in DCSS media.
SB 203580 may be useful at reducing resistant cell proliferation to a certain extent,
but the concentrations required even to inhibit resistant cell growth by half are
encroaching on the border of non-specific effects (>30pM). Moreover, p38 MAPK
activity is effectively and completely abrogated at lOpM in cell based assays (Davies
et al, 2000), indicating p38 MAPK is probably not be the only kinase inhibited and
the antiproliferative effects of this drug may not be accredited to the blockade of this
protein solely. At higher concentrations LCK, GSK3(3, PKBa and Raf are also
sensitive to the inhibitory properties of SB 203580 (Davies et al, 2000). Non-specific
inhibition suggests any reductions in proliferation beyond lOpM SB 203580 may
result from inhibition of downstream effectors of molecules such as Raf including the
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MEK/ERK pathway. Davies et al (2000) concluded that caution must be taken when
evaluating the data provided by inhibitors such as SB 203580 and that the use of two
or more inhibitors may provide more reliable inhibition of a specific protein.
In summary, this chapter provides evidence that several pathways are involved in the
mRNA expression regulation and proliferation of the MCF- 7 and resistant cell lines.
All cell lines appear to display Akt-dependent proliferation which is inhibited by
LY 294002, which also suggests some form of 'RaffAkt' crosstalk. U0126 inhibited
E2-regulated pS2 expression in all cell lines, indicating the involvement of the
MEK/ERK pathway in mRNA expression in parental and resistant cell lines alike. In
contrast, the general failure of LY 294002 to affect mRNA expression suggests the
PI3-K/Akt pathway is not as crucial in the control of E?-regulated genes as the
MEK/ERK pathway.
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Table 5. 1 Summary of the effects of various inhibitors on mRNA expression levels in a
panel of breast cancer cell lines
Cell line/ treatment MCF-7 LCC1 LCC9 LY2
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Chapter 6
Does inhibition of the erbB2 receptor
overcome endocrine resistance in this
model of breast cancer?
253
Kate Moore Chapter 6: Inhibition oferbB2 & endocrine resistance
6. 1. Does the blockade of the erbB2 receptor inhibit
signalling or growth responses in the resistant cell lines?
One route by which resistance to oestrogen and antioestrogens can develop in breast
cancer is "cross-talk" between the oestrogen and erbB2 signalling pathways (Gee et
al, 2005; Campbell et al, 2001). Overexpression of the erbB2 receptor occurs in 15-
25% of human breast cancers (Revillion et al, 1998; Hynes & Stern, 1994) and is
associated with malignant transformation and oncogenesis (Hudziak et al, 1987).
Contrastingly, overexpression of erbB3 or erbB4 is less frequent in breast cancer and
does not appear to affect prognosis (Travis et al, 1996). TGFa is often co-expressed
with erbBl and found in multiple breast cancer cell lines (Vyhlidal et al, 2000); it
stimulates growth of ovarian cancer cells in culture (Crew et al, 1992; Morishige et
al, 1991) supporting the resistance theory. Co-expression in ovarian cancer has also
been associated with growth stimulation (Prenzel et al, 2001), again supporting this
theory. TGFa and other growth factors operating through overexpressed erbB
receptors and the ligand-independent pathway may account for the null effect of
tamoxifen and the development of endocrine therapy resistance as erbB receptor
ligands operate via AF-1 as opposed to AF-2, which tamoxifen targets. TGFa has
also been shown to be induced by E2 treatment in ER-positive cell lines (Clarke et al,
1989; Gong et al, 1992).
The discovery that monoclonal antibodies raised against the erbB2 receptor were able
to inhibit growth of cancer cells with amplified levels of this receptor on their cell
surface led to the development of herceptin (Hudziak et al, 1989). However,
resistance to herceptin has been documented in the creation of the JIMT-1 cell line
from a breast cancer patient, which overexpresses the HER-2 oncogene and should
therefore have been a suitable candidate for herceptin (Tanner et al, 2004). This
group reasoned that factors other than erbB2 receptor expression must play a role in
determining the response to herceptin. Chapters 3, 4 and 5 showed that the LCC-
model of resistance was insensitive to anti-oestrogens and to the growth effects of
TGFa and HRG(3, and also E2 in the LCC9 and LY2 cell lines, and that this
potentially occurs via changes in upstream signalling molecules such as the
overexpression of Akt.
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Investigation into the development of insensitivity was performed upstream ofAkt by
targeting the erbB2 receptor with the novel recombinant humanised anti-erbB2
monoclonal antibody 2C4. The monoclonal antibody, or dimerisation inhibitor 2C4
(Agus et al, 2005), binds to the extracellular domain 11 of the erbB2 receptor,
blocking dimerisation with other members of the erbB receptor family.
In contrast to herceptin, which is more effective in breast cancer with over expression
of the erbB2 receptor, 2C4 is able to target cancers which express moderate to low
levels of erbB2 receptor (Albanell et al, 2003; Mass, 2004). This is of particular
relevance in this model of resistance as these cell lines have been documented as
having erbB2 levels relatively similar, and even somewhat reduced, to those of the
parental MCF-7 cell line (Gu et al, 2001). Totpal et al (2003) and Agus et al (2002)
found that the blockade of dimerisation formation involving erbB2 receptors reduced
ligand-activated signalling via this family of receptors, including diminished
phosphorylation of the erbB2 receptor itself and activation of MARK and Akt (Agus
et al, 2002; Totpal et al, 2003). It was hypothesised that by targeting erbB2, an
upstream regulator of Akt, and the dimerisation of erbB2 with 2C4, that this would be
of particular significance in the resistant cell lines where Akt over expression
occurred. It may be that the resistant cell lines are more sensitive to the anti¬
proliferative effects of 2C4 due to Akt over expression, but this is dependent on the
role ofAkt in the proliferation of these cell lines.
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6. 2. Anti-proliferative Response
The anti-proliferative effect of 2C4 on the MCF-7 cell line has previously been
documented (Agus et al, 2002). This characterisation of 2C4 in the parental cell line
allowed for subsequent direct comparison to the resistant cell lines when subjected to
the same treatment conditions. Any differences between the sensitive and resistant
cell lines due to signalling via the erbB2 receptor will hopefully become apparent. It
was hypothesised that the elevated expression of Akt in the resistant cell lines was
triggered upstream by the crbB pathway. Therefore, the blockade of the erbB
pathway using a dimerisation inhibitor such as 2C4 would suppress proliferation in
the resistant cell lines, perhaps to a greater extent than the MCF-7 cells due to the
enhanced levels of constitutively active Akt.
All cells were charcoal stripped 48h prior to treatment and were then pre-treated with
lOOnM 2C4 for 30 min then the cells were treated with control media lOOnM 2C4
alone, TGFa, HRGp or E2 (all at InM), or a combination of ligand plus 2C4 (lOOnM
+ InM) for 72h. TGFa and HRGp were again chosen as these ligands signal via
combinations involving erbBl and erbB3 receptors respectively, hence different
heterodimer combinations could be tested. Phosphorylated erbB 1/2 and 1/3
heterodimers have been linked with the development of tamoxifen resistance in
MCF-7 cells (Knowlden et al, 2003).
6. 2. 1. Does 2C4 inhibit proliferation when cells are treated
with E2?
Figure 6.1 shows the effects of 2C4 on E2 treated breast cancer cells. All cell lines
were treated with control media, E2, 2C4 alone and a combination of the inhibitor
plus hormone. Figure 6.1 shows that all the resistant cell lines proliferated under
control conditions in the absence of any stimuli as previously reported while the
MCF-7 and LCCl cell lines were the only cell lines to proliferate significantly in
response to E2 as previously described (PO.OOl). 2C4 reduced proliferation in
MCF-7 cells (~9% reduction), but not significantly so, and did not significantly affect
proliferation in any of the resistant cell lines. 2C4 was unable to reverse the E2-
enhanced proliferation in either MCF-7 or LCCl cells to any degree, with day 3
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proliferation remaining elevated with values of -437% and -450% in the absence and
presence of 2C4 in MCF-7 cells and -288% and -278% in the absence and presence
of 2C4 in the LCC1 cell line. However, the absence of proliferation inhibition does
not necessarily correlate with an absence of stimulation of signalling pathways
downstream of erbB2 via E2. The combination treatment of E2 + 2C4 did not produce
any significant differential effects in the LCC9 or LY2 cell line to those of E2 or 2C4
treatments alone.
6. 2. .2. Does 2C4 inhibit proliferation when cells are treated
with growth factors?
6. 2. 2. 1 TGFa
Figure 6.2 shows the effects of 2C4 on TGFa treated breast cancer cells. All cell
lines were treated with control media, TGFa, 2C4 alone and a combination of the
inhibitor plus TGFa. All the resistant cell lines proliferated under control conditions
in the absence of any stimuli as previously reported, while the parental MCF-7 cell
line was the only cell line to proliferate significantly in response to TGFa as
previously described (P<0.05). 2C4 alone reduced proliferation in MCF-7 cells, but
not significantly so (-12.5% reduction), and did not significantly affect proliferation
in any of the resistant cell lines.
2C4 reduced TGFa-enhanced proliferation in MCF-7 cells from -133% to -110%,
which was considered significant (P<0.05). However, 2C4 was unable to completely
abrogate TGFa-induced MCF-7 cell proliferation, with a combined treatment value
-10% above that of cells treated with control media.
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Figure 6.1. The effect of 2C4 in the presence and absence of E2 on the proliferation of
MCF-7 cells and a panel of resistant breast cancer cell lines A-E, histograms of the
proliferation of a panel of breast cancer cell lines, where all cells were charcoal stripped 48h
prior to treatment and were then pre-treated with 100nM 2C4 for 30 min then the cells were
treated with control media (■), E2 (■) (1nM), 2C4 alone (■) or 2C4+E2 (■) for 72h. ANOVA
test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent statistically
significant changes between control and a treatment in the MCF-7 cell line. Histograms are
representative of 1 of 3 independent experiments.
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Figure 6.2 The effect of 2C4 in the presence and absence of TGFa on the proliferation
of MCF-7 cells and a panel of resistant breast cancer cell lines. A-E, histograms of the
proliferation of a panel of breast cancer cell lines, where all cells were charcoal stripped 48h
prior to treatment and were then pre-treated with 100nM 2C4 for 30 min then the cells were
treated with control media (■), TGFa ( ) (1nM), 2C4 alone (■) or 2C4+TGFa (■) for 72h.
ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent
statistically significant changes between control and a treatment in the MCF-7 cell line and
those in red represent any statistically significant changes post-treatment with 2C4 in the
MCF-7 cell line. Histograms are representative of 1 of 3 independent experiments.
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6. 2. 2. 2 HRG/3
Figure 6.3 shows the effects of 2C4 on HRGp treated breast cancer cells. All cell
lines were treated with control media, HRGp, 2C4 alone and a combination of the
inhibitor plus HRGp. All the resistant cell lines proliferated under control conditions
in the absence of any stimuli as previously reported, while the parental MCF-7 cell
line was the only cell line to proliferate significantly in response to HRGp as
previously described (P<0.001 when compared across all treatments in that cell line).
2C4 alone did not significantly affect proliferation in any of the cell lines. 2C4
almost completely abolished HRGp-enhanced proliferation in MCF-7 cells from
—161% to -105%, which was considered extremely significant (P<0.001). 2C4 was
unable to completely abrogate HRGP-induced MCF-7 cell proliferation, with a
combined treatment value -5% above that of cells treated with control media.
260













































Figure 6.3 The effect of 2C4 in the presence and absence of HRGp on the proliferation
of MCF-7 cells and a panel of resistant breast cancer cell lines. A-E, histograms of the
proliferation of a panel of breast cancer cell lines, where all cells were charcoal stripped 48h
prior to treatment and were then pre-treated with 100nM 2C4 for 30 min then the cells were
treated with control media (■), HRGp ( ) (1nM), 2C4 alone (■) or 2C4 + HRGp (■) for 72h.
ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent
statistically significant changes between control and a treatment and those in red represent
any statistically significant changes post-treatment with 2C4 in the MCF-7 cell line.
Histograms are representative of 1 of 3 independent experiments.
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6. 3. The Effect of 2C4 on signalling pathways
Pre-treatment of the MCF-7 cell line with 2C4 produced inhibition of cellular
proliferation as expected, however, in contrast to the initial proposed hypothesis, the
resistant cell lines appeared to be completely insensitive to the effects of this anti-
erbB2 agent. It was therefore hypothesised that signalling via Akt and ERK,
molecules downstream of erbB2, may not be inhibited as is the case for the MCF-7
cell line. In particular, it was newly hypothesised that the constitutively
phosphorylated Akt may in fact de-sensitise the resistant cell lines to the anti¬
proliferative nature of 2C4, in contrast to what was initially believed to occur. The
following section will scrutinise the Akt and ERK signalling molecules known to be
inhibited by 2C4 in the MCF-7 cell line. TGFa and HRGp growth factors were used
as they operate via different erbB2 heterodimer conformations, which has been
suggested to play a role in the 2C4 sensitivity of certain ovarian cell lines (Takai et al,
2005). Cells were also subjected to E2 treatment to investigate the possibility of
hormonal interaction with erbB2 via the Akt and ERK pathways. These studies will
hopefully enable any alterations in the resistant cell lines to become apparent and
enable elucidation of a potential mechanism of resistance.
6. 3. 1. The Effect of 2C4 on the Akt signalling pathway
6. 3. 1. 1. E2
The effect of2C4 pre-treatment in the presence and absence of E2 on MCF-7, LCCl
and LCC9 cell lines is illustrated in figure 6.4. Figure 6.4A is a representative
western blot which shows the absence of effect of either E2 or 2C4 alone on P-Akt
expression as previously described in chapter 4. 2C4 did not appear to significantly
alter P-Akt levels of any treatment in any cell line as shown by bands of similar
signal intensity across all treatments and cell lines. This is confirmed in the
histogram in figure 6.4B, where no significant difference was observed between any
treatment or cell line (P>0.05).
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Figure 6.4 The effect of 2C4 in the presence and absence of E2 on P-Akt signalling in
MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-Akt, where all
cells were charcoal stripped 48h prior to treatment and were then pre-treated with 100nM
2C4 for 30 min then the cells were treated with control media, E2 (1nM), 2C4 alone or 2C4 +
E2 for 72h. Membranes were probed with P-Akt primary antibody (1:1000). T-Akt levels were
used as loading controls. B, histogram of P-Akt OD values of all cell lines treated with control
media (■), E2 (■) (1 nM), 2C4 alone (■) or 2C4 + E2 (■) for 72h. ANOVA test: * = P<0.05, ** =
P<0.01 & *** = P<0.001. Asterisks in black represent statistically significant changes
between control and a treatment in that cell line, those in green represent statistically
significant differences between the MCF-7 and resistant cell lines (between the same
treatments). Western blots are representative of 1 of 3 independent experiments which are
amalgamated in the histogram (B).
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6. 3. 1. 2. TGFa
Figure 6.5 shows the effect of 2C4 in the presence and absence of TGFa on the Akt
signalling pathway in MCF-7 cells versus resistant breast cancer cell lines. Figure
6.5A shows a representational western blot of P-Akt levels, where all cells were
charcoal stripped 48h prior to treatment and were then pre-treated with lOOnM 2C4
for 30 min then the cells were treated with control media or TGFa (l nM) for 15 min.
Membranes were probed with P-Akt primary antibody (l :1000).
T-Akt levels were used as loading controls. Figure 6.5B is a histogram of P-Akt
expression relative to positive control derived from triplicate OD values of all cell
lines treated with control media, lOOnM 2C4, TGFa (InM) or TGFa + 2C4 (InM +
lOOpM), where data are in triplicate +/-SD. MCF-7 cells treated with TGFa were
used as the positive control. LCCl and LCC9 cell lines were significantly
constitutively phosphorylated at the Akt position (P<0.05) compared to the parental
MCF-7 cell line as previously described in chapter 4. TGFa significantly enhanced
P-Akt in all three cell lines as shown by bands with a strong signal intensity in figure
6.5A and in the histogram in figure 6.5B (P<0.00l compared to control and other
treatments run simultaneously). 2C4 alone did not significantly affect any cell line
(P>0.05). 2C4 pre-treatment significantly reduced TGFa-enhanced P-Akt by ~6.4-
fold (-87%) in the MCF-7 cell line from an initial —9-fold induction with TGFa alone
(P<0.00l). 2C4 did not significantly alter the TGFa-enhanced P-Akt expression
levels of either of the resistant cell lines (P>0.05 compared to MCF-7 reduction
observed with the same treatments).
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Figure 6.5 The effect of 2C4 in the presence and absence of TGFa on P-Akt signalling
in MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-Akt, where
all cells were charcoal stripped 48h prior to treatment and were then pre-treated with 100nM
2C4 for 30 min then the cells were treated with control media, TGFa (1nM), 2C4 alone or 2C4
+ TGFa for 72h. Membranes were probed with P-Akt primary antibody (1:1000). T-Akt levels
were used as loading controls. B, histogram of P-Akt OD values of all cell lines treated with
control media (■),TGFa ( ) (1nM), 2C4 alone (■) or 2C4 + TGFa (■) for 72h. ANOVA test: * =
P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent statistically significant
changes between control and a treatment in that cell line, those in green represent
statistically significance differences between the control treated MCF-7 and resistant cell
lines, and those in red represent any statistically significant changes post-treatment with 2C4
in each cell line. Western blots are representative of 1 of 3 independent experiments
amalgamated in the histogram (B).
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6. 3. 1. 3. HRGp
Figure 6.6A is a representational western blot of the effect of 2C4 pre-treatment on
HRGp-enhanced P-Akt in MCF-7, LCCl and LCC9 cell lines. The blot shows basal
levels were increased in the resistant cell lines in the first column and that TGFa
enhanced P-Akt expression in all three cell lines which was observed as increased
signal intensity in the second column. This is in agreement with previous data in
chapter 4. 2C4 did not affect the basal signal of any cell line. The histogram in
figure 6.6B showed that 2C4 reduced P-Akt significantly in all three cell lines
(P<0.00l), with fold reductions of —l 5-fold (-93%) in the MCF-7 cell line, ~37-fold
(-97%) in the LCCl cell line and -31-fold (-97%) in LCC9 cells.
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Figure 6.6 The effect of 2C4 in the presence and absence of HRGp on P-Akt signalling
in MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-Akt, where
all cells were charcoal stripped 48h prior to treatment and were then pre-treated with 100nM
2C4 for 30 min then the cells were treated with control media, HRGp (1nM), 2C4 alone or
2C4 + HRGP for 72h. Membranes were probed with P-Akt primary antibody (1:1000). T-Akt
levels were used as loading controls. B, histogram of P-Akt OD values of all cell lines treated
with control media (■), HRGp (■) (1nM), 2C4 alone (■) or 2C4 + HRGp (■) for 72h. ANOVA
test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent statistically
significant changes between control and a treatment in that cell line and those in red
represent any statistically significant changes post-treatment with 2C4 in each cell line.
Western blots are representative of 1 of 3 independent experiments amalgamated in the
histogram (B).
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6. 3. 2. The Effect of 2C4 on the ERK signalling pathway
6. 3. 2. 1. E2
The effect of 2C4 pre-treatment in the presence and absence of E2 on the three cell
lines is shown in figure 6.7. As before, a western blot which was representative of a
series of repeat experiments is depicted in figure 6.7A, while a composite of triplicate
OD values is shown in figure 6.7B. No treatment alone or in combination had any
significant differential effect on P-ERKI/II expression (P>0.05).
6. 3. 2. 2. TGFa
Figure 6.8 shows the effect of 2C4 on the P-ERKI/Il signal enhanced by TGFa in the
MCF-7, LCCl and LCC9 cell lines. Figure 6.7A depicts a representational western
blot, and figure 6.8B shows a histogram of relative P-Akt expression derived from
triplicate OD values of all cell lines treated with control media, TGFa, 2C4 alone or
TGFa + 2C4. Single agent treatments were as before, with no change in basal level
expression, and significantly elevated P-ERKl/II levels upon treatment with TGFa.
Pre-treatment with 2C4 alone had no significant effect on the levels of P-ERKI/II in
any of the cell lines (P>0.05). 2C4 reduced TGFa-enhanced P-ERKI/II in the MCF-7
cell line only (~0.4-fold or by -30%, P<0.01 compared to control in conjunction with
treatments). No significant changes were observed in the P-ERKI/II bands of either
of the resistant cell lines when the cells were pre-treated w ith 2C4 and then subjected
to TGFa (P>0.05, comparison across all treatments in each cell line separately or
simultaneously).
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Figure 6.7 The effect of 2C4 in the presence and absence of E2 on P-ERKI/II signalling
in MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-ERKI/II,
where all cells were charcoal stripped 48h prior to treatment and were then pre-treated with
100nM 2C4 for 30 min then the cells were treated with control media, E2 (1nM), 2C4 alone or
2C4 + E2 for 72h. Membranes were probed with P-ERKI/II primary antibody (1:1000).
T-ERKI/II levels were used as loading controls. B, histogram of P-ERKI/II OD values of all
cell lines treated with control media (■), E2 (■) (1nM), 2C4 alone (■) or 2C4 + E2 (■) for 72h.
ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. The absence of any asterisks
indicates no treatment was significant in any cell line individually or between the cell lines.
Western blots are representative of 1 of 3 independent experiments which are amalgamated
in the histogram (B).
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6. 3. 2. 3. HRGp
The effect of 2C4 pre-treatment on P-ERK expression is illustrated in figure 6.9.
Figure 6.9A and B are a representational western blot and histogram of triplicate OD
values from western blots respectively. Cells were treated as in section 6. 3. 1.2 and
were probed with a P-ERK1/II antibody. As previously described, control treatment
did not enhance P-ERKI/II (P>0.05), while HRGP significantly enhanced P-ERKI/11
(P<0.001) (Chapter 4). Pre-treatment of the cell lines with 2C4 dramatically reduced
HRGP-enhanced P-ERK in MCF-7 cells as demonstrated by a loss of signal intensity
(figure 6.9A). There was a -61% reduction which was extremely significant
(P<0.001, figure 6.9B). 2C4 pre-treatment completely abolished HRGp-enhanced
P-ERKI/11 signal in the resistant cell lines with reductions of-100% and -99% in the
LCC1 and LCC9 cell lines respectively (figure 6.9A). This was again found to be
extremely significant in both cell lines (P<0.001, figure 6.9B). Thus, HRGp-
enhanced P-ERKI/11 signal appears to be at least as susceptible to 2C4 inhibition in









































































Figure 6.8. The effect of 2C4 in the presence and absence of TGFa on P-ERKI/II
signalling in MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-
ERKI/II, where all cells were charcoal stripped 48h prior to treatment and were then pre-
treated with 100nM 2C4 for 30 min then the cells were treated with control media, TGFa
(1nM), 2C4 alone or 2C4 + TGFa for 72h. Membranes were probed with P-ERKI/II primary
antibody (1:1000). T-ERKI/II levels were used as loading controls. B, histogram of P-ERKI/II
OD values of all cell lines treated with control media (■), TGFa ( ) (1nM), 2C4 alone (■) or
2C4 + TGFa (■) for 72h. ANOVA test: * = P<0.05, " = P<0.01 & *" = P0.001. Asterisks in
black represent statistically significant changes between control and a treatment in that cell
line and those in red represent any statistically significant changes post-treatment with 2C4 in
the MCF-7 cell line. Western blots are representative of 1 of 3 independent experiments
amalgamated in the histogram (B).
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Figure 6.9. The effect of 2C4 in the presence and absence of HRGp on P-ERKI/II
signalling in MCF-7, LCC1 and LCC9 cell lines. A, western blot of the effect of 2C4 on P-
ERKI/II, where all cells were charcoal stripped 48h prior to treatment and were then pre-
treated with 100nM 2C4 for 30 min then the cells were treated with control media, HRGp
(1nM), 2C4 alone or 2C4 + HRGp for 72h. Membranes were probed with P-ERKI/II primary
antibody (1:1000). T-ERKI/II levels were used as loading controls. B, histogram of P-ERKI/II
OD values of all cell lines treated with control media (■), HRGp ( ) (1nM), 2C4 alone (■) or
2C4 + HRGP (■) for 72h. ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in
black represent statistically significant changes between control and a treatment, in that cell
line and those in red represent any statistically significant changes post-treatment with 2C4 in
each cell line. Western blots are representative of 1 of 3 independent experiments
amalgamated in the histogram (B).
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6. 4. The Effect of 2C4 in combination with anti-oestrogen
treatment
It has been hypothesised by a number of studies that endocrine therapy resistance is a
result of the 'cross-talk' between the erbB receptor pathway and the ligand dependent
pathway and this resistance may be overcome by targeting the two pathways
simultaneously (Mass, 2005; Martin et al, 2005). The discovery that 2C4 alone was
ineffective at reducing the proliferation of the resistant cell lines but remained able to
inhibit HRGP-enhanced Akt and ERK signalling of these cells led to speculation that
a combination strategy may be more successful. The JIMT-1 cell line is resistant to
the anti-erbB2 agent herceptin despite overexpressing the HER-2 oncogene (Tanner et
al, 2004). There is evidence from other studies that combining an anti-oestrogen such
as tamoxifen with an erbB receptor blocker, such as herceptin leads to a reduction in
cell proliferation and signalling via the erbB receptor pathway.
It was therefore hypothesised that in this model system, the inhibition of both the
erbB2 receptor pathway with 2C4 and the ligand-dependent pathway with tamoxifen
could prove to be more effective than either single agent alone in reducing cellular
proliferation.
6. 4. 1. Does combined 2C4 and anti-oestrogen treatment
inhibit proliferation in this model?
6. 4. 1. 1. E2
The effect of 2C4 in various combinations with tamoxifen and/or E2 on the
proliferation of the panel of breast cancer cell lines is shown in figure 6.10. Figure
6.10A is a histogram of the effect of the various treatments on the MCF-7 cell line.
The histogram shows that, as before, E2 significantly increased proliferation by ~3-
fold (P<0.00l) and this enhanced proliferation was not significantly affected by 2C4
pre-treatment (P>0.05).
Tamoxifen did not alter cell proliferation when administered alone, and proliferation
was also unchanged when tamoxifen was combined with 2C4 pre-treatment (P>0.05).
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Tamoxifen significantly reduced MCF-7 proliferation enhanced by E2 by -0.7-fold
(-175% reduction, P<0.001). This reduction was not significantly affected when
cells were pre-treated with 2C4 (P>0.05), with proliferation remaining at -250% on
day 3 relative to day 0 control growth.
Figure 6.1 OB is a histogram of the effects of these treatments on LCC1 proliferation.
As previously described in chapter 3, E2 significantly increased the already elevated
basal level of proliferation by -0.3-fold (P<0.001) from -220% to -288% day 3
growth relative to day 0 control. 2C4 did not affect E2-enhanced proliferation
(P>0.05), while tamoxifen significantly reduced this increase by -38% (P<0.001).
2C4 did not significantly alter the reduction in proliferation caused by tamoxifen.
Figures 6.10C to E are histograms of the LCC2, LCC9 and LY2 resistant cell lines
subjected to the same treatments. As previously described earlier in this chapter, the
cells all proliferated in the absence of stimulation (between -200-300% by day 3
compared to day 0). No significant differences were observed with any treatment
combination in any of these cell lines (P>0.05).
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Figure 6.10. The effect of 2C4 combined with tamoxifen in the presence and absence of
E2 on the proliferation of MCF-7 cells and a panel of resistant breast cancer cell lines.
A-E, histograms of the proliferation of a panel of breast cancer cell lines, where all cells were
charcoal stripped 48h prior to treatment and were then pre-treated with 100nM 2C4 for 30
min then the cells were treated with control media (■), E2 (■) (1nM), 2C4 alone (■), 2C4 + E2
(■), tamoxifen (1pM) (■), tamoxifen + 2C4 (■), E2 + tamoxifen (a) or E2 + tamoxifen + 2C4 (■)
for 72h. ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks in black represent
statistically significant changes between control and a treatment in each cell line, those in
blue represent statistical significance post treatment with tamoxifen in each cell line
compared to the other treatment combinations performed without tamoxifen. Histograms are
representative of 1 of 3 independent experiments.
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6. 4. 1. 2. TGFa
The effect of 2C4 in various combinations with tamoxifen and/or TGFa on the
proliferation of the panel of breast cancer cell lines is shown in figure 6.11. Figure
6.1 lA is a histogram of the effect of the various treatments on the MCF-7 cell line.
The histogram shows that, as before, TGFa-enhanced proliferation was reduced by
2C4 pre-treatment (PO.Ol). 2C4 alone did not statistically significantly alter the
proliferation of the MCF-7 cell line (P>0.05).
Tamoxifen did not alter cell proliferation when administered alone, and proliferation
was also unchanged when tamoxifen was combined with 2C4 pre-treatment (P>0.05).
Also of interest are the data showing tamoxifen to significantly enhance the
proliferation of MCF-7 cells already increased by TGFa alone, although this further
increase itself was not found to be significant. A -59% (P<0.00l) increase with the
two agents was noted compared to a -33% (P<0.0l) increase when cells were treated
with TGFa alone. This increase was significantly reduced when cells were pre-
treated with 2C4 (P<0.0l) to a level just above that produced by TGFa + 2C4.
Figures 6.1 IB to E are histograms of the LCCl, LCC2, LCC9 and LY2 resistant cell
lines subjected to the same treatments. As previously described earlier in this
chapter, the cells all proliferated in the absence of stimulation (between -200-300%
by day 3 compared to day 0). No significant differences were observed with any
treatment combination in any of the cell lines (P>0.05).
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Figure 6.11. The effect of 2C4 combined with tamoxifen in the presence and absence of
TGFa on the proliferation of MCF-7 cells and a panel of resistant breast cancer cell
lines. A-E, histograms of the proliferation of a panel of breast cancer cell lines, where all cells
were charcoal stripped 48h prior to treatment and were then pre-treated with 100nM 2C4 for
30 min then the cells were treated with control media (■), TGFa ( ) (1nM), 2C4 alone (■),
2C4 + TGFa (■), tamoxifen (1pM) (■), tamoxifen + 2C4 (■), TGFa + tamoxifen (») or TGFa +
tamoxifen + 2C4 (■) for 72h. ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001. Asterisks
in black represent statistically significant changes between control and a treatment in that cell
line and those in red represent any statistically significant changes post-treatment with 2C4 in
each cell line. Histograms are representative of 1 of 3 independent experiments.
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6. 4. 1. 3. HRGfi
The effect of 2C4 in various combinations with tamoxifen and/or HRGP on the
proliferation of the panel of breast cancer cell lines is shown in figure 6.12. Figure
6.12A is a histogram of the effect of the various treatments on the MCF-7 cell line.
The histogram shows that, as before, HRGP-enhanced proliferation was reduced by
2C4 pre-treatment (P<0.001). Tamoxifen did not alter cell proliferation when
administered alone, and proliferation was also unchanged when tamoxifen was
combined with 2C4 pre-treatment (P>0.05). Interestingly, as with TGFa treatment,
data here showed tamoxifen significantly enhanced the proliferation of MCF-7 cells
already increased by HRGP alone (P<0.01). A ~0.9-fold (-92%, P<0.001) increase
with the two agents was noted compared to a ~0.6-fold (-62%, P<0.001) increase
when cells were treated with HRGP alone. This increase was significantly reduced
when cells were pre-treated with 2C4 (P<0.001) to a level just above that produced by
HRGp + 2C4. It should be noted that tamoxifen appears to be preventing the same
extent of reversal as seen with 2C4 and growth factor alone (tamoxifen elevated the
proliferation of this combination by -16.5% compared to HRGP + 2C4 alone).
Figures 6.12B to E are histograms of the LCC1, LCC2, LCC9 and LY2 resistant cell
lines subjected to the same treatments. As previously described earlier in this
chapter, the cells all proliferated in the absence of stimulation (between -200-300%
by day 3 compared to day 0). No significant differences were observed with any
treatment combination in any of the cell lines (P>0.05).
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Figure 6.12. The effect of 2C4 combined with tamoxifen in the presence and absence of
HRGp on the proliferation of MCF-7 cells and a panel of resistant breast cancer cell
lines. A-E, histograms of the proliferation of a panel of breast cancer cell lines, where all cells
were charcoal stripped 48h prior to treatment and were then pre-treated with 100nM 2C4 for
30 min then the cells were treated with control media (■), HRGp (■) (1nM), 2C4 alone (■),
2C4 + HRGP (■), tamoxifen (1pM) (■), tamoxifen + 2C4 (■), HRGp + tamoxifen (a) or HRGp
+ tamoxifen + 2C4 (■) for 72h. ANOVA test: * = P<0.05, ** = P<0.01 & *** = P<0.001.
Asterisks in black represent statistically significant changes between control and a treatment,
in the MCF-7 cell line, those in blue represent statistical significance post treatment with
tamoxifen compared with the same treatment without in MCF-7 cells, and those in red
represent any statistically significant changes post-treatment with 2C4 in MCF-7 cells.
Histograms are representative of 1 of 3 independent experiments.
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6. 5. The Effect of 2C4 in combination with tamoxifen on
signalling pathways
The proliferation studies discussed in the previous section showed that tamoxifen
appeared to be interfering with the anti-proliferative nature of 2C4 when MCF-7 cells
were treated with growth factors. This is the opposite of what was expected to occur.
The blockade of the two pathways was believed to act synergistically in the inhibition
of proliferation, not interfere or compete with each other. Importantly, these data
demonstrated that the combined treatment of 2C4 and tamoxifen was ineffective at
inhibiting proliferation with any ligand in any combination in any of the resistant cell
lines. The following section demonstrates the effect of 2C4 and tamoxifen on the Akt
and MEK/ERK signalling pathways in this model. Akt, ERK and MEK were
investigated in an attempt to observe any changes which may account for the
differential response to 2C4 between TGFa and HRG(3.
Unfortunately, due to a failure in the suppliers' batch of TGFa it was not possible to
complete some aspects of the investigation in the LCC9 cell line in combination with
tamoxifen, therefore P-Akt and P-ERKI/I1 expression data were not obtained. Also,
studies into the levels of P-MEK in all cell lines treated with TGFa were not
monitored due to the failure of TGFa to enhance either P-Akt or P-ERK1/I1 under
positive control conditions.
6. 5. 1. The Effect of 2C4 and tamoxifen on the Akt signalling
pathway
Figure 6.13 shows western blots performed to characterise the effects of 2C4 and
tamoxifen with either TGFa, HRG[3 or E2 in various combinations on P-Akt
expression. Figure 6.13A shows combinations involving TGFa, where band
intensities for control, TGFa, 2C4 and TGFa + 2C4 were as previously detailed in
this chapter. Tamoxifen alone or in combination with 2C4 did not appear to alter
P-Akt expression in either MCF-7 or LCC1 cell line from their original basal levels.
In agreement with proliferation studies, the signal intensity for P-Akt treated with
TGFa + tamoxifen did not appear too dissimilar to that of TGFa alone in MCF-7
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cells. Tamoxifen did not appear to affect the reversal of TGFa-enhanced P-Akt by
2C4 in the MCF-7 cell line. In the LCC1 cell line, tamoxifen appeared to increase the
signal intensity of the TGFa-enhanced P-Akt band, although 2C4 was able to reverse
this back to the level of TGFa + 2C4 and TGFa alone. This effect was not observed
in proliferation studies as all levels remained constant irrespective of treatment.
Figure 6.13B illustrates western blots of P-Akt expression of the MCF-7, LCC1 and
LCC9 cell lines when subjected to 2C4 in the presence and absence of tamoxifen and
HRGp. Only the tamoxifen combinations will be discussed as other treatments have
been previously described. In agreement with the MCF-7 cell proliferation,
tamoxifen treatment further increased HRGp-enhanced P-Akt signal intensity. 2C4
reduced the HRGp + tamoxifen enhancement of P-Akt signal, but was unable to
reduce the signal to that of HRGp + 2C4. The same pattern occurred in both the
LCC1 and LCC9 cell lines as in the parental cell line. This pattern was not reflected
in the cell proliferation of the resistant cell lines.
Figure 6.13C depicts any changes in P-Akt expression when the three cell lines were
treated with 2C4, E2 and tamoxifen. Only the tamoxifen combinations will be
discussed here as all other single and dual combinations are detailed previously in this
chapter. Tamoxifen did not affect the original P-Akt basal expression or any other
treatment combination in any cell line.
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Figure 6.13 The effect of 2C4 in combination with tamoxifen on P-Akt expression levels
in breast cancer cells treated with TGFa, HRGp and E2. A-C, western blots of P-Akt
levels, where all cells were charcoal stripped 48h prior to treatment and were then pre-treated
with 100nM 2C4 for 30 min then the cells were treated with control media, TGFa, HRGp or E2
(all 1nM, A-C respectively), tamoxifen (1pM), or various combinations of these treatments for
15 min. Membranes were probed with P-Akt primary antibody (1:1000). T-Akt levels were
used as loading controls. Western blots are representative of 1 of 3 independent
experiments.
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6. 5. 2. The Effect of 2C4 plus tamoxifen on the MEK/ERK
signalling pathway
6. 5. 2. 1. ERKI/II
Figure 6.14A shows the effects of 2C4, TGFa and tamoxifen on the pattern of
P-ERKI/II expression were very similar to that of P-Akt in MCF-7 and LCCl cell
lines, where tamoxifen increased TGFa-enhanced P-ERKl/II signal intensity. Also,
2C4 reversed P-ERKI/Il expression when both cell lines were treated with TGFa +
tamoxifen to that of TGFa + 2C4.
The effect of 2C4, HRG(3 and tamoxifen on P-ERKI/II expression is shown in figure
6.14B. Again, tamoxifen increased the growth factor-enhanced P-ERKI/ll band
intensity in MCF-7, LCCl and LCC9 cell lines. In the MCF-7 cell line, 2C4 reduced
HRGp + tamoxifen enhanced P-ERKI/II signal, but not to the level of HRGp + 2C4.
In the LCCl and LCC9 cell lines 2C4 appeared to be more effective and the
P-ERKI/II signal was almost completely abrogated back to the level of HRGp + 2C4.
The western blots for P-ERKI/II levels post treatment with 2C4, E2 and tamoxifen are
presented in figure 6.14C. Levels tended to fluctuate around basal levels but no
treatment clearly changed the expression.
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Figure 6.14 The effect of 2C4 in combination with tamoxifen on P-ERKI/II expression
levels in breast cancer cells treated with TGFa, HRGP and E2. A-C, western blots of P-
ERKI/II levels, where all cells were charcoal stripped 48h prior to treatment and were then
pre-treated with 100nM 2C4 for 30 min then the cells were treated with control media, TGFa,
HRGp or E2 (all 1nM, A-C respectively), tamoxifen (1pM), or various combinations of these
treatments for 15 min. Membranes were probed with P-ERKI/II primary antibody (1:1000).
T-ERKI/II levels were used as loading controls. Western blots are representative of 1 of 3
independent experiments.
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6. 5. 2. 2. MEK
The effects of various treatment combinations involving a ligand, 2C4 and tamoxifen
on the P-MEK expression pattern of the MCF-7, LCC1 and LCC9 cell lines are
shown in figure 6.15. The effects of single agents have previously been discussed in
this chapter, as have cells pre-treated with 2C4 and a ligand. Figure 6.15A shows the
effect of tamoxifen on the HRG[3 and 2C4 study. The western blots show that
tamoxifen may slightly reduce the P-MEK signal enhanced by HRGp in the MCF-7
and FCC1 cell lines, but clearly dramatically diminished the HRGfTenhanced P-MEK
signal in the 1CC9 cells. 2C4 reversed HRGf3-enhanced P-MEK in the presence and
absence of tamoxifen in all cell lines, although a signal was still faintly visible in the
presence of tamoxifen in all the cell lines (visible on western blots themselves, signal
less clearly seen in scanned images). Extremely faint bands were also visible in all
cells treated with tamoxifen, although again these are less clear in the scanned
images.
Figure 6.15B illustrates the effect of oestrogen and antioestrogen treatment in the
presence and absence of the anti-erbB2 agent 2C4 on P-MEK expression. A longer
film exposure showed that E2 did in fact increase P-MEK in the MCF-7 cell line and
that 2C4 was able to reverse this stimulation. 2C4 alone was also seen to reduce the
control treatment level of P-MEK. Tamoxifen was observed to reduce E2-enhanced
P-MEK, but did not alter the basal level of P-MEK when administered alone.
Tamoxifen did not alter the extremely low level of P-MEK signal intensity caused by
2C4 treatment. Tamoxifen did not drastically alter the P-MEK band intensity of E2 +
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T-MEK
Figure 6.15 The effect of 2C4 in combination with tamoxifen on P-MEK expression
levels in breast cancer cells treated with HRGp and E2. A-B, western blots of P-MEK
levels, where all cells were charcoal stripped 48h prior to treatment and were then pre-treated
with 100nM 2C4 for 30 min then the cells were treated with control media, HRGp or E2 (both
1nM, A & B respectively), tamoxifen (1pM), or various combinations of these treatments for
15 min. Membranes were probed with P-MEK primary antibody (1:1000). T-MEK levels were
used as loading controls. Western blots are representative of 1 of 3 independent
experiments.
286
Kate Moore Chapter 6: Inhibition of erbB2 & endocrine resistance
6. 6. ErbB receptor expression
Figure 6.16 represents a western blot of total erbBl and erbB2 (T-erbBl and 2)
expression in the MCF-7 cell line subjected to control, E2, HRG(3, 2C4 and HRGP +
2C4 treatments. The blot shows that this cell line expresses a low level of T-ErbBl
which remains relatively constant irrespective of treatment. T-ErbB2 levels were
higher in the MCF-7 cell line than T-erbBl. The levels were unaffected by E2 but
appeared to be elevated by HRGp. 2C4 alone appeared to slightly reduce T-erbB2
expression, and also appears to return HRGP-enhanced T-ErbB2 expression back to
control level.
Figure 6.17 shows T-erbB2 expression in MCF-7, LCC1 and LCC9 cell lines and the
effect of E2 and HRGp treatment on P-ErbB2 activation at position 1248. MCF-7
cells treated with HRGP (InM, 15 min) were used as the positive control. Figure
6.17A shows the T-erbB2 expression levels of the MCF-7, LCC1 and LCC9 cell
lines. Control (15 min) samples were used and showed that LCC1 cells had a
marginally increase expression of T-erbB2 compared to the MCF-7 cell line. In
contrast, LCC9 cells had a marginally reduced T-erbB2 expression level compared to
the MCF-7 cell line. It was hypothesised that differential T-erbB2 expression would
result in differential efficacy of anti-erbB2 agents such as 2C4. However, elevated
and reduced T-erbB2 expression was reported in LCC1 and LCC9 cell lines
respectively, and as neither cell line was affected by the anti-proliferative nature of
2C4, this suggests T-erbB2 expression is not the sole contributing factor to 2C4
resistance.
Figure 6.17B shows MCF-7, LCC1 and LCC9 cell lines did not constitutively express
P-erbB2 (1248) at control level. E2 did not affect P-erbB2 levels in any of the cell
lines. HRGp only enhanced P-erbB2 (1248) expression in the MCF-7 cell line. To
explore the mechanism by which tamoxifen interacted with 2C4, cells were treated
with HRGp, a ligand found to enhance P-erbB2 (1248) in the MCF-7 cell line, 2C4
and tamoxifen (figure 6.18). Neither tamoxifen nor 2C4 alone or in combination
altered P-erbB2 expression compared to control treated cells. 2C4 completely
abrogated HRGp-enhanced P-erbB2 expression in MCF-7 cells.
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Figure 6.16 The effect of E2, HRGp and 2C4 on T-ErbB1 and T-ErbB2 expression levels
in the MCF-7 breast cancer cell line. Western blots of T-ErbB1 and 2 levels, where all cells
were charcoal stripped 48h prior to treatment and then cells were then pre-treated with
100nM 2C4 or control media for 30 min and then treated with control media or HRGp (1nM)
for 15 min. Membranes were probed with T-erbB1 and T-erbB2 primary antibodies (1:1000).






















Figure 6.17 Comparison of T-ErbB2 expression and the effect of E2 and HRGp on
P-ErbB2 (1248) expression levels in parental and resistant breast cancer cells. Western
blots of T-rbB2 (A) and P-erbB2 (1248) (B) expression levels, where all cells were charcoal
stripped 48h prior to treatment and were then cells were treated with control media, E2 or
HRGP (both 1nM) for 15 min. Membranes were probed with T-erbB2 or P-erbB2 (1248)
primary antibody (1:1000). Western blots are representative of 1 of 3 independent
experiments.
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The most apparent alteration to P-erbB2 expression was the dramatic increase in
HRGp-enhanced P-erbB2 signal upon the addition of tamoxifen. 2C4 was able to
return this induction back to basal levels, but not to the low levels reached with
HRGp and 2C4 solely. No P-erbB2 was detected in either the LCC1 or LCC9 cell
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Figure 6.18 The effect of 2C4 alone and in combination with tamoxifen on P-ErbB2
(1248) expression levels in breast cancer cells treated with HRGp. Western blots of
P-erbB2 levels, where all cells were charcoal stripped 48h prior to treatment and were then
pre-treated with 100nM 2C4 for 30 min then the cells were treated with control media, HRGp
(1nM), tamoxifen (1pM), or various combinations of these treatments for 15 min. Membranes
were probed with P-erbB2 (1248) primary antibody (1:1000). Western blots are
representative of 1 of 3 independent experiments.
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6. 7. The Effect of 2C4 on phosphorylation of ERa
The data provided in this chapter show that 2C4 inhibited signalling in the resistant
cell lines, but this did not correlate with a reduction in cell number. Therefore,
another component possibly downstream of the PI3-K/Akt and MEK/ERK pathways
may play a role in proliferation in this model. The effect of 2C4 on the activation of
ERa via phosphorylation of serine residues is discussed in the following sections. It
was hypothesised that 2C4 would inhibit ERa activation at both SI 18 and SI67 in the
MCF-7 cell line as these cells responded to the antiproliferative nature of 2C4.
Subsequently it was further hypothesised that 2C4 would be unable to inhibit P-Sl 18
and P-S167 in the LCC1 cell line and P-S167 in the LCC9 cell line.
6. 7. 1. 2C4 and P-S118
Figure 6.19 represents western blots of the effect of E2, TGFa, HRG{3 and 2C4 alone
and in combination with tamoxifen on P-Sl 18 expression levels in MCF-7, LCC1 and
LCC9 cell lines. E2, TGFa and HRGp all enhanced P-Sl 18 in the MCF-7 cell line.
2C4 alone reduced P-Sl 18 slightly, and reduced E^-enhanced P-Sl 18 and abrogated
growth factor-enhanced P-Sl 18 back to control level. E2 induced a dramatic increase
in P-Sl 18 in the LCC1 cell line in agreement with previous findings. TGFa and
HRG[3 both enhanced P-Sl 18, but to a much lesser degree then E2, while 2C4 alone
did not alter P-Sl 18 levels from that of control treated LCC1 cells. In contrast to
MCF-7 cells, 2C4 was unable to reverse, or even reduce E2-enhanced P-Sl 18 to any
extent. 2C4 abolished HRG(3-enhanced P-Sl 18, but was unable to reduce TGFa-
enhanced P-Sl 18. These findings are similar to the data obtained for P-Akt and P-
ERK. when subjected to the same treatment conditions. Very little if any P-Sl 18 was
observed in the LCC9 cell line, as previously detailed, irrespective of treatment.
The MCF-7 cell line was the only cell line in which tamoxifen actually reduced the
antiproliferative nature of 2C4, hence the combination of tamoxifen plus 2C4 was
investigated against P-Sl 18 of MCF-7 cells. Figure 6.20 shows the effect of 2C4
alone and in combination with tamoxifen on ERa P-Sl 18 expression levels in MCF-7
breast cancer cells treated with E2. 2C4 and tamoxifen were both able to reduce E2-
enhanced P-Sl 18 alone, but appeared to antagonise each other when combined
against E2 as the signal was not reduced to the same extent.
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Figure 6.19 The effect of E2, TGFa, HRGP and 2C4 alone and in combination with
tamoxifen on ERa P-S118 expression levels in breast cancer cells. Western blots of
P-S118 levels, where all cells were charcoal stripped 48h prior to treatment and were then
pre-treated with 100nM 2C4 for 30 min then the cells were treated with control media, E2,
TGFa, HRGp (all 1nM), tamoxifen (1pM), or various combinations of these treatments for 15
min. Membranes were probed with P-S118 primary antibody (1:1000). Actin levels were
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Figure 6.20 The effect of 2C4 alone and in combination with tamoxifen on ERa P-S118
expression levels in MCF-7 breast cancer cells treated with E2. Western blots of ERa P-
S118 levels, where MCF-7 cells were charcoal stripped 48h prior to treatment and were then
pre-treated with 100nM 2C4 for 30 min then the cells were treated with control media, E2
(1 nM), tamoxifen (1 pM), or various combinations of these treatments for 15 min. Membranes
were probed with P-S167 primary antibody (1:1000). Actin levels were used as loading
controls. Western blots are representative of 1 of 3 independent experiments.
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6. 7. 2. 2C4 and P-S167
HRGP is known to regulate ERa activity via the erbB2/P!3-K/Akt pathway (Stoica et
al, 2003) and was found to enhance P-S167 in not only MCF-7 cells, but also both
LCCl and LCC9 cell lines. Figure 6.21 shows the effect of 2C4 alone and in
combination with tamoxifen on ERa P-S167 expression levels in MCF-7, LCCl and
LCC9 cells treated with HRG(3. Control levels were equivalent in all cell lines and
HRG(3 enhanced P-S167 in all cell lines. 2C4 and tamoxifen alone did not affect
P-Sl67of any cell line. 2C4 reduced HRG[3-enhanced P-S176 in all cells. Tamoxifen
did not appear to affect HRGP-enhanced P-S167 in the MCF-7 and LCCl cell lines.
Tamoxifen appeared to decrease P-S167 in LCC9 cells treated with HRGp.
Tamoxifen prevented 2C4 from fully reversing HRGP-enhanced P-S167 in MCF-7
cells, while it did not appear to affect the ability of 2C4 to abrogate P-S167 increased
by HRGp in the resistant cells.
Figure 6.21 The effect of 2C4 alone and in combination with tamoxifen on ERa P-S167
expression levels in breast cancer cells treated with HRGp. Western blots of ERa P-
S167 levels, where all cells were charcoal stripped 48h prior to treatment and were then pre-
treated with 100nM 2C4 for 30 min then the cells were treated with control media, HRGp
(1nM), tamoxifen (1pM), or various combinations of these treatments for 15 min. Membranes
were probed with P-S167 primary antibody (1:1000). Actin levels were used as loading
controls. Western blots are representative of 1 of 3 independent experiments.
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6. 8. The effect of 2C4 on apoptosis in this model of
resistance
The effect of 2C4 on Annexin V staining, and thus apoptosis, on MCF-7, LCC1 and
LCC9 cell lines treated with HRG(3 is illustrated in figure 6.22. Cells were charcoal
stripped 48h prior to treatment and were then pre-treated with lOOnM 2C4 for 30 min.
The cells were then treated with control media, HRGp or HRGp +2C4 (InM +
lOOnM) for 15 min. The histogram of MCF-7 cells shows that Annexin V staining is
significantly diminished by the addition of HRGp as previously described in chapter
3. 2C4 did not significantly affect the percentage of MCF-7 cells with positive
Annexin V staining and thus the number of cells undergoing apoptosis. 2C4 was able
to significantly increase Annexin V staining originally reduced by HRGP by -0.6-
fold (P<0.01) implying that the proportion of apoptotic cells was increased.
No significant differences were observed in Annexin V staining in the LCC1 cell line,
indicating HRGp and 2C4 do not affect the number of cells undergoing apoptosis in
the LCC1 cell line. The only significant difference observed with this combination of
treatments in the LCC9 cell line was with the combination of HRGp plus 2C4.
However, this was only a small increase (-0.1-fold, P<0.05) in Annexin V staining
and did not correlate with a reduction in proliferation. It is interesting to note that
both the LCC1 and LCC9 control levels of Annexin V staining are less than that of
the MCF-7 cell line (~1.7% and -0.9% in the LCC1 and LCC9 cell lines respectively,
compared with -3.9% in MCF-7 cells). This implies the NETT growth rate balance
has shifted, indicating a reduction in the number of LCC- cells undergoing apoptosis
may coincide with an increase in the proliferation of the resistant cell lines.
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Figure 6.22 The effect of 2C4 on annexin-v staining in breast cancer cells treated with
HRGp and 2C4. Cells were charcoal stripped 48h prior to treatment and were then pre-
treated with 100nM 2C4 for 30 min then the cells were treated with control media, HRGp or
HRGp +2C4 (1 nM + 100nM) for 15 min. ANOVA test: * = P<0.05, " = PO.01 & *** =
P<0.001. Asterisks in black represent statistically significant changes between control and a
treatment and those in red represent any statistically significant changes post-treatment with
2C4 in each cell line. Histograms are representative of 1 of 3 independent experiments.
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6. 9. The effect of 2C4 on cell cycle progression in this model
of resistance
6. 9. 1. E2
Histograms of the effect of 2C4 and E2 on cell cycle distribution of MCF-7, LCCl
and LCC9 cell lines are shown in figure 6.23. Control and E? treatments in all cell
lines are as previously reported in chapter 4. Figure 6.23A is a histogram of the
effect of these treatments on the percentage of MCF-7 cells in G0/1, S and G2/M
phases of cell cycle.
2C4 pre-treatment did not alter E2-induced progression in general, with the only
significant increase of -2% observed in the Go i phase (P<0.05) (as indicated by the
red asterisk). The E2+2C4 combined treated was significantly different to the control
treatment (P<0.001), but was generally similar to E2 alone.
The LCCl cell cycle distribution pattern is shown in figure 6.23B. Interestingly,
compared to E2 treatment alone, the combined treatment significantly decreased the
percentage of cells in Go i phase by -30% and significantly increased cells in S- and
G2/M phases by -23% and -7.5% respectively (all P<0.00l). This suggests 2C4 may
be causing a block in cell cycle, or contrastingly, inducing progression. However, the
effect of 2C4 on cell cycle did not translate to any significant affect on the
proliferation of the LCCl cell line in the presence or absence ofEt. Figure 6.23C is a
histogram of the same experiment in the LCC9 cell line where 2C4 pre-treatment did
not significantly alter the cell cycle distribution compared to E2 alone
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Figure 6.23. The effect of 2C4 pre-treatment on the cell cycle distribution of breast
cancer cell lines treated with E2. Cells were charcoal stripped 48h prior to treatment and
were then pre-treated with 100nM 2C4 for 30 min then the cells were treated with control
media, E2 or E2+2C4 (1nM+100nM) for 15 min. Changes in G0/i (■), S (■) and G2/M (■)-
phases of the cell cycle were plotted as the mean of triplicate samples +/- SD as a
percentage of the cell cycle. ANOVA test: * (P<0.05), ** (P<0.01) and *** (P<0.001)
represent significant, highly significant and extremely significant changes. Black asterisks
represent significance between the same cell cycle phase with each treatment, while red
asterisks represent significance change between the same phase after E2 treatment
compared to E2+2C4 in each cell line. Histograms are representative of 1 of 3 independent
experiments.
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6. 9. 2. TGFa
Histograms representing the effect of TGFa in the presence and absence of 2C4 on
the cell cycle distribution of MCF-7, LCC1 and LCC9 cell lines are shown in figure
6.24. Figure 6.24A shows the effect of these treatments in the MCF-7 cell line.
TGFa significantly increased the proportion of cells in S and G2/M phase and reduced
those in the G0/1 phase as previously described in chapter 3 (P<0.001). 2C4 alone
significantly elevated the percentage of cells in S and G2/M phases (P<0.001) and
reduced the number of cells in G01 phase. However, 2C4 generally decreased MCF-7
proliferation slightly; therefore the increase in the proportion of cells in S- and G2/M-
phases could indicate a cell cycle block which would be consistent with a small
degree of growth inhibition. 2C4 significantly reduced the increase in the percentage
of cells in S-phase caused by TGFa by ~11% by decreasing the number of cells in S-
phase to -19% (P<0.001), a value near to that of 2C4 treatment alone (-18%). There
was a similar significant increase of cells in Go/i phase of -13% (P<0.001).
A histogram of the same treatment combinations in the LCC1 cell line is presented in
figure 6.24B. TGFa significantly increased the percentage of cells in Go 1 -phase by
-10% (P<0.01), while a decrease of -8% was observed in the S-phase of the cell
cycle distribution (P<0.001). 2C4 alone produced a similar pattern to that of TGFa
treatment, with a reduction in G2/M phase also documented. 2C4 pre-treatment did
not affect cell cycle distribution when treated with TGFa compared to TGFa alone.
TGFa only affected LCC9 cell cycle distribution between the S and G2/M phases
(figure 6.24C). 2C4 significantly increased the proportion of TGFa-treated cells in S-
phase by -1.8% (P<0.05).
Generally speaking, the largest numerical percentage changes were observed in the
MCF-7 cell line. The changes between treatments in the resistant cell lines may be
classified as significant, but the actual percentages are not particularly large in
comparison to the changes observed in the MCF-7 cell line. This indicates that
changes between the cell lines are more important.
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Figure 6.24 The effect of 2C4 pre-treatment on the cell cycle distribution of breast
cancer cell lines treated with TGFa. Cells were charcoal stripped 48h prior to treatment
and were then pre-treated with 100pM 2C4 for 30 min then the cells were treated with control
media, TGFa or TGFa+2C4 (1nM+100nM) for 15 min. Changes in G0/i (■), S ( ) and G2/M
(■)-phases of the cell cycle were plotted as the mean of triplicate samples +/- SD as a
percentage of the cell cycle. * (P<0.05), ** (P<0.01) and *** (P<0.001) represent significant,
highly significant and extremely significant changes. Black asterisks represent significance
between the same cell cycle phase with each treatment in that cell line, while red asterisks
represent significance change between the same phase after TGFa treatment compared to
TGFa+2C4 in each cell line. Histograms are representative of 1 of 3 independent
experiments.
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6. 9. 3. HRGP
Figures 6.25A-C are histograms of cell cycle distribution in the three cell lines treated
in the same manner as figure 6.24, but with HRGP substituted for TGFa. Control and
HRGp treatments were as previously described in chapter 4 in all cell lines. In this
experiment 2C4 did not significantly alter MCF-7 cell cycle distribution (figure
6.25A), which would support signalling and proliferation data where MCF-7 cell
response to 2C4 was minimal. The cell cycle progression stimulated by HRGP was
actually enhanced further by 2C4 pre-treatment, with a reduction in Go i phase of
-10.5% (P<0.05) and an increase of-12% (P<0.01) in S-phase.
Figure 6.25B is a histogram representing the LCC1 cell line under the same
conditions. The only significant change with 2C4 pre-treatment was an increase of
less than 1% in G2/M phase. 2C4 pre-treatment produced the opposite effect to that
in the MCF-7 cell line. A significant reduction of -5.5% (P<0.001) of cells in S-
phase and an increase in cells in G0/1 phase (-5% increase, P<0.001) was observed in
cells treated with the combination of HRGP and 2C4, indicating 2C4 may arrest
HRGP-treated LCC1 cells, but this does not translate to a reduction in cell number.
Figure 6.25C is a histogram of the effect of HRGp in the presence and absence of
2C4 on LCC9 cell cycle distribution. Chapter 4 details the elevated percentage of
resistant cells in S and G2/M phases of cell cycle compared to the MCF-7 cell line
which can again be observed here and in figures 6.23 and 6.24. 2C4 alone again had
a minor affect only by reducing the number of LCC9 cells in S-phase (-4%, P<0.()5).
2C4 pre-treatment did significantly change the cell cycle distribution compared to
HRGP alone or control treatments.
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Figure 6.25 The effect of 2C4 pre-treatment on the cell cycle distribution of breast
cancer cell lines treated with HRGp. Cells were charcoal stripped 48h prior to treatment
and were then pre-treated with 100nM 2C4 for 30 min then the cells were treated with control
media, HRGp or HRGP+2C4 (1nM+100nM) for 15 min. Changes in G0/1 (■), S ( ) and G2/M
(■)-phases of the cell cycle were plotted as the mean of triplicate samples +/- SD as a
percentage of the cell cycle. ANOVA test: * (P<0.05), ** (P<0.01) and *** (P<0.001)
represent significant, highly significant and extremely significant changes. Black asterisks
represent significance between the same cell cycle phase with each treatment in that cell
line, while red asterices represent significance change between the same phase after HRGp
treatment compared to HRGP+2C4 in each cell line. Histograms are representative of 1 of 3
independent experiments.
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6. 10. The effect of tamoxifen and 2C4 on cell cycle
progression in this model of resistance
Figure 6.26 presents three histograms of the 2C4 combined with tamoxifen in the
presence and absence of HRGP on the cell cycle distribution of MCF-7, LCC1 and
LCC9 cell lines. Only the relevant combination treatments are shown (with control
and tamoxifen alone for comparison) as all other treatments were as previously
described. Tamoxifen significantly reduced the proportion of MCF-7 cells in G2/M
and dividing in S-phase due to HRGP-treatment, and significantly increased the
percentage of cells undergoing arrest from ~5l% with HRGP to ~7l% (PO.OOl)
(figure 6.26A). Tamoxifen in combination with 2C4 also significantly increased the
percentage of cells in Gon arrest from -72% with 2C4 alone, to -84% (PO.OOl). The
addition of tamoxifen to the HRGP+2C4 treatment reversed the effect of 2C4 on
HRGp and increased MCF-7 cell arrest. Tamoxifen appeared to be reversing the
effect of 2C4. This may have ramifications on the anti-proliferative effect of 2C4.
A similar pattern was observed in the LCCl cell cycle distribution (figure 6.26B),
where tamoxifen reduced the proportion of cells dividing in S-phase. Tamoxifen
reversed the action of 2C4 on HRGp, increasing the number of cells in S-phase from
-13% with HRGP + 2C4 to -16% in the presence of the triple treatment (PO.OOl, as
indicated by the green asterices).
Tamoxifen did not significantly affect the LCC9 cell cycle distribution when cells
treated with HRGp (P>0.05). This contrasts with LCCl and MCF-7 cell line data.
The addition of tamoxifen to cells treated with HRGp + 2C4 pushed more cells into
G0/1 arrest (-2% increase, PO.05) and reduced S-phase dividing cells by -4%
(PO.OOl).
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Figure 6.26 The effect of 2C4 combined with tamoxifen in the presence and absence of
HRGp on the cell cycle distribution of breast cancer cell lines. Cells were charcoal
stripped 48h prior to treatment and were then pre-treated with 100nM 2C4 for 30 min then the
cells were treated with control media, HRGp (1nM), tamoxifen (1pM), and various
combinations of these agents for 15 min. Changes in G0/i (■), S ( ) and G2/M (■J-phases of
the cell cycle were plotted as the mean of triplicate samples +/- SD as a percentage of the
cell cycle. ANOVAtest: * (P<0.05), ** (P<0.01) and *** (P<0.001) represent significant, highly
significant and extremely significant changes. Black asterices represent significance
between the same cell cycle phase with each treatment compared to control, blue asterices
represent significance after tamoxifen treatment compared to 2C4 alone and green asterices
represent significance between HRGp + 2C4 vs. HRGp + tamoxifen + 2C4 treatment.
Histograms are representative of 1 of 3 independent experiments
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6. 11. Discussion
Overexpression of erbB2 occurs in ~l 2-20% of ERa+ human breast cancer (Witton et
al, 2003), and is associated with malignant transformation, poor overall survival and
oncogenesis (Yu and Hung, 2000). This receptor has therefore become a useful target
for drug development for treatment of hyperproliferative diseases including breast
cancer (Mass, 2004; Shawyer et al, 2002).
A reduction in the level of P-Akt (and P-ERK) had been suggested as a requirement
for another anti-erbB2 agent herceptin to reduce cell proliferation, hence it has been
hypothesised that this is also the mechanism of action of 2C4 (Tanner et al, 2004;
Agus et al, 2003). The anti-erbB2 agent 2C4 abolished the stimulatory effects on
both Akt and F.RK and growth effects of TGFa and HRGp in the MCF-7 cell line in
agreement with data produced by Agus et al (2003) in the same cell line and Totpal et
al (2002) in ovarian cells. 2C4 was less effective at reducing TGFa than HRGP-
stimulated proliferation suggesting that the nature of erbB2 heterodimer(s) formed in
the MCF-7 cell line dictates the efficacy of this agent. This is supported by data
found in ovarian cell lines by Takai et al (2005). This contrasts with T-erbBl
expression, which was found to be less than T-erbB2 expression in the MCF-7 cell
line, suggesting less of a drive through TGFa heterodimers. Therefore, this indicates
that perhaps even low T-erbBl levels in this cell line are sufficient for some degree of
TGFa signalling, perhaps via erbBl homodimers.
The Akt and ERKI/ll signalling pathways are intact in the parental MCF-7 and
resistant LCCl and LCC9 cell lines alike. Interestingly, 2C4 only abolished the
elevated level of P-Akt and P-ERK (and P-Sl 18 in the LCCl cell line) enhanced by
HRGP in the resistant cells, indicating these pathways may be partially responsible
for some growth of the cell lines, and that this is dependent on the ligand involved.
However, the abrogation of signalling did not translate to the growth data in the
resistant cell lines, as neither growth factor increased proliferation by day 3, and 2C4
did not reduce cell proliferation in either resistant cell line. 2C4 was able to reverse
the activation of certain pathways by certain ligands, in particular HRGp, but was
unable to reverse P-Akt or P-ERK expression (or P-S118 in the LCCl cell line)
enhanced by TGFa in these cells. Again, this could be associated with the
heterodimers formed. T-erbBl levels in the MCF-7 cell line were found to be low,
303
Kate Moore Chapter 6: Inhibition of erbB2 & endocrine resistance
which is consistent with published data (Hager et al, 2005), the T-erbBl expression
of the LCC1 and LCC9 resistant cell lines requires investigation in order to assess
their involvement in 2C4 resistance.
The antiproliferative nature of 2C4 is dependent on the initial ligand stimulating
growth. Takai et al (2005) suggested that in cells where 2C4 was able to inhibit
MEK/ERK signalling such as the MCF-7 cell line, recruitment of erbB2 into erbB
receptor complexes was necessary for maximal signalling response. Previous studies
have shown that this occurs for erbBl, where the blockade of erbB2 recruitment into
erbB 1-ligand complexes does not abrogate signalling, but instead diminishes the
signal intensity, duration and diversity (Anido et al, 2003). This information is
summarised in figure 6.27.
Figure 6.27 Schematic diagram showing 2C4 targeting erbB2-containing heterodimers.
2C4 acts as a 'dimerisation inhibitor' and blocks activation of ERK and Akt via any
heterodimers erbB2 only. A, TGFa treatment facilitated phosphorylation of erbBl-based
dimers, where signal intensity may not be completely abolished but instead reduced in
intensity (Anido et al, 2003) (dashed black arrows). ErbBl homodimers (shown as example)
or erbB1/3 or 4 heterodimers induced by TGFa stimulation would not be inhibited by 2C4
(solid black arrows). B, 2C4 treatment abolished the formation of phosphorylated erbB2/3
heterodimers induced by HRGp (red arrows) possibly by sequestration of the receptors into
unphosphorylated inactive erbB1/2 and erbB1/3 heterodimers. The abrogation of HRGp-
induced P-Akt and P-ERK suggests only erbB2 containing heterodimers are formed in the
presence of this ligand in MCF-7 and resistant cell lines alike.
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This may account for the differential blockade of HRGf) but not TGFa-enhanced
signalling in the resistant cell lines as HRGP creates erbB2/3 heterodimers as opposed
to erbBl/2 heterodimers formed due to TGFa stimulation.
Interestingly, a long western blot exposure showed that E2 elevated P-MEK in MCF-7
cells, which is consistent with a study by Keshamouni et al (2002). This group
reported that, in contrast to the rapid TGFa-enhanced ERK activation, E2 only
enhanced P-ERK after 2h. This is consistent with the weak P-MEK signal observed
here after 15 min, which would, in time, activate ERK.
Cell cycle distribution data gathered here demonstrates that a smaller proportion of
resistant cells than MCF-7 cells undergo cell cycle arrest. These data are in
accordance with the fact that breast cancer is due to an imbalance between
proliferation and apoptosis (Meteoglu et al, 2005; McCloskey et al, 1996). Thus, a
heightened rate of cell division may account for the elevated basal proliferation of the
resistant cell lines.
Published findings show that tamoxifen arrests breast cancer cells in Gi phase and
those cells which were not retained in the Gq/Gi phase appear to progress into the
remainder of the cell cycle at a similar rate to that of untreated control cells (Prall et
al, 1997; Taylor et al, 1983). The slight oestrogenic action of tamoxifen may account
for this, and while the majority of MCF-7 cells undergo this arrest, not all of the cells
do, which may also contribute to induction ofMCF-7 cells into the cell cycle. This is
consistent with a study by Liu et al (2003), who reported that tamoxifen resistance
involved changes preventing apoptosis and enhancing cell survival and proliferation.
The 2C4 reversal of TGFa-enhanced signalling and MCF-7 proliferation was linked
with a reversal of cell cycle progression and an increased number of cells undergoing
cell cycle arrest. This is supported by a study using another anti-erbB2 antibody
Herceptin, which also was found to increase the proportion of cells arresting and
subsequently decrease the percentage of cells in S-phase (Le et al, 2003). TGFa data
contrasts with HRGp-enhanced signalling and proliferation which were completely
abrogated by 2C4 and are linked with an increase in dividing cells. The variation in
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responses to growth factors is in agreement with published data by Takai et al (2005)
and Anido et al (2003). This indicates the erbB2/3 conformation is more sensitive to
2C4 than erbBl/2 heterodimer and supports the differential erbB heterodimer
conformation theory proposed by these authors. Interestingly, cell cycle data
indicates that 2C4 was more efficacious as an anti-proliferative agent when cells were
pushed into S-phase as opposed to arrest.
The combination of HRGp and tamoxifen was greater than either agent alone on
P-Akt, P-ERK and proliferation as previously discussed, and this was observed
downstream as a reduction in MCF-7 cells in Go i phase and an increase in cells in S-
and G2/M phases compared to tamoxifen treatment alone.
Overall, tamoxifen enhanced growth factor signalling in all cell lines. This increase
indicates that tamoxifen might act as a partial agonist via erbB2, which is in
agreement with a theory proposed by Shou et al (2004). Shou et al (2004) proposed
that increased bi-directional cross-talk between ERa and erbB2 converted tamoxifen
into an agonist. Tamoxifen would then activate both the erbBl and erbB2 signalling
pathways including Akt and ERK, leading to the phosphorylation of the relevant ERa
serine residues. This occurs in this scenario but only when tamoxifen was in the
presence of a growth factor. Akt and ERK are both activated and this translated to an
increase in P-S167 and P-Sl 18.
Anido et al (2003) suggested that in cells overexpressing erbB2, the erbBl inhibitor
ZD 1839 inhibited proliferation by sequesting the erbB2 and 3 into an inactive
conformation with erbBl. It is possible that tamoxifen sterically hinders 2C4 by a
similar mechanism or by binding to 2C4 itself or part of the extracellular domain 11 of
the erbB2 receptor, where 2C4 binds, thus preventing the complete blockade of
dimerisation with other members of the erbB receptor family
ErbB2 was phosphorylated by HRGP in MCF-7 cells, consistent with published data
(Sadick et al, 1996) and further enhanced when this was combined with tamoxifen as
previously discussed. However, unlike in the MCF-7 cell line, P-erbB2 was not
enhanced in the resistant cell lines. This was unexpected and suggests that HRGp and
tamoxifen may be acting on a component(s) downstream of erbB2 or via an entirely
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different receptor. This component or receptor-ligand complex would subsequently
have to activate both the PI3-K/Akt and MEK/ERK pathways. For example, IGFR
may play a role in the phosphorylation ofAkt and ERa SI 67 as it may activate PI3-K
by direct binding to the p85 subunit (Jackson et al, 1998). However, this activation
was stimulated by 1GF-I via IGFR, not HRG[3. Therefore, an alternative and more
likely theory may be that the phosphorylation of erbB2 is occurring at a different
residue than that being detected by the P-erbB2 1248 antibody in the resistant cell
lines. The phosphorylation of an alternative P-erbB2 residue may account for the
activation of downstream targets Akt, ERK and ERa SI67 in the resistant cell lines,
while the phosphorylation of residue 1248 may account for the sensitivity of MCF-7
cells to 2C4. It has also been shown that growth factors activate JNKs (Logan et al,
1997), thus it may be that HRGp is activating this pathway and subsequent cross-talk
may allow for activation of Akt, ERK and ERa SI 67 via this route.
6. 11. 1. Resistance to 2C4
Resistance to anti-erbB2 agents has previously been reported (Mass, 2004; reviewed
in Miller, 2004). Reports into resistance against agents which also target erbB2 may
help explain why resistance to 2C4 develops. For example, Herceptin was found to
be effective in -40% of metastatic breast cancer patients, which can be increased to
-60-80% when combined with taxanes or vinorelbine (Cardoso et al, 2002), however,
no tumour regression was observed in the remainder of patients. This was despite the
presence of amplified erbB2 gene and overexpression of the protein in the primary
and metastatic tumour sites (Tanner et al, 2002). Herceptin resistance was therefore
due to another component other than erbB2 expression (Mass, 2004). This supports
the data collected in this investigation, where the resistant cell lines were not
activated at erbB2, suggesting another mechanism is responsible for resistance to
2C4.
LCCl cells had a marginally increase expression of T-erbB2 compared to the MCF-7
cell line. In contrast, LCC9 cells had a marginally reduced T-erbB2 expression level
compared to the MCF-7 cell line. This is consistent with data reported by Gu et al
(2002), where erbBl gene expression was found to be 50% less in the LCC9 cell line
than in LCCl cells. The differential T-erbB2 expression and yet absence of effect in
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any circumstance in the resistant cell lines suggests T-erbB2 expression may only be
part of the mechanism of resistance to 2C4. As previously discussed, HRG(3
enhanced P-erbB2 in MCF-7 cells but did not appear to enhance erbB2
phosphorylation in the LCC- cell lines. Ovarian data suggest levels of P-erbB2 may
predict sensitivity to 2C4 (Gordon et al, 2005). Gordon et al (2005) reported that the
overall median time to progression was greater in P-erbB2-positive ovarian cancer
patients (20.9 weeks) compared to P-erbB2-negative patients (5.7 weeks) when
treated with 2C4. This theory is consistent with the absence of an anti-proliferative
effect of 2C4 in the resistant cell lines, where no, or very low levels of P-erbB2 were
detected.
The ineffectiveness of drugs targeting erbBl/erbB2 has been previously been
suggested to be a result of constitutive activation of downstream signalling molecules
such as ERK and Akt that support cell growth in the presence of antioestrogens.
Studies have shown that the activation of ERK (Benz et al, 1993; Kurokawa et al,
2000) and/or Akt (Lin et al, 2005; Jordan et al, 2004; Campbell et al, 2001; Sun et al,
2001) are extremely relevant in the development of antioestrogen resistance. A study
by Knowlden et al (2003), recorded elevated levels of P-ERKI/H in studies
performed in similar resistant cell lines. This contrasts with the ERK levels reported
in the resistant cell lines here, which were found to expressed at levels equivalent to
the MCF-7 cell line, indicating that in this model ERK overexpression was not
responsible for 2C4 resistance.
Contrastingly, Akt was observed to be constitutively overexpressed in the resistant
cell lines (as previously discussed in chapter 4), suggesting Akt does indeed play a
role in 2C4 resistance in LCC1 and LCC9 cell lines. However, as much as the
resistant cell lines are dependent on Akt signalling, as shown via LY 294002
cytotoxicity studies (chapter 5), the basal rate of proliferation remained unchanged
and still outweighed that of the MCF-7 cell line when HRGp-enhanced P-Akt was
blocked with 2C4 in the resistant cells. These data suggest another mechanism of
signalling is also responsible in the LCC1 and LCC9 cell lines other than erbB2,
perhaps another receptor that is stimulated by TGFa, and may be overexpressed in the
resistant cell lines. Alternatively, the autocrine secretion of TGFa by a tumour cell
may lead to the extended stimulation of erbBl and of the heterodimerised members
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and may lead to resistance to anti-erbB2 agents (Valabrega et al, 2005). The group
hypothesised that Herceptin resistance occurred not as a result of an intrinsic defect of
the erbB2 degradation machinery, but was probably associated with impaired erbB2
downregulation due to Cbl uncoupling and ultimately altered endocytosis. Valabrega
et al (2005) suggested that TGFa production was involved in the uncoupling
mechanism and may therefore account for resistance to herceptin.
The presence of 'Akt-Raf crosstalk in MCF-7 cells has been documented by
Moelling et al (2002) and is also discussed in chapter 5. Blockade of this negative
feedback between Akt and Rafl causes cell cycle arrest via elevation of MEK and
ERK. It is possible that the elevated levels of P-Akt in the resistant cell lines
compensate for any MEK/ERK pathway arrest and therefore the balance remains in
favour of proliferation. 2C4 is unable to reverse basal P-Akt levels of the resistant
cell lines and these alone may allow for the blockade of Rafl.
Other potential theories as to the growth factor receptor signalling redundancy and
erbB2-neutralisation observed in the resistant cell lines include the possible activation
of the insulin-like growth factor-1 receptor as well as other members of the erbB
family of receptors (Holboro and Hynes, 2004; Smith et al, 2004; Albanell and
Baselga, 2001). These studies were carried out using Herceptin, resistance to which
has also been linked with decreased levels of p27kipl and a deficiency in PTEN
(Nagata et al, 2004; Nahta et al, 2004).
It is more than likely the overexpression of ERa in the LCC1 cell line may be one
direct mechanism of resistance. This would not apply to the LCC9 cell line. The
possible mechanisms of resistance will be discussed in the following chapter, based
on the findings of all chapters.
6. 11. 2. Overcoming resistance to 2C4
It remains uncertain as to whether the targeting of individual tyrosine kinases such as
Akt and MEK will overcome anti-oestrogen resistance in general, or whether a
combination strategy would be more effective. Several studies, reviewed by Miller
(2004) and also by Mass (2004), have concluded that a combination of targeted
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therapies may be required to bypass anti-erbB2 resistance when agents are used as a
monotherapy. For example, as the binding sites for Herceptin and 2C4 do not overlap
it may be more efficacious to administer the two agents together. Preliminary data
supports this hypothesis (Nahta et al, 2004). Clinical studies looking into this
combination are currently being planned.
It was thought that one of the reasons for the limited success of drugs targeted against
erbBl/erbB2 to reverse or prevent the antioestrogen resistance was due to elevated
levels of components of signalling pathways including Akt and ERK. However, the
blockade of P-Akt did not abrogate elevated basal growth and the absence of ERK
activation in this model suggests otherwise. It may be that a combination strategy
would be more advantageous, with the blockade of not only elevated pathways, such
as the PI3-K/Akt, but potential alternative pathways which operate as 'back up' when
Akt is inhibited. A study by Nabha et al (2005) showed that rottlerin inhibition of
Akt and ERK activity significantly reduced cell proliferation in a panel of four
antioestrogen-resistant cell lines. The group suggested that over expression of PKC5
may play a role in the development of antioestrogen resistance in ER+ breast tumour
cells and could therefore be a potential future drug target.
2C4 has been shown to inhibit EGF-induced P-ERK but not that induced by HRG(3
(Takai et al, 2005). This is in contrast to the effect observed in this model of
resistance where HRGp-induced P-ERK was reversed upon 2C4 pre-treatment. Takai
et al (2005) also observed that 2C4 was unable to reverse P-ERK levels of certain cell
lines and suggested that the specificity of 2C4 in their panel of ovarian cell lines may
be due to the expression of various combinations of homo and/or heterodimers of the
erbBR family. The group suggested that 2C4 may be the most effective in tumours
with where the ligand induced erbB2 heterodimers that stimulated proliferative
signals.
Several other factors have been implicated in the development of resistance to
tamoxifen. For example, Shou et al (2004) found that tamoxifen behaved as an
oestrogen agonist in breast cancer cells which expressed high levels not only erbB2
but also the ER coactivator AIB1, with de novo resistance as a result. The group
found that the anti-erbBl agent Gefitinib eliminated cross-talk and re-established the
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antitumour effects of tamoxifen. However, unlike the model used here, the cell lines
used by Shou et al (2004) did not grow in the absence of oestrogen, hence AIB1
cannot be the only factor causing resistance in the model here.
6. 11. 3. Concluding remarks
In conclusion, 2C4 reversed P-Akt and P-ERK stimulated by HRGp in all three cell
lines but this did not translate to an antiproliferative effect in the resistant cell lines.
TGFa-enhanced P-Akt and P-ERK was not reduced by 2C4 in LCCl and LCC9 cell
lines, suggesting both pathways are partly responsible for the proliferation resistant
cell lines. Therefore, the expression of particular homo and heterodimer
combinations of the erbB receptor family in any given cell line may dictate the
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This investigation has implicated the involvement of several factors in the
development of oestrogen independence and anti-oestrogen resistance. These factors
and potential further studies which could be performed will be summarised in this
final chapter.
7. 1. ERa dependence and overexpression
Elevated levels of ERa expression are associated with an increased rate of cellular
proliferation (Jordan, 2006) and also with poor prognosis in patients with breast
cancer who are not receiving adjuvant therapy (Jordan, 2006; Dowsett et al, 2005).
Therefore, it has been hypothesised that these heightened levels may in turn be
responsible for constitutive activation of ERa (Fowler et al, 2003). Fowler et al
(2003) demonstrated this mechanism using a tetracycline-inducible ERa expression
model of the MCF-7 cell line. The model had elevated ERa expression and
subsequent gene activation via atypical promoter occupancy in the absence of
oestrogen. They reported that increased ERa activity was via AF-1 and was
independent of P-Sl 18. The elevated levels of ERa observed in the Mill, LCC1 and
LCC2 cell lines (and perhaps a slight increase in the LCC9 cell line) are similar to
those found by Fowler et al (2003) and also with the heightened levels reported by
Staka et al (2005). However, Fowler et al (2003) also suggested this mechanism was
independent of P-Sl 18 which may partially explain the absence of P-Sl 18 observed
in the LCC9 cell line, but does not account for the elevated levels observed in the
other three lines upon ligand stimulation. A recent publication by our laboratory ,
(Kuske et al, 2006) in which data from this study was published, hypothesised the
reduced P-Sl 18 expression observed in the LCC9 cell line may more than likely
affect coactivator binding. Initial results indicated that pi 60 binding, and in particular
AIB1, was reduced in the LCC9 cell line, and suggested that this was again consistent
with endocrine insensitivity as reported earlier by Kuske et al (2004).
Several studies using LTED cells have characterised the phenomena of oestrogen
hypersensitivity and supersensitivity (Staka et al, 2005; Santen et al, 2005; Martin et
al, 2005; Yue et al, 2003). Some of these studies indicated that oestrogen
independence arose as a result of enhanced ERa expression, ERK activation and
P-Sl 18 via this hypersensitivity or supersensitivity to oestrogen. These factors are
not in agreement with the results reported here, as no heightened ERK activation was
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observed and in stark contrast, ERa did not display supersensitisation to growth factor
activation (Martin et al, 2005; Martin et al 2003). Unlike LTED cell lines, which
were hyper- or supersensitive (Martin et al, 2005; Santen et al, 2005; Yue et al,
2002), the resistant cells in this investigation displayed true oestrogen-independent
growth (unpublished data produced by K. Macloud, Cell Biology Group). Moreover,
studies using siRNA and 1CI 182 780 performed by Kuske et al (2006) have shown
that the growth of the LCC1 and LCC9 cell lines is ERa dependent. Our group
reported that a reduction in ERa protein using siRNA was accompanied by a decline
in PR protein, indicating gene expression in the MCF-7, LCC1 and LCC9 cell lines
tested was ERa-dependent. The paper suggested that the elevated ERa expression
alone may account for the increased binding of DNA. This was supported by the
enhanced ERa binding to the pS2 promoter in the LCC1 and LCC9 cell lines in the
absence ofEi, reported in this publication, and also by Fowler et al (2004, 2006).
The Fowler publications used a tetracycline-inducible system to increase ERa
expression in the MCF-7 cell line and results suggested these elevated levels resulted
in activation of the transcriptional function of the receptor, and that this occurred via a
separate mechanism to those involving P-S118 or P-S104/6 activation via growth
factors or ligand binding. Fowler et al (2004) hypothesised that elevated ERa in their
unbound state stabilised any interactions with the transcriptional machinery, allowing
transcription which may not be possible with normal potentially 'weaker' receptor
levels. This theory could be applied to the resistant LCC1 and LCC9 cell lines
utilised in this study and is consistent with the majority of reports of acquired anti-
oestrogen resistance, where ERa expression is retained, indicating resistance is
associated with altered ERa function.
Previous studies have shown that phosphorylation of serine residues on ERa at
positions 118 and 167 cause activation of ERa and that mutation of these residues
reduces ERa activation, gene transcription and eventually cell proliferation (reviewed
in Lannigan, 2003). Indirect evidence has shown that phosphorylation is involved in
receptor function, for example, oestrogen causes a rapid increase in phosphorylation
by several fold, and TGFa is able to elicit ligand-independent ERa activation (Joel et
al, 1995; Bunone et al, 1996). Staka et al (2005) demonstrated that levels of P-S 118
were elevated in their MCF-7X cell line in keeping with the increase in ERa
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expression. Heightened P-Sl 18 was observed in the Mill, LCC1 and LCC2 cell lines,
but only upon ligand stimulation, thus the results are only partially in agreement as
ERa was not constitutively activated at SI 18. Kuske et al (2006) also directly
features the P-S118 expression profiles reported in this study, where ERa
overexpression, again reported in this study, may solely account for the elevated
P-Sl 18 levels observed upon E2 treatment in the LCC1 cell line.
A study by Weitsman et al (2006) supports data reported here, as direct evidence is
provided for a functional role of E2-regulated P-Sl 18 of ERa. The ERa and ERa
P-Sl 18 time courses shown in the MCF-7 cells, although only up to lh, are very
comparable and therefore support data shown in this study. Weitsman et al (2006)
also used the chromatin immunoprecipitation assay (chlP) to 'pull down' any DNA
associated with ERa P-Sl 18, which was amplified using PCR and primers to specific
genes. The group found that ERa P-Sl 18 was present at the promoters of several E2-
regulated genes, including pS2 and PR which were used in this report, but was not
altered due to HER-2 overexpression when the receptor was overexpressed in the
MCF-7 cell line. The group reported that overexpression of the erbB2 protein did not
affect E2-enhanced P-Sl 18, or its presence at the promoters of E2-regulated genes.
This further supports conclusions reached in this study as to the redundant role of
erbB2 (via the ineffectiveness of 2C4) in the development of endocrine resistance in
these cell lines. Weitsman et al (2006) confirms this by stating the groups' data do
not support the proposed theory of endocrine therapy resistance in breast tumours
being attributed to constitutive ERa P-S 118 via a constitutively activated MAPK
pathway and ligand independent activation. This again supports the absence of any
anti-proliferative activity of 2C4 in the LCC1 and LCC9 cell lines, and may account
for the Akt inhibitor LY 294002 not having a greater efficacy in these 'resistant' cell
lines. Weitsman et al (2006) did not use LY 294002, however, the group observed
that the MEK/ERK inhibitor U0126 did not affect P-Sl 18 in the presence or absence
of E2, which could be explained by the elevated Akt levels seen upon U0126
treatment. The increase may be a compensatory or bypass mechanism which operates
in the absence of the MEK/ERK signalling pathway being operational. Weitsman et
al (2006) concluded that another signalling molecule IKK-a, but not Cdk7, was partly
involved in E2-mediated P-Sl 18 in the MCF-7 cell line. It may be that this molecule
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is overexpressed in the LCC1 and/or LCC9 cell lines or other cell lines including
LY2.
The study by Sarwar et al (2006) used immunohistochemical analysis of breast
tumour biopsies to determine the relationship, if any, between ERa P-Sl 18 expression
and patient response to tamoxifen in breast cancer. The importance of such a
publication (along with others such as Murphy et al, 2004) is in linking previously in
vitro observations in cell line models such as the one here, with actual tumours and
clinical responses. The group reported that ERa P-S118 expression was increased in
tumour biopsies taken from patients who had relapsed after receiving tamoxifen
therapy compared with biopsies taken from patients who had yet to receive treatment.
This supports observations reported in this study, where the Mill, LCC1 and LCC2
cell lines with elevated P-S118 had diminished response to tamoxifen treatment
compared to the fully tamoxifen-responsive MCF-7 cell line. Sarwar et al (2006) also
produced P-Sl 18 expression time courses and U0126 inhibitor studies in the MCF-7
cell line and a tamoxifen-resistant MCF-7 cell line which supported data reported in
this study. Therefore, the data reported here and the publication by Sarwar et al
(2006) support the theory that increased P-Sl 18 may play a vital role in the
development of endocrine resistance in breast cancer. However, the data produced by
Sarwar et al (2006) does not account for tamoxifen resistance observed in the FCC9
cell line, which displayed reduced P-Sl 18 expression. The tamoxifen resistant cell
line used by Sarwar et al (2006) also had elevated MAPK activity, which shows their
model of tamoxifen-resistance is not comparable to the one utilised here as different
pathways are in operation. Sarwar et al (2006) also reported that P-S 118 was elevated
in more differentiated tumours, and suggested that P-Sl 18 was therefore associated
with a good prognosis in patients who had not previously received endocrine agents.
The authors suggested that ERa P-Sl 18 may therefore play a role in normal ERa
function. This may also account for the endocrine agent response in the MCF-7 cell
line which expressed lower levels of P-S 118 than the LCC1 cell line, but higher than
the LCC9 cell line. The growth of the LCC9 cell line must be operating via a distinct
mechanism other than ERa P-Sl 18.
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The report by Staka et al (2005) used an oestrogen-independent MCF-7 cell line
which was also insensitive to classical growth factor receptor stimulation. These
MCF-7X cells possessed similar signalling alterations in relation to the LCC- model,
including elevated P-Akt and similar P-ERK expression to the parental cell line. The
data from the study by Staka et al (2005) evaluated the efficacy of 1CI 182 780, LY
294002 and PD 98059 in combination and concluding that the only way to prevent
resistance was to adopt a triple-combination strategy targeting multiple pathways and
ERa simultaneously. The similarities in the profile of the MCF-7X model suggest
this would be an appropriate strategy to adopt in the LCC- model.
Heightened ER and pS2 mRNA expression in the LCC1 and LCC9 resistant cell lines
in the absence of oestrogen or growth factor stimulation was generally associated with
elevated ERa expression. This is subsequently associated with increased transcription
of the relevant genes and is consistent with published data (Staka et al, 2005; de
Cremoux et al, 2003; Briinner et al, 1993). These results are consistent with ERa,
pS2 and PR transcription being increased by ligand-independent mechanisms in the
resistant cell lines, where oestrogen induced further ligand-dependent increases. This
contrasts with CTD, which demonstrated only ligand-dependent activation (and no
ligand independent activation) at this 24h time point.
Kuske et al (2006) also reported that growth responses to E2 and tamoxifen were
reflected in their response to transcriptional changes. The mRNA expression profiles
produced in this study are supported by Kuske et al (2006), although it should be
noted that the time points differ (48h versus 24h treatments used in this study).
7. 2. Changes in signalling in the resistant cell lines
7. 2. 1. P-Akt overexpression
Overexpression of P-Akt is frequently observed in breast cancer (Murray et al, 2005)
and has been implicated in the development of tamoxifen resistance (Kirkegaard et al,
2005; deGraffenried et al, 2004). The LCC- and LY2 cell lines all expressed
constitutively activated Akt consistent with this theory and with several reports using
oestrogen-independent cell lines, including Tam-R MCF-7 cell line variants (Lin et al,
2005; Jordan et al, 2004; Frogne et al, 2004; Campbell et al, 2001). Soderlund et al
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(2005) reported that MCF-7 cells transfected with constitutively active Akt increased
resistance against apoptosis, which reinforces the reduction in apoptosis observed in
LCC1 and LCC9 cell lines. Proliferation assays using LY 294002 confirmed the
MCF-7 and resistant cell lines alike were Akt-dependent, although cell proliferation
was reduced only to a slightly lesser extent using U0126 indicating the MEK/ERK
pathway also remains actively involved in this model (data consistent with studies by
several groups, including Moelling et al (2005)). In contrast to the total abrogation of
P-Akt and P-ERK expression observed with LY 294002 and U0126 respectively,
neither inhibitor reduced resistant cell proliferation to the same extent as the MCF-7
cell line. It may be that some resistant cells are Akt-dependent whilst others remain
ERK-dependent, and therefore a combination of the two inhibitors would have been
more effective. Alternatively, yet another pathway may be involved in oestrogen-
independent growth.
Several reports have described the significance of the PI3-K/Akt pathway in erbB2
signalling (Dubska et al, 2005; Soderlund et al, 2005; Kim and Muller, 1999), thus
the constitutive activation of Akt led to the hypothesis an anti-erbB2 agent, 2C4,
would abrogate oestrogen-independent cellular proliferation. However, 2C4 did not
affect the proliferation of the resistant cell lines. Moreover, P-Akt and P-ERKI/II
expression were reduced, or even abrogated by 2C4, again indicating both pathways
remain intact and are involved in proliferation, although they may not necessarily be
solely responsible for the increased rate of basal proliferation. The inability of 2C4 to
have any anti-proliferative action against the resistant cell lines may instead be due to
the dominant erbB receptor conformation (Takai et al, 2005). It is possible that TGFa
preferentially induces erbBl homodimers as opposed to erbB 1/2 heterodimers, and/or
erbB 1/2 heterodimers are formed, but are sequestered into an inactive conformation.
Either possibility would render 2C4 ineffective, as demonstrated by the nil effect on
TGFa-enhanced P-Akt and P-ERK signalling in the LCC1 and LCC9 cell lines.
HRG(3 signalling was still intact in the resistant cell lines. HRGp has been shown to
be responsible for cell aggregation, which signals via the PI3-K/Akt pathway and can
be abrogated with LY 294002 (Tan et al, 1999b). Therefore, although no increase in
resistant proliferation was observed with growth factor stimulation, there may be
alterations in the extent of cell aggregation and cell-cell adhesion in the resistant cell
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lines. This theory is consistent with initial observations of all cell line growth assays
in 24-well plates, where HRGp treatment caused 'clumping' of the cells, perhaps
more so in the resistant lines, which made them more adherent to each other and less
adherent to the dish. These observations suggest the involvement of cell-surface
molecules such as cadherins, which are involved in signalling pathways controlling
proliferation and apoptosis. Abnormal cadherin expression has been associated with
breast carcinoma. For example, cadherin-E was found to be overexpressed in low-
grade DCIS breast cancer (Tan et al, 1999a). Conversely, the same molecule was
downregulated in high-grade breast cancer (Oka et al, 1993), suggesting cadherin
expression is involved in the early stages of breast cancer development and
progression. Tan et al (1999a) demonstrated that PI3-K was vital for cell aggregation
induced by HRGp, in contrast with the MEK/ERK pathway, which was found not to
play a role in cell aggregation. Tan et al (1999a) proposed that because aggregation
can contribute to the invasion and metastasis of breast cancer cells, HRGP-activation
of erbB receptors may affect these properties of MCF-7 cells. An increase in resistant
cell aggregation may be attributed to the elevated P-Akt expression and diminished P-
MEK signal in the LCC- and LY2 cell lines. Further studies are required in order to
confirm these initial findings and whether cadherin expression is relevant in this
particular model.
Another possible mechanism which may account for the redundancy of growth factor
receptor signalling and resistance to 2C4 and neutralisation of erbB2, would be the
activity of another ligand independent pathway, such as the 1GFR-1 pathway (Smith
te al, 2004; Holboro and Hynes, 2004; Albanell and Baselga, 2001) . This may also
explain the development of oestrogen-independence and anti-oestrogen resistance.
Reduced expression of PTEN may also account for the absence of any anti-erbB2
anti-proliferative effect. PTEN negatively regulates Akt activity by antagonising
PI3-K (Lu et al, 1999; Li and Sun, 1998). PTEN has been previously demonstrated to
confer resistance to another anti-erbB2 agent herceptin in cells overexpressing erbB2
(Nagata et al, 2004). PTEN may also play a pivotal role in any anti-tumour effect
mediated by erbB2/PI3-K/Akt and may prove to be a useful predictive marker for the
efficacy of herceptin in erbB2 overexpressing breast cancer (Fujita et al, 2006).
These data suggest PTEN may also be reduced in the LCC- and LY2 resistant cell
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lines. It was therefore proposed that anti-erbB2 monotherapy resistance may only be
overcome by using a combination of targeted therapies (Miller, 2004).
7. 2. 2. P-MEK and P-ERKI/II
P-MEK and P-ERKI/II have also both been implicated in the progression of breast
cancer. The overexpression of both these tyrosine kinases has been documented to
possess a strong association with breast cancer many times over (Martin et al, 2005;
Navolanic et al, 2003). The reduction in P-MEK expression levels in the resistant cell
lines is inconsistent with these studies. However, a study by Glaros et al (2006)
reported that transfection of MCF-7 with MEK led to the maintenance of tamoxifen
sensitivity, which is in agreement with the progressive loss of growth factor-enhanced
P-MEK with a progression in resistance from MCF-7 to LCC1 to the LCC9 cell line.
Moreover, the study by Fowler et al (2004) also reported that P-ERKI/II levels were
not elevated in their MCF-7 Tet-On model overexpressing ERa. The group therefore
concluded that the elevated transcriptional activity ofERa in the absence of ligand did
not involve the MEK/ERK pathway, in agreement with results obtained in the LCC-
and LY2 cell lines.
In addition, the elevated levels ofAkt in the resistant cell lines may induce some form
of 'Raf/Akt' crosstalk in these cells, which has previously only been observed in the
presence of high ligand concentrations in the MCF-7 cell line (Moelling et al, 2002).
This may account for the reduced growth factor enhanced P-MEK expression
compared to the parental cell line. P-ERKI/II was not elevated in the resistant lines,
with the expression pattern remaining similar to that of the parental MCF-7 cell line.
This is again inconsistent with published data which report constitutively activated
ERK in oestrogen-independent MCF-7 cells (Martin et al, 2005; Martin et al, 2003).
However, the majority of these studies, as previously discussed, utilised LTED cell
lines, which were either hyper- or supersensitive to oestrogen and did not have
elevated P-Akt expression either, indicating different a signalling mechanism(s) was
responsible for the regulation ofproliferation.
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7. 3. Future Studies
This investigation has proposed a number of areas of interest in the understanding of
the development and progression of breast cancer. There are several further areas and
studies which could be explored, a few examples of which have been detailed in the
following section.
As previously stated, current studies in the Cell Biology group (performed by C.
Naughton) are taking the form of ERa knockout using siRNA and ICI 182 780 and
confirmed the involvement of ERa in the LCC1 and LCC9 resistant cell lines. Initial
results showed a reduction in ERa reduced the proliferation of the resistant cell lines,
consistent with data reported by Fowler et al (2003).
It is necessary to fully characterise the total and phosphorylated expression patterns of
erbBl, erbB2, erbB3 and erbB4 receptors of all cell lines in the presence and
absence of ligand stimulation (including E2, HRGp and TGFa) and 2C4. This should
be performed over a time course as initial studies have indicated that the effects of E2
may be somewhat delayed to those of the growth factors. These expression patterns
may indicate whether overexpression or reduced expression of a receptor, erbB2 for
example, is partly responsible for the absence of any anti-proliferative effect of 2C4.
It would be useful to investigate the effect of LY 294002 and U0126 on P-S118 and
P-SI67 in this model of resistance. This has already been carried out by Staka et al
(2005) in LTED MCF-7 cells. Staka et al (2005) found that along with ERa
expression, SI 18 phosphorylation was elevated, in agreement with the data reported
here. SI67 phosphorylation was partly reduced with LY 294002 treatment in the
study by Staka et al (2005). It is therefore hypothesised the elevated P-Akt
expression in the resistant cell lines would be more sensitive to the inhibitory
properties of LY 294002. Also of interest would be the effect of LY 294002 and
U0126 on the cell cycle and apoptosis of MCF-7 cells compared to the resistant cell
lines. LY 294002 appeared to reduce the number of cells below 100% irrespective of
treatment, indicating some form of cell death is occurring. This may or may not occur
in the resistant cell lines. It may prove valuable to investigate the effect of E2 on
P-S167 expression to ascertain the involvement, if any, of non-genomic signalling in
this model of breast cancer resistance. Initial western blots at a 15 min time point
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showed E2 did not enhance P-S167 in either the parental or resistant cell lines but this
needs to be confirmed. A time course study would confirm whether there was any
involvement at a later stage.
More confirmation is still required between proliferation and apoptosis and
constitutively activated Akt and reduced P-MEK. It is proposed that observing the
cell cycle distribution and the number of cells undergoing apoptosis when the cells are
subject to LY 294002 and U0126 using FACS analysis may show the resistant cells
to be more sensitive to the effects of LY 294002. An interesting observation reported
in Chapter 6 was the effect of tamoxifen on growth factor-enhanced P-Akt, P-MEK
and P-ERK in all cell lines. The exact mechanism by which this occurs needs to be
confirmed. A potential first step in this process would be to confirm or rule out the
involvement of the erbB receptors by further characterising the effect of tamoxifen
in the presence and absence of growth factors and E2 on these receptors. Also, as
HRGp has been implicated in tumour metastases and invasion (Tan et al, 1999), an
invasion assay could be performed to assess the effect of repressing pathways
stimulated by HRGP (e.g. P13-K/Akt and MEK/ERK in this instance).
p38 MAPK has been implicated in the development of breast cancer resistance via
activation of ERK3 (Zimmermann et al, 2001), hence it may prove useful to
characterise the expression of ERK3 and p38 MAPK proteins in this model. Also of
interest would be the characterisation of PTEN expression in relation to the
development of resistance to anti-erbB2 agents such as 2C4 and Herceptin. PTEN
antagonises PI3-K and subsequently negatively regulates Akt activation (Crowder et
al, 2004; Nagata et al, 2004; Pandolfi, 2004).
The combined blockade of several signalling pathways simultaneously by combining
inhibitors such as LY 294002, U0126 and an anti-oestrogen to target the PI3-K/Akt
and MEK/ERK pathways and the ER directly may prove to more efficacious than
targeting a single pathway alone in this model. This strategy has previously been
successfully implemented in other resistant breast cancer models (Martin et al, 2003;
Yue et al, 2003).
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7. 4. Proposed Mechanisms of Resistance
The development and progression of resistance from the parental oestrogen and anti-
oestrogen sensitive MCF-7 cell line to the LCC- cell lines is summarised in figure 7.1.
The development of oestrogen independent growth appears to occur alongside several
alterations to signalling (in the form of constitutively activated Akt and a reduction in
growth factor-enhanced P-MEK), cell cycle (in the form of an elevated proportion of
cells undergoing division in S-phase) and apoptosis (observed as a reduction in the
percentage ofLCCl and LCC9 cells undergoing apoptosis). The acquisition of
resistance to tamoxifen and ICI 182 780 observed between the LCC1 the LCC9 cell
lines was accompanied by a reduction in P-Sl 18. The Mill cell line would logically
fall between the MCF-7 and LCC1 cell lines, while LCC2 cells would lie somewhere
between the LCC1 and LCC9 cell lines. The LY2 cell line was derived in a different
manner to these cell lines, but some phenotypic aspects are similar. It is therefore not
surprising that change such as elevated P-Akt expression also occurs in the LY2 cell
line.
Signalling j •t P-Akt 4- P-MEK •T P-MEK -F P-S118
Cell cycle
T1 cells in S-phase
with ligand treatment
4* cells in S-phase (control conditions)
NO change in distribution with ligand
treatment
Figure 7.1. Development and progression of resistance in the LCC- breast cancer
model. Schematic diagram showing the factors which may contribute to the development
and progression of oestrogen insensitivity and anti-oestrogen resistance from the parental
MCF-7 cell line to the LCC1 and LCC9 cell lines. Resistance progression is accompanied by
alterations to signalling and cell cycle distribution.
Figure 7.2 shows the proposed mechanism of resistance for oestrogen independence
and anti-oestrogen resistance. The proposed mechanism is based on the mechanisms
suggested by Schiff et al (2004) and Moelling et al (2002). The mechanism takes into
account the ability of LY 294002 to abrogate growth factor signalling (HRGP is
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shown as an example), crosstalk and proliferation in the resistant cell lines. The
mechanism also factors in the ability of tamoxifen to further enhance growth factor-
enhanced P-Akt, P-MEK and P-ERK1/II. This is consistent with data published by
Hatakeyama et al (2002), who also observed LY 294002 abrogated HRGp signalling
as reported here.
Figure 7.2 shows a growth factor binds to the appropriate erbB receptor, inducing
erbB receptor homo or heterodimerisation (HRGP is shown as the example here, with
a possible corresponding heterodimer conformation of erbB2/erbB3). Upon HRGP
binding and hcterodimer formation, the heterodimer undergoes a conformational
change allowing activation of downstream PI3-K/Akt and Ras/Raf/MEK/ERK
signalling cascades. The MCF-7 and resistant cell lines alike appear to signal via both
these pathways, but to differing extents. The elevated P-Akt in the resistant cell lines
may induce 'Raf-Akt' cross-talk which may subsequently account for the reduction in
P-MEK observed in the resistant cell lines. This differential activation of Akt and
MEK in the resistant cell lines is consistent with the reduced rate of apoptosis, the
elevated percentage of cells in S-phase and therefore an increased rate of cellular
proliferation.
Oestrogen and tamoxifen are shown to induce gene transcription by both directly
binding to ERa (genomic action) and via the MEK/ERK signalling pathway (non-
genomic action). Tamoxifen is also indicated to induce transcription via the
P13-K/Akt pathway. These genomic and non-genomic actions of oestrogen and
tamoxifen are consistent with previously published theories (Schiff et al, 2004;
Hatakeyama et al, 2002; Duh et al, 1997).
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Figure 7.2. Proposed mechanism of resistance in the LCC- cell lines. The parental
MCF-7 cell line signalling pathways are depicted by the lighter lines compared to the LCC-
cell lines which are represented by the bold lines and arrows. A growth factor binds to the
appropriate erbB receptor, inducing erbB receptor homo or heterodimerisation (heregulin p
(HRGP) is shown as an example here, with one of the possible corresponding heterodimer
conformation of erbB2/erbB3). Upon HRGp binding and heterodimer formation, the
heterodimer undergoes a conformational change allowing activation of downstream PI3-K/Akt
and Ras/Raf/MEK/ERK signalling cascades. The MCF-7 and resistant cell lines alike appear
to signal via both these pathways, but to differing extents. The elevated P-Akt in the resistant
cell lines may induce 'Raf-Akt' cross-talk (shown by horizontal bar between the
aforementioned proteins) which may subsequently account for the reduction in P-MEK
observed in the resistant cell lines (bold dashed lines). This differential activation of Akt and
MEK in the resistant cell lines is consistent with the reduced rate of apoptosis, the elevated
percentage of cells in S-phase and therefore an increased rate of cellular proliferation.
Oestrogen (E2) and tamoxifen (Tarn) induce gene transcription by binding directly to ERa at
AF-2, enhancing P-S118 at AF-1 or potentially via a non-genomic mechanism involving the
Ras/Raf/MEK/ERK pathway. Tarn may also act via the PI3-K/Akt pathway. Other pathways
and proteins may also be linked with the overexpression of Akt, such as PLCy activation as
discussed previously in chapter 5.
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7. 5. Potential contributing factors to resistance development
Gratton et al (2001) reported that VEGF-induced activation of the PI3-K/Akt pathway
led to the inhibition of p38 MAPK and protected the cells from apoptosis. This and
other studies (Park et al, 2002) suggest Akt may reduce stress kinase activation.
Thus, constitutively activated Akt in the LCC- and LY2 cell lines may diminish
apoptosis further still in conjunction with the effect of 'Raf/Akt' crosstalk.
Zimmermann et al (2001) further explored this theory and reported that that ERK3
expression arose as a consequence of p38 pathway activation and more than likely
represented an intracellular defence or rescue mechanism against cell stress and
damage induced by proteasome inhibition. In addition, ERK3 overexpression
protected cells from the anti-proliferative effect induced by proteasome inhibition.
Inversely, Zimmermann et al (2001) reported that inhibition of p38 specifically
sensitised various cells to proteasome inhibitors. It may be that the resistant cells have
elevated expression of ERK3, while any other activation of the p38 stress kinase
pathway is reduced.
Ligand activated ERa classically interact with the ERE, and indirectly regulate gene
expression by interacting directly with the AP-1 protein complex (Webb et al, 1999),
the Spl protein (Safe, 2001) or the nerve factor-xB (NFkB) protein (Harnish et al,
2000). These are all genomic actions of oestrogen which occur in conjunction with or
aside from non-genomic signalling (Kousteni et al, 2001). Alterations to any of these
components may lead to the development or progression of resistance. Specifically,
increased activity of the AP-1 transcription factor has been found to lead to
tamoxifen-resistance in MCF-7 cells (Liu et al, 2002). Gu et al (2002) suggested that
the LCC9 cell line may survive treatment with anti-oestrogens by 'bypassing specific
growth inhibitory signals' induced by ERa occupied with an antagonist. This cell line
was further studied by Riggins et al (2005), who reported that overexpression of the
transcription factor NFkB was associated with the development and progression of
ICI 182 780 resistance in the LCC9 cell line, and inhibition of this factor restored ICI
182 780 sensitivity. NFkB was not overexpressed in the LCC1 cell line and therefore
anchorage-dependent proliferation was not affected by NFkB inhibition.
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Another factor which may contribute to tamoxifen resistance and oestrogen
insensitivity is the inhibition of NK cell activity. Tamoxifen exerts some of its
antitumour properties via elevated NK activity and resistance may arise as a result of
elevated secretion of growth factors or cytokines which inhibit this activity. This
would potentially account for tamoxifen resistance in the LCC2 cell line, as these
cells secrete a significant quantity of cytokine TGF|32 (Artega et al, 1999). In
addition, both IGFR and erbBl expression was lower in the LY2 cell line than in the
parent line (Boylan et al, 1998), implicating the involvement of alterative signalling
pathways.
In summary, this study reports that multiple factors appear to be contributing to the
development and progression of oestrogen independence and anti-oestrogen
resistance in this model. These factors occur at different stages of oestrogen-
independent growth and endocrine agent resistance development andprogression and
include elevated ERa and P-S118 expression (in the Mill, LCC1 and LCC2 cell
lines), which may be linked with elevated E2-responsive gene expression in these cell
lines (as shown in the LCCI cell line), constitutive activation ofAkt as shown in both
the LCC1 andLCC9 cell lines, reduced expression ofMEK as resistance to endocrine
agents increases (decreasing in magnitude from the MCF-7 cell line to LCCI cells
and further still in the LCC9 cell line), a reduction in the number of 'resistant' cells
undergoing apoptosis (LCCI and LCC9 cell lines) and an increase in the number of
cells undergoing S-phase cell division (LCCI and LCC9 cells). The absence of
elevated MEKJERK activity (in the LCCI and LCC9 cell lines) as observed in other
tamoxifen-resistant models also supports the conclusion that several different
pathways contribute to the resistance process. In addition, LCC9 cells have a
comparable level ofERa expression to MCF-7 cells and yet possess reduced ERa P-
SJ18 levels, which also indicates a distinct pathway to those utilised by the Mill,
LCCI and LCC2 cell lines which overexpress P-Sl 18. Therefore ERa overexpression
cannot solely account for endocrine resistance in this cell model, indicating
resistance progression is likely to be a multifactorial process.
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Abstract
Hormone-dependent estrogen receptor (ER)-positive breast cancer cells may adapt to low
estrogen environments such as produced by aromatase inhibitors. In many instances, cells
become insensitive to the effects of estrogen but may still retain dependence on ER. We have
investigated the expression, function, and activation of ERa in two endocrine-resistant MCF-7
models to identify mechanisms that could contribute to resistance. While MCF-7/LCC1 cells are
partially estrogen dependent, MCF-7/LCC9 cells are fully estrogen insensitive and fulvestrant and
tamoxifen resistant. In both MCF-7/LCC1 and MCF-7/LCC9 cell lines, high expression of ERa was
associated with enhanced binding to the trefoil factor 1 (TFF1) promoter in the absence of
estrogen and increased transcription of TFF1 and progesterone receptor. In contrast to the
observations derived from hypersensitive and supersensitive models, these cells were truly
estrogen independent; nevertheless, removal of ERa by siRNA, or fulvestrant, a specific ER
downregulator, inhibited growth indicating dependence on ERa. In the absence of estrogen,
neither ERa Ser118 nor Ser167 were phosphorylated as frequently found in other ligand-
independent cell line models. Addition of estrogen activated ERa Ser118 in MCF-7 and LCC1 cells
but not in L.CC9 cells. We suggest that the estrogen-independent growth within these cell lines is
accounted for by high levels of ERa expression driving transcription and full estrogen
independence explained by lack of ERa activation through Ser118.
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Introduction
Estrogen receptor a (ERa) is a major growth regulator
for many breast cancers and has provided an
exploitable target for therapy (Ali & Coombes 2002).
Estrogen binding to ERa promotes conformational
changes in the receptor leading to dimerization and
attachment to DNA, generally at the site of conserved
estrogen response elements in the promoter regions of
target genes (Ali & Coombes 2002). Functional
regulation of ERa is additionally mediated via
phosphorylation of key residues in the activation
function 1 (AF-1) domain of ERa including Ser118
and Ser167 and these influence both DNA binding and
recruitment of cofactor molecules (reviewed in
Lannigan 2003). The activation of ER involves
crosstalk with other growth factor-signaling pathways.
There is extensive evidence that activation of the
mitogen-activated protein kinase (MAPK)-signaling
cascade and the phosphoinositol 3 kinase (PI3-K)
pathway phosphorylate ERa at Ser118 and Ser167, via
extracellular signal-regulated kinase (ERK)l/2 and Akt
respectively (Bunone et al. 1996, Martin et al. 2000,
Lannigan 2003). Transcriptional activation of ERa
then involves a dynamic process where large transcrip¬
tion complexes incorporating co-activator proteins are
assembled in an ordered and combinatorial manner
DOI:10.1677/erc.1.01257
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(Glass & Rosenfeld 2000, Metivier et al. 2003).
Well-defined estrogen-regulated genes include trefoil
factor 1 (TFFl)/pS2 (Masiakowski et al. 1982,
Jakowlew et al. 1984) and progesterone receptor
(PGR; Nardulli et al. 1988).
While tamoxifen has been the established form of
treatment for ER-positive breast cancers for more than
20 years, other anti-estrogen strategies, notably
aromatase inhibitors (Johnston & Dowsett 2003) and
selective estrogen downregulators (SERDs), are
increasingly being used (Robertson 2002). Despite
initial responsiveness to these agents, most tumors
eventually recur with acquired resistance (Clarke et al.
2001, 2003). Multiple mechanisms, dependent on the
form of endocrine treatment, are involved in the
development of resistance and, in many cases, these
mechanisms remain unclear. During the acquisition of
endocrine resistance, progressive changes are fre¬
quently observed, with ER-positive breast cancer
cells progressing in a stepwise manner from a fully
estrogen-sensitive phenotype to an estrogen-sensitive,
but no longer dependent phenotype, to a fully resistant
phenotype (Clarke et al. 2001, 2003).
With the increasing clinical use of aromatase
inhibitors, such as letrozole, anastrazole, and
exemestane which act by inhibiting estrogen
synthesis (Johnston & Dowsett 2003), there has
been great interest in how breast cancer cells can
adapt to low estrogen environments and become
resistant to the effects of these drugs. In most cases
of acquired anti-estrogen resistance, expression of
ERa is retained, suggesting that resistance involves
either changed functionality or bypass of the
receptor. Culturing breast cancer cells in estrogen-
low conditions to produce long-term estrogen
deprivation (LTED) has identified mechanisms of
estrogen hypersensitivity and estrogen supersensitiv¬
ity (Yue et al. 2002, Martin et al. 2003, 2005a,b,
Santen et al. 2005). Estrogen hypersensitivity is
characterized by the ability of cells to respond to
levels of estrogen at concentrations 2-3 log lower
than required to stimulate wild-type cells (Yue et al.
2002, Santen et al. 2005). This mechanism involves
increased expression of ERa alongside enhanced
phosphorylation of ERa Ser118 and is associated
with activation of the ERK1/2 and PI3-K pathways.
Estrogen supersensitivity, wherein cells are appa¬
rently estrogen independent, is a mechanism again
associated with enhanced ERa expression, ERK
activation, and activation of ERa Ser118 and involves
ERa being supersensitized by growth factor acti¬
vation (Martin et al. 2003, 2005a).
While higher levels of ERa expression are
generally associated with enhanced estrogen
response, in certain cases tumors expressing high
levels of ERa can be insensitive to endocrine
manipulation. High levels of ERa expression have
been associated with increased proliferation rates
(Black et al. 1983) and poor prognosis in breast
cancer patients not receiving adjuvant therapy
(Black et al. 1983, Thorpe et al. 1993). It has
been suggested that a high level of ERa may lead
to constitutive activation (Fowler et al. 2004). This
mechanism has recently been demonstrated by
Fowler et al. (2004, 2006) in a tetracycline-
inducible ERa expression model of the MCF-7
cell line, wherein increased ERa expression
resulted in aberrant promoter occupancy and gene
activation in the absence of estrogen. The increased
receptor activity required the amino-terminal
domain and was not inhibited by tamoxifen,
supporting the notion of AF-1 activation, yet was
independent of Ser104/106 and Ser118 phosphoryl¬
ation (Fowler et al. 2004).
In these models, the expression of ERa is still
critical to the response and it has been suggested that
use of a SERD such as fulvestrant (faslodex, ICI
182 780) would be a beneficial strategy once resistance
to aromatase inhibitors has developed (Johnston et al.
2005, Martin et al. 2005b). A number of laboratories
are developing models of resistance to this agent to
identify strategies that might be tried at the onset of
resistance (Dowsett et al. 2005, Howell 2005, Johnston
et al. 2005, Martin et al. 2005b, Nicholson et al. 2005,
Normanno et al. 2005).
We have investigated two MCF-7 cell lines
(MCF-7/LCC1 and MCF-7/LCC9), which have
acquired estrogen insensitivity and with variable
sensitivity to tamoxifen and fulvestrant to identify
novel mechanisms of endocrine resistance that might
arise in clinical specimens. The wild-type ER-positive
MCF-7 breast cancer cell line is both estrogen
dependent and responsive to anti-estrogens, such as
tamoxifen and fulvestrant. The MCF-7/LCC1 (LCC1)
cell line was derived from an MCF-7 xenograft, which
had grown in a low estrogen environment in an
immuno-deprived mouse and which was known to be
estrogen independent but with a degree of estrogen
sensitivity (Brunner et al. 1993). Treatment of the cell
line with fulvestrant produced the MCF-7/LCC9
(LCC9) cell line which is fully resistant to both
estrogen and fulvestrant (Brunner et al. 1997). A
number of novel features of these lines were identified
within this study and are reported here.
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Materials and methods
Cell proliferation
MCF-7 cells were routinely grown in phenol red
containing Dulbecco's modified Eagle medium
(DMEM) supplemented with 10% fetal calf serum
(FCS), penicillin (100 units/ml), and streptomycin
(100 (g/ml). LCC1 and LCC9 cells (source: Dr Robert
Clarke, V T Lombardi Cancer Research Center,
Georgetown University Medical School, Washington,
DC, USA) were routinely kept in phenol-free
containing DMEM supplemented with 5% dextran-
activated charcoal-stripped fetal calf serum (DCC),
penicillin (100 units/ml), streptomycin (100 (g/ml),
and 2 mM glutamine. All cells were grown at 37 °C
in 5% C02. To determine the effects of 173-estradiol
(E2) and tamoxifen on cell proliferation, MCF-7 cells
were seeded in six-well plates in phenol red containing
DMEM with 10% fetal bovine serum (FBS) for 24 h.
The media were changed to phenol red-free DMEM
with 5% DCC for 48 h. The cells were then
supplemented with media containing either 1 nM E2,
1 pM tamoxifen or both. LCC1 and LCC9 cells were
seeded in six-well plates in phenol red-free containing
DMEM with 5% DCC and after 24 h supplemented
with E2 and/or tamoxifen. Cell growth was evaluated
using a Coulter counter. Fulvestrant was a kind gift
from Dr Alan Wakeling (AstraZeneca, Macclesfield,
Cheshire, UK). For studies exploring growth in
DMEM without serum, the sulforhodamine-B (SRB)
colorimetric assay was used.
Briefly, log phase cells were seeded into 96-well
fiatbottom tissue culture plates. The following day,
cells were washed in PBS and media replaced with
phenol red-free DMEM for 48 h. Cells were then
treated with concentrations of E2 varying from 10 fM
to 1 pM in the absence or presence of 100 nM
fulvestrant. After 72 h, plates were removed from the
incubator and ice-cold 25% trichloroacetic acid (TCA)
solution (50 pi) added to each well. All plates were
placed on ice for 60 min after which the TCA solution
was removed. The plates were washed under running
water and dried prior to staining with SRB dye solution
(30 min at room temperature) and the trays were
washed with 1% glacial acetic acid (X4) at room
temperature, air-dried, and resuspended in 10 mM Tris
buffer (pH 10.5; 150 pi) before reading at 540 nm.
RNA extraction and RT-PCR
Extraction of total RNA from whole cells was
performed using Tri-Reagent (Sigma) as per the
manufacturers' instructions. RNA concentration was
measured using a spectrophotometer. QuantiTect
SYBR Green system (Qiagen, cat no. 204243) was
used according to the manufacturers instructions for
one step RT-PCR in a total of 15 pi reaction volumes,
including 0.5 pM each primer and 40 ng RNA. Real¬
time cycler conditions were RT: 50 °C for 30 min;
PCR: initial activation 95 °C for 15 min followed by 40
cycles of denaturation 94 °C for 15 s, annealing 57 °C
for 30 s, extension 72 °C for 30 s, and a final extension










Cells were washed twice with PBS and lysed in
ice-cold lysis buffer (50 mM Tris (pH 7.5), 5 mM
EDTA (pH 8.5), 150 mM NaCl, 1% Triton X-100,
aprotinin 10 pg/ml, and 1X protease cocktail inhibitor
(Roche) for 10 min and the debris was cleared by
centrifugation at 13 000r.p.m. for 6 min at 4°C).
Protein lysates (100 pg) were resolved on 7.5-12%
SDS-PAGE and electrophoretically transferred to
Immobilon-P membranes. After transfer, membranes
were blocked and probed with primary antibody
overnight at 4 °C. Immunoreactive bands were
detected using chemiluminescent reagents (ECL or
SuperLuminol) and photographic paper (Hyperfilm,
Amersham). The following antibodies were used: ERa
(F-10; Santa Cruz Biotech, Santa Cruz, CA, USA sc-
8002), PGR (ab-8; Neomarkers, Stratech Scientific
Ltd, Newmarket, Suffolk, UK (MS-298)), P-ERK1/2
(1:1000, Cell Signaling, New England Biolabs,
Hitchin, Herts, UK #9101), phospho-Ser118 ERa
(1:500, Cell Signaling #2511), phospho-Ser167 ERa
(1:500, Cell Signaling #2514), and actin (1:120 000,
CP01, Calbiochem, La Jolla, CA, USA). Integrated
optical density absorbance values were obtained by
densitometric analysis using a gel scanner and
analyzed by 'Labworks' gel analysis software (UVP
Life Sciences, Cambridge, UK).
Chromatin immunoprecipitation assays (ChIP)
Cells were grown to 85-90% confluence in phenol red-
free DMEM with 5% DCC for at least 48 h. Cells were
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cross-linked with 1% formaldehyde (37 °C for 10 min)
at 10-min interval over a 90-min time course.
Unreacted formaldehyde was quenched by gentle
agitation at room temperature for 10 min with
0.125 M glycine. Cells were then washed twice with
ice-cold PBS, collected into PBS containing protease
inhibitors (Roche), and centrifuged for 4 min at
2000 r.p.m. at 4 °C. The pellets were resuspended in
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl
(pH 8.1), and IX protease inhibitor cocktail),
incubated on ice for 10 min, and sonicated (12X20 s
at two amplitude microns, Soniprep 150, MSE) to
fragment DNA to ~ 500 bp. Following centrifugation
for 15 min at 13 000 r.p.m. and 4 °C, supernatants were
collected and rcsuspended in dilution buffer (0.01%
SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris-HCl (pH 8.1), 167 mM NaCl, and IX protease
inhibitor cocktail). Chromatin were precleared with
1 pg anti-rabbit or anti-mouse IgG, 2 pg sheared
salmon sperm DNA, and Protein-G-Agarose (50 pi of
50% slurry in dilution buffer) for 3 h at 4 °C.
Immunoprecipitation using Protein-G-Agarose Beads
(Roche) was performed overnight at 4°C with anti-
ERa HC-20 antibody (sc-543, Santa Cruz). Beads were
washed sequentially for 5 min each at 4 °C with TSE I
(20 mM Tris (pH 8.1), 2 mM EDTA, 150 mM NaCl,
1% Triton X-100, and 0.1% SDS), TSE 11 (20 mM Tris
(pH 8.1), 2 mM EDTA, 500 mM NaCl, 1% Triton
X-100, and 0.1% SDS), and buffer III (10 mM Tris (pH
8.1), 0.25 M LiCl, 1 mM EDTA, 1% NP40, and 1%
deoxycholate). Precipitates were then washed twice
with TE buffer and the protein/DNA complexes were
eluted twice with 0.1 M NaHC03 and 1% SDS. Heat
treatment at 65 °C overnight reversed formaldehyde
cross-links. DNA fragments were purified using
QIAquick Spin Kit columns (Qiagen) and amplified
using the QuantiTect SYBR Green system (Qiagen, cat
no. 204242). TFF1 PCR conditions were: initial
activation of 95 °C for 15 min followed by 45 cycles
of 94 °C for 15 s, 55 °C for 30 s, 72 °C for 30 s, and a
final extension of 72 °C for 5 min. TFF1 primer
sequences: fwd GACGGAATGGGCTTCATGAGC
and rev CTGAGACAATAATCTCCACTG. For the
distal region, primers were: fwd GAGTTTGGCCTCC-
CACATTA and rev CTTGCCTCTGCATTCTCTCC.
Short interfering (siRNA) transfections
MCF-7 cells were seeded at 0.5 X106 cells per T75 flask
in DMEM as mentioned previously. After 24 h, the
media were changed to phenol red-free containing
DMEM with 5% DCC for 48 h. LCC1 and LCC9 cells
were seeded directly into phenol red-free containing
DMEM with 5% DCC for 24 h prior to transfection.
Cells were transfected with siRNA for 4 h using
Oligofectamine reagent (Invitrogen) after which time
1 nM E2 was added for a further 48 h prior to RNA and
protein extraction. For the 7-day time course, the media
were left unchanged after the initial changes. For siRNA
growth assays, cells were seeded as for growth
characterization as mentioned previously. siRNA
transfections were carried out as described earlier but
scaled down for 24-well plates. Following siRNA
treatment for 4 h, cells were treated with 1 nM E2 or
100 nM fulvestrant or a combination and cell counts on
days 0,3, and 6 were estimated using a Coulter counter.
The following siRNA sequences were used: ER RNAi
1; ESR1 SMARTpool (four pooled sequences; Upstate
Biotechnology, Lake Placed, NY, USA; M-003401;
lOOnmol), ER RNAi 2; 5'-AAACAGGAGGAA-
GAGCTGCCA (Ambion; 40 nmol), ER RNAi 3; 5'-
AACCTCGGGCTGTGCTCTTTT (Ambion, Hunting¬
don, Cambridgeshire, UK; 40 nmol), and negative
RNAi: Upstate (D-001206; 100 nmol).
Results
Increased ERa expression in resistant cell lines
To explore the possibility that high ERa expression
leads to estrogen-independent growth in endocrine-
resistant cells, the expression levels of ERa in resistant
lines (LCC1 and LCC9) were compared with levels in
wild-type MCF-7 cells. Both resistant lines expressed
between four- and elevenfold more ERa mRNA than
wild-type cells (Fig. 1A). ERa protein levels were
clearly elevated in LCC1 cells relative to MCF-7 cells
(sevenfold) and less markedly in LCC9 cells (Fig. IB).
E2 decreased ERa protein in MCF-7 cells at 48 h and
this has been explained by proteosomal degradation, a
process speculated to limit the action of estrogen
signaling (Nawaz etal. 1999; Fig. 1C). Similarly, both
resistant lines demonstrated ERa turnover, suggesting
that ERa is binding to E2 in all cases. In contrast,
tamoxifen treatment results in maintenance of the
receptor expression levels in all three cell lines
(Fig. 1C).
Addition of 1 nM 17 p-estradiol (E2) to MCF-7 cells
produced a marked stimulation of growth to cells
cultured in estrogen-depleted (double charcoal-
stripped FCS) medium (Fig. 2A). In the absence of
E2, MCF-7 cells are essentially static (Fig. 2A). In
contrast, LCC1 cells grow rapidly in estrogen-depleted
conditions and show an approximately twofold
stimulation of growth on addition of E2 (Fig. 2B).
LCC9 cells showed a lack of response to E2, again
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Figure 1 ERa expression in MCF-7, LCC1, and LCC9 ceils. (A) ERa mRNA expression. Cells were grown in charcoal-stripped
serum-containing medium for at least 48 h and RNA was collected. A representative experiment is shown of at least two experiments
carried out. Each column presents mean of triplicate RT-PCR analysis for each sample demonstrating mRNA expression relative to
actin expression. Error bars = s.o. Statistical significance noted for treatment groups versus matched control (one-way ANOVA and
multiple comparison Tukey-Kramer test; *P<0.05). (B) Western blot analysis of ERa (66 kDa) in breast cancer cell lines grown in
charcoal-stripped serum-containing medium for 48 h prior to protein collection. One hundred micrograms of protein were loaded per
lane and detected using either anti-ERa (Santa Cruz Biotech) or anti-actin (Calbiochem) antibodies as described in Materials and
methods. (C) Western blot analysis of ERa (66 kDa) in breast cancer cell lines grown in charcoal-stripped serum-containing medium
for at least 48 h prior to protein collection. One hundred micrograms of protein were loaded per lane and detected using either anti-
ERa (Santa Cruz Biotech) or anti-actin (Calbiochem) antibodies as described in Materials and methods. (D) ERa binding to the TFF1
promoter. Basal recruitment of ERa to the TFF1 promoter was determined by ChIP analysis on untreated cells. The ChIP method
used was as described in Materials and methods and immunoprecipitated TFF1 promoter was quantified by real-time PCR. The
input-corrected expression values were determined by normalizing to the inputs. Data are presented as mean + s.E. Groups were
compared with the Kruskal-Wallis test with Dunn's multiple comparison test (*P< 0.05). Binding to the promoter region is compared
with binding to a region 3.5 kb distal to the promoter wherein only background binding was observed.
growing very rapidly in the absence of E2 (Fig. 2C).
Addition of 1 pM tamoxifen to MCF-7 cells antag¬
onized the E2-stimulated growth in this cell line.
Tamoxifen also inhibited the E2-stimulated growth of
LCC1 cells but had no effect on LCC9 cells (Fig. 2B
and C). These results are consistent with wild-type
cells being estrogen dependent, LCC1 cells demon¬
strating partial estrogen dependence and LCC9 cells
being fully estrogen independent.
Reduced ERa Ser118 phosphorylation
in LCC9 cells
Several frequently cited mechanisms of estrogen-
independent activation of ERa involve phosphoryl¬
ation of ERa at the Ser118 or Ser167 residues mediated
via ERK or Akt respectively (Bunone et al. 1996,
Martin et al 2000, Lannigan 2003). While the Ser118
residue is a major site of E2-induced phosphorylation,
Ser167 is not (Lannigan 2003). The latter site is
activated by growth factor signaling. In view of these
previous observations, we first investigated whether
ERa Ser118 or Ser167 phosphorylation were increased
in the absence of estrogen in the resistant cell lines.
Neither was there evidence of increased Ser118
phosphorylation in the resistant lines relative to
MCF-7 under basal conditions, nor was Ser167
phosphorylation increased (Fig. 3A-C). Furthermore,
phospho-ERKl/2 expression was unchanged in the
lines (Fig. 3C). On E2 addition, there was a marked
increase in Ser'18 phosphorylation in MCF-7 cells and
this was also observed in the LCC1 cell line (Fig. 3A
and B). However, minimal change was observed on E2
addition to LCC9 cells (Fig. 3A and B). Ser118
phosphorylation has been proposed to affect cofactor
recruitment and this might explain the reduced
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Figure 2 Growth characterization of MCF-7 and MCF-7 variant cells. (A) MCF-7 cells, (B) LCC1, and (C) LCC9 cells were plated for
24 h and maintained in reduced media for 48 h before treatment. Cells were then left untreated (control group), treated with 1 nM E2,
1 gM tamoxifen or 1 nM E2 and 1 |iM tamoxifen. Cells were counted on day 0 (72 h after plating/day of treatment start) and days 2/4/6
using a Coulter counter. Mean cell counts of triplicate samples and duplicate counts for each time point in each treatment group are
expressed. Error bars=s.D. A representative experiment is shown of at least four experiments carried out.
transcriptional (as mentioned below) and growth
responses observed on E2 addition to this cell line.
Tamoxifen alone produced a small increase in Ser118
phosphorylation in MCF-7 and LCC1 cells but not in
LCC9 cells (Fig. 3A and B). Tamoxifen also produced
a reduction of estrogen's Ser118 phosphorylation in the
MCF-7 and LCC1 cell lines (Fig. 3A and B).
Modified DNA binding of ERa in resistant
cell lines
To explore whether highERa expression was reflected in
enhanced DNA binding in the absence of E2, ChIP
methodology was used to examine ERa binding to the
promoter of the E2-responsive gene TFF1 in the MCF-7,
LCC1, and LCC9 cell lines. LCC9 cells had > 2.5-fold
greater ERa binding to the TFF1 promoter than MCF-7
cells (Fig. ID). However, this binding was significantly
higher in LCC1 cells with levels greater than eightfold
aboveMCF-7 cells. This enhanced ERa binding in LCC1
cells was equivalent to the increased expression of ERa
protein and is consistent with the suggestion by Fowler et
al. (2004) that enhanced ERa protein expression can lead
to increased DNA binding. As a control, binding to a
region 3.5 kb distal to this region indicated only
background levels as expected (Fig. ID).
Growth responses to estrogen and tamoxifen
in the wild-type and variant cell lines are reflected
in transcriptional changes
To investigate the differences in estrogen and anti-
estrogen activation processes, indicator genes that
reflected the different growth responses were next
investigated. Transcriptional changes in the estrogen-
regulated genes TFF1 and PGR were measured
and modulated expression was compared with the
growth changes.
Expression of TFF1 mRNA in the absence of E2 was
higher in both resistant lines compared with MCF-7 cells
(Fig. 4A). After 48-h E2 (1 nM) treatment, TFF1 mRNA
was increased by > 20-fold in MCF-7 cells, but only one-
to twofold in the resistant lines although this increase was
significant. Tamoxifen (1 qM) produced a small increase
in TFF1 expression in MCF-7 and LCC1 cells but not in
the LCC9 cell line (Fig. 4A). These levels broadly reflect
the growth differences observed.
The expression of PGR mRNA in the absence of E2
was greater in LCC1 and LCC9 lines compared with
MCF-7 cells (Fig. 4B). As for TFF1, after 48-h E2
treatment, PGR mRNA was increased by > 20-fold in
MCF-7 cells and 2-5-fold in LCC1 and LCC9 cell lines
(Fig. 4B). Tamoxifen also increased the PGR mRNA
1126 www.endocrinology-joumals.org
























































Figure 3 Effects of E2and tamoxifen on ERa phosphorylation in the resistant cell lines. (A) Western analysis of ERa phospho-Ser118
after 30-min treatment with control (no treatment), 1 nM E2,1 (iM tamoxifen, or 1 nM E2 and 1 pM tamoxifen. Lysates were run on a
10% SDS gel and membranes probed with anti-phospho ERa Ser118 antibody (1:1000). Lysates were also probed for actin
expression to compare protein loading. (B) Histogram representing optical densities from triplicate western blots of ERa phospho-
Ser1 18 after 30-min treatment with control (no treatment), 1 nM E2,1 pM tamoxifen, or 1 nM E2 and 1 pM tamoxifen. Values were actin
corrected and then standardized to a control sample. The control sample was a 30 min E2-treated MCF-7 sample and was used on
all gels as a standard to allow comparisons between runs. Statistical comparisons were made with each cell line's control level;
*P<0.01; +P<0.001 (ANOVA). (C) Western analysis of ERa phospho-Ser167 and phospho-ERK1/2 in cell lines. Untreated lysates
were probed with antibodies specific for ERa phospho-Ser167 and phospho-ERK1/2. A positive control lane of MCF-7 cells treated
with 1 nM HRG3 was used. Lysates were also probed for actin expression.
expression level not only in MCF-7 cells, but also in
LCC1 cells producing effects equivalent to that of E2 in
the latter cell line. No change was observed in the
LCC9 cell line.
These results are consistent with transcription of
TFF1 and PGR being increased by ligand-independent
mechanisms in LCC1 and LCC9 cell lines with
estrogen and tamoxifen producing an additional
ligand-dependent increase.
Effect of removal of ERa on the growth
of the cell lines
To determine the relative importance of ERa on
downstream gene expression and growth of MCF-7,
LCC1, and LCC9 cells, we investigated the effects of
removing ERa, either by specific siRNA inhibition of
receptor synthesis or through inhibition and
degradation of the receptor by fulvestrant.
A panel of interfering RNAs (siRNAs) were initially
compared for their ability to transiently reduce ERa
expression and were transfected into the MCF-7 cell
line. RNAi 1 is a pooled set of four targeted sequences
(Imai et al. 2005) while RNAi 2 (5'-AAACAGGAG-
GAAGAGCTGCCA) and RNAi 3 (5'-AACCT-
CGGGCTGTGCTCTTTT) are individually targeted
sequences (Leu et al. 2004). Of the three, RNAi 2
produced the best reduction of ERa mRNA and protein
and was selected for further experiments (Fig. 5A and
B). Quantitative RT-PCR analysis showed that, 48 h
after transfection, ERa RNAi 2 treatment resulted in an
85% decrease in ERa mRNA expression and an 87%
decrease in the presence of E2 (Fig. 5C). LCC1 and
LCC9 cells have significantly higher basal expression
of ERa mRNA and siRNA removal caused an 82 and
73% decrease respectively with similar reductions in
the presence of E2 (Fig. 5C). Western analysis of the
MCF-7 and LCC1 cell lines demonstrated that RNAi 2
produced ERa protein knockdown over a 7-day period
(Fig. 5D) and it was effective in all three cell lines
(Fig. 5E). This reduction in ERa protein was
accompanied by a decrease in PGR protein (Fig. 5E).
Thus, it appeared that gene expression in all three cell
lines was ERa dependent.
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Figure 4 Effect of estrogen, tamoxifen, and fulvestrant on (A) TFF1 expression and (B) PGR mRNA expression in the cell
lines. Relative mRNA expression values of TFF1 and PGR in the cell lines were measured by real-time RT-PCR using
specific primer pairs. RNA was collected at 48 h and was extracted from either untreated (control) cells or cells treated with
1 nM E2, 1 pM tamoxifen, 1 nM E2 + 1 pM tamoxifen, 100 nM fulvestrant, or 1 nM E2+100nM fulvestrant. Each column
represents mean of triplicate PCR analysis for each sample demonstrating mRNA expression relative to actin expression.
Error bars=s.D. Statistical significance noted for treatment groups compared to matched control where *P<0.05, untreated
control versus treatment group; +P<0.05, E2 control versus treatment group (ANOVA and multiple Tukey-Kramer
comparison test).
This was investigated further using fulvestrant.
Fulvestrant abrogates E2-induced gene transcription
by binding, blocking, and causing the degradation of
ERa (Parker 1993). Fulvestrant treatment in MCF-7
cells blocked E2-induced expression of TFF1 and PGR
(Fig. 4A and B). In addition, ligand-independent and
E2-induced TFF1 and PGR expression in LCCI cells
were reduced on fulvestrant treatment. These data
confirm that for LCCI cells TFF1 and PGR induction
are dependent on ERa expression. However, LCC9
cells are resistant to fulvestrant treatment and as such
no change in TFF1 expression and only a minor change
in PGR expression was observed. The effect of
fulvestrant on the growth of all three cell lines was
also investigated in the complete absence of serum
(Fig. 6). Under these conditions, MCF-7 cells did not
grow over a 72-h period. LCCI cells, however, still
proliferated and the addition of E2 had little effect on
growth confirming their independence of E2. Under
these conditions, fulvestrant was able to oppose the
effect of low concentrations of E2 again indicating
dependence on ERa. In contrast, LCC9 cells
were completely insensitive to both E2 and
1128
fulvestrant. Fulvestrant degraded ERa protein in all
three lines which is shown in Fig. 7A.
To determine how critical levels of ERa expression
were for the growth of MCF-7, LCCI, and LCC9 cell
lines, we used RNAi removal with or without fulvestrant
to inhibit the synthesis of ERa protein (Fig. 7B-D). E2-
induced MCF-7 cell growth was significantly decreased
(33%) by ERa removal and abolished by all com¬
binations of fulvestrant alone or with RNAi. LCCI cells
grew in the absence of E2 and RNAi removal had only a
minor effect on growth. E2-induced LCCI cell growth
was reduced by approximately 40% when ERa was
removed through RNAi, but, unlike MCF-7 cells,
fulvestrant alone was not enough to abolish growth -
this, however, could be accomplished though through
combination with RNAi. LCC9 cell growth in the
absence of E2 was reduced by ERa RNAi. A similar
decrease was observed in the presence of E2. LCC9 cells
are fulvestrant resistant and no effect on growth was
observed with this agent. No combinations of fulvestrant
or RNAi were able to totally abolish growth. These
results indicate a varying degree of dependence on ERa
for growth in the three cell lines.
www.endocrinology-joumals.org
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Figure 5 Effects of ERa RNAi on ERa and PGR expression in the cell lines. (A) Expression of ERa mRNA after treatment with a
range of ERa mRNA-targeted RNAis. ERa mRNA expression was measured by quantitative RT-PCR of mRNA from MCF-7 cells
48 h after RNAi treatment in the presence of 1 nM E2. Data are presented as mean+s.D. of actin-corrected values from triplicate
samples. The RNAi transfection method and RNAi sequences used are described in Materials and methods. Statistical significance
noted for treatment groups compared with matched control where *P<0.05, untreated control versus treatment group (ANOVA and
multiple Tukey-Kramer comparison test). (B) Western analysis of ERa protein expression in MCF-7 cells 48 h after siRNA treatment.
ERa was probed with the F-10 antibody and actin is shown as a loading control. (C) Expression of ERa mRNA after treatment with
RNAi 2. ERa mRNA expression was measured by quantitative RT-PCR of mRNA from cell lines 48 h after RNAi 2 treatment in the
presence or absence of 1 nM E2. Data are presented as mean+s.D. of actin-corrected values from triplicate samples. The RNAi
transfection method and RNAi sequences used are described in Materials and Methods. Statistically significance differences are
noted for treatment groups compared with matched control where *P<0.05, untreated control versus treatment group (ANOVA and
multiple Tukey-Kramer comparison test). (D) Western analysis time course of the effect of RNAi 2 treatment on ERa protein
expression in the MCF-7 and LCC1 cell lines. ERa was probed with the F-10 antibody and actin is shown as a loading control. (E)
Western analysis of ERa and PGR protein expression in the cell lines 48 h after siRNA treatment. ERa was probed with the F-10
antibody, PGR with Ab 8 and actin is shown as a loading control.
Discussion
Aromatase inhibitors are now used for the adjuvant
treatment of most hormone receptor-positive early
breast cancer. Despite the improvement they offer over
tamoxifen alone, recurrences still occur, and thus
models of resistance to both tamoxifen and estrogen
deprivation are required. The series of MCF-7-derived
cell lines provides an excellent model system for the
exploration of mechanisms of stepwise acquisition of
resistance to tamoxifen and estrogen deprivation. Most
models to date have been derived in vitro, which makes
LCC1 cells interesting as the initial estrogen depri¬
vation was achieved in vivo and therefore might reflect
features that could arise in a primary breast cancer
(Brunner et al. 1993). In many of the in vhro-derived
LTED models, acquired resistance is due to enhanced
sensitization to low concentrations of estrogen, which
often involves crosstalk with growth factor-signaling
pathways (Martin et al. 2003, 2005a,b). LCC1 cells
have certain of the characteristics of the LTED
phenotype (Yue et al. 2002, Martin et al. 2003,
2005a,b, Santen et al. 2005) such as a higher
expression level of ERa, an ability to grow in low-
estrogen conditions and elevated TFF1 expression. The
continuous culturing of LCC1 cells in low estrogen
conditions may well contribute to the increased
expression of ERa in this cell line.
However, unlike most LTED-derived cells, which
show little response to physiological levels of estrogen
yet are sensitive to very low levels of estrogen, LCC1
cells appear truly insensitive to the addition of low
levels of exogenous estrogen. Similarly, while most
LTED cells show basal activation of ERK1/2 acti¬
vation and ERa via Ser118 phosphorylation, LCC1 and
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Figure 6 Effect of the growth of the cell lines in serum-free
media and treated with varying concentrations of E2 in the
absence or presence of fulvestrant (1 nM). Cells were plated
and after establishment placed in serum-free medium for 48 h.
E2 with or without fulvestrant was added and plates left for 72 h.
Relative cell numbers were then assessed by SRB assay as
described in Materials and methods. Inset in MCF-7 figure:
effect of E2 on MCF-7 cells grown in 5% double charcoal-
stripped fetal serum.
LCC9 cells do not. The ER, however, is still clearly
functional in LCC1 cells and linked to growth
regulation as estrogen addition can produce an increase
in growth which could be reversed by tamoxifen. ERa
is also downregulated by the addition of estrogen and
markedly phosphorylated at Ser1 IX. Additionally, the
ERa downregulator fulvestrant reduces expression of
TFF1 and inhibits growth. These effects are more
marked when cells are exposed to fulvestrant with
siRNA removal of ERa.
While constitutive activation of ERa may be
achieved in some instances by phosphorylation of
Ser118 mediated by growth factor-driven activation of
ERK, an increased expression of ERa alone might
account for increased DNA binding. In support of this,
there was enhanced binding of ERa to the TFF1
promoter in the absence of added estrogen in both the
LCC1 and LCC9 cell lines. In addition, TFF1
transcription was markedly increased in the resistant
cell lines consistent with this enhanced ERa-binding
driving transcription. Direct support for such a
mechanism has recently been demonstrated in an
MCF-7 cell line using a tetracycline-inducible ERa
overexpression model (Fowler et al. 2004, 2006). As
with the data mentioned earlier, the results suggested
that elevated levels of ERa resulted in activation of
receptor transcriptional function in a manner distinct
from mechanisms that involve ligand binding or
growth factor-induced phosphorylation of the Ser104,
Ser106 or Ser118 sites. The mechanism required the
amino-terminal A/B domain and was not inhibited by
tamoxifen. It was also uncoupled from ERK activation.
The hypothesis proposed was that overexpression of
unliganded ERa stabilized interactions with the basal
transcriptional machinery, which at normal receptor
levels may be too weak to support effective transcrip¬
tion (Fowler et al. 2004).
These results together support a model wherein
growth (and TFF1 transcriptional activation) in LCC1
cells is dependent on ERa. This dependency has some
ligand (i.e., estrogen) responsiveness but is largely
ligand independent. The ligand-dependent component
may be reversed by tamoxifen. The ligand indepen¬
dency appears to involve neither growth factor
activation via the Ser118 or Ser167 phosphorylation
routes nor hypersensitization (where low levels of
estrogen produce apparent independence). Instead the
ligand independence appears to be explained by the
high level of ER expression leading to constitutive
activation and promoting DNA binding and transcrip¬
tional activation.
We have shown that ERa is functionally active in
the LCC1 model and since this has also been shown in
models demonstrating LTED, a logical clinical
strategy to attempt after development of resistance in
a low estrogen environment (such as produced by
aromatase inhibitor treatment) is to downregulate the
receptor using fulvestrant (Johnston et al. 2005, Martin
et al. 2005a,b). This strategy clearly is effective at
inhibiting growth in LCC1 cells. However, the LCC9
variant was derived after exposure and development of
resistance to fulvestrant (Brunner et al. 1997) and
showed no growth response to either estrogen or
tamoxifen. In this cell line, the negligible changes of
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Figure 7 Effect of fulvestrant on ERa expression and combined with ERa siRNA on the growth of the cell lines. (A) Western blot
analysis of ERa (66 kDa) in breast cancer cell lines in control, 1 nM E2, 100 nM fulvestrant, or 1 nM E2 and 100 nM fulvestrant-
treated groups at 48 h. One hundred micrograms of protein were loaded per lane and detected using anti-ERa (Santa Cruz Biotech)
antibody as described in Materials and Methods. Actin expression is also shown. (B-D) Effects of fulvestrant, ERa siRNA, or
combinations on the growth of the cell lines. (B) MCF-7, (C) LCC1, and (D) LCC9 cells were treated with 1 nM E2,100 nM fulvestrant,
40 nM ERa siRNA, or combinations of these. siRNA treatment was for 4 h only, while E2 and fulvestrant were present throughout the
time course. Comparisons are made with the negative siRNA control which gave an equivalent growth effect to no treatment. Data
are presented as mean + s.E. from quadruplicate samples. Statistical significance noted for treatment groups compared with
matched control where *P<0.05, negative RNAi control versus treatment group; tP<0.05, negative RNAi + E2 control versus
treatment group (ANOVA and multiple Tukey-Kramer comparison test).
ERa Ser118 phosphorylation obtained on estrogen or
tamoxifen addition contrasted with observations in the
other cell lines. Markedly reduced phosphorylation is
likely to affect cofactor binding and our initial findings
suggest that pi60 binding (specifically AIB1) is
reduced in this cell line, again consistent with
endocrine insensitivity (Kuske et al. 2004). However,
it is quite clear that fulvestrant can downregulate the
receptor and even extremely high levels of fulvestrant
(10 pM) were unable to influence growth (data not
shown). Despite this, siRNA removal of ERa produced
some growth inhibition suggesting a reduced but still
measurable dependency on ERa.
In conclusion, these results suggest that multiple
changes contribute to endocrine resistance. While ER
still demonstrates functionality in LCC1 cells, there is a
major shift to ligand independence. This independence
can be explained by the high level of ER expression
found in these cells and could lead to constitutive
activation of the receptor. These cells still show a degree
of dependency on estrogen and this can be blocked by
tamoxifen. Further changes were produced by exposure
and development of resistance to fulvestrant including a
loss of ERa Ser118 activation, which could account for
its loss of sensitivity to estrogen. These data support the
view that in the early stages of resistance, SERDs may
provide a useful therapeutic option, but other
approaches will be required when resistance has
developed to these agents.
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